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The purpose of this dissertation was to use a theoretical model to examine family 
physicians’ willingness to prescribe controlled-release opiate analgesics (CR opioids) to 
patients with moderate to severe chronic non-malignant pain (CNMP).  The study 
explored the utility of the Theory of Planned Behavior (TPB) constructs (attitude, 
subjective norm, and perceived behavioral control), in addition to recent past behavior 
(RPB), in predicting physicians’ willingness to prescribe CR opioids to patients with 
CNMP. 
A web-based survey was developed from three structured focus group interviews, 
pretested, and e-mailed to 2,750 Texas family physicians.  Based on responses from 267 
physicians, the TPB constructs were significant predictors in assessing family physicians’ 
willingness to prescribe CR opioids for CNMP, accounting for 39 percent of the variance.  
Overall, two-thirds of physicians (N=179) indicated they were willing to prescribe CR 
opioids for CNMP.  The attitude construct was found to be a key determinant of 
physicians’ willingness to prescribe.  Physicians holding unfavorable attitudes tended to 
believe that prescribing CR opioids for CNMP would lead to patient abuse, addiction, 
and regulatory scrutiny.  The subjective norm construct was also a significant predictor of 
physicians’ willingness.  In general, a majority of physicians indicated that they were 
 
vii 
more likely to be influenced by regulatory agencies, pain specialty groups, other primary 
care physicians, and their patients when deciding whether to prescribe CR opioids for 
CNMP.  The perceived behavioral control construct was also a significant predictor.  
Physicians indicated that possessing more knowledge in pain management, additional 
evidence-based studies, and access to pain management tools would improve their level 
of control over prescribing CR opioids for CNMP.  The inclusion of recent past behavior 
significantly increased the explanatory power of the study model to 57 percent.   
In summary, this study identified some key factors that explained family 
physicians’ willingness to prescribe CR opioids for moderate to severe CNMP.  Attitude, 
subjective norm, perceived behavioral control, and recent past behavior were strong 
predictors of physicians’ willingness.  Factors identified from this study should be 
targeted to increase awareness and reduce the impact of barriers that affect prescribing of 
CR opioids for CNMP.   
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The following definitions were provided from a consensus document from the American 
Academy of Pain Medicine, the American Pain Society, and the American Society of 
Addiction Medicine (Consensus Document AAPM APS ASAM, 2001; Evans et al., 
2003b).   
 
Addiction – “A primary, chronic, neurobiological disease, with genetic, psychosocial, 
and environmental factors influencing its development and manifestations; addiction is 
characterized by behaviors that include one or more of the following: impaired control 
over drug use, compulsive use, continued use despite harm, and craving.” 
 
Chronic non-malignant pain (CNMP) – Traditionally described as pain persisting for 
longer than three to six months beyond the usual course of an acute illness, or the time 
required for an injury to heal.  This type of pain may also be associated with a persistent 
pathologic process or pain recurring at intervals of months or years. 
 
Controlled-release opioids (CR opioids) – Also known as "sustained-release," 
“extended-release,” or "long-acting” opioids, this group of opiate analgesics is considered 
to provide analgesia in the same manner as immediate-release (short-acting) opioids but 
over longer periods of time.  
 
Physical dependence – “A state of adaptation that is manifested by a drug class specific 
withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, 
decreasing blood level of the drug, and/or administration of an antagonist.” 
 
Tolerance – “A state of adaptation in which exposure to a drug induces changes that 





ACRONYMS AND ABBREVIATIONS 
The following is a list of acronyms and abbreviations that are used throughout the 
dissertation manuscript. 
 
Ao - Attitude 
AAFP - American Academy of Family Physicians 
AAPM - American Association of Pain Medicine 
APS - American Pain Society 
B - Behavior 
b - Behavioral Beliefs 
BI - Behavioral Intention 
CE - Continuing Education 
CNMP - Chronic Nonmalignant Pain 
CNS - Central Nervous System 
CR opioid - Controlled-release opioid 
DEA - Drug Enforcement Agency 
e - Outcome Evaluation 
FDA- Food and Drug Administration 
FP - Family Physician 
FSMB – Federation of State Medical Boards 
GP - General Practitioner 
PBC - Perceived Behavioral Control 
PCP - Primary Care Physician 
PNS - Peripheral Nervous System 
RPB - Recent Past Behavior 
SN - Subjective Norm (also known as social norm) 
TAFP - Texas Academy of Family Physicians 
TMB - Texas Medical Board 
TPB - Theory of Planned Behavior 
TRA - Theory of Reasoned Action 
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CHAPTER 1:  INTRODUCTION 
 
“Pain is perfect misery, the worst of evils, and excessive, overturns all patience.” 
 
- John Milton, Paradise Lost 
 
1.1 Background 
The adequate treatment of chronic non-malignant pain (CNMP) continues to be a 
major public health concern.  It is estimated that close to one-third of the industrialized 
world population suffers from some type of chronic pain (Loesser, 1999).  The American 
Pain Society (APS) (2000) estimates that nine percent of the U.S. population suffers from 
moderate to severe CNMP.  Of these sufferers, many individuals have been living with 
their pain virtually on a daily basis for more than five years.  CNMP is considered a 
pervasive and costly health care problem.  Seen by experts as a leading reason why 
patients seek medical care in developed countries, the adequate management of CNMP is 
considered an important problem in both primary care and out-patient medicine (Zagari et 
al., 1996; Loesser, 1999).  The intrinsic sensory, emotional and behavioral components 
associated with the etiology and severity of CNMP often makes treatment of this type of 
pain complex.  Fortunately, a number of therapeutic alternatives are available to treat 
chronic pain.  The use of opioid analgesics is one treatment option that is considered to 
have an important role in this type of pain management.   
Advancements in pharmacotherapeutics have produced a number of medications 
created to assist physicians in managing their patients’ chronic pain.  Opiate analgesics 
(schedule II – IV), which until 30 to 40 years ago were primarily confined to hospital and 
inpatient settings, are becoming widely used to treat various levels of chronic pain in the 
outpatient setting (Anesthetic and Life Support Drugs Advisory Committee, 2003).  The 
use of “long-acting” or controlled-release opioids (CR opioids) is one treatment option 
that has achieved wide-spread acceptance among health practitioners in its role to treat 
pain in cancer and terminally-ill patients.  However, the use of this class of analgesics to 
manage moderate to severe CNMP is somewhat controversial (Goli& Finley, 2005).    
 
2 
The controversy over the use of CR opioids to treat patients in pain has been 
extensively discussed in the lay press and scientific literature.  Empirical evidence has 
shown CR opioids to be an effective tool in treating patients suffering from moderate to 
severe CNMP, especially among patients who require sustained analgesia (Simpson et 
al., 1997; Allan et al., 2001; Glajchen, 2001; Washington State Department of Labor and 
Industries, 2002; Davis et al., 2003; Lauretti et al., 2003; Fisher, 2004a).  In fact, many of 
the more recently published pain management guidelines and evidenced-based studies 
recommend the use of “long-acting” opioids to treat a specific group of patients suffering 
from moderate to severe CNMP (Gardner-Nix, 2003).  However, the use of CR opioids to 
treat this type of pain has not been widely accepted among many practitioners (Gureje et 
al., 1998; American Pain Society, 2000; AMA, 2004).  Previous research suggests that 
some physicians are reluctant to prescribe CR opioids to CNMP patients that may benefit 
from its long-acting analgesic properties.  In fact, some physicians are reluctant or 
unwilling to prescribe CR opioids to treat CNMP patients, even when it is medically 
appropriate (Turk et al., 1994; Turk, 1996; Potter et al., 2001; Gourlay et al., 2004; 
Clark, 2005).  Concerns of patient addiction, physical dependence, illicit usage, and fear 
of regulatory scrutiny are some of the factors that may affect physicians’ willingness to 
prescribe CR opioids (Glajchen, 2001; Gardner-Nix, 2003).  Consequentially, these 
physician-related barriers may result in CNMP patients receiving inadequate treatment 
for their pain.   
Primary care physicians (PCPs) play a critical role in the management of chronic 
pain among a diverse group of patients.  PCPs see more patients than any other specialty 
(U.S. Department of Health and Human Services, 2005).  They are also considered to be 
on the front-line in providing treatment to patients seeking pain relief.  As a result, the 
successful management of CNMP patients is dependent on the ability of PCPs to 
understand and utilize effective pain management therapies including the use of CR 
opioids.   
Experts agree that many physician-related barriers hinder the delivery of adequate 
pain management to patients with CNMP (Gilson& Joranson, 2001).  But, what causes 
physicians to under treat pain?  In addition, what underlying factors could influence 
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physicians’ decisions to use CR opioid analgesics for patients with CNMP?  Numerous 
studies have attempted to examine the knowledge and beliefs of physicians to better 
understand the reasoning underlying their treatment behaviors (Weissman et al., 1991; 
Turk et al., 1994; Polit& Hungler, 1995; Turk, 1996; Weinstein et al., 2000, 2000a; 
Potter et al., 2001).  However, little is known about primary care physicians’ attitudes or 
willingness to prescribe CR opioids to patients suffering from moderate to severe CNMP.   
Attitudes toward CR opioids and their role in treating pain may affect physicians’ 
decisions to prescribe this type of analgesic for CNMP.  In addition to their own attitudes, 
physicians may consider the beliefs of other individuals and groups (e.g., patients, 
colleagues, staff, family, medical boards) in their decision-making to prescribe this type 
of opioid analgesic.  Further, the level of control physicians have in their prescribing 
decisions may be influenced by external factors such as formularies, regulatory policies, 
or utilization management strategies.  As a result, it is suspected that the above mentioned 
factors play some role in the formation of physicians’ intentions (i.e., willingness) to 
prescribe CR opioids for CNMP. 
 The proposed study will examine some of the issues affecting the use of CR 
opioids in pain management.  In particular, it will identify and explore factors that are 
believed to influence physicians’ willingness to prescribe CR opioids.   
 
 
1.2 Statement of Purpose  
 The purpose of this study is to use the Theory of Planned Behavior (TPB) model 
to identify and examine factors affecting family physicians (FPs) attitudes and beliefs 
toward the use of CR opioids to treat patients with moderate to severe CNMP.  Further, 
the study will explore the predictive utility of the TPB in understanding FPs willingness 








1.3 Statement of Problem 
Primary care physicians (PCPs) play a critical role in the management of chronic 
pain among a diverse group of patients.  Though management of severe chronic pain will 
likely continue to be handled by pain specialists, PCPs are beginning to take on an 
increased responsibility for managing patients suffering from moderate to severe CNMP.  
Many therapeutic alternatives are available to physicians when it comes to treating 
CNMP patients.  One treatment modality that is gradually gaining acceptance is the use 
of CR opioid analgesics (Davis et al., 2003).  Recently published pain management 
guidelines recommend the use of CR opioids to treat a specific group of patients suffering 
from moderate to severe CNMP (Gardner-Nix, 2003).  However, some physicians are 
reluctant to prescribe CR opioids to CNMP patients, even when it is medically 
appropriate.  Physicians’ beliefs regarding the use of CR opioids for CNMP and 
educational deficiencies in pain management are believed to create barriers that lead to 
ineffective pain management.  Consequentially, their reluctance in prescribing CR 
opioids may result in the unnecessary suffering of their CNMP patients. 
Little research has been conducted to investigate what factors influence 
physicians’ attitudes toward prescribing CR opioids.  In addition, little is known about 
PCPs’ willingness to prescribe CR opioids to patients suffering from moderate to severe 
CNMP.  Therefore, a need exists to identify and examine factors that influence 
physicians’ willingness to prescribe CR opioids for moderate to severe CNMP.  A study 
of this type will increase our understanding of physicians’ intentions and behaviors in 
prescribing CR opioids to CNMP patients. 
 
 
1.4 Significance of Objectives 
 The significance of the proposed study is that, through the use of the Theory of 
Planned Behavior (TPB), investigators may be able to identify and better understand 
those factors (i.e., attitudes, social norms, and behavioral control beliefs) that influence 
family physicians’ willingness to prescribe CR opioids to patients with moderate to 
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severe CNMP.  Study findings could provide insight into behavioral concepts influencing 
physician CNMP treatment decisions.  This information would be valuable to the 
initiatives of health care practitioners, public health officials, regulatory agencies and 
continuing educational programs.  As a result, this information could be used to better 
meet the educational needs of primary care providers and ultimately the needs of their 
CNMP patients and the community. 
 
 
1.5 Overview of Dissertation 
 A review of the literature on CNMP, CR opioid analgesics, physician pain 
management practices, and physician attitudes and views toward prescribing opioid 
analgesics was conducted to identify and examine areas perceived to affect physicians’ 
willingness to prescribe long-acting opiate analgesics to patients diagnosed with 
moderate to severe CNMP.  The Theory of Planned Behavior (TPB) was utilized to 
examine family physicians’ willingness (intention) to prescribe CR opioids.  The 
constructs of the model were used to assess family physicians’ attitudes, subjective norms 
and perceived behavioral control toward the use of CR opioids to treat CNMP.  In 
Chapter 2, an overview of the etiology and impact of CNMP is discussed, a review of 
opioid analgesics used to treat chronic pain is provided, and a review of the literature of 
physician beliefs toward the use of opioids to treat CNMP is presented.  In Chapter 3, the 
research model, Theory of Planned Behavior, and the constructs associated with the 
model is discussed.  In Chapter 4, the research methodology is presented.  In Chapter 5, 
study results are presented and Chapter 6 provides a discussion of the results, limitations, 
and conclusions of the research study. 
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CHAPTER 2:  LITERATURE REVIEW 
 
“Chronic pain is one of the most pervasive and costly health care problems today” 
(Zagari et al., 1996).  Seen by experts as the leading reason why patients seek medical 
care in developed countries, the adequate management of chronic pain is considered an 
important problem in both primary care and outpatient medicine (Zagari et al., 1996; 
Loesser, 1999).  Numerous therapeutic options have become available to treat individuals 
suffering from moderate to severe chronic pain. The use of controlled-release opioids 
(CR opioids) is one treatment option that has achieved wide-spread acceptance among 
health practitioners in its role to treat chronic malignant pain.  However, the use of this 
class of analgesics to manage chronic non-malignant pain (CNMP) is somewhat 
controversial (Goli& Finley, 2005).   
A lack of consensus exists among physicians and other health practitioners on 
how and when to prescribe this class of opioid analgesics to patients suffering from 
CNMP (Dickinson et al., 2000).  Physicians’ beliefs toward the use of CR opioids for 
CNMP and deficiencies in education in pain management are believed to create barriers 
that lead to ineffective pain management.  As a result, a substantial number of physicians 
continue to under treat patients suffering from moderate to severe CNMP (American Pain 
Society, 2000).  This chapter provides an overview of CNMP and the therapeutic options 
used to treat the condition.  It will examine the economic and epidemiological impact of 
CNMP and review CR opioid analgesics.  The latter half of the chapter will examine the 
role of family physicians in pain management and barriers to prescribing CR opioids. 
 
 
2.1 Chronic Non-Malignant Pain (CNMP) 
 
Types of Pain 
CNMP is considered a complex disorder with a myriad of intrinsic sensory, 
emotional, and behavioral components contributing to its etiology and severity 
(McCarberg, 2004).  Left untreated or under treated, CNMP can have a substantial 
 
7 
negative impact on an individual’s quality of life.  It may affect a person’s ability to 
concentrate, function at work, exercise, socialize, participate in leisure time activities, or 
even attain proper rest.  The impact of CNMP can also be emotionally detrimental.   
Individuals suffering from unrelieved chronic pain are at increased risk of depression, 
anxiety, or other psychological conditions that may manifest as a result of uncontrolled 
pain (American Pain Society, 2000). 
Numerous definitions have been created to describe pain.  The International 
Association for the Study of Pain (IASP) describes it as “an unpleasant sensory and 
emotional experience associated with actual or potential tissue damage or described in 
terms of such damage” (Merskey& Bogduk, 1994).  Pain is often considered a subjective 
experience.  Many clinicians see pain as being so subjective in meaning that they often 
define pain as “whatever the patient says it is” (Baumann, 2002).   
Pain can arise from a myriad of physiologic pathways depending on the type of 
injury experienced by the patient.  Other definitions have been established to describe 
specific types of pain as it relates to its origin, severity, and duration (McPherson et al., 
2004).  The IASP developed a list of standardized pain terms for use by physicians in 




















2.1.1 Pathophysiology of Pain 
Pain arises from a variety of causes and is classified on the basis of the presumed 
underlying pathophysiology.  A number of models have proposed mechanisms that 
explain pain as it affects individuals.  The gate control theory (GCT), proposed by 
Melzack and Wall in 1965, is considered one of the more generally accepted models used 
to explain the perception of pain.  According to the GCT, pain perception is attributed to 
mechanical and psychological stimuli.  Further, pain is considered not only to involve 
sensory perceptions, but also affective and cognitive dimensions (Melzack& Wall, 1965).   
Typically associated with tissue damage, pain is considered a primary indicator of 
physiological trauma.  However, pain does not always have a direct correlation to an 
identifiable cause of injury.  The perception of pain commonly develops from a system of 
sensory neurons (i.e., nociceptors) and neural afferent pathways that are responding to 
potentially noxious tissue-damaging stimuli.  Conversely, non-nociceptive 
 




Allodynia    Pain due to a stimulus that does not normally provoke pain. 
  
Analgesia     Absence of pain in response to stimulation which would  
normally be painful. 
  
Causalgia    Persistent burning pain, allodynia, and hyperpathia following  
traumatic nerve lesion. 
  
Central pain  Pain initiated or caused by a primary lesion or dysfunction  
in the central nervous system. 
  
Dysesthesia   An unpleasant abnormal sensation, whether spontaneous or evoked. 
  
Hyperalgesia An increased response to a stimulus which is normally painful. 
  
Hyperpathia Abnormally painful reaction to a stimulus, especially a repetitive 
stimulus, as well as an increased threshold. 
  
Hypoalgesia    Diminished pain in response to a normally painful stimulus. 
  
Neuralgia     Pain in the distribution of a nerve or nerves. 
  
Neuritis     Inflammation of a nerve or nerves. 
  
Neuropathic pain   Pain initiated or caused by a primary lesion or dysfunction in the  
nervous system. 
  
Paresthesia   An abnormal sensation, whether spontaneous or evoked. 
1. IASP =  International Association for the Study of Pain 




pathophysiologic causes (e.g., abnormal nervous system processing or psychological 
factors) can influence nociception (Besson& Chaouch, 1987; Turk& Okifuji, 2000; 
Baumann, 2002; Evans et al., 2003d).   
According to the American Medical Association (2003a), the pathophysiology of 
pain can be divided into one of three categories: (1) nociceptive, (2) neuropathic, and (3) 
idiopathic.  The processes and the interrelationships of the various underlying 
mechanisms that are believed to cause each of the categories of pain are highly complex 
(McCarberg, 2004).  A brief overview of each of the categories will discuss how each of 
these factors work together to produce the pain response.  A more in-depth explanation of 
the pain process is provided by Besson and Chaouch (1987).  
 
Nociceptive Pain  
The first category of pain is nociceptive pain which involves the normal activation 
of the nociceptive system by noxious stimuli (Evans et al., 2003d).  Nociceptive pain 
occurs subsequent to tissue damage and is commonly associated with superficial somatic, 
deep somatic, and visceral pain syndromes.  The severity of this type of pain is related to 
the degree of receptor stimulation (as related to the degree of injury) transmitted by nerve 
fibers to the central nervous system (CNS) (American Pain Society, 2000; Baumann, 
2002).   
Generally, normal processing of nociceptive stimuli involves the interaction of 
primary and afferent pain modulating systems.  Normal processing of painful stimuli is 
transmitted via nociceptors (A-delta nerve and C-fibers) to the CNS (Figure 2.1).  Signal 
processing continues in the dorsal horn of the spinal cord, ascending neural pathways, 







































Examples of nociceptive pain include: (1) trauma of the skin, subcutaneous tissue, 
or mucous membranes; (2) deep somatic pain of the muscle, tendons and bones which 
commonly occurs in individuals suffering from arthritis pain, or tendonitis;  and (3) 
visceral pain including colic, appendicitis, pancreatitis, peptic ulcer or bladder distension.   
Conceptually, pain of this type can be thought of as being composed of three 
hierarchical levels: a sensory-discriminatory component, a motivational-affective 



























component, and a cognitive-evaluative component (Evans et al., 2003d).  Researchers are 
not completely clear on how the body perceives this information as being painful, but this 
type of pain arises from inflammation of tissue caused from stimulus of nociceptor 
sensory receptors reacting to acute tissue trauma or prolonged damage to tissue 
(McCarberg, 2004).   
Most nociceptive pain disorders are temporary conditions and may or may not 
require the use of medications to reduce inflammation and relieve pain.  These disorders 
resolve when inflammation of the tissue is removed or treated (American Pain Society, 
2000; McCarberg, 2004).  Patients experiencing nociceptive pain describe it as stimuli 
that is sharp, dull, aching or throbbing in nature (McCarberg, 2004).  Nociceptive pain 
processes can be associated with both acute and chronic pain.  For example, 
inflammation may result from the stimulation of both inflammatory cells and nociceptors 
caused by acute tissue trauma.  In addition, chronic inflammation with nociceptive 
stimulation may be the source of persistent pain.  Further, secondary neural changes that 
lead to chronic nociceptive pain may also be caused by tissue injury (McCarberg, 2004). 
 
Neuropathic Pain 
Neuropathic pain is the second pain syndrome category that arises from 
pathophysiologic changes in the CNS or peripheral nervous systems (PNS).  Generally, 
these changes may stem from injury to the neural or non-neural tissues (Evans et al., 
2003d).  Neuropathic pain may originally stem from disease, nervous system injury or 
impairment which leads to irregular signal processing of the PNS and CNS.  This pain 
syndrome may be a result of nerve injury, secondary to tissue damage.  Meaning, this 
type of pain becomes independent of the initial injury or damage, resulting in a sustained 
chronic pain state (American Pain Society, 2000; Dickinson et al., 2000; Baumann, 2002; 
Evans et al., 2003d; McCarberg, 2004). 
Neuropathic pain can be referred to as “pathologic pain” because it serves “no 
purpose” (Baumann, 2002).  Unlike nociceptive pain, which arises from pain due to 
inflammatory processes, neuropathic pain is generally caused by a primary lesion or 
nerve dysfunction.  The pathophysiological process of neuropathic pain is not completely 
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understood due to this type of pain arising in the absence of obvious tissue damage.  
However, research has shown that this pain syndrome may be associated with referred 
pain, allodynia (i.e., pain induced by light touch), hyperalgesia (i.e., increased response to 
noxious stimuli), or hyperpathia (i.e., exaggerated responses to painful stimuli, with 
continuing sensation of pain after the stimulation has ceased) (Baumann, 2002; Burke& 
Weitz, 2002; Evans et al., 2003d; Argoff et al., 2005). 
Researchers hypothesize that neuropathic pain arises from neurophysiologic and 
neuroanatomic changes that occur following injury to neural tissue (Evans et al., 2003d).  
Abnormal nerve regenerations can occur as a result of injury to peripheral neural axons 













Figure 2.2 Neuropathic Pain: Regeneration of Damaged Neural Tissue 
 






2. Neural tissue regeneration- 
    Nerves sprouting and forming Neurommas 
1. Neural tissue damage-  
    May be acute in nature and nociceptive 
3. Neural tissue regenerated, axon injury healed- 





Damaged axons may grow multiple nerve sprouts (e.g., neuromas) which can 
generate spontaneous activity, allowing pain pathways to be more sensitive to physical 
distention.  Atypical neural connections may develop between damaged nerves (e.g., 
nerve sprouts or demyelinated axons) allowing "cross-talk" to occur between somatic 
nerves, sympathetic efferent nerves and nociceptors.  In addition, dorsal root fibers may 
also sprout following injury to peripheral nerves.  This rewiring process can produce 
persistent nerve or neuronal pain stimulation weeks or months after healing has occurred 
(Baumann, 2002; Evans et al., 2003d; Argoff et al., 2005).   
Neuropathic pain is often described as a burning, tingling, or electrical sensation 
(McPherson et al., 2004).  Examples of neuropathic pain include: spinal cord injury, post-
stroke pain, HIV myelopathy, diabetic neuropathy, plexus avulsion injury, post-herpetic 
neuralgia, trigeminal neuralgia, peripheral nerve injury, carpal tunnel syndrome, post-
mastectomy pain, and pain associated with some cancers (American Pain Society, 2000; 
Baumann, 2002; Burke& Weitz, 2002; Argoff et al., 2005).   
 
Idiopathic Pain 
The third pain category is idiopathic pain.  Also known as psychogenic pain, 
idiopathic pain is a syndrome that occurs spontaneously and is not associated with any 
known cause.  Idiopathic pain lacks a demonstrable organic cause and is attributed to a 
high prevalence of anxiety and depression experienced among patients (Burton, 2005).  
Conditions included in this pain syndrome include idiopathic facial pain and atypical 
odontalgia (European Association of Oral Medicine, 2005).   
Psychological factors can contribute to idiopathic pain severity.  The 
psychological state of an individual experiencing this type of pain can have a major 
impact on their perceived severity of pain, the subjective nature of pain, and how well it 
is accepted (Evans et al., 2003d).  Idiopathic pain often accompanies anxiety, depression, 
and other affective or psychological disorders, which may contribute to the physiological 
symptoms associated with both nociceptive and neuropathic pain (Evans et al., 2003d).  
As a result, the ability to identify and assess idiopathic or “psychogenic” pain is 




Another type of pain not included in the previously discussed categories is 
“mixed” or “unspecified” pain.  This type of pain can be a result of a combination of 
nociceptive and neuropathic pain.  Examples of mixed pain syndrome include chronic 
recurrent headaches and vasculopathic pain (Burke& Weitz, 2002).  Treatment of mixed 
nociceptive or neuropathic chronic pain is considered rarely effective in completely 
eliminating pain.  As a result, the pain management goals associated with this condition 
are primarily focused in the improvement of quality of life (McCarberg, 2004). 
 
2.1.2 Classification of Pain 
Several classification systems have been developed to describe the forms of pain 
(McPherson et al., 2004), most of which divide pain syndromes into three groups: acute, 
persistent or chronic, and malignant pain (Ashburn& Staats, 1999; American Pain 
Society, 2000; Evans et al., 2003b; McPherson et al., 2004).  These classifications 
encompass a wide variety of pain syndromes.  The American Pain Society classifies the 
division as (1) acute pain, (2) chronic malignant pain, and (3) chronic non-malignant 
pain.   
Although there are many distinctions between the categories, the fundamental 
differences relate to the duration of pain, its etiology, and its prognosis (Table 2.2) 
(McPherson et al., 2004).  The ability to distinguish between acute and chronic pain is 
particularly relevant in the selection of analgesia.  Once pain becomes chronic, specific 










Table 2.2 Classifications of Pain: Acute and Chronic Pain 
 
Characteristic Acute Pain 
Chronic Non-Malignant 
Pain Chronic Malignant Pain1 





Hours to weeks, 
depending on 
cause 
Months to years Unpredictable 
Pathology 
  
Present  Often little or none  Usually present 









Ongoing tissue injury (e.g., 
arthritis), back pain (with or 
without associated 
pathology), headache  
Cancer or cancer treatments, 
acquired immunodeficiency 
syndrome, congestive heart 







Unpredictable Increasing pain with the 






Uncommon  Profound complications 
including depression, 
anxiety, and financial issues 
Usually profound, including 
loss of control, issues of 
confronting one’s mortality 











Present  Generally absent  Present or absent 
Biologic value 
  





Multimodal  Multimodal 
1. Defined as pain resulting from any progressive, potentially life-threatening disease. 
Source: (Ashburn& Lipman, 2004) 
 
 
Acute pain  
According to Chapman and Nakamura (1999), acute pain is described as “a 
complex, unpleasant experience with emotional and cognitive, as well as sensory features 
that occur in response to tissue trauma” (Chapman& Nakamura, 1999).  Acute pain 
characteristically manifests following an injury, surgery or tissue trauma.  This form of 
pain is generally nociceptive in nature and serves as a biological defense mechanism that 
warns the sufferer of tissue damage or the potential for further injury (Baumann, 2002; 
McPherson et al., 2004).   
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The etiology of acute pain is typically described to have recent onset having a 
short duration, usually lasting no more than a few days or weeks (Evans et al., 2003d).  
Acute pain can be seen as an adaptive beneficial response needed for the preservation of 
tissue integrity.  The key characteristic of this type of pain is that it generally subsides as 
healing occurs and pain producing stimuli remits with the resolution of injury (American 
Pain Society, 2000; Brennan& Heit, 2005).   
 
Chronic Pain 
The second and third categories of pain are chronic malignant and chronic non-
malignant pain.  Chapman and Stillman (1996) generally describe chronic pain as pain 
that extends beyond the period of healing, usually beyond three to six months.  This type 
of pain often does not relate directly to injury or provide physiologic value but instead is 
considered as pain that has outlived its usefulness (Chapman& Stillman, 1996; American 
Pain Society, 2000; Edwards et al., 2001; Potter et al., 2001; McPherson et al., 2004).  
The etiology of chronic pain is not well-understood.  Unlike acute pain, chronic 
pain can persist for months or years and is generally considered neuropathic (McCarberg, 
2004; Goli& Finley, 2005).  The pathology associated with this type of pain is not clearly 
defined which makes it difficult to diagnose and treat (Chapman& Stillman, 1996).  This 
type of pain can be caused from persistent stimulation of nociceptors, specifically in the 
area of ongoing tissue damage (e.g., osteoarthritis).  Frequently, however, chronic pain 
perpetuates from factors that are remote to the cause or damage, long after trauma has 
occurred (Ashburn& Staats, 1999).  Chronic pain can lead to poor physical functioning, 
depression, irritability, social withdrawal, vegetative like symptoms, disruption of work 
and interference of social relationships (American Pain Society, 2000; Gerstle et al., 
2001; Baumann, 2002; McCarberg, 2004; McPherson et al., 2004).   
 
Chronic Malignant Pain 
Chronic malignant pain is traditionally described as pain arising from either 
tumors or treatments such as chemotherapy, radiation or surgery (Ashburn& Staats, 
1999).  More recent definitions have expanded chronic malignant pain to include pain 
 
17 
associated with a progressive disease that is potentially life limiting, resulting from 
conditions such as acquired immunodeficiency syndrome (AIDS), progressive 
neurological diseases, end-stage organ failure, and dementia (Ashburn& Lipman, 2004).   
 
Chronic Non-Malignant Pain  
Chronic non-malignant pain (CNMP) is traditionally described as “pain that has 
lasted three to six months or longer, is ongoing, due to non-life-threatening causes, has 
not responded to current available treatment methods and can continue for the remainder 
of the patient’s life” (Dunajcik, 1999).  A more recent definition, however, describes 
CNMP as “pain persisting for at least one month beyond the usual course of an acute 
illness, or the time required for an injury to heal; or pain associated with a persistent 
pathologic process; or pain recurring at intervals of months or years” (Evans et al., 
2003b).   
The etiology of CNMP is not well understood.  Further, CNMP pain syndromes 
frequently have poorly understood organic causes and less well-defined patterns 
(Dunajcik, 1999).  The American Pain Society (2000), describes CNMP as pain resulting 
from a persistent debilitating condition that may result in significant physical, emotional 
and social disabilities.  Consequentially, CNMP can be difficult to diagnose if it develops 
in the absence of a defined injury or disease process (Dunajcik, 1999; American Pain 
Society, 2000).  CNMP is often mulitfactorial in origin and may originate from acute 
injuries that ultimately lead to chronic pain conditions.  It often cannot be explained by 
objective clinical measures alone and its cause may be idiopathic in nature.  The severity 
of this type of pain condition can range from mild to severe and may affect any region of 
the body (Woolf, 1993; Baumann, 2002).   
According to the American Pain Society (2000), CNMP is considered a non-life-
threatening condition or illness (American Pain Society, 2000).  Examples of this type of 
chronic pain included chronic lower back pain, osteoarthritis and other types of 
musculoskeletal conditions (Gerstle et al., 2001).  Depending on its severity, CNMP can 




Patients experiencing CNMP may develop a psychological disorder known as 
chronic pain syndrome (CPS).  Patients with persistent pain who exhibit two of the 
following characteristics are classified as having CPS: (1) report persistent pain lasting 
longer than three months–with or without physical causes, (2) demonstrate progressive 
deterioration in their ability to function at home, socially or in the work place, (3) 
experience increased health care utilization (e.g., repeated physical evaluations, 
diagnostic tests, request for pain medications or invasive medical procedures), (4) 
demonstrate mood disturbance, and (5) exhibit clinically significant anger and hostility 
(Sanders et al., 1999). Though not all CNMP patients develop this syndrome, the pain 
experienced by this group is real  (Dunajcik, 1999).  As a result, “appropriate 
management of both CNMP and CPS requires an interdisciplinary approach that 
addresses the complex interaction of physical, psychological, and social factors that 
contribute to the ongoing pain” (American Pain Society, 2000). 
 
 
2.2 Epidemiology and Economics of CNMP 
 
Epidemiology   
Previous studies have estimated the prevalence of chronic pain to be between two 
and 45 percent of the world’s population (Crook et al., 1986; Brattberg et al., 1989a; 
Magni et al., 1993; Gureje et al., 1998; Verhaak et al., 1998).  This variability in 
prevalence may be attributed to the heterogeneity in definitions used to describe chronic 
pain, types of populations studied, and survey methodologies used to conduct the study.  
 Among industrialized nations, chronic pain is projected to affect one-third of the 
populace with almost half of sufferers experiencing some level of disability resulting 
from their pain (Table 2.3) (Verhaak et al., 1998; Loesser, 1999).  The prevalence of 
chronic pain within the U.S. is estimated to be between 12 and 26 percent of the 
population, or somewhere between 35 to 75 million people (Schnitzer, 1998; American 





Table 2.3 Prevalence of Chronic Pain: Results of International Studies Conducted 







 Non-  
 response 
(Potter& Jones, 1992) England < 1%a GPb >6 months n.a. 
(Kohlmann, 1991)  Germany 2% Postal >1 month 20% 
(Bowsher et al., 1991) Great 
Britain 
7% Telephone >3 months --c 
(VonKorff et al., 1988; 
VonKorff et al., 1990, 1993) 
USA 8% Postal “Persistent” 20% 
(Frelund& Frelund, 1986) Denmark 9% GPb >3months n.a. 
(Crook et al., 1984) Canada 11% Telephone >2 weeks 
(Persistent) 
5% 
(Croft et al., 1993) England 13% Postal >3 months 34% 
(Magni et al., 1990, 1992)d USA 14% - 20% Survey >1 month --c 
(Andersson et al., 1993; 
Andersson, 1994) 
Sweden 18% Postal >3 months 15% 
(Sternbach, 1986) USA 10 - 29% Telephone >3 months --c 
(Ma¨ke´la¨& Helio¨vaara, 
1991) 





Denmark 30% Postal --c 10% 
(Brattberg et al., 1989b) Sweden 40% Postal >6 months 33% 
(James et al., 1991) New 
Zealand 
82%e Survey No time limit 30% 
a Incidence, not the prevalence 
b General practitioner 
c No data given 
d Musculoskeletal and abdominal pain 
e Life-time prevalence 
Source: adapted from (Verhaak et al., 1998) Table summary     
 
 
Prevalence of CNMP 
CNMP is seen as a significant problem throughout the industrialized world, with a 
prevalence of 10 to 55 percent, depending on the definition used to characterize the 
disorder (Novak et al., 2004).  Results from a 1992 World Health Organization (WHO) 
survey conducted on 5,438 primary care patients located in 15 countries throughout Asia, 
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Africa, Europe and the Americas, found that persistent pain was a commonly reported 
health problem among primary care patients (Gureje et al., 1998).  The international 
study found 40 percent of respondents living in industrialized countries experienced some 
level of CNMP due to arthritic or muscoskelatal disorders.  Back pain, headache, and 
joint pain were the most common types of pain reported.  Of the patients who were 
admitted to primary care facilities, 22 percent (n=1196) reported having experienced 
persistent pain lasting longer than six months (Gureje et al., 1998).   
The American Pain Society (2000) estimates that nine percent of the U.S. 
population suffers from moderate to severe CNMP.  A 1988 U.S. National Health 
Interview Survey (NHIS) found chronic daily back pain to be the most prevalent 
impairment in individuals 65 years and older.  According to the survey, this form of back 
pain was responsible for more disability than cancer, heart disease, stroke and AIDS 
combined among individuals 18 to 55 years of age (Praemer et al., 1992; Stoddard et al., 
1998; Loesser, 1999).  Approximately 55 percent of Americans aged 65 and over 
experience pain on a daily basis.  Results from a 1999 U.S. Gallup survey found that 42 
percent of adults–approximately 80 million people–experienced some level of pain every 
day.  Of those experiencing pain, fewer than half (43%) reported that they had a “great 
deal of control” over their pain.  In addition, 28 percent believed that there was no 
solution to their pain (Arthritis Foundation, 2003).   
Data from a 1998 U.S. National Institute on Disability and Rehabilitation 
Research report indicated that 22.7 million people aged 18 to 69 had some level of work 
limitation directly resulting from chronic pain (Stoddard et al., 1998).  Findings from the 
1999 “National Pain Survey” show that 24 percent (48 million) of Americans live with 
some type of chronic pain which lasted for six months or longer (Ortho-McNeil 
Pharmaceutical, 1999; American Pain Society, 2000; Weiner, 2001).  Of these 
individuals, 20 million experienced such severe pain that they were unable to work and 
30 million were unable to engage in daily routine activities.  A 2000 report published by 
the Joint Commission on Accreditation of Healthcare Organization (JCAHO) found that 
on average 50 million Americans are either partially or totally disabled due to pain each 
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year (JCAHO, 2000).  The economic impact associated with this group of pain sufferers 
will be discussed in the next section. 
 
 Economics 
 The total annual cost associated with treating chronic pain in the U.S. is estimated 
to be in the billions of dollars.  Few studies, however, have been able to accurately assess 
the true direct and indirect costs of CNMP (Grichnik& Ferrante, 1991; Praemer et al., 
1992; Andersson, 1999; Gallagher, 1999; Schnitzer et al., 2000; Thomsen et al., 2001; 
Breen, 2002).  National economic data available for CNMP is particularly sparse 
especially for the utilization of health care services, drug utilization and, changes in work 
and occupational status as related to productivity (Thomsen et al., 2001).  In addition, 
there is limited comprehensive data that incorporates the costs of treating co-morbid 
conditions that may develop from or become exacerbated as a result of chronic pain.   
 Annual economic costs associated with chronic pain appear to be increasing over 
the past several decades.  A 1983 study conducted by Anronoff et al. (1983) estimated 
the annual economic costs associated with treating chronic pain in the U.S. to be $US40 
billion a year.  By 1991, that number had grown to $US65 billion (Grichnik& Ferrante, 
1991).  A study published in 2000 estimated the costs to be as high as $US100 billion per 
year (Schnitzer et al., 2000).   
 Hospital charges and physician-related expenses comprise a substantial portion of 
the costs related to chronic pain treatment (Von Korff et al., 1991).  A United Kingdom 
study estimated the direct costs of treating chronic back pain to be £UK1.6 billion, of 
which physiotherapy and hospital utilization accounted for the majority of costs.  Indirect 
costs (e.g., time lost from work and caregiver time) of back pain in the British health 
system was estimated to be £UK5 billion annually (Maniadakis& Gray, 2000).  A 1989 
New Zealand study found that physician-related expenses were higher among chronic 
pain patients.  In the study, patients reported seeing their general practitioner 12.9 times a 
year compared with 4.2 visits in the general population (James& Large, 1992).   
 In the U.S., low-back pain and osteoarthritis are considered significant drivers of 
both inpatient and outpatient health care utilization (Emons, 2003).  Total U.S. direct 
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costs associated with lower back pain in 1994 was estimated to be $US34 billion with 
approximately $US11 billion related to hospital charges and $US300 million from drug 
costs (Lee, 1994; Emons, 2003). Figure 2.3 illustrates a breakdown of direct health costs 
in the long-term care of chronic lower back pain (Frymoyer, 1997). 
 
 A 1998 MacLean et al. retrospective cohort study conducted among a managed 
care population in the U.S. found the total costs for treating patients with persistent 
osteoarthritic pain under the age of 65 to be $US5,294 per patient per year (in 1993 
dollars).  This cost was seen to be more than twice that for age-matched non-
osteoarthritic patients (Figure 2.4).  Approximately 61 percent of the cost differential was 
attributed to inpatient hospital costs.  Osteoarthritis was also seen to be a substantial 
component of indirect and nondirect medical costs (i.e., indirect costs- work absenteeism, 
 
Figure 2.3 Annual U.S. Direct Health Care Costs of Chronic Lower Back Pain 
 















Hospital Providers Drugs LTC Outpatient Total
LTC =long-term care
Source: (Frymoyer, 1997) 
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lost productivity, disability; and nondirect costs- transportation, custodial care, and child 
care).  Total indirect and nondirect costs were US$726 per person per year (in 1993 
dollars), compared to US$335 for nonosteoarthritic patients (MacLean et al., 1998). 
 
 
 For individuals suffering from CNMP, the recovery process can be slow and their 
demand on the health-care system can be large and costly.  Aside from treatment costs, 
these patients often require major disability compensation and absence from work which 
translates to lost productivity (Andersson, 1999).  It is projected that the economic costs 
associated with treating CNMP will continue to rise as more Americans elect to work 
beyond 60 years of age and survive into their 80s (Gallagher, 1999; Scanlon& Chugh, 
2004).  Future studies should focus on collecting pharmacoeconomic data as it relates to 
 
Figure 2.4 Annual Treatment Costs of Chronic Osteoarthritic Pain within the U.S. 
 





















Source:(MacLean et al., 1998)  
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the direct, nondirect, and indirect costs of treating CNMP syndromes.  The information 
gathered can enable researchers to better understand the impact of costs of chronic pain 
from the patient, health system, and societal perspectives.   
 
 
2.3 Therapeutic Options to Treat CNMP 
 Many therapeutic alternatives are available to treat CNMP.  Most treatment 
regimes used for chronic pain generally involve a multidisciplinary approach, utilizing 





 Research demonstrates that multidisciplinary programs incorporating non-
pharmacologic therapies with pharmacologic therapies provide a comprehensive 
approach to managing chronic pain and improving functional outcomes in patients with  
moderate to severe pain (Allegrante, 1996; American Pain Society, 2000; Dickinson et 
al., 2000; Baumann, 2002).  Physical therapy, occupational therapy, and behavioral 
  




































Note: TCA = tricyclic antidepressants; SSRI = selective serotonin reuptake inhibitors 
































































approaches are often utilized to manage the underlying pain condition and symptoms 
associated with CNMP (e.g., depression, sleep disturbances, anxiety, and other 
sociopyschological conditions) (Allegrante, 1996).  The goals of incorporating many of 
these strategies are pain reduction, improved physical and mental functioning, and 
improved overall quality of life (Marcus, 2000). 
 
2.3.1 Non-Pharmacologic Therapy 
 Non-pharmacologic therapies, also known as adjunctive therapy, can play an 
important role in relieving moderate to severe CNMP, especially when used in 
conjunction with pharmacologic therapy.  Physical, psychoeducational and other 
multidisciplinary interventions have been shown to help patients cope with various pain 
syndromes (Allegrante, 1996; Marcus, 2000; Baumann, 2002).  The pain goals of non-
pharmacologic therapy are consistent with those of pharmacologic modalities.  They are 
to prevent disability, restore physical function, improve social functioning, and improve 
overall mental well-being of the patient (American Pain Society, 2000; Dickinson et al., 
2000; Baumann, 2002). 
 Traditional adjunctive therapies used to manage chronic muscoskeletal pain 
include acupuncture, biofeedback, cold (superficial), cold laser, electrotherapy (e.g., 
transcutaneous electrical nerve stimulation [TENS]), exercise, heat (superficial or deep), 
splints and braces, and topical agents (e.g., capsaicin) (Allegrante, 1996).  
Psychoeducational adjunctive interventions may also be used in relieving CNMP.  This 
treatment modality focuses on patients experiencing psychological side effects and 
depression that can often arise among CNMP patients.  Pyschoeducational therapies 
include cognitive-behavioral interventions, family and social support, patient education, 
and psychotherapy.  Other adjunctive interventions include: assistive devices, hypnosis, 








2.3.2 Pharmacologic Therapy 
Medicinal therapies play a critical role in the management of chronic pain.  There 
are three broad categories of analgesic medications used to treat moderate to severe 
CNMP: (1) non-opioid analgesics, which includes the nonsteroidal anti-inflammatory 
drugs (NSAIDs), acetaminophen, dipyrone, and others; (2) adjuvant analgesics, which are 
described as medications with primary indications other than pain but may be analgesic 
in selected circumstances; and (3) opioid analgesics (Portenoy, 2000). 
 
Non-Opioid Analgesics  
Non-opioid analgesics are widely used to treat chronic pain (Baumann, 2002).  
This class of drugs includes NSAIDs, the most commonly used method to treat CNMP 
(Dickinson et al., 2000).  Drugs within this class of analgesics are generally used as a 
first-line therapy in the treatment of mild to moderate pain because they are effective and 
easily accessible, over the counter (Ehrlich, 2003).  Common NSAIDs used to treat 
chronic pain include acetylsalicylic acid (aspirin), ibuprofen, naproxen and until recently, 
COX-2 inhibitors.  Acetaminophen is also included within this class of analgesics 
because of its pharmacologic properties (Baumann, 2002).   
NSAIDs are a nonspecific type of analgesic that can be used to treat a variety of 
pain syndromes such as chronic headaches, back pain, arthritis and other pain arising 
from trauma.  NSAIDs work by decreasing the level of inflammatory mediators 
generated at the site of tissue injury by inhibiting the enzyme cyclooxygenase. This 
action catalyzes the conversion of arachidonic acid to prostaglandins and leukotrienes 
which results in a desensitization of nerves to painful stimuli (Sunshine& Olson, 1989).   
NSAIDs have a dose-dependent effect and produce no physical dependence or 
tolerance.  However, this class of analgesic does have its limitations.  NSAIDs have a 
ceiling effect on their analgesic potential.  Further, as the dose increases so does the 
potential for adverse events and side effects (Portenoy, 2000).  NSAID use has been 
associated with both minor (dyspepsia, heartburn, nausea, vomiting, anorexia, diarrhea, 
constipation, flatulence, bloating, epigastric pain, and abdominal pain) and major 
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(bleeding, ulceration, and perforation) gastro-intestinal toxicities (Sunshine& Olson, 
1989).  Serious side effects of acetaminophen include hepatic damage or failure and 
aspirin or ibuprofen can cause gastrointestinal bleeding, ulceration, renal damage or renal 
failure.  In addition, new information from recent studies shows a potentially increased 
risk for cardiovascular events (e.g., heart attack and stroke) among users of some COX-2 
inhibitors (Solomon, 2005; Nussmeier, 2005; Motsko, 2006).  
Though NSAIDs alone can be effective in treating mild to moderate CNMP, they 
may not provide sufficient analgesia for moderate to severe cases.  As previously 
mentioned, research has shown that increasing the dose or prolonging the use of these 
types of medications may prove more harmful than beneficial.  Moreover, the unintended 
side effects of these drugs have been associated with thousands of hospitalizations 
annually (Dickinson et al., 2000; Portenoy, 2000).  As a result, clinicians often seek 
other, more effective, analgesic options when needed to treat patients with moderate to 
severe CNMP. 
 
 Adjuvant Analgesics  
 Adjuvant analgesics are a very broad and diverse group of medications that can be 
used to treat CNMP.  These types of drugs are FDA approved for indications other than 
pain, but may be prescribed as an analgesic in select circumstances (Evans et al., 2003a).  
Adjuvant drugs can be used alone or in combination with a non-opioid or opioid 
analgesic to treat chronic pain conditions (AGS Panel on Persistent Pain in Older 
Persons, 2002).  Adjuvant analgesics have been shown to have independent or additive 
pain relief properties to treat persistent pain syndromes as diverse as daily headache, 
lower back pain, neuropathic pain, and cancer pain (Portenoy, 2000; Gordon, 2003; 
DUAL Corp, 2005).   
 Adjuvant analgesics can be grouped into four broad classes, based on their 
intended use: (1) multipurpose analgesics— e.g., antidepressants, α2-adrenergic agonists, 
and corticosteroids; (2) neuropathic pain analgesics— e.g., local anesthetics, 
anticonvulsants, GABA agonists, neuroleptics, topical analgesics, calcitonin, and 
sympatholytics; (3) musculoskeletal pain analgesics— e.g., muscle relaxants and some 
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benzodiazepines; and (4) cancer pain analgesics— e.g., osteoclast inhibitors, 
radiopharmaceuticals, anticholinergics, and octreotides.   
 Adjuvant analgesics commonly used to treat moderate to severe CNMP include 
tricyclic antidepressants, anticonvulsants, N-Methyl-D-Aspartate receptor antagonists, 
lidocaine, and skeletal muscle relaxants (Portenoy, 2000).  These types of drugs may be 
used in all three stages of the analgesic ladder to enhance the efficacy of NSAIDs and 
opioids by treating the concurrent symptoms that may exacerbate pain (Portenoy, 2000).  
However, many adjuvant analgesics have side-effects that require careful titration and 
frequent monitoring (Portenoy, 2000; Ehrlich, 2003).  
 
2.3.3 Opiate Analgesics 
Opiate analgesics (opioids) are a third category of pharmacologic therapy that 
may be used to treat CNMP.  Opioids are a class of drugs (e.g., morphine, codeine, 
heroin, and methadone) that are derived from the opium poppy plant or are produced 
synthetically.  Opioids primary indication is to relieve pain and they are considered the 
most powerful class of analgesics that may be used to manage moderate to severe CNMP.  
They are favored based on their effectiveness, ease of titration, and favorable risk-to-
benefit ratio (Antoin& Beasley, 2004; Centre for Addiction and Mental Health, 2005; 
DiPiro et al., 2005; San Francisco AIDS Foundation, 2005).  Other medical uses of 
opiates include cough suppression, anti-diarrheal and treatment of addiction to other 
opioids.  The use of opiates to manage pain is commonly pursued after NSAIDs and 
adjunctive therapies have been explored (Baumann, 2002).   
Morphine and codeine are the principal components of naturally occurring 
opioids.  Derived from the poppy plant, these two ingredients are extracted from the seed 
pod of the opium poppy for their analgesic and euphoric properties (Centre for Addiction 
and Mental Health, 2005).  Today, many opiate analgesics used to control pain either 
contain pure morphine or codeine extracts or are synthetically manufactured (derived 
from the morphine structure) to induce opium-like effects.  Opioids work by binding to 
specific opioid receptors in the CNS and other tissues found throughout the mid-brain 
and spinal cord.  The analgesic effects produced by opioids are a result of their 
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interaction with at least four different types of CNS receptors: mu (µ), delta (δ), kappa 
(κ), and sigma (σ).  By attaching to these opioid receptors, opiate analgesics can 
effectively block the transmission of pain messages to the brain (Baumann, 2002; 
Kumar& Demeria, 2003; Lauretti et al., 2003).  The pharmacologic activity of an opioid 
depends on its affinity for these receptors, to which receptor it binds, and whether the 
opioid is an agonist or an antagonist (Kumar& Demeria, 2003).  The major role in 
analgesia appears to occur with opioids binding with the µ and κ receptors.  A 
comprehensive review of the pharmacokinetics of opioid analgesics is provided by        
Di Piro et al. (2002). 
Opiate analgesics are traditionally divided into three categories: (1) pure-agonists, 
(2) partial agonists-antagonists, and (3) mixed agonist-antagonists (Baumann, 2002).  
Prescription opioids belonging to these categories are available in various dosage forms 
including tablets, capsules, syrups, solutions and suppositories (Table 2.4).  The route of 
administration typically depends on the patient’s needs such as level of pain, speed of 
onset and duration of action (Baumann, 2002; Centre for Addiction and Mental Health, 
2005).  Most opioids are well absorbed through oral or rectal administration.  However, 
complete absorption may not occur by the GI system and first-pass metabolism in the 
liver may require the need for higher doses to be administered.  Other administration 
routes include intravenous, subcutaneous, and intramuscular and intrathecal (Baumann, 
2002; DUAL Corp, 2005). 
Pure-agonists include natural and synthetic opioids like morphine sulfate (MS 
Contin®), hydromorphone (Dilaudid®), oxymorphone (Numorphan®), levorphanol 
(Levo-Dromoran®), codeine (Tylenol w/Codeine 3®), hydrocodone (Vicodin®), 
oxycodone (OxyContin®), methadone (Dolophine HCl®), and fentanyl (Duragesic®).  
This group of opioids do not have a ceiling effect for their analgesic efficacy nor do they 
antagonize (reverse) the effects of other pure opioids (Baumann, 2002).  Morphine is the 
most widely used type of opioid analgesic for the treatment of moderate to severe pain 





Table 2.4 Opiate Analgesics Classifications 
 
Class and Generic Name Route Description 
Pure Agonists    
Morphine like Agonists   
Morphine PO,IM,IV,SQ, R Drug of choice for severe pain 
   
Hydromorphone PO,IM,IV,SQ, R Used for severe pain; More powerful than 
morphine (No advantages over morphine) 
   
Oxymorphone PO,IM,IV,SQ, R Used for severe pain (No advantages over 
morphine) 
   
Levorphanol PO,IM Used for severe pain 
   
Codeine PO,IM,IV,SQ, R Used for moderate pain 
   
Hydrocodone PO Used for moderate/ severe pain 
   
Oxycodone PO,IM,IV Used for moderate/ severe pain 
      
Meperidine-Like Agonists     
Meperidine PO,IM,IV Used for severe pain 
      
Fentanyl IM,TD,TM Used for severe pain; do not use in acute pain; 
transmucosal for "breakthrough" cancer pain 
      
Methadone-Like Agonists    
Methadone PO,IM Effective for severe chronic pain 
   
Propoxyphene PO Used for moderate pain; weak analgesics 
      
Agonist-Antagonist Derivatives   
Pentazocine PO,IM 3rd line agent for moderate to severe pain;  
   
Butorphanol IM,IV,IN 2nd line agent for moderate to severe pain; 
   
Nalbuphine IM,IV 2nd line agent for moderate to severe pain; 
   
Buprenorphine IM,IV 2nd line agent for moderate to severe pain; 
   
Dezocine IM,IV 2nd line agent for moderate to severe pain; 
      
Antagonists     
Naloxone IV Used when reversing opiate side effects in 
patients needing analgesia 
      
Central Analgesic     
Tramadol PO Used in treating neuropathic pain 
  
Legend: IM = Intramuscular; IN = Intranasal; IV = Intravenous; PO = By mouth;  R = Rectal; SQ = Subcutaneous; 
               TD = Transdermal; TM = Transmucosal 
 





Partial agonists-antagonists are agents that stimulate the analgesic portion of 
opioid receptors while blocking or having little or no effect on toxicity (Baumann, 2002).  
This group of opiates include buprenorphine and may be used as second line therapy 
among pain patients (Baumann, 2002).  Partial agonists-antagonists have lower abuse 
potential than pure-agonists, however the side-effects of this class of analgesics include 
hallucinations and dysphoria.  Included in the partial agonists-antagonists drug class, 
opioid antagonists are agents most often used to reverse the effects of agonists and 
agonist-antagonist derived opioids. This class of analgesics (e.g., naloxone) does this by 
binding competitively to opioid receptors to prevent an analgesic response (Baumann, 
2002).   
Mixed agonists-antagonists are another type of opiate analgesics that may be used 
to treat pain. They include such drugs as butorphanol (Stadol®), dezocine (Dalgan®), 
nalbuphine (Nubain®) and pentazocine (Talwin®) (Baumann, 2002).  Mixed agonists-
antagonists have limited use among chronic pain patients because of their ceiling effect 
for analgesia which results in the analgesic effect not increasing with dose escalation. 
An emerging fourth class of opiate analgesic that may be used to treat CNMP are 
central analgesics.  This small class of synthetic opioids (e.g., Tramadol) exhibits µ 
receptor activity and a mechanism of action that inhibits the reuptake of serotonin and 
norepinephrine.  Central analgesics drugs such as Tramadol (Ultram®) are reported to be 
effective in managing neuropathic pain (Kumar& Demeria, 2003).  Side effects are 
similar to traditional opioids. 
 Dosage and scheduling. Opioid effectiveness varies among patients and is 
dependent on pain condition type and patient physiology (McPherson et al., 2004).  
Dosage for one type of opioid that provides effective analgesia for a particular patient 
may not be efficacious in another patient experiencing similar symptoms.  Repeated dose 
adjustments may be necessary if the initial dosage does not provide adequate pain relief.  
If this occurs, experts recommend titrating opioid dosages upwards until adequate pain 
relief is achieved or intolerable adverse events occur.  Refer to Table 2.5 for an 





Table 2.5 Equianalgesic Dosages of Opioids 
 
 
Dose Equianalgesic to             




         IM                         Oral      
Codeine 130 200 
Oxycodone 15 30 
Propoxyphene 100 50 
Morphine 10 30 
Hydromorphone 2 – 3 7.5 
Methadone 10 3 – 5 
Meperidine 75 300 
Oxymorphone 1 NA 
Levorphanol 2 4 
Fentanyl  
Transdermal 
100 µ/hr = 
2 - 4 mg/hr of 
IV morphine 
NA 
IM = intramuscular; IV = intravenous; NA = not available 
Source: (McPherson et al., 2004) 
 
 Risks and side effects. All three classes of opioids exhibit related pharmacologic 
attributes and affect the CNS and gastrointestinal system.  Common side effects include 
mood changes, sedation, respiratory depression, nausea, vomiting, constipation, 
dependence, and tolerance (Table 2.6).  
 
 
Table 2.6 Side Effects of Opioid Analgesics 
 
Effect  Manifestation 
   
Mood changes  Dysphoria, euphoria 
   
Somnolence  Lethargy, drowsiness, apathy, inability to concentrate 
   
Stimulation of chemoreceptor 
trigger zone 
 Nausea, vomiting 
   
Respiratory depression  Decreased respiratory rate 
   
Decreased gastrointestinal motility  Constipation 
   
Increase in sphincter tone  Bilary spasm, urniary retention (varies among agents) 
   
Histamine release  Urticaria, pruritus, rarely exacerbation of asthma 
(varies among agents) 
   
Tolerance  Larger doses for same effect 
   
Dependence  Withdrawal symptoms upon abrupt discontinuance 
Source: (adapted from Baumann, 2002) 
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 The severity of these side effects vary among opioid classes and agents 
(Baumann, 2002).  Other serious problems related to opioid therapy include weight gain, 
myoclonus, adrenal suppression, immunosuppression, and hypogonadism (Antoin& 
Beasley, 2004). 
 Prolonged exposure to opioid analgesics may result in physical dependence, 
tolerance, and possibly addiction (Arkinstall et al., 1995; Baumann, 2002; Kumar& 
Demeria, 2003).  Sudden cessation of opioids can produce drug withdrawal symptoms 
among patients.  As a result, patients who become physically dependent should be 
tapered off opiate analgesics over a period of time to eliminate or reduce drug withdrawal 
side effects.  Tolerance may also develop from prolonged exposure to opiates. The cause 
of opiate tolerance is unknown, however patients who are exposed to opioids experience 
a gradual decrease in analgesic effect over time.  Consequentially, increased dosage of 
the drug or switching to another type of opiate analgesic may be required to maintain 
adequate pain control (Kumar& Demeria, 2003).  Under medical supervision, there is 
little risk of addiction to opiates.  Study findings indicate, that in patients without a 
history of substance abuse, long term use of opiate analgesics rarely leads to addiction 
(Zenz et al., 1992; Kumar& Demeria, 2003).  Risks for addiction to opioids will be 
discussed in more detail in Section 2.7.1.   
 
 
2.4 Role of Controlled-Release Opioids (CR opioids) 
 Management of moderate to severe chronic pain often includes the use of opioids 
in combination therapies, but their effectiveness is dependent upon clinician management 
techniques and patient adherence (Simpson et al., 1997).  Short-acting opioids also 
known as “normal-release” or “immediate-release” opioids are seen as an effective 
method in controlling both acute and chronic pain (Baumann, 2002).  Short-acting 
opioids such as Vicodin® (hydrocodone and acetaminophen) are usually taken every two 
to four hours and are often useful in managing patients with intermittent and 
breakthrough pain, that is pain that “breaks through” the level of relief provided by 





Table 2.7 Opioid Analgesics 
 
 Generic Name Brand Name 
Short-Acting Morphine  MSIR®, Roxanol® 
   
 Oxycodone OxyIR®, Oxyfast®, Endocodone® 
   
 Oxycodone 
(with acetaminophen) 
Roxilox®, Roxicet®, Percocet®, 
Tylox®, Endocet® 
   
 hydrocodone  
(with acetaminophen) 
Vicodin®, Lorcet®, Lortab®, 
Zydone®, Hydrocet®, Norco® 
   
 Hydromorphone Dilaudid®, Hydrostat® 
   
Long-Acting Morphine MSContin®, Oramorph SR®, 
Kadian®, Avinza® 
   
 Oxycodone Oxycontin® 
   
 Fentanyl Duragesic Patch® 
   
 Hydromorphone Palladone® 
Source:(Granville et al., 2005)  
 
 
 Controlled-release opioids (CR opioids), also known as “sustained-release” or 
“long-acting” opioids, are a highly potent form of opiate analgesic.  This group of opiate 
analgesics was designed to provide analgesia in the same manner as immediate-release 
(short-acting) opioids but over longer periods of time, hence requiring less administration 
(Roth et al., 2000).  Available evidence suggests that long-acting opiate analgesics, when 
used under the right circumstances, can hold considerable potential in helping moderate 
to severe CNMP patients better manage their pain (Moulin& Iezzi, 1996).  As a result, 
longer acting opiates may be preferred over short-acting agents in patients who require 
around-the-clock analgesic therapy because they allow less frequent dosing, potentially 
reducing pain fluctuations (e.g., break-through pain), and improving compliance 
(Arkinstall et al., 1995; Davis et al., 2003; Goli& Finley, 2005).   
 The decision to use CR opioids for moderate to severe CNMP is influenced by 
many factors: (1) the condition causing pain, (2) the severity and intractability of pain, (3) 
the relationship between the physician and patient, (4) the availability of other treatments, 
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(5) the physician’s type of practice, (6) the regulatory climate of the community, (7) the 
acceptance of opioid analgesic within the community, (8) the availability and access to 
pain specialists, (9) the patient’s desire for opioid therapy, (10) the physician’s 
experience, (11) the patient addiction history, and (12) the patient’s social environment 
(Belgrade, 1999). 
 Experts agree that CR opioids may be particularly beneficial among CNMP 
patients that require sustained analgesia (Portenoy, 1996a).  Available data suggest that 
this class of opiates holds considerable potential in effectively managing CNMP 
(Simpson et al., 1997; Allan et al., 2001; Glajchen, 2001; Washington State Department 
of Labor and Industries, 2002; Davis et al., 2003; Lauretti et al., 2003; Fisher, 2004a). 
Though previous research is unclear as to how much more effective CR opioids are in 
comparison to their short-acting counterparts, several studies suggest that patients are 
able to obtain a better response to pain control when given around-the-clock analgesic 
therapy (Arkinstall et al., 1995; Simpson et al., 1997; Allan et al., 2001; Glajchen, 2001; 
Davis et al., 2003; Lauretti et al., 2003; Fisher, 2004a).  Other research has shown that 
significant improvements in quality of life and reduction in opioid side-effects may be 
achieved among CNMP patients taking CR opioids compared to shorter acting opioids 
(Simpson et al., 1997; Caldwell et al., 1999; Hale et al., 1999; Peat et al., 1999; Salzman 
et al., 1999; Caldwell et al., 2002; Veterans Health Administration, 2003).   
A primary clinical benefit of CR opioids is that by virtue of their prolonged pain 
relief, they eliminate the need to take a pill every two to four hours.  Scheduled dosing of 
these types of medications requires administration once or twice a day (McPherson et al., 
2004).  Refer to Table 2.8 for dosage frequency and available dosages for selected 
opioids.  In addition, previous studies show that fewer side effects such as reduced 
euphoria, potential for addiction, and sleep disturbances are seen when using these types 
of opioids (Otis& Fudin, 2005).   
CR opioids are available in a number of different formulations.  Morphine (MS 
Contin® and Avinza®), hydromorphone, (Palladone™), oxycodone (OxyContin®), and 
transdermal fentanyl (Duragesic®) are the most commonly used CR opioids used to treat 
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pain (Goli& Finley, 2005).  Common routes for administration of these types of opioids 























“Extended-release morphine is the standard against which other CR opioids are 
measured” (Otis& Fudin, 2005).  The bioavailability of this type of opiate analgesic is 
less than 40 percent.  However, due to presystemic metabolism, the bioavailability of 
morphine can vary greatly among individuals.  CR formulations of morphine are 
available in a wide range of dosages to provide sustained levels of analgesia during a 12 
to 24 hour period (Allan et al., 2001). 
Hydromorphone is a semi-synthetic opioid which is more potent than morphine 
and is generally used among patients that experience intolerable side effects to morphine 
(Goli& Finley, 2005).  Dosage frequency for the drug is once daily.  Until recently, the 
long-acting brand name version, Palladone™ was available by prescription within the 
United States.  However, in June of 2005, the Food and Drug Administration (FDA) 
requested that sale of the drug be voluntarily suspended by the manufacturer.  Co-
ingestion of Palladone with alcohol resulted in dangerous peak plasma concentrations of 
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the drug.  As a result, the FDA concluded that that the overall risk to benefit ratio was 
unfavorable (FDA, 2005).  
CR oxycodone was designed as an alternative to morphine.  Also more potent 
than morphine and originally designed as a second-line treatment to morphine, CR 
oxycodone is gaining wider acceptance among clinicians as a first-line schedule II option 
(Davis et al., 2003).  This type of CR opioid is seen as a good option for patients who 
may have a previous history of being intolerant to morphine (Otis& Fudin, 2005).  CR 
oxycodone is commonly administered orally or rectally in tablet or pellet form and 
provides a controlled delivery of the drug over a 12-hour period (Davis et al., 2003; 
Purdue Pharma LP, 2003). 
Another commonly used CR opioid is the transdermal fentanyl patch.  Fentanyl is 
a highly lipophilic opioid which is readily absorbed into the bloodstream.  The 
transdermal delivery system provides continuous systemic delivery of opiate over a 72-
hour period (Simpson et al., 1997; Allan et al., 2001; Janssen Pharmaceutica Products 
L.P., 2003; Otis& Fudin, 2005).  Opioids with longer half-lives, such as methadone and 
levorphanol, are also used to treat chronic pain.  These opiate analgesics are prescribed to 
provide around-the-clock relief for an extended period of time to prevent pain relapse that 
can result from gaps in medication adherence (Arkinstall et al., 1995; PDR Health, 2005).     
 
 Limitations of CR opioids   
 The side effects and risks associated with CR opioids are similar to those of short-
acting opiate analgesics.  Common side effects include mood changes, sedation, 
respiratory depression, nausea, vomiting, constipation, dependence, and physical 
tolerance.  However, one serious risk associated with this type of opiate analgesic is due 
to the metabolic half-life.  Research suggests that CR opioid formulations with long half-
lives may pose a problem with delayed toxicity when the interval between doses is 
shorter than the drug’s half-life (Goli& Finley, 2005).  This concern emphasizes the 
importance of safe administration of CR opioids.  For example, oral formulations of CR 
opioids require tablets not to be physically altered or damaged prior to swallowing.  
Tablets that are crushed, broken or chewed prior to swallowing will result in large doses 
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of opiate intended for slow absorption to be released at once.  This higher dosage could 
result in overdose and possible death.  Similarly, capsule preparations that contain pellets, 
which may either be swallowed whole or opened so that the pellets can be sprinkled on 
soft foods, should not be crushed or chewed.  Crushing, chewing, or dissolution of the 
pellets may also result in overdose or death (Roth, 2002; Goli& Finley, 2005).  The use 
of long-acting opioids can be an essential step to effective CNMP management but many 
physicians still have concerns regarding drug efficacy, patient addiction, tolerance, 
physical dependency and side-effects (Simpson et al., 1997; Dickinson et al., 2000). 
 
 
2.5 Pain Management Guidelines 
Recent pain management guidelines and evidenced-based studies have 
recommended the use of “long-acting” opioids in certain chronic pain conditions 
(American Academy of Pain Medicine and the American Pain Society  AAPM&APS, 
1997; National Pharmaceutical Council, 2001; FSMB, 2003; Gardner-Nix, 2003; 
Veterans Health Administration, 2003; Wisconsin Medical Society: Task Force on Pain 
Management, 2004).  However, health practitioners have been cautious in adopting the 
treatment guidelines that encourage the use of opiate analgesics among patients with 
moderate to severe CNMP.  Physicians have expressed a need for a “gold-standard” or 
general guidance in  opioid prescribing protocols when used in the treatment for CNMP 
(AAPM & APS, 1997).   
While no particular treatment program for CNMP has been universally endorsed 
by any of the medical guideline-issuing organizations, numerous guidelines have been 
created to assist physicians in treating chronic pain patients (JCAHO, 2000; National 
Pharmaceutical Council, 2001).  The Agency for Healthcare Research and Policy 
(AHRQ) formerly known as the Agency for Health Care Policy and Research (AHCPR), 
introduced the first U.S. clinical practice guidelines for pain management in 1992 (Table 
2.9).  Since that time, other groups such as the American Society of Anesthesiologists 
(ASA), the American Pain Society (APS), and the American Academy of Family 
Physicians (AAFP) have produced an assortment of guidelines, adopted by physicians 
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and other health care providers in managing CNMP patients (National Pharmaceutical 
Council, 2001).  Each of the chronic pain guidelines listed in Table 2.9 contain a mixture 
of consensual strategies and differences in treatment approaches for patients suffering 
from CNMP, yet, they are all guided by two important objectives: (1) patient comfort, 
and (2) improved psychological and social functioning (Portenoy, 1996a; Sanders et al., 
1999; American Pain Society, 2000; Wisconsin Medical Society, 2004). 
 
 
Table 2.9 Examples of Practice Guidelines for Management of Chronic Pain 
 
   
1992 AHCPR Acute Pain Management: Operative or Medical Procedures and Trauma 
Clinical Practice Guideline No. 1 (Publication No. 92-0032) 
 
1995 ACR Guidelines for the Medical Management of Osteoarthritis 
 
1996 ASA Practice Guidelines for Sedation and Analgesia by Non-Anesthesiologists 
 
1996 ASA Practice Guidelines for Chronic Pain Management 
 
1997 ASA The Management of Chronic Pain in Older Persons 
 
1997 UIGNIC Acute Pain Management 
 
1998 AGS The Management of Chronic Pain in Older Persons 
 
1999 ICSI Adult Low Back Pain 
 
1999 AAOS Clinical Guideline on Hip, Knee, and Wrist Pain 
 
1999 APS Guideline for the Management of Acute and Chronic Pain in Sickle Cell 
Disease 
 
1999 APS Principles of Analgesic Use in The Treatment of Acute Pain and Cancer 
Pain Diagnosis and Management 
 
1999 AMDA Chronic Pain Management in the Long Term Care Setting 
 
2000 AAFP Treatment of Non-Malignant Chronic Pain 
 
2000 ICSI Assessment and Management of Acute Pain Disease of the Knee 
Abbreviations: AAFP: American Academy of Family Physicians; AAOS: American Academy of Orthopaedic Surgeons; 
ACR: American College of Rheumatology; AGS: American Geriatrics Society; AHCPR: Agency for Health Care Policy and 
Research; AMDA: American Medical Directors Association; APS: American Pain Society; ASA: American Society of 
Anesthesiologists; ICSI: Institute for Clinical Systems Improvement; UIGNIC: University of Iowa Gerontological Nursing 
Interventions Center. 
Source: (National Pharmaceutical Council, 2001) 
 
In a 1997 joint consensus statement, the American Academy of Pain Medicine 
(AAPM) and the APS recognized opioids as playing an essential role in managing both 
the social and economic costs of CNMP (American Academy of Pain Medicine and the 
American Pain Society  AAPM&APS, 1997).  The group acknowledged that chronic pain 
is often managed inadequately due to suboptimal treatment methods and that a standard 
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principle of practice should be developed for clinicians to follow when deciding to use 
opiate analgesics (Dickinson et al., 2000).   
Most pain management guidelines acknowledge the need for good clinical 
practice when prescribing opiate analgesics to treat chronic pain.  Many of these 
guidelines emphasize that treatments must be individually tailored to chronic pain 
patients with consideration given to different treatment modalities.  The pain practice 
guidelines outline the best methods to administer opioid therapy (e.g., long-term use) and 
underline the importance of monitoring patients to evaluate treatment effectiveness and 
patient functioning.  Many of the guidelines agree that the use of opioids should be 
considered only after other treatment alternatives have been explored.  However, minimal 
guidance is provided on which patients should receive opioids or the type of criteria that 
should be used to select them (Dickinson et al., 2000).  Table 2.10 summarizes the 2001 
JCAHO recommendations for prescribing opioids to CNMP patients (National 
























1. Perform comprehensive assessment, including a pain history and assessment of the impact of 
the pain, a directed physical examination, a review of prior diagnostic study results or 
interventions, a drug history (i.e., past abuse), and an assessment of coexisting diseases or 
conditions. 
2. Consider obtaining a second opinion from a physician or psychologist with expertise in pain 
management and use of interdisciplinary team. 
3. Optimize nonpharmacologic and nonopioid therapies. 
4. Inform patient of potential risks of use of controlled substances, including addiction (informed 
consent). 
5. Agree on issues including how drugs will be provided, acceptable number of rescue doses, 
pharmacy to be used for prescription refills, and the follow-up interval. 
 
During treatment: 
1. Administer opioids primarily via oral or transdermal routes, using long-acting medications when 
possible. 
2. Use a fixed dosed (“around-the-clock”) regimen. 
3. Perform careful drug titration, balancing analgesia against side effects. 
4. Continue efforts to improve analgesia via complementary approaches (e.g., behavioral 
approaches, formal rehabilitation program, and other medications). 
5. Consider use of hospitalization for pain that is not treated by transient, small dose increments. 
6. Monitor for evidence of drug hoarding, unauthorized dose increases, and other aberrant 
behavior. Reconsider therapy in the occurrence of such behaviors. 
7. Perform frequent follow-up evaluation to monitor analgesia, side effects, functional status, 
quality of life, and any evidence of medication misuse. 
8. Consider use of self-report instruments (e.g., pain diary). 
9. Carefully document the overall pain management treatment plan and include the reason for 
opioid prescribing, any consultations received, and results of periodic review of patient’s status. 
Source: (National Pharmaceutical Council, 2001)  
 
 
Many of the recent chronic pain guidelines have been modeled after the 1986 
World Health Organization’s (WHO) analgesic ladder (World Health Organization, 
1990).  Originally developed for treating terminally-ill or end-of-life patients, the WHO 
analgesic ladder outlines the pharmacologic treatment strategies clinicians may follow 
when treating chronic pain patients.  Today’s advocates of the analgesic ladder point out 
that the choice of analgesic should be based on the severity of the pain rather than the 
stage of the patient’s disease (Gardner-Nix, 2003; McCarberg, 2004).  Further, 
proponents recognize the need for analgesics to be taken regularly and the dose gradually 
increased, as necessary.  In the absence of clear CNMP guidelines, the WHO tool has 
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As depicted in the ladder, non-opioids analgesic drugs are generally the first-line 
treatment for pain. The use of acetaminophen or NSAIDs are widely used first-line 
therapy among patients suffering from mild to moderate pain (Step 1).  The use of mild 
opioid analgesic agents (e.g., codeine) are recommended in Step 2, while the more potent 
opiate analgesics (e.g., CR morphine, CR oxycodone) are reserved for Step 3.  Adjuvant 
therapy such as antidepressants, anticonvulsants and muscle relaxants may be used during 
each step to assist with pain symptoms (Gardner-Nix, 2003). 
Figure 2.7 illustrates Gallagher’s flow diagram for implementing and assessing 
opioid therapy in chronic pain management. 
 
 
Figure 2.6 World Health Organization Analgesic Ladder  
 
MILD – TO – MODERATE PAIN MODERATE – TO SEVERE PAIN 
 




Figure 2.7 Implementing and Assessing Opioid Therapy in 
Chronic Pain Management  
 
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          













Source: (Gallagher, 2004) 
Monitor efficacy and safety 
• Function improved by 50% 
• Pain reduced to moderate level (6/10) 
• Reduction in excessive analgesic overuse 
• Reduction in emergency department visits 
• Side effects acceptable with/without management 
Thorough history and  
physical examination 
Appropriate screening to establish patient as a candidate 
for opioid therapy 
Consider consultation or referral 
Complete informed consent 
Select opioid formulation and dosage
Assure medication compliance 
• Provide medications only when prescription is due
• One physician will provide all pain medication 
prescriptions 
• One pharmacy will be used to obtain all pain 
medications 
• Provide limited supply (e.g., 1 or  2 weeks) 
• Use the minimum effective dose 
• Conduct planned/random dosage count 
• Conduct unscheduled office visits 
• Perform random urine toxicology screening 
• Conduct behavior assessment 
• Wean periodically to reassess pain control 
• Use nonpsychotropic pain medications when 
possible 
Complete opioid treatment agreement      
with patient 
Complete/update medical record 
• Medical history and physical 
examination
• Diagnostic, therapeutic, and laboratory 
results 
• Evaluations and consultations 
• Treatment goals 
• Discussion of risks and benefits 
• Informed consent 
• Treatments 
• Medications, including date, type, 
dosage, and quantity prescribed 
• Instructions and agreements 
• Periodic reviews 




An example of the New Hampshire Medical Society (NHMS) guidelines for using 
controlled substances in CNMP patients are outlined in Table 2.11.  These guidelines 
were taken from the Federation of State Medical Boards’ (FSMB) “Model Policy for the 
Use of Controlled Substances for the Treatment of Pain” and incorporated into the 
medical organization’s chronic pain treatment practices (the role of the FSMB will be 
discussed in Section 2.7.2).  The guidelines are not intended to define complete or best 
practice, but rather to communicate what the medical society considers to be within the 
boundaries of professional practice. 
As of January 2004, 22 of the U.S. state medical boards have adopted policies, 
rules, regulations, or statutes reflecting the FSMB model guidelines into their state pain 
management policies (FSMB, 2003).  No information was found that acknowledged the 
Texas Medical Board’s (TMB) endorsement of the guidelines.   
In an April 2005 TMB official newsletter statement, sent out to Texas physicians 
and state medical associations, the TMB formally acknowledged the value of opioids in 
pain management.  In the newsletter, the TMB stated that they “recognized that opioids 
(narcotics) and other scheduled-controlled substances, are indispensable for the treatment 
of pain; and are useful for relieving and controlling many other distressing symptoms that 
patients may suffer” (Texas Medical Board, 2005). The TMB further clarified that “it is 
the position of the Board that these drugs be prescribed for the treatment of these 
symptoms in appropriate and adequate doses after an appropriate diagnosis is made” 













Table 2.11 New Hampshire Medical Society (NHMS) Guidelines for Evaluating the Physician’s 
Treatment of Pain, Including the Use of Controlled Substances 
 
 
1. Evaluation of the Patient 
A medical history and physical examination must be obtained, evaluated, and documented in the medical record. 
Pain intensity, current and past treatments for pain, co-morbidities, physical and psychological functioning, and 
history of substance abuse should be considered. 
 
2. Treatment Plan 
A written treatment plan stating objectives to be used to determine treatment success (i.e., pain relief and 
improved physical and psychosocial function) should indicate if any further diagnostic evaluations or other 
treatments are planned. After treatment begins, the physician should adjust drug therapy to the individual 
medical needs of each patient. Other treatment modalities should be considered. 
 
3. Informed Consent and Agreement for Treatment 
A discussion of the risks and benefits of the use of controlled substances with the patient, family members or 
persons designated by the patient guardian. The patient should receive prescriptions from one physician and one 
pharmacy whenever possible. If the patient is at high risk for medication abuse or has a history of substance 
abuse, the physician should consider the use of a written agreement between physician and patient outlining 
patient responsibilities, including: urine/serum medication levels screening when requested; number and 
frequency of all prescription refills; and reasons for which drug therapy may be discontinued (e.g., violation of 
agreement). 
 
4. Periodic Review 
A periodic review of the course of pain treatment and any new information regarding etiology of the pain or 
patient’s health. Continuation or modification of controlled substances for pain management depends on the 
physician’s evaluation of progress toward treatment objectives. Adherence to treatment and satisfactory response 
to treatment should be considered in future treatment. 
 
5. Consultation 
Referral to a pain specialist for additional evaluation and treatment should be considered in order to achieve 
treatment objectives. Special attention should be given to patients at risk for medication misuse or diversion, 
patients with a history of substance abuse or with a co-morbid psychiatric disorder. 
 
6. Medical Records 
Accurate and complete records to include the medical history and physical examination; diagnostic, therapeutic 
and laboratory results; evaluations and consultations; treatment objectives; discussion of risks and benefits; 
informed consent; treatments; medications (including date, type, dosage and quantity prescribed); instructions 
and agreements; and periodic reviews. Records should remain current and be maintained in an accessible manner 
and readily available for review. 
 
7. Compliance With Controlled Substances Laws and Regulations 
Must be licensed in the state and comply with applicable federal and state regulations to dispense controlled 
substances. Refer to the Physicians Manual of the U.S. Drug Enforcement Administration for specific rules 
governing controlled substances as well as applicable state regulations. 
 
Source:(New Hampshire Medical Society, 1998) 
 
 
Traditionally, health practitioners have been cautious in adopting the treatment 
guidelines that encourage the use of opiate analgesics among patients with moderate to  
severe CNMP.  This prudence is due, in part, to physicians’ knowledge and beliefs 
regarding the use of opioids and lack of a “gold standard” for the clinical practice in 
chronic pain management.  Many pain specialty organizations acknowledge a need for 
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some type of clinically accepted guidelines for CNMP management (American Pain 
Society, 1995; American Academy of Pain Medicine and the American Pain Society  
AAPM&APS, 1997; FSMB, 2003; AMA, 2004).  While different health organizations 
have developed guidelines for opioid therapy in CNMP, the AAPM and the APS 
emphasize that health providers recognize these guidelines as an additional strategy to 
basic principles of good professional practice.   
The therapeutic options used in CNMP management have traditionally been 
focused on a wide array of therapeutic interventions designed to decrease pain and 
simultaneously improve function (Burchman& Pagel, 1995).  Many of the guidelines 
have been developed and promoted by pain practice associations, government health 
agencies, medical organizations and practicing physicians (Canadian Pain Society, 1998; 
American Pain Society, 2000; Ehrlich, 2003; AMA, 2004; Wisconsin Medical Society: 
Task Force on Pain Management, 2004).      
 
 
2.6 Role of Family Physicians 
 Family physicians (FPs) are in a unique position to provide an essential level of 
palliative care to patients unable to achieve adequate pain control.  Guidelines issued by 
JCAHO have increased the FP’s role in managing CNMP.  However, as previously 
discussed, no specific treatment program for CNMP has been endorsed by any of the 
medical guideline-issuing organizations (JCAHO, 2000; National Pharmaceutical 
Council, 2001).  As a result, FPs are often required to select pain guidelines for which 
they are comfortable using.  They are expected to be capable of managing routine chronic 
pain and be able to identify situations for which opioid analgesics are appropriate 
(Marcus, 2002). 
 As the coordinator of care for many CNMP patients, FPs must be able to identify 
those chronic pain conditions (e.g., neuropathic pain, joint pain, lower back pain) that 
require specific therapy.  FPs should be able to identify co-morbid psychiatric illnesses, 
evaluate musculoskeletal abnormalities, evaluate physical disability, and inform patients 
of outcome expectations from therapy (Marcus, 2002).  CNMP management plans 
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implemented by FPs should include treating co-morbid illnesses and disability, with 
consideration of subspecialty referrals for appropriate care and therapy (e.g., psychologic 
or psychiatric care, physical or occupational therapy).     
 Pharmacotherapy recommendations that sanction the use of opioids should be 
contingent on available pain management guidelines and the patient’s compliance with 
the treatment program (Marcus, 2002).  According to pain management experts, FPs 
should be able to understand that the use of CR opioids be considered only in patients 
who have a clear medical diagnosis, disabling pain, no recent or active history of 
medication or alcohol abuse, demonstrated compliance with treatment recommendations, 
and pain that has not responded to initial analgesic or neuropathic medication therapies 
(Portenoy, 1996b; Marcus, 2002, 2003).  A recent AAFP article discussing CNMP 
management in the primary care setting recommends that FPs use CR opioids for patients 
suffering from constant disabling pain (Marcus, 2002). 
 When necessary, FPs may turn to pain specialists or interdisciplinary pain 
management teams to assist them with managing their CNMP patients.  These teams 
usually consist of a physician specializing in pain management (e.g., neurologist, 
anesthesiologist, family physician, internist, physical medicine and rehabilitation 
specialist), a clinical health psychologist, and a physical therapist.  Often, patients whose 
chronic pain is unresolved by family physicians are sent to pain specialists.  Referral to 
pain specialists should be considered when the FP becomes uncomfortable with the 
current treatment protocol or outcome (Jamison et al., 2002).   
 The complexity of CNMP management is a challenge faced by many FPs.  
Successful CNMP management depends on the ability of FPs to understand and utilize 
the fundamental pain management concepts governing the pathophysiology, 
psychodynamics, and diagnostic and therapeutic modalities associated with chronic pain 
syndromes (Bergman& Werblun, 1978).  As previously discussed, the use of analgesics, 
particularly CR opioids, requires frequent patient assessment and a readiness to re-





2.7 Barriers Toward Prescribing CR opioids for CNMP 
 Many health care experts agree that using opiate analgesics should be considered 
the next logical step in the management of CNMP when other nonpharmacologic and 
non-opiate analgesic alternatives have been exhausted.  Despite recently published pain 
management guidelines and evidenced-based studies that recommend the use of “long-
acting” opioid analgesics, many physicians are reluctant to prescribe these types of 
opioids, even when appropriate indications exist (Gardner-Nix, 2003). 
 Obstacles to prescribing CR opioids include inadequate education and training, 
reinforced by concerns of patient addiction, potential for abuse or misuse, side-effects, 
and fear of regulatory scrutiny (Weinstein et al., 2000b; Morley-Forster et al., 2003; 
Gallagher, 2004).  Based on the literature, these barriers extend to both pain specialty and 
non-pain specialty physicians (i.e. primary care physicians).  However, findings from 
several published studies have shown that these barriers can have a greater impact among 
primary care physicians decision-making to use opioids for chronic pain (Morley-Forster 
et al, 2003; Turk, 1996; Turk et al, 1994).  Issues causing physician uncertainty, some 
valid and some based solely on knowledge deficits or misconceptions, may act as barriers 
to appropriate prescribing of CR opioids (Table 2.12).  Experts believe that knowledge 
gaps, fear of patient addiction, deficient pain-assessment skills, fear of regulatory scrutiny 
and timidity in prescribing may lead to “opioid-phobia,” a prejudice against the use of 


















1. Fear of causing addiction; misunderstanding of the definition of addiction 
  
2. Cognitive and psychomotor effects 
  
3. Incomplete resolution of pain 
  
4. Physical dependency and episodic withdrawals 
  
5. Fear of legal/regulatory authorities 
  
6. Fear of attracting addicts to one’s practice 
  
7. Fear of regulatory authorities (e.g., provincial colleges’ restricting licenses) 
  
8. Misunderstanding of lowered efficacy of opioids in treatment of chronic pain 
  
9. Fear of development of tolerance; confusion of tolerance with addiction 
  
10. Additional prescription requirements: Triplicate forms; No refills (schedule-II)  
  
11. Fear of diversion, abuse, and illicit usage 
  
12. Cost of sustained-release opioids 
  
13. Formulary restrictions 
  
14. Lack of knowledge about opioids, in terms of choices, doses, side effects and withdrawal effects 
  
15. Inadequate reimbursement for the care of patients with complex conditions causing chronic pain 
  
Sources: (Gardner-Nix, 2003; Gallagher, 2004) 
 
The next section reviews perceived barriers toward prescribing CR opioids for 
CNMP conditions.  A search of the literature was conducted to examine the knowledge, 
beliefs and attitudes of physicians and other health care professionals toward the use of 
opioids in treating patients with chronic pain.  Information presented will be used to 
better understand physicians’ beliefs toward prescribing CR opioids to CNMP patients. 
 
2.7.1 Fear of Patient Addiction, Physical Dependence and Tolerance 
Although effective in treating many types of chronic pain, CR opioids are often 
used limitedly due to concerns of addiction and abuse and confusion between the 
concepts (terms) of physical dependence, tolerance, and addiction (Turk et al., 1994; 
Turk, 1996; Potter et al., 2001; Gourlay et al., 2004; Clark, 2005).  A 1973 study 
revealed that clinicians practice with a considerable amount of misinformation regarding 
pain management, as well as opioid addiction (Marks& Sachar, 1973).  Results from 
more recent studies continue to demonstrate that physicians may be undereducated in 
these areas (Marks& Sachar, 1973; Von Roenn et al., 1993; Turk et al., 1994; Von 
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Gunten& Von Roenn, 1994; Weinstein et al., 2000b; Gilson& Joranson, 2001; Potter et 
al., 2001).  Lack of knowledge and inconsistent use of these terms can lead to physician 
misunderstanding of the risks associated with using CR opioids for pain.  Consequently, 
patients experiencing moderate to severe CNMP may be under treated and stigmatized 
for their use of this class of opiate analgesics (Gourlay et al., 2004; Von Roenn et al., 
1993).   
Since the clinical implications of physical dependence, tolerance, and addiction 
are managed differently, it is important for physicians to understand standardized 
definitions used to describe the concepts.  A consensus statement developed by the 
American Academy of Pain Medicine (AAPM), American Pain Society (APS), and 
American Society of Addiction Medicine (ASAM) established definitions related to the 
use of opioids (Consensus Document AAPM APS ASAM, 2001). These definitions, are 
described in Table 2.13.  This section will examine some of the more prevalent issues of 
opioid function in relation to physical dependence, addiction, and tolerance and will 
review several studies that examined physicians’ perceptions of the use of opioids and 
their effect on patient physical dependence, tolerance, and addiction. 
 
 
Table 2.13 Definitions Related to the Use of Opioids for the  




A state of adaptation in which exposure to a drug induces changes that result 




A state of adaptation that is manifested by a drug-class-specific withdrawal 
syndrome that can be produced by abrupt cessation, rapid dose reduction, 




A primary, chronic, neurobiological disease characterized by behaviors that 
include one or more of the following: impaired control over drug use, 




A term that has been used to describe patient behaviors that may occur when 
pain is under treated. It can be distinguished from true addiction in that the 
behaviors resolve when pain is effectively treated. 
Source: (Consensus Document AAPM, APS, ASAM, 2001) 
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As with any medication that acts on the nervous system, physical dependence can 
occur and is seen as a state of neuroadaptation characterized by “withdrawal syndrome.”  
This condition is seen as a normal physiologic phenomenon and should not be confused 
with the concept of addiction (Otis& Fudin, 2005).  It is not uncommon for patients on 
prolonged opioid therapy to develop physical dependence.  Physical dependence is often 
seen as a problem when opioid doses are not tapered among patients whose pain resolves 
or if the analgesic is inappropriately withheld (Savage, 1999). 
Patients placed on long-term opioid therapy often develop a tolerance to the 
effects of the analgesic (American Pain Society, 2000).  Tolerance to opioids is a natural 
physiological phenomenon that results in the reduced effect of the analgesic at a 
consistent dosage over time.  The reduced effectiveness of the opioid to relieve pain often 
requires patients to receive an increased dosage regimen or switch to an alternative opioid 
analgesic to produce the desired analgesic effect (Baumann, 2002; Otis& Fudin, 2005).  
Experts recommend patients achieve adequate pain control while receiving consistent 
opioid doses.  Increased pain should be further evaluated for etiology, daily activity, or 
missed doses.  Continued opioid titration is appropriate if no increase in severity of pain 
occurs, however, if analgesia cannot be achieved without significant side effects, then 
rotation to alternative opioids may be considered (Gourlay et al., 2004).   
Addiction is characterized by behaviors that include one or more of the following: 
impaired control over drug use, compulsive use, continued use despite harm, and craving 
(American Pain Society, 2000; Consensus Document AAPM APS ASAM, 2001).  It 
affects genetically predisposed, biologic and psychosocially vulnerable individuals 
(Gourlay et al., 2004).  Addiction can develop from an interaction of the inherent 
reinforcing properties (side-effects) of the opioid drug, such as euphoria, diminished 
perception of negative feelings, and elated psychosocial and physiological experiences 
(Dickinson et al., 2000).  Table 2.14 illustrates some aberrant behaviors associated with 
















Confusion exists among clinicians regarding the risks associated with opioid use 
and addiction.  Factors believed to predispose individual patients are not well understood 
among many health care providers and no proven method has been established for 
screening people at risk of addiction (Glajchen, 2001).  The prevalence of opioid 
addiction among patients with CNMP is not clear although previous research suggests 
that addiction to opioid therapy is relatively uncommon among patients who have no 
previous history of addiction (Urban et al., 1986; Weissman et al., 1991; Turk, 1996; 
Glajchen, 2001; Gilron& Bailey, 2003).  One study documented only four cases of 
addiction out of 11,882 patients who were placed on opioid therapy (Porter& Jick, 1980).  
Another study reported no cases of addiction among the 10,000 patients receiving opioid 
therapy (Perry& Heidrich, 1982).  A more recent survey of opioid use among CNMP 
patients also revealed little risk of addiction among patients who had no history of abuse 
(Portenoy, 1994).  Conversely, results from other studies suggest addiction to opioids as a 
considerable risk, particularly among patients with a history of addictive behaviors.  
Several articles estimate the rate of opioid addiction among these types of patients to be 
between 3.2 and 18.9 percent (Fishbain et al., 1992; Dickinson et al., 2000; Gilron& 
 
 
Table 2.14 Aberrant Drug-Related Behaviors 
 
Behaviors that are less problematic 
• Drug hoarding during periods of reduced symptoms 
• Acquisition of similar drugs from other medical sources 
• Aggressive complaining about the need for higher doses 
• Unapproved use of the drug to treat other symptoms 
• One or two cases of unsanctioned dose escalation 
• Reporting psychic effects not intended by the health care professional 
• Requesting specific drugs 
Behaviors that are more problematic 
• Prescription forgery 
• Concurrent abuse of related illicit drugs 
• Recurrent prescription losses 
• Selling prescription drugs 
• Multiple unsanctioned dose escalations 
• Stealing or borrowing another patient’s drugs 
• Obtaining prescription drugs from nonmedical sources 
 
Source:(Gourlay et al., 2004) 
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Bailey, 2003).  Results from a study examining the use of long-acting opioids for patients 
with severe, refractive chronic-daily headache observed high addictive behavior among 
13 percent of patients (n=7/52) being treated with long-acting CR oxycodone (Robbins& 
Akbarnia, 2000). 
Pseudoaddiction is a more recent term used to describe behaviors that may occur 
when pain is under treated (Weissman& Haddox, 1989).  Pseudoaddiction involves 
patients who seek additional medications appropriately or inappropriately secondary to 
significant under treatment of the pain syndrome (Weissman& Haddox, 1989). Unlike 
addiction, pseudoaddictive behaviors resolve when pain is effectively treated through 
opioids or other means (Gourlay et al., 2004).  This condition occurs among patients who 
become more focused on obtaining medications and appear to be inappropriately drug 
seeking.  Physicians may misinterpret the drug-seeking for pain relief with aberrant drug-
seeking behaviors commonly associated with addicted patients who seek medication for 
nontherapeutic purposes.  Dickson et al. (2000) suggest that physicians should recognize 
CNMP patients who are seeking opioids for inadequate pain relief and understand the 
behavioral changes that can accompany these types of patients (Dickinson et al., 2000).   
As previously discussed, physician understanding of the concepts of physical 
addiction, dependence, and tolerance may affect their willingness to use CR opioids to 
treat moderate to severe CNMP.  Confusion of these terms, such as labeling a CNMP 
patient as an addict instead of physically dependent, can contribute to the ongoing 
confusion in understanding the appropriateness of CR opioids in the treatment of CNMP.  
 
Studies Examining Clinicians’ Views on Addiction, Dependence and Tolerance 
Several studies have shown that physicians’ concerns of addiction, physical 
dependence, and tolerance may act as barriers to prescribing opioids to patients with 
CNMP (Coniam, 1989; Weissman et al., 1991; Turk et al., 1994; Turk, 1996; Weinstein 
et al., 2000a; Potter et al., 2001; Morley-Forster et al., 2003).  Some studies contradict 
this conventional wisdom, showing that physicians have relatively little concern about 
addiction, dependence, and tolerance with regards to prescribing opioids for CNMP 
(Turk& Brody, 1992; Turk et al., 1994). 
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A 1973 study of health practitioners practicing in two New York teaching 
hospitals reported that physicians practiced with a considerable amount of 
misinformation on pain management and had mistaken beliefs about opioid addiction 
(Marks& Sachar, 1973).  A questionnaire of 102 hospital physicians found that 
respondents who exaggerated the dangers of addiction were more likely to prescribe 
lower dosages of meperidine and subsequently under treat their patients’ pain.  To 
determine if patients’ pain was being under treated, investigators interviewed hospital 
inpatients being treated with meperidine and discovered that 32 percent of patients did 
not reach pain “break-through” and over 40 percent of patients continued to be in 
moderate distress (Marks& Sachar, 1973). 
Since the 1973 study, relatively little has changed with regard to physicians’ 
perceptions and concerns about opioid addiction, tolerance, and physical dependence.  In 
a 1991 survey assessing knowledge and beliefs of 90 Wisconsin physicians on 
prescribing opioids for chronic pain, 57 percent of survey respondents indicated concerns 
of patient addiction to the opioids they prescribed.  Only 13 percent of respondents 
indicated concerns of patients’ tolerance to opioids (Weissman et al., 1991).  A 1992 
Joransen et al. survey of 304 medical state board members found respondents 
inaccurately described the concepts of physical dependence and tolerance.  Findings 
revealed that 85 percent of respondents mistakenly described physical dependence as 
addiction and 41 percent described tolerance as addiction (Joranson et al., 1992).    
Another 1994 study of Texas physicians found that 41 percent of respondents believed 
that addiction was a common outcome when prescribing narcotics for chronic pain.  Of 
the 386 respondents surveyed, 28 percent felt that any patient prescribed opioids was at 
significant risk of addiction.  Approximately 40 percent of the physicians indicated that 
they would be extremely concerned about possible patient addiction if a member of their 
family was given an opioid (Weinstein et al., 2000).   
Concerns of addiction, physical dependence, and tolerance are considered a 
barrier to prescribing CR opioids for CNMP among primary care physicians (PCPs).  A 
1997 University of California, San Francisco/Stanford Collaborative Research Network 
(UCSF/CRN) study examined the beliefs of 161 California primary care physicians 
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(Potter et al., 2001).  Based on the responses to three clinical vignettes (i.e., scenarios for 
chronic back-pain, post-herpetic neuralgia, and chronic daily headache) presented in 
Table 2.15, approximately 60 percent of respondents believed that prescribing CR 
opioids to patients with chronic-daily headache would lead to physical dependence. 
Whereas, concern for dependence was lower for chronic back pain at 33 percent, and 
post-herpetic neuralgia at 25 percent.  Under the same vignettes, PCPs reported concern 
about the potential for opioids to cause addiction to chronic-daily headache patients at 74 
percent, chronic back pain at 29 percent, and post-herpetic neuralgia at 17 percent.  A 
similar trend was seen for responses to the potential for opioids to cause tolerance, with 
chronic-daily headache at 49 percent, chronic back pain at 32 percent, and post-herpetic 
neuralgia at 27 percent.  Additional study findings revealed that 35 percent of 
respondents refused to prescribe long-acting morphine on an “around-the-clock” schedule 
for CNMP patients due to concerns of addiction, physical dependence and tolerance.   
 
 
Table 2.15 Results from USCF/CRN Survey of Primary Care Physicians (n=161): 
Frequency (%) Distribution of Respondents Level of Agreement with 
Statements Related To 3 Case Vignettes 
 
Statement  
Case 1:       
Chronic 
Back Pain 
 Case 2: 
Post-herpetic 
Neuralgia 
Case 3:  
Chronic Daily 
Headache 
    
I could realistically encounter this patient in my practice*            96% 96% 96% 
I know how to evaluate and treat this medical condition† 73% 78% 69% 
I feel optimistic about helping this patient† 40% 66% 29% 
I would refer this patient for further evaluation or treatment*  56% 32% 40% 
I would now treat this patient with an opioid*  38% 80% 40% 
I would treat with long- acting opioids if the pain persisted† 28% 58% 20% 
I would be very concerned about the following complications     
if I prescribed this patient opioids‡    
        Addiction 29% 17% 74% 
        Diversion for illegal use 3% 1% 37% 
        Physical dependence 33% 25% 60% 
        Regulatory scrutiny 9% 7% 23% 
        Side effects 15% 20% 14% 
        Tolerance 32% 27% 49% 
    
*These variables were constructed as dichotomous yes/no variables. 
†Variables constructed with a 5-point Likert scale. Percentages reflect physicians who either strongly agree or agree with the statement. 
‡Variables were constructed with a 3-point scale. Respondents were asked to indicate if they were not concerned, somewhat concerned, or 
very concerned. The responses reflect those who were very concerned. 
Source: (Potter et al., 2001) 
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Researchers also reported that respondents were less willing to prescribe more 
potent schedule II opioids for CNMP compared to schedule III opioids.  Of the 161 
physician respondents, 42 percent indicated they would never prescribe CR opioids 
(schedule II) to patients with post-herpetic neuralgia, 57 percent would never prescribe 
them for lower back pain, and 75 percent would never prescribe them for daily headache 
(Potter et al., 2001).   
A 2001 study examining the beliefs of 100 Canadian physicians (70 general 
practitioners and 30 palliative care practitioners) identified the barriers of addiction as an 
obstacle to prescribing strong opioids (Morley-Forster et al., 2003).  Similar to findings 
of the UCSF/CRN study, 35 percent of general practitioners (GPs) indicated that they 
would never use opioids for CNMP, even as a third-line treatment after two previous 
medications had failed.  Further, 40 percent of GP respondents listed addiction as a 
primary obstacle to prescribing long-acting opioids to patients with CNMP.  However, 
only 30 percent of pain specialty physicians (PSPs) cited addiction as an obstacle.  
Thirty-one percent of GPs cited the potential for abuse/misuse as another major barrier 
versus 23 percent of PSPs (Morley-Forster et al., 2003). 
A review of the literature found one published study that used a social cognition 
model to assess the influence of clinician’s attitudes toward opioid use for pain.  Results 
from a 2000 survey of 466 Australian registered nurses’ (RNs) revealed that their 
intention to administer opioids to patients was influenced in part by their negative 
attitudes toward patient addiction (Edwards et al., 2001).  The study used the theory of 
planned behavior (TPB) to predict nurses’ intentions to administer opioids to patients in 
pain (acute and chronic) in the hospital setting.  Using a direct attitude scale, researchers 
found that unfavorable attitudes toward opiate analgesics held among nurse respondents 
caused them to withhold administration of opioids to patients with chronic pain.  Of the 
respondents, 40 percent indicated that patients with a history of addiction should not be 
given opioids for their pain.  Results also showed that only seven percent of respondents 
believed opioids to be addictive and 11 percent were unsure if opioids were addictive or 
not.  Overall, a majority of respondents (88%) believed that it would be undesirable for 
patients to become addicted to opioids (Edwards et al., 2001).   
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2.7.2 Fear of Regulatory Scrutiny 
Concern about regulatory scrutiny is another physician-related barrier believed to 
affect the prescribing of CR opioids to treat CNMP.  Physicians from different  
specialties report that fear of investigation by state medical boards and drug enforcement 
agencies regarding their prescribing of strong opioids (e.g., schedule II) affects the way 
they manage their patients’ pain (Gilson& Joranson, 2001).  Prescribing what may be 
considered by regulators as excessive amounts of opioids or prescribing to the wrong 
type of patient has been shown to negatively influence how physicians handle their 
chronic pain patients (McIntosh, 1991; Fisher, 2004b).  These studies also showed fear of 
disciplinary action, license revocation and criminal prosecution have been further 
heightened by sensational media events which spotlight a small number of investigations 
of physicians charged with excessive prescribing of schedule II and III opioids 
(McIntosh, 1991; Gilson& Joranson, 2001; Fisher, 2004b). 
Studies and discussions by experts have found that a substantial number of 
physicians express concerns regarding potential disciplinary action against them for 
prescribing controlled substances to chronic pain patients (McIntosh, 1991; Weissman et 
al., 1991; Turk& Brody, 1992; Turk et al., 1994; Joranson& Gilson, 1997; Portenoy, 
2000).  Some of these studies have found that physicians’ reluctance to prescribe opioids 
for CNMP has resulted in ineffective pain relief for large groups of patients (American 
Pain Society, 2000).  
 
Brief History of Regulatory Scrutiny of Controlled Substances 
Over the last decade, pain specialists and patient advocacy groups have brought 
increased awareness to doctors regarding the under treatment of chronic pain.  As a 
result, several pain management guidelines (refer to Section 2.5) have been developed to 
assist physicians in using stronger long-acting opioids to treat patients suffering from 
persistent pain.  But as physicians have expanded their use of longer-acting opioids, 
attention to their prescribing practices by regulatory bodies has also increased.  
Regulatory investigation by federal and state agencies have become focused on those 
physicians believed to be prescribing “excessive amounts” of opioids or prescribing to 
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the “wrong type of patient.”  Regulatory agencies are profiling physicians who 
improperly prescribe opioids for the purpose of abuse or profit.  These agencies also 
investigate physicians who are disabled by personal problems with drugs or alcohol, 
possess dated clinical and therapeutic knowledge, or are duped by various fraudulent 
patients (Potter et al., 2004).   
The actual number of physicians who are investigated by regulatory or state board 
agencies is relatively low.  A 2004 Drug Enforcement Administration (DEA) report 
showed that a majority of physicians are compliant with medical prescribing laws and 
appropriately prescribe controlled substances to treat their patients’ medical needs (U.S. 
Drug Enforcement Administration, 2003).  It reported that of the 963,385 physicians 
registered with DEA in 2003, only 557 investigations were conducted on individuals 
suspected of violating controlled substances laws.  Of those physicians investigated, only 
34 physicians were arrested (Table 2.16).   
 
 
Table 2.16 Investigation of, Actions Taken, and Arrests of Physicians 
by the Drug Enforcement Agency (DEA) in 2003 
 
 N 
% of physician 
registrants 
Total number of physician Registrants 963,385 100% 
   
Investigations of physicians in FY 2003* 557 0.06% 
   
Actions taken against physicians in FY 2003* 441 0.05% 
   
Arrests of physicians  in FY 2003* 34 <0.01% 
*partial data year- First three quarters of 2003 
Source: (Drug enforcement Administration. News from DEA. 2004) 
 
Similar data reported by the Federation of State Medical Boards (FSMB) indicate 
that less than 10 percent of medical board sanctions imposed on physicians for 
inappropriate prescribing involved controlled substances (Figure 2.8) (Potter et al., 2004).  
According to the FSMB report, approximately 1 in 20,000 registered physicians were 
sanctioned in the U.S. for inappropriate prescribing of controlled substances.  Most 
physicians who were sanctioned were found to be prescribing opioids far outside the 
scope of legitimate medical practice and were in violation of the law.  Yet, cases exist 
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where physicians have been investigated “simply because a large proportion of pain 
patients in their practice were being prescribed opioids” (Potter et al., 2004).  As a result, 
physicians’ awareness of this increased attention by regulatory and state agencies is 
believed to adversely affect many physicians’ pain management practices (Gilson& 




Federal and State Regulators 
Since CR opioids have a potential for abuse, these schedule II drugs are regulated 
by federal and state controlled substance laws and regulations.  The intent of the 
controlled substance policies are to prevent drug diversion and abuse (Potter et al., 2004). 
Physicians are given authority through federal and state regulatory agencies (i.e., DEA 
and state medical boards) to prescribe and dispense “scheduled” substances as long as it 
 
Figure 2.8 Controlled Substances Prescribing Violations 
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 Source:  Table adapted from Federal State Medical Board, 2004 (Potter et al., 2004) 
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is for legitimate medical purposes and follows good medical practice  (Angarola& 
Joranson, 1992; Potter et al., 2004).   
The Harrison Narcotic Control Act of 1914, as well as the more recent Controlled 
Substances Act of 1970 (CSA) were enacted by the federal government to limit the 
possession and sale of opioids (Brecher, 1972; U.S. Drug Enforcement Administration, 
2005).  In particular, the more recent CSA was designed to limit the manufacturing and 
distribution of narcotics, stimulants, depressants, hallucinogens, anabolic steroids, and 
chemicals used in the illicit production of controlled substances.  According to the CSA, 
all substances regulated under existing law are placed into one of five schedules 
(categories).  These categories are based on the medicinal value, harmfulness, potential 
for abuse, and addiction of the controlled substance.  Schedule I is reserved for the most 
dangerous drugs that are considered to have no recognized medical use while Schedule V 
is designated for the least dangerous drugs (U.S. Drug Enforcement Administration, 
2005).  The most potent analgesics, such as morphine, hydromorphone, oxycodone and 
fentanyl have been placed in a schedule II category.  As a result, CR opioids are 
considered a schedule II drug. 
In a further effort to prevent abuse of CR opioids, many states have imposed 
greater controls over the medical use of schedule II opioids. These controls include 
dosage size limitations and the required use of government-issued prescribing forms 
(duplicate or triplicate prescriptions) (Joranson& Gilson, 1998).  In Texas, the adoption 
of the triplicate prescription system in 1982 required all prescriptions for schedule II 
drugs to be completed in triplicate forms.  Subsequently, an increased use of schedule III 
medications (e.g., hydrocodone and acetaminophen combinations) for pain control 
resulted (Berina et al., 1985).  Many states have enacted policies that limit the amount of 
opioids that can be prescribed or dispensed to a patient.  Further, 11 states require 
consultation in specific circumstances when using opioids to treat patients in pain and 10 
states have policy provisions that mandate opioids as a therapeutic option of last resort 
(Pain & Policy Studies Group, 2004). 
Over the last two decades, considerable advancement has been achieved in state 
policy issues involving pain management.  The adoption of “intractable pain treatment 
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acts” (IPTAs) by state legislatures has focused on improving clinician pain management 
practices by specifically permitting the prescribing of opioid medications for chronic pain 
patients.  The primary intention of these statutes has been to address physician concerns 
of prescribing opioids for the legitimate treatment of chronic pain by providing certain 
immunities from disciplinary action pursued by the state (Potter et al., 2004).  Texas and 
California were two of the first states to pass intractable pain laws in the late 1980s, 
authorizing physicians to prescribe opioids for the treatment of pain (Clark& Sees, 1993; 
Ralston, 1996).   
Today, many of the IPTAs adopted by other states are modeled after the 1989 
Texas IPTA.  To reinforce state pain acts, medical specialty groups and state board 
agencies have come together to endorse the Model Guidelines for the “Use of Controlled 
Substances for the Treatment of Pain” (refer to Section 2.5).  In a monumental move to 
“win the war on pain,” the Federation of State Medical Boards of the United States, Inc., 
(FSMB) published the model guidelines for the “Use of Controlled Substances for the 
Treatment of Pain” (Potter et al., 2004).  These policy guidelines were developed to 
clarify the U.S. state medical board’s position on pain control and acknowledge the 
inadequate management of pain and barriers to appropriate treatment.  Endorsed by 24 
state boards and 21 health organizations, and recognized by the DEA, the model 
guidelines were created to reassure physicians that they would not be “disciplined for 
prescribing opioids to patients with chronic pain if they conform to the standards of ‘good 
clinical practice’ and ‘state pain policies’” (Potter et al., 2004).  The FSMB policy 
emphasized the need for government and physicians to develop a system that prevents 
abuse and diversion of controlled substances while ensuring prescribers wide access for 
legitimate medical use in pain management (Potter et al., 2004).  The positive influence 
of the FSBM guidelines has encouraged state policy makers to recognize the need to 
encourage more appropriate pain management practices (Potter et al., 2004). 
 
Studies Examining Clinicians’ Views on Regulatory Scrutiny 
Even though few physicians have been investigated by the DEA or state board 
agencies, physicians continue to cite fear of regulatory investigation as one of the 
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prominent reasons for not prescribing CR opioids (Fisher, 2004b).  Although available 
research suggests that there is little evidence to support theses concerns (Joranson& 
Gilson, 1996; Gilson& Joranson, 2001; Potter et al., 2001; Potter et al., 2004), results 
from several studies suggest that physicians’ fear of regulatory scrutiny may act as a 
barrier to prescribing opioids to patients with CNMP (Coniam, 1989; Weissman et al., 
1991; Turk et al., 1994; Turk, 1996; Weinstein et al., 2000a, 2000b; Gilson& Joranson, 
2001; Potter et al., 2001; Morley-Forster et al., 2003).  Conversely, a few studies found 
physicians to have relatively low concern about the effects regulatory scrutiny has on 
their prescribing practices (Weissman et al., 1991; Turk et al., 1994).  
Results from the Weissman et al. (1991) survey found that only six percent of 
physician respondents considered regulatory investigation as a primary concern when 
prescribing opioids (Weissman et al., 1991).  Yet, over half of respondents (n=49/90) 
indicated that they altered their prescribing practice because of fear of regulatory 
investigation.  Researchers found that physician respondents generally had poor 
knowledge of controlled substance regulations, which caused them to do one of the 
following: reduce opioid drug dose or quantity, reduce the number of refills, or choose a 
lower dose schedule (Weissman et al., 1991). 
Turk et al.’s 1992 national survey found that more family physicians believed that 
“regulatory pressures” restricted their use of opioids for CNMP compared to respondents 
from other physician specialty groups (Turk et al., 1994).  Though no statistically 
significant differences were found among respondents with respect to geographic region, 
investigators did find that physicians’ responses to the item differed among groups from 
states that had legal statutes requiring multiple prescriptions (triplicates) for schedule II 
drugs.  Triplicate states (e.g., California, Michigan and Texas) and non-multiple 
prescription states (e.g., Washington, Minnesota, and Arizona) were compared.  
Interestingly, study findings indicated that regulatory pressure was seen to have a smaller 
effect in states requiring multiple prescriptions versus those states that do not require it 
(F1,1214=5.42, p<0.003).  ANOVA analyses revealed that physician respondents in 
triplicate states reported a greater frequency of opioid prescriptions compared to those in 
non-multiple prescription states (F 1, 1225=12.04, p<0.001) (Turk et al., 1994). 
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Physician views toward the legality of prescribing opioids for extended periods of 
time appear to have shifted in the last decade.  A 1992 Joransen et al. study found nearly 
half (47%) of respondents believed that prescribing opioids to treat CNMP for extended 
periods of time should be discouraged.  Furthermore, 32 percent of respondents believed  
extended opioid prescribing violated medical practice laws and should be investigated 
(Joranson et al., 1992).  A 1997 follow-up survey to the Joransen et al. (1992) study 
found a substantial change in regulatory beliefs among medical board members in regards 
to prescribing opioids for CNMP (Gilson& Joranson, 2001).  Fewer respondents (40%) 
believed that extended opioid prescribing should be discouraged.  Only 11 percent of 
respondents believed this type of prescribing practice violated medical practice laws and 
should be investigated (Gilson& Joranson, 2001).    
Findings from more recent studies appear to be consistent with the results of 
earlier 1990 studies.  The Weinstein et al. (2000b) survey of Texas physicians found that 
one-fourth of respondents believed that prescribing opioids to patients with chronic pain 
would lead to DEA investigation.  Nearly the same number of respondents (24%) 
believed that if they prescribed a limited supply of pain medications they could avoid 
regulatory investigation.  Approximately 50 percent of respondents believed that too 
many narcotic prescriptions will lead to utilization reviews but, if they followed the same 
prescribing practices as other doctors in their field, they would avoid investigation 
(Weinstein et al., 2000b). 
The 2001 Morley-Forster et al. survey of Canadian physicians (n =100) found that 
17 percent of general practitioners (GPs) indicated regulatory scrutiny as a barrier to 
prescribing long-acting opioids and 24 percent of GPs indicated that they would use 
stronger opioids more frequently if not for the perceived threat of sanctions (Morley-
Forster et al., 2003).  Results from the Ponte and Johnson-Tribino (2005) study found 
that 68 percent (n=126/185) of family physician respondents indicated that regulatory 
scrutiny affected their willingness to prescribe opioids. 
The Potter et al. (2000) study found that 40 percent of physician respondents 
indicated that fear of legal sanctions limited their use of opioids for CNMP.  Results of 
the survey showed that the level of physicians’ concerns of regulatory scrutiny was 
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dependent on the type of CNMP they were treating.  Among the PCPs surveyed, 23 
percent of respondents indicated they would be “very concerned” of regulatory 
investigation if they prescribed opioids for chronic daily headache, however only nine 
percent of the same physicians indicated they would be “very concerned” of regulatory 
scrutiny if prescribing opioids for chronic back pain and only seven percent would be 
very concerned for post-herpetic neuralgia (Potter et al., 2001).   
The emergence of another dilemma has arisen–the under treatment of pain.  
Physicians are now at risk of regulatory scrutiny and successfully being sued for under 
treating patients suffering in pain.  In a 1999 case, the Oregon State Medical Board 
disciplined a physician for failure to adequately treat several of his patients for pain. In 
2003, a California physician was successfully sued for under treating a patient’s pain. 
“These cases reflect a changing attitude toward pain treatment in the U.S.” (Hoffmann& 
Tarzian, 2003).   
 
2.7.3 Illicit Usage 
 Fear of illicit usage (e.g., misuse, abuse and diversion) is another barrier that may 
affect physicians’ prescribing of long-acting opiate analgesics.  Misuse is commonly 
described as any inappropriate use of a pharmaceutical substance that doesn’t meet the 
criteria of addiction.  Individuals that misuse opioids often use the medication for non-
medicinal purposes to get high or to experience the drugs’ euphoric effects (Brookoff, 
2000).  Abusers may use opioids to medicate symptoms that are not pain-related such as 
anxiety, depression, insomnia or adjustment problems (Gourlay et al., 2004).  While 
misuse of CR opioids may lead to addiction, depending on the addictive history of the 
individual, it does not necessarily constitute addiction.  Individuals that abuse drugs often 
exhibit drug seeking behaviors similar to those seen in addicted patients (Savage, 2002).    
 Most opioids have a street value that makes them a lucrative commodity in the 
illicit drug market.  This is particularly true of CR opioids, which have recently emerged 
as a major street drug in the U.S. (Collett, 2001; Roth, 2002).  As previously discussed in 
Section 2.4, abusers have learned that they can destroy the controlled-release mechanisms 
of certain oral forms of long-acting opioids such as CR oxycodone.  Crushing and 
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ingesting or diluting this CR opioid in water and injecting it intravenously allows for the 
full strength of the drug’s effects to be felt immediately by the abuser (Roth, 2002).  This 
has caused CR opioids to be highly sought after by illicit drug users.   
 Prescription opioid abuse is considered a serious and growing problem within the 
U.S.  A 1999 National Household Survey on Drug Abuse (NHSDA) estimated that 1.6 
million people used prescription analgesics for non-medical reasons for the first time 
(Collett, 2001).  This is a substantial increase since 1990 when only 564,000 initiates 
were observed.  The 2000 National Survey on Drug Use and Health (formally called the 
NHSDA) reported that approximately 2 million people in the U.S. aged 12 and older used 
prescription opioids for non-medical reasons (U.S. Department of Health and Human 
Services, 2002; Zacny et al., 2003).  During that same time period, the NHSDA reported 





Figure 2.9 Number of New Users Taking Prescription Pain 



































 The wider availability of opioid medications is believed to contribute to the 
increased illicit trafficking of opioids within the U.S.  Novak et al. (2004) examined data 
from the DEA’s Automation of Reports and Consolidated Orders System (ARCOS) 
database and found a substantial increase in the retail distribution of CR opioids like 
morphine, fentanyl, oxycodone, hydromorphone, and meperidine over the period of 1997 
to 2001 (Novak et al., 2004) (Table 2.17).  
 
 
Table 2.17 Trends in Medical Use of Selected Opiate Analgesics Between 1997 to 2001 
 
Substances 1997 1998 1999 2000 2001 
Percentage change 
from 1997 to 2001 
 
Fentanyl* 74,085 90,618 107,141 --† 186,083   151.18%  (141.32%) 
 (27.76) (33.96) (38.57) --† (66.99)  
 
Morphine* 5,922,872  6,408,322 6,804,935 --† 8,810,700    48.76%  (42.91%) 
 (2,219.66) (2,401.59) (2,450.02) --† (3172.17)  
 
Oxycodone* 4,449,562  6,579,719 9,717,600 15,305,914 19,927,287   347.85% (328.51%) 
 (1667.52) (2,466.82) (3,498.69) (5,510.69) (7,145.55)  
         
    * Values are expressed as grams (grams/100,000 population). 
    † Dash (—) indicates that data are unavailable for this time period. 
    Source:(Novak et al., 2004) 
   
 Though trends in opioid abuse appear to be increasing, the actual level of abuse 
and adverse events relating to CR opioids remain unclear.  A Joranson et al. (2000) study 
found that the trend of increased medical use of opioid analgesics to treat pain between 
1990 to 1996 did not appear to contribute to increases in opioid analgesic abuse (Joranson 
et al., 2000).  From their study, the proportion of opioid abuse compared to the total 
number of reports of all drugs abused decreased from 5.1 percent to 3.8 percent during 
the 1990 to 1996 period.  However, a more recent study conducted by Novak et al. 
(2004), examining abuse of controlled substances between 1997 and 2001, found an 
increase in opioid abuse.  Researchers examined data from the Drug Abuse Warning 
Network (DAWN) database and found an increase in total opioid analgesic abuse, as 
evidenced by the total number of drug mentions (from 5.7% to 8.5%) in their analysis of 
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the DAWN database.  A large percentage of the increase in mentions was attributed to the 
CR opioid oxycodone (Novak et al., 2004).   
 Opioid abuse trends are further substantiated by the 2003 report by the National 
Center on Addiction and Substance Abuse (CASA) at Columbia University.  The report 
found that the largest group of prescription drug abusers in the U.S. were individuals who  
abused prescription opioids, comprising 11.4 million people or 4.9% of the U.S. 
population (Figure 2.10) (National Center on Addiction and Substance Abuse at 
Columbia University, 2003). 
 
 Compared to other illicit drugs, opioid abuse comprised less than 9 percent of 
drugs misused by illicit drug users (alcohol in-combination at 19%; cocaine at 17%; 
marijuana at 10%; and other non-opioid drugs at 45%).  Official statements from the 
National Drug Intelligence Center affirms that “the illegal abuse of these [opioids] types 
of medicinal drugs is the lowest threat among all major drug categories” (National Drug 
Intelligence Center, 2001).  Still, physicians remain cautious when using CR opioids to 
treat CNMP patients for fear of illicit usage.  Physicians are aware that the opioids they 
 
Figure 2.10 Controlled Prescription Drug Abuse 2003: Report of the 
























Source: adapted from  Substance Abuse and Mental Health Services Administration Office of 




prescribe may be abused or diverted by patients.  Thus, many physicians may be hesitant 
in prescribing stronger long-acting opioids to their CNMP patients.   
 
 Studies Examining Clinicians’ views on Illicit Usage 
 Findings from several studies have shown mixed responses among physicians 
regarding patient abuse of opioid analgesics (Gilson& Joranson, 2001; Potter et al., 2001; 
Hoffmann& Tarzian, 2003; Morley-Forster et al., 2003; Ponte& Johnson-Tribino, 2005).  
Results from the 1997 Potter et al. survey found that physicians’ concerns regarding 
illicit opioid use may be influenced by the type of CNMP the patient may experience 
(refer to Section 2.7.1, Table 2.15).  In their study, more physician respondents indicated 
that they were very concerned about opioid diversion among patients who had chronic 
daily headache (37%) compared to those patients who experienced chronic daily back 
pain (3%) or post herpetic neuralgia (1%) (Potter et al., 2001).  When asked about 
prescribing opioids to patients with a previous history of substance abuse, 16 percent of 
respondents indicated that they would never prescribe opioids to a patient with previous 
substance abuse and 42 percent indicated that they would not prescribe opioids to current 
substance abusers (Potter et al., 2001). 
 The 2001 Morley-Forester study of Canadian physicians found that 31 percent of 
general practitioners cited the potential of patient abuse/misuse as being a major obstacle 
to prescribing long-acting opioids (Morley-Forster et al., 2003).  Respondents indicated 
that a major influence in deciding whether to administer opioids to CNMP patients is 
based on their history of abuse.  Similar results were also seen in the Ponte and Johnson-
Tribino study (2005).  The survey of West Virginian family physicians found that 92 
percent of respondents would not administer opioids to patients with a history of 
substance abuse (Ponte& Johnson-Tribino, 2005).   
 State medical regulators had mixed views on the severity of opioid diversion. 
Findings from the 1997 Gilson and Joranson study indicated that state medical regulators 
considered opioid diversion to be a minor or moderate problem (Gilson& Joranson, 
2001).  However, results from the Hoffman and Tarzian (2003) study of 38 state medical 
board directors, indicated that almost 50 percent of respondents felt drug diversion had 
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become worse in their state while 18 percent felt it had stayed the same.  Furthermore, 40 
percent felt that the abuse of oxycodone contributed to the trend of illicit opioid diversion 
(Hoffmann& Tarzian, 2003). 
 
2.7.4 Physician Education  
Another barrier to the appropriate prescribing of CR opioids includes insufficient 
physician education and training in pain management (Otis& Fudin, 2005).  Medical 
educators acknowledge that proper clinical knowledge and positive beliefs toward pain 
therapy and palliative care can be positively influenced through proper education (Von 
Roenn et al., 1993).  However, though educators recognize the need for improved 
training in pain management, it is not seen as a priority in medical programs (Benedetti et 
al., 2001). 
Experts agree that physician barriers that result in ineffective CNMP management 
(e.g., reluctance to prescribing opioids) may originally stem from the low priority pain 
management is given in medical schools and residency programs (Oneschuk et al., 2000; 
Benedetti et al., 2001; Glajchen, 2001).  Traditionally, medical school curricula have 
trained physicians to diagnose and treat disease, which commonly is the cause of most 
pain, rather than treating pain itself (Evans et al., 2003c).  Several studies have suggested 
that physicians’ knowledge about the use of opioids in chronic pain management is 
deficient (Marks& Sachar, 1973; Von Roenn et al., 1993; Turk et al., 1994; Von 
Gunten& Von Roenn, 1994; Turk, 1996; Weinstein et al., 2000a, 2000b; Gilson& 
Joranson, 2001; Potter et al., 2001).   
 
Studies Examining Clinicians Views on Education in Pain Management 
A Vonn Roenn et al. (1993) pain management survey found that 76 percent of 
physicians surveyed (n=682/897) believed that their limited patient-pain assessment skill 
was the single most important barrier to adequate pain management.  As a result, their 
reluctance to prescribe opioids may be due, in part, to their limited training, which was 
cited as the second most important barrier among 61 percent of the respondents.  
Researchers concluded that proper knowledge in the assessment of pain, the management 
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of side effects, and better understanding of opioid analgesics were needed (Von Roenn et 
al., 1993).  Similar findings were reported in the Turk et al. (1994) study where, family 
physicians felt they had received less than satisfactory education in pain management 
during medical school and residency (Turk et al., 1994).  
Evidence of inadequate education as a barrier in pain management is further 
supported in Von Grunten and Von Roenn’s (1994) study.  Results from the 1994 survey 
revealed that 88 percent of physicians reported their medical school education in pain 
management was “fair” or “poor” (Von Gunten& Von Roenn, 1994).  Further, 73 percent 
of respondents rated their residency training in pain management as “fair” to “poor.”  
Consequentially, only half of physicians (51%) rated pain management in their own 
practices as good or very good.  Similar responses were observed in the 2002 West 
Virginia Academy of Family Physicians survey.  Of 185 family physicians surveyed, 60 
percent of respondents believed that their formal medical training did not prepare them to 
effectively manage pain (Ponte& Johnson-Tribino, 2005).   
Physician continuing education (CE) in pain management should be considered a 
key strategy in overcoming many of the previously discussed barriers (Oneschuk et al., 
2000).  In addition to medical school training, post-graduate education activities in pain 
management may serve as a supplemental training tool to enhance physician knowledge 
of opiate analgesics and its role in chronic pain management.  Research suggests that 
physicians are more likely to report having accurate knowledge about pain management 
and opioid analgesics after attending CE courses (Gilson& Joranson, 2001; Gourlay et 
al., 2004; McCarberg, 2004; Potter et al., 2004; Otis& Fudin, 2005).   
Results from the Morley-Forster (2003) study found that most family physician 
respondents believed that improving their knowledge of pain management could improve 
their chronic pain treatment practices.  Over half of respondents (57%) felt that CE 
workshops could lead to better educated physicians in pain management (Morley-Forster 
et al., 2003).  Another study found the use of CE training on controlled substances in pain 
management improved physicians’ knowledge and beliefs toward prescribing opioids in 
CNMP (Gilson& Joranson, 2003).  Respondents who attended CE workshops were more 
likely to view prescribing opioids for CNMP as a lawful and generally acceptable 
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medical practice compared to those who did not attend.  Findings showed that at posttest, 
75 percent of respondents considered extended opioid prescribing to CNMP patients as 
legal and medically acceptable to CNMP patients compared to pretest results of 38 
percent.  The investigators concluded that up-to-date education regarding opioid 
regulatory policies and opioid pain management could positively affect physician beliefs 
and lower barriers affecting adequate pain management practices (Gilson& Joranson, 
2001).   
As previously mentioned, it appears that traditional medical education may not 
provide physicians with the adequate training needed to effectively manage CNMP 
patients.  Insufficient pain management training in core medical school curricula may 
allow for negative physician bias toward opioid use in CNMP.  Primary care physicians 
and other health care providers require up-to-date education on topics addressing 
prevailing treatment options for CNMP.  Also, health practitioners need current education 
to assist them in developing the skills needed to properly evaluate and manage this type 
of chronic pain among at-risk populations.  It is therefore important to examine how post-
graduate medical learning (continuing education) may be used to help physicians 
improve their pain management practices (Sloan et al., 1998). 
 
2.7.5 Other Barriers     
Various types of physician-related barriers may affect the appropriate prescribing 
of CR opioids to treat CNMP patients.  As previously discussed, gaps in physician 
knowledge, negative beliefs toward opioids, inadequate assessment skills, and fear of 
patient addiction have been recognized as critical obstacles to prescribing opioids. 
In addition to those barriers previously discussed, other less-well known 
physician barriers are believed to influence their prescribing of opiate analgesics for 
CNMP (Weinstein et al., 2000b; Weisse et al., 2001; Probst et al., 2002; Tamayo-Sarver 
et al., 2003; Weisse et al., 2003; Goli& Finley, 2005).  These barriers can extend to 
ethnic, racial, gender, and geographic biases which may result in inadequate pain 
assessment.  For example, geographic barriers were observed in the Probst et al. (2002) 
study.  Researchers found that rural patients generally had limited access to primary care 
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physicians properly trained in chronic pain management and knowledgeable in the role of 
opioids in chronic pain therapy (Probst et al., 2002).  Compared to urban family 
physicians, rural family practitioners (who on average see more patients for pain 
conditions) required additional training in chronic pain syndromes to better meet the 
needs of their chronic pain patients.  Similar findings were also observed in the Weinstein 
et al. (2000) study.  In their study, physician respondents practicing in rural areas held 
more negative views toward opioids, were generally less knowledgeable about pain 
management, and held more negative views about pain patients than physicians in larger 
communities (Weinstein et al., 2000). 
 Physician gender may also play a role in willingness to prescribe opioids to 
patients with moderate to severe CNMP.  Several studies have examined treatment 
patterns that suggest “possible differences in the treatment approaches of male and 
female physicians” (Weisse et al., 2001; Weisse et al., 2003; Goli& Finley, 2005).  A 
2001 survey of 111 primary care physicians examined differences in opioid prescribing 
practices between male and female physicians (Weisse et al., 2001).  Results of the study 
showed that the rate and dosage of opioids prescribed to chronic pain patients varied 
between male and female respondents.  In a hypothetical scenario of chronic back pain, 
male physicians indicated that they were more likely to prescribe higher doses of 
hydrocodone to male patients with chronic back pain than to female patients (406mg vs. 
201mg).  Similar findings were observed among female physicians prescribing higher 
doses of hydrocodone to female patients compared to males for the same condition 
during follow-up (327mg vs. 163mg).  Further, male physicians were more likely to 
prescribe refills of hydrocodone than female physicians for patients with recurrent back 
pain.  ANOVA revealed a significant interaction between physician gender and patient 
gender (F1,28=5.50, P =0.03).  Investigators concluded that when treating CNMP, 
differences in opioid prescribing practices may exist when the role of physician gender 
was examined (Weisse et al., 2001). 
Racial, ethnic and socio-economic disparities may also influence physicians’ 
willingness to prescribe CR opioids for certain CNMP conditions.  Several studies have 
found racial and ethnic differences in physicians’ treatment decisions, (Todd et al., 1993; 
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Ng et al., 1996; Cleeland et al., 1997; Bernabei et al., 1998; Bach et al., 1999; Todd et 
al., 2000; Stewart et al., 2003), however, some studies have not (Karpman et al., 1997; 
Tamayo-Sarver et al., 2003).  It remains unclear, what role, if any, race or ethnicity plays 
in opioid treatment decisions.  Equally questionable is the degree of influence socio-
economic status has on physicians’ willingness to prescribe opiate analgesics (van Ryn& 
Burke, 2000).   
Only a handful of studies have shown that physicians prescribe fewer analgesics 
to minorities compared to majority patients despite their similar estimates of pain (Todd 
et al., 1993; Todd et al., 2000; Weisse et al., 2001; Weisse et al., 2003).  Results from the 
Weisse et al. (2001) study revealed that some physicians were predisposed to different 
treatment decisions based on patient race/ethnicity.  Male physicians were willing to 
prescribe higher doses of hydrocodone to white patients for chronic back pain compared 
to black patients (468mg vs. 238mg), while female physicians did the opposite (161mg 
vs. 335mg).  ANOVA revealed a significant interaction between physician gender and 
patient race (F1,85=9.65, P=0.03).  Researchers concluded that gender and racial 
differences may exist and be influenced by the gender and/or racial cues of the patient 
(Weisse et al., 2001). 
 
 
2.8 Summary of Literature Review 
The adequate treatment of moderate to severe CNMP is a considerable challenge 
for both the patient and health care provider.  The intrinsic sensory, emotional and 
behavioral components associated with the etiology and severity of CNMP often makes 
treatment of this type of pain complex.  Various pharmacologic and non-pharmacologic 
options exist to manage patients suffering from moderate to severe CNMP. 
Over the last decade, the use of opioids has gained slow acceptance among 
physicians as an essential component in the management of CNMP when other treatment 
approaches have failed.  Health care experts are beginning to recognize the utility of 
using longer-acting opioids among a particular subpopulation of patients who experience 
unremitting CNMP.  In fact, many of the more recently published pain management 
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guidelines and evidenced-based studies recommend the use of “sustained release” or 
“long-acting” opioids to treat a specific group of patients suffering from moderate to 
severe CNMP (Gardner-Nix, 2003).  However, physicians are reluctant to prescribe CR 
opioids to CNMP patients who may benefit from its long-acting analgesic properties.  
Their reluctance in prescribing CR opioids may result in inadequate pain management.  
Primary care physicians (PCPs) play a critical role in the management of chronic 
pain among a diverse group of patients.  PCPs see more patients than any other specialty 
(U.S. Department of Health and Human Services, 2005).  They are also considered to be 
on the front-line in providing treatment to patients seeking pain relief.  As a result, the 
successful management of CNMP patients is dependent on the ability of PCPs to 
understand and utilize effective pain management therapies, including the use of CR 
opioids.   
Numerous studies have attempted to examine the knowledge and beliefs of 
physicians to better understand the reasoning underlying their treatment behaviors.  
However, little is known about family physicians’ attitudes toward the use of CR opioids 
for patients suffering from moderate to severe CNMP.  This literature review examined 
some of the issues affecting CNMP and the use of CR opioids in pain management.  In 
particular, the chapter examined some of the issues that are believed to cause physicians 
to under treat CNMP patients and some of the more prominent barriers believed to affect 
physicians’ willingness to prescribe CR opioids.  Some of the physician-related barriers 
identified included fear of patient addiction, concerns of opioid abuse, regulatory 
scrutiny, and inadequate education.  Factors causing these barriers may be attributed to 
knowledge deficits or pre-existing beliefs toward opioids or pain.  These factors can lead 
to misconceptions about the role of CR opioids in CNMP.  As a result, these factors may 
act as barriers to the appropriate prescribing of CR opioids for CNMP. 
 Though some studies were found examining primary care physician beliefs 
toward opioid prescribing for CNMP, a need exists to better understand how these 
barriers affect physician beliefs and behavioral intentions.  The next chapter will examine 
the theoretical model that will be used to assess physicians’ willingness to prescribe CR 
opioids for moderate to severe CNMP. 
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CHAPTER 3:  THEORY 
 
3.1 Rationale of Study 
The controversy over the use of controlled-release opioids (CR opioids) to treat 
patients in pain has been extensively discussed in the lay press and scientific literature.  
Empirical evidence has shown CR opioids to be an effective tool in treating patients 
suffering from chronic non-malignant pain (CNMP).  However, the use of CR opioids to 
treat CNMP has not been widely accepted among many practitioners.  In fact, some 
physicians are reluctant or unwilling to prescribe CR opioids to treat CNMP patients, 
even when it is medically appropriate.  Concerns of patient addiction, physical 
dependence, illicit usage, and fear of regulatory scrutiny are some of the factors that may 
affect physicians’ willingness to prescribe CR opioids.  Consequentially, these physician-
related barriers may result in CNMP patients receiving inadequate pain treatment. 
Attitudes toward CR opioids and their role in treating pain may affect physicians’ 
decisions to prescribe this type of opioid for CNMP.  In addition to their own attitudes 
toward prescribing CR opioids, physicians may consider the beliefs of other individuals 
and groups (e.g., patients, colleagues, staff, family, medical boards) in their decision-
making.  Further, the level of control physicians have in their prescribing decisions may 
be influenced by external factors such as formularies, regulatory policies, or utilization 
management strategies.  As a result, it is suspected that these factors play some role in the 
formation of physicians’ intentions (i.e., willingness) to prescribe CR opioids. 
A systematic examination of physicians’ attitudes and their underlying beliefs 
toward prescribing CR opioids for CNMP should be explored.  No known research has 
been conducted that specifically examines physicians’ beliefs, attitudes, or willingness to 
prescribe CR opioids to CNMP patients using a grounded theoretical model.  This study 
will contribute to the literature by providing insight into factors perceived to influence 
physicians’ decision-making in prescribing CR opioids to patients with moderate to 
severe CNMP.   
Several models have been used to better understand the intentions and behaviors 
of health care providers.  Models such as the theory of reasoned action and the theory of 
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planned behavior have been used successfully to predict future behavior.  Such models 
could be applied to this study in order to determine physicians’ intentions (i.e. 
willingness) to prescribe long-acting opioids to CNMP patients. 
 
 
3.2 Theoretical Models to Predict Attitude and Behavior 
 
 History 
 The concept of attitude and its role in explaining behavior first received serious 
attention in the late 1800s.  During this time period, theorists described attitude as a 
“motor concept” or “physical expression of emotion” (Kantowitz, 1997).  Early 
understanding of the attitude concept posited that various mental or motor states of 
preparedness influenced people’s thoughts or actions (Ajzen& Fishbein, 1980).  During 
the early 1900s, researchers began using the attitude concept to explain social behavior 
(Thomas& Znaniecki, 1927).  Theorists viewed attitudes as individual mental processes 
that determine a person’s actual and potential responses.  Theoretical models were 
designed to measure attitudes as a behavioral predisposition that could be used to explain 
human action.  Much of the early attitude research was descriptive in nature and used to 
compare attitudes of different segments of the population across a variety of behaviors 
(e.g., examining attitudes toward prohibition, birth control, voting, race relations and 
consumer buying habits) (Ajzen& Fishbein, 1980).   
 Beginning in the 1930s, researchers began a series of debates on the concept of 
attitude.  Many of the discussions focused on identifying the essential components of 
attitude formation and its relation to behavior.  A general consensus held among theorists 
was that the attitude concept contained an affective (i.e., evaluative) component.  
However, theorists disagreed on whether beliefs (i.e., cognitions) and behaviors should 
be included as part of the attitude concept.  As the debate persisted over the components 
of attitude, investigators continued to construct a variety of instruments to assess attitudes 
across particular domains.  The accuracy and validity of these instruments, however, 
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were questionable and this led to a need to develop a valid and standard technique for 
measuring attitudes (Ajzen& Fishbein, 1980).   
 Thurstone (1931) introduced the use of pyschometric methods to assist 
researchers in their assessment of the attitude-behavior relationship (Ajzen& Fishbein, 
1980).  He developed several different methods to assign scale values to belief statements 
which measured attitude.  These early measurement techniques included the utilization of 
bipolar adjective scales (e.g., favorable—unfavorable) to rate attitude-behavior items.  
Thurstone’s methods enabled researchers to examine belief-based items perceived to be 
related to the attitude object under consideration (Thurstone, 1931).   
 Over the next 30 years, researchers continued to develop various models to 
explain the complex relationship between attitude and behavior.  Additional theories were 
developed to test and explain the direct link between the two concepts.  During this time 
period, attitude-behavior models conceptualized attitudes in the framework of cognition, 
affect, and conation (Ajzen& Fishbein, 1980).  One of the more well-known theoretical 
models developed during the late 1950s was the multicomponent model (Figure 3.1).  
This paradigm was used to explain the attitude concept using three components (1) the 
person’s feelings toward the object, (2) the person’s beliefs about the object, and (3) the 
person’s action tendencies with respect to the object.  Theories, such as this, were used by 
investigators to explain the attitude-behavior relationship and went unchallenged until the 









Source: (Rosenberg et al., 1960) 
Figure 3.1 Multicomponent View of Attitude (Three-component view) 
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 In more recent years, social scientists have shown a growing interest in the 
relationship between attitudes and behavior (Ajzen& Fishbein, 1980).  A re-examination 
of the attitude concept has led to a growing recognition among investigators that a low 
empirical relation may exist between attitude and behavior.  Some investigators have 
concluded that attitudes cannot be used to predict behavior.  Other researchers have 
suggested that certain behaviors are dependent on the situational context in which they 
are observed and are unpredictable from measures of attitude (Ajzen& Fishbein, 1980).   
 Today, general agreement exists among theorists that attitude is only one of many 
factors believed to influence behavior (Ajzen& Fishbein, 1980).  Investigators have 
identified additional variables that may contribute to behavioral outcomes.  Variables 
such as personal beliefs, social norms, behavioral intention, self-efficacy, previous 
experience and demographic characteristics have been linked to behavioral performance 
(Ajzen& Fishbein, 1980).  These variables may be seen as either independent 
contributors to behavior or as moderators of the attitude-behavior relationship.   
 Some of the more recent models that have been developed to explain the attitude-
behavior relationship include Fishbein and Ajzen’s (1975) theory of reasoned action, 
Ajzen’s (1985) theory of planned behavior, and Fazios’ (1986) attitude accessibility 
model.  Each theory attempts to predict behavior using the attitude construct with 
additional predictor variables.  In addition, these theoretical models have drawn a clear 
distinction between an individual’s personal beliefs, attitudes, and intentions with respect 
to behavior (Fishbein& Ajzen, 1975; Ajzen, 1985; Fazio& Williams, 1986).   
 The remainder of this chapter will review two theoretical models: (1) the theory 
of reasoned action and (2) the theory of planned behavior.  Each of the models have been 
widely used in the literature to predict behavior through the assessment of attitudes and 
other variables believed to influence intention and behavior.  A brief overview will be 
provided for each of the theories along with an explanation of methodologies used in 
their assessment.  Relevant research studies using the models will also be examined.  
Finally, the theoretical framework, objectives and hypotheses for this research study will 




3.3 Theory of Reasoned Action (TRA) 
 Introduced by Martin Fishbein in 1967, the theory of reasoned action (TRA) was 
originally developed to understand the relationship between attitudes and behaviors 
(Fishbein, 1967).  According to the theory, human action (behavior) is guided by two 
types of considerations: (1) one’s beliefs about the likely outcomes of a particular 
behavior and the evaluations of those outcomes, and (2) one’s beliefs about the normative 
expectations of others and the motivation to comply with these expectations (Fishbein& 
Ajzen, 1975).   
 The TRA reasons that, when dealing with “rational actors,” most behaviors can be 
predicted and explained almost exclusively by intentional beliefs and attitudes 
(Fishbein& Ajzen, 1975).  Furthermore, the model assumes that most actions (i.e., 
behaviors) of social relevance are under the complete volitional control of the actor and 
their intention to perform (or not perform) a behavior is the immediate determinant of the 
action (Ajzen& Fishbein, 1980).  It is important to note that unlike prior attitude-behavior 
models which attempted to explain the relationship of a person’s attitude toward an 
object, the TRA examines a person’s attitude toward a behavior with respect to that 
object (Montano& Kasprzyk, 2002).  For example, if investigators were interested in 
assessing parents’ attitudes toward administering specific medications (such as statins) to 
their child, instead of assessing attitudes toward these medications, the TRA model would 


























 The TRA is comprised of three constructs: (1) behavioral intention, (2) attitude, 
and (3) subjective norm (Figure 3.2).  According to the model, the direct determinants of 
behavioral intention are the attitude toward performing the behavior of interest and the 
subjective norm associated with the behavior (Montano& Kasprzyk, 2002).  
Subsequently, the direct determinant of behavior is behavioral intention.  Using a 
mathematical approach, the theory examines the relationship of the attitude and 
subjective norm constructs to predict behavioral intention and ultimately behavior.   
 The following sections will discuss each of the constructs and methods used to 
assess the direct and indirect measures of the TRA model (Table 3.1) 
 
 
Figure 3.2 Theory of Reasoned Action  
 

















Table 3.1 Theory of Reasoned Action Constructs and Definitions 
 
Construct Definition Measure 
   
1. Behavioral Intention   
     a. Direct Measure Perceived likelihood of performing the 
behavior 
Bipolar scale; e.g., unlikely-
likely; 
scored –3 to +3 
   
2. Attitude   




   
     b. Indirect Measure   
         - Behavioral Belief Belief that behavioral performance is 
associated with certain attributes or 
outcomes 
 
Unipolar or bipolar scale;  
e.g., unlikely-likely  
scored 1 to 7 or –3 to +3 
         - Evaluation Value attached to a behavioral outcome 
or attribute 
Bipolar scale; e.g., bad-good, 
undesirable-desirable  
scored –3  to +3 
   
3. Subjective Norm   
     a. Direct Measure Belief about whether most people 
approve or disapprove of the behavior 
Semantic differential scales;  
e.g., disagree-agree, likely-
unlikely, would-would not  
   
     b. Indirect Measure   
         - Normative Belief Belief about whether each referent 
approves or disapproves of the behavior
 
Bipolar scale; e.g., likely-
unlikely; approve-disapprove; 
scored –3 to +3  
 
         - Motivation to comply Motivation to do what each referent 
thinks 
Unipolar or bipolar scale;  
e.g., likely-unlikely; 
scored 1 to 7 or –3 to +3 
   




 According to the TRA, attitudes are a function of beliefs (Ajzen& Fishbein, 
1980).  Fishbein and Ajzen (1975) define attitudes as “a learned predisposition to respond 
in a consistently favorable or unfavorable manner with respect to a given object.”  
Generally speaking, an attitude toward a concept is simply a person’s feelings of 
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favorableness or unfavorableness toward the concept (Ajzen& Fishbein, 1980).  For 
example, “a person who believes that performing a specific behavior will lead to mostly 
positive outcomes will hold a favorable attitude toward performing the behavior, while a 
person who believes that performing the behavior will lead to mostly negative outcomes 
will hold an unfavorable attitude” (Ajzen& Fishbein, 1980).   
 The attitude construct has been operationalized as both a global (i.e., direct) and 
belief-based (i.e., indirect) measure (Fishbein& Ajzen, 1975).  Global and belief-based 
measures are alternate ways of measuring the same construct.  Under the TRA, a direct 
measure of attitude is considered to be the strongest predictor of behavioral intention that 
leads to the behavior of interest (Montano& Kasprzyk, 2002).  However, direct measures 
are unable to examine the specific personal beliefs that may lead to attitude formation 
(Fishbein& Ajzen, 1975).  Indirect measures are employed to examine specific salient 
beliefs that may influence attitude formation.  Table 3.1 summarizes the direct and 
indirect measures used for attitude. 
 It is important to demonstrate that indirect measures are strongly associated with 
direct measures, in order to establish confidence that the appropriate behavioral beliefs 
are being measured and that the composite of these beliefs are adequate measures of the 
TRA construct (Montano& Kasprzyk, 2002).  The following sections will discuss each 
type of attitude measure in more detail.   
 
 Direct Measure of Attitudes   
 Under the TRA framework, a direct measure of attitude can be assessed using 
questions each made up of a 5-point or 7-point semantic differential scale (refer back to 
Table 3.1).  Direct attitude may be measured using bipolar adjective scales, such as 
instrumental adjective pairs (e.g., such as, valuable—worthless, and harmful—beneficial) 
or experiential adjective scales (e.g., pleasant—unpleasant, and enjoyable—unenjoyable).  
These bipolar adjective scales may be taken from a list of published adjective scales that 
have been shown to load highly on the evaluative factor, across the concepts and 
populations of interest (Ajzen& Fishbein, 1980; Ajzen, 2002b).   
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 The semantic differential scale is commonly employed to assess attitudes (Ajzen, 
2002b).  Scaling techniques, such as Likert scaling, Thurston scaling, or Osgood scaling 
methods, may be used to obtain a respondent’s direct attitude.  The Osgood semantic 
scale is recognized as the standard measurement tool used to assess attitudes under the 
TRA (Osgood et al., 1957; Fishbein& Ajzen, 1975).  In this context, the Osgood scale 
consists of a set of bipolar evaluative adjective scales typically measured using 5-point or 
7-point scales.   
 To illustrate how it is used, consider a hypothetical scenario in which researchers 
are interested in understanding parents’ attitudes toward administering a statin 
medication on a daily basis to children with hyperlipidemia (high cholesterol).  Direct 
measure items used to assess attitudes could take the following form:  
 
Attitude - Direct measure item 
  
Administering statins on a daily basis to children with hyperlipidemia is 
good: ____: ____: ____: ____: ____: ____: ____:
   (+3)   (+2)   (+1)   ( 0 )    (-1)    (-2)    (-3) 
bad 
harmful: ____: ____: ____: ____: ____: ____: ____:
    (-3)    (-2)    (-1)   ( 0 )   (+1)   (+2)   (+3) 
beneficial 
pleasant: ____: ____: ____: ____: ____: ____: ____:
   (+3)   (+2)   (+1)   ( 0 )    (-1)    (-2)    (-3) 
unpleasant 
 
 Summing the scale-items used in this direct measure of attitude results in a single 
score which represents a person’s general evaluation or overall feeling of “favorableness” 
or “unfavorableness” toward daily administration of statins to hyperlipidemic children. 
 
 Indirect Measures of Attitudes  
 Under the TRA framework, indirect measures of attitude (Ao) are determined by 
two factors: (1) behavioral beliefs (b), and (2) outcome evaluations (e) (Fishbein& Ajzen, 
1975; Ajzen& Fishbein, 1980).  The expectancy-value model uses the equation A= Σ biei 
to calculate an overall belief-based measure for attitude (Ajzen, 1991).   
 The first component, b involves the salient beliefs an individual holds about 
performing the behavior of interest.  Behavioral beliefs are described as “readily 
available beliefs” that a person holds about the behavior of interest.  These salient beliefs 
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may be formed from a person’s direct observation, or acquired indirectly by accepting 
information from outside sources, or self-generated through inference processes (Ajzen& 
Fishbein, 1980).   
 Indirect measure items are developed from data gathered through elicitation 
interviews of the target population.  Like direct attitudinal measures, behavioral beliefs 
are typically measured using a 5-point or 7-point semantic differential scale anchored by 
bipolar adjective pairs (Osgood et al., 1957; Fishbein& Ajzen, 1975).  Behavioral belief 
measures may be assessed using either a unipolar response scale (1 to 7) or bipolar scale 
(-3 to +3) (Ajzen, 1991; Francis, 2004).  An illustration of a behavioral belief question 
using a bipolar response scale is presented as follows:  
 
Attitude - Indirect measure item 
Behavioral belief (b) 
  
Administering statins on a daily basis to children with hyperlipidemia will cause 
muscle pain. 
 
extremely unlikely : ____: ____: ____: ____: ____: ____: ____:
   (-3)    (-2)    (-1)     (0)    (+1)    (+2)   (+3) 
extremely likely 
 
 The second component of the attitude construct, outcome evaluation (e), refers to 
the individual’s evaluation of consequences when performing the specific behavior of 
interest.  Considered affective in nature, outcome evaluation is described as the value 
attached to a behavioral outcome or attribute (Ajzen& Fishbein, 1980).  The concept 
refers to the degree to which a person believes that performing a behavior will result in a 
“positive” or “negative” outcome and the level to which the outcome is “good” or “bad.”  
Similar to assessing behavioral beliefs, outcome evaluation is measured using a 5-point 
or 7-point bipolar response scale.  An example of an outcome evaluative item using a 
bipolar response scale is presented as follows:   
 
Attitude – Indirect measure item  
Outcome evaluation (e) 
 
Children experiencing muscle pain from daily statin use is 
extremely bad : ____: ____: ____: ____: ____: ____: ____:




 Calculating Indirect Measures of Attitudes 
 Using the expectancy-value model, a person’s attitude toward a behavior can be 
predicted by multiplying his/her behavioral beliefs (b) by the evaluation of each 
consequence to the respective behavior (e).  Each of the cross-products are then summed 
to generate an index score (Petty& Cacioppo, 1981).  Table 3.2 illustrates how indirect 
measures would be calculated and interpreted for attitude.   Using the hypothetical statin 
example, a parent was asked to rate the likelihood that daily administration of statins to 
their hyperlipidemic child would result in the following consequences: (1) lowering 
child’s cholesterol; (2) healthier eating habits; and (3) rhabdomyolysis.   
 
 
Table 3.2 Determining Attitude (Ao) from bi and ei 
Consequences of administering statins to 






(bi) x (ei) 
 
1. Lowered cholesterol 
 




2. Healthier eating habits 
 




3. Rhabdomyolysis (i.e., muscle pain)   
 
(+2) x (-3) 
 
= -6 
     +6 
N                . 
AB = Σ eibi  =  + 6 
I=1               . 
 
Because there are 3 items, the possible range of total scores is (3x ±3) x 3 = - 27 to +27  
----------------------------------------------------------------------------------------------------------------------------------- 
AB = Parents’ attitude toward prescribing statins to treat children with hyperlipidemia. 
bi = Parents’ beliefs have about prescribing statins to treat children with hyperlipidemia. 




 Interpreting the results from Table 3.2 shows the respondent believes that by 
administering statins to his/her hyperlipidemic child, lowering cholesterol is extremely 
likely to occur (+3) and would be an extremely desirable outcome (+3).  The second item 
shows the respondent to slightly believe administering statins will result in healthier 
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eating habits (+1) among children and this would be a highly favorable outcome (+3).  
For the third item, the respondent moderately believes (+2) that daily statin use will cause 
muscle pain among children, and he/she feels that this outcome is very undesirable (-3).  
The overall cross product results in a positive attitude score of +6 for the respondent 
(possible score range -27 to +27).  Therefore, the attitude score of the participant reflects 
a slightly positive attitude (i.e., in favor of administering statins on a daily basis to 
hyperlipidemic children).   
 
3.3.2 Subjective Norm 
According to the TRA, the second predictor of behavioral intention is subjective 
norm (refer back to Figure 3.2).  Subjective Norm (SN) is the perceived social pressure to 
engage or not to engage in a specific behavior.  It is described by Ajzen and Fishbein, as 
“a person’s belief that most of his or her important others think he/she should or should 
not perform the behavior in question” (Ajzen& Fishbein, 1980).  The TRA recognizes the 
role social influences play in behavior.  The model implies that when forming SN, an 
individual takes into consideration the normative expectations of other people (e.g., 
peers, family, friends) when considering to engage or not to engage in a specific behavior 
(Ajzen& Fishbein, 1980).   
Similar to the attitude construct, subjective norms are assessed using direct or 
indirect measures (refer back to Table 3.1).  Indirect items are developed from responses 
collected from elicitation interviews of the target population.  SN items are rated using a 
5-point or 7-point semantic differential scale anchored with bipolar adjectives for both 
direct and indirect measures item pairs such as disagree—agree, likely—unlikely, 
should—should not, or not at all—very much.   
 
 Direct measures of Subjective Norm 
Ajzen recommends that several item-questions be formulated to obtain a direct 
measure of subjective norm.  Questions constructed should possess both injunctive and 
descriptive qualities to enhance the variability associated with each item (Ajzen, 2002b).  
Examples of injunctive item measures are as follows:   
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Subjective norm - Direct measure item  
Injunctive quality 
 
Most people who are important to me think that  
I should not : ____: ____: ____: ____: ____: ____: ____:
   (-3)    (-2)    (-1)     (0)    (+1)    (+2)   (+3) 
I should 




Subjective norm - Direct measure item   
Injunctive quality 
 
If my child has high cholesterol, it is expected of me to administer statins on a 
daily basis. 
 
extremely unlikely: ____: ____: ____: ____: ____: ____: ____: 
   (-3)    (-2)    (-1)     (0)    (+1)    (+2)   (+3) 
extremely likely 
 
It should be pointed out that using injunctive items alone may result in low 
variability for the SN direct measure.  This is due, in part, to the likelihood that an 
individual would perceive that important others would have the same (if not identical) 
approval of desirable behaviors and similar disapproval of undesirable ones (Ajzen, 
2002b).  Ajzen recommends that a descriptive quality measure be employed to capture 
descriptive norms (i.e., to determine if important others would perform the behavior in 
question).  Examples of SN direct measure items containing a descriptive quality are:   
 
Subjective norm - Direct measure item  
Descriptive quality 
 
The people in my life whose opinions I value 
would not : ____: ____: ____: ____: ____: ____: ____:
   (-3)    (-2)    (-1)     (0)    (+1)    (+2)   (+3) 
would 
 administer statins on a daily basis to their 
child with hyperlipidemia. 
 
 
Subjective norm - Direct measure item  
Descriptive quality 
 
Most people who are important to me would administer statins to their child 




: ____: ____: ____: ____: ____: ____: ____:
   (-3)    (-2)    (-1)     (0)    (+1)    (+2)   (+3) 
completely true  
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Summing the scale-items used in the direct measure of SN results in a single score 
which represents the level of influence referents have on the individual’s behavior. 
 
 Indirect measures of Subjective Norm 
The indirect measures of the SN construct are determined by two factors: (1) 
normative beliefs (n), and (2) motivation to comply (m). The first component, n, involves 
the individual’s perceptions of salient group norms— that is a person’s expectations that 
important individuals or groups (i.e., referents) endorse his/her performing a specific 
behavior.  The second component, m, measures the degree to which an individual is 
motivated to comply with each of the referents.  The expectancy-value model uses the 
equation SN = Σ nimi to calculate an overall belief-based measure for SN (Ajzen, 1991).   
Methods used to assess normative beliefs and motivation to comply follow a 
similar logic to methods used in measuring behavioral beliefs for attitude (Ajzen, 1991).  
Normative belief measures are assessed using a bipolar rating scale (-3 to +3).  However, 
motivation to comply measures may be assessed using a unipolar (1 to 7) or bipolar 
response scale (-3 to +3)  (Ajzen, 1991; Francis, 2004).  Examples of n and m item-
questions using bipolar rating scales are as follows:   
 
Subjective norm - Indirect measure item 
Normative beliefs (n) 
 
My spouse thinks that  
I  should not : ____: ____: ____: ____: ____: ____: ____:
   (-3)     (-2)    (-1)   ( 0 )   (+1)    (+2)   (+3) 
I should 




Subjective norm – Indirect measure item  
Motivation to comply (m) 
 
Generally speaking, how likely will you do what your spouse thinks  
you should do? 
 
not at all : ____: ____: ____: ____: ____: ____: ____:






 Calculating Subjective Norm 
Table 3.3 illustrates how n and m would be calculated and interpreted for 
subjective norm.  Using the statin scenario, elicitation interviews found that members of 
the target population believed the following referents influenced their decisions to 
administer statins on a daily basis to a child with hyperlipidemia: (1) spouse, (2) mother, 
(3) father, (4) physician, and (5) best friend.  From the table, the respondent rated how 
likely (n) they believed each referent favored the behavior.  The respondent was then 
asked to rate the likelihood that they would comply (m) with the referents’ beliefs.  The 
cross-products of n and m are summed for a total SN score.   
 
Table 3.3 Determining Subjective Norm (SN) from ni and mi 
Referents belief of administering statins to 























3. Father   
 










5. Best friend   
 
(0) X (0) 
 
= 0 
     +8 
N              .     
SN = Σ nimi =  + 8 
i=1             . 
Because there are 5 items, the possible range of total scores is (±3 x 3)x 5 = -45 to +45  
----------------------------------------------------------------------------------------------------------------------------------- 
SN =  Respondent’s subjective norm about administering statins to treat children with hyperlipidemia. 
ni   =  Respondent’s normative beliefs about administering statins to treat children with hyperlipidemia. 
mi  =  Respondent’s motivation to comply with referents’ beliefs. 
 
 
Interpretation of Table 3.3 shows that the respondent believes that it is extremely 
likely (+3) that his/her spouse would approve of him/her administering statins on daily 
basis to children; and the respondent is extremely likely (+3) to comply with what the 
spouse would want him/her to do.  On the other hand, the respondent believes that it is 
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extremely unlikely that his/her father would approve of the behavior (-3) and he/she 
would be somewhat likely to comply (+1) with his/her father.  Similar interpretations can 
be observed for other referents listed in the table. Overall, the respondent shows a slightly 
favorable subjective norm score of +8 (possible range -45 to +45), indicating a weak 
positive social support to administer statins to a hyperlipidemic child. 
 
3.3.3 Behavioral Intention 
Defined by Fishbein and Ajzen, behavioral intention is “a measure of the 
likelihood that a person will engage in a given behavior” (Ajzen& Fishbein, 1980).  
According to the TRA, behavioral intention (intention) is the immediate determinant of 
behavior.  Intention is specified as a person's readiness to perform a given behavior and is 
based on one’s attitude toward the target behavior and subjective norm with respect to the 
target.  The TRA makes the assumption that most actions of social relevance are under 
the volitional control of an individual.  The intention to perform the action of interest is 
seen to be an immediate antecedent of the behavior itself.  Equation 3.1 presents the full 
TRA model relating behavioral intentions to attitudes and subjective norms. Equation 3.2 
presents the short form of the equation.   
 
Equations 3.1  Behavioral Intention Formation 
                                                  N                                N 
                  I = w1 [ Σ biei] + w2  [ Σ nimi] 
                                           i=1                              i=1 
             Equation 3.2 (short form) 
 
                    I = (w1) (AB)  +  (w2) (SN) 
 
I = behavioral intention 
w = weights 
bi   = belief about object's attributes or about    
        act's consequences 
ei  = evaluations of attributes or consequences 
ni = normative beliefs (strength) 
mi = motivation to comply (with the referent) 
 
AB = attitude toward object, issue, etc. 
SN = subjective norm toward the object 
 
Note: i refers to the specific belief number where beliefs are numbered 1 to N 




Direct Measure of Behavioral Intention 
Behavioral intention is assessed using global (direct) measures.  Intention is 
measured using a 5-point or 7-point semantic differential scale.  Measurement scales 
consist of bipolar adjective pairs anchored at –3 and +3.  Bipolar adjective pairs include 
terms such as unlikely—likely, true—untrue, or disagree—agree (Ajzen, 2002b).  
Examples of the intention direct measure items are as follows:   
 
Behavioral Intention - Direct measure item  
 
I intend to administer statins on a daily basis to my child diagnosed with high 
cholesterol. 
 
extremely unlikely: ____: ____: ____: ____: ____: ____: ____: 
   (-3)    (-2)    (-1)     (0)    (+1)    (+2)   (+3) 
extremely likely 
 
Behavioral Intention - Direct measure item  
 
I will try to administer statins on a daily basis to my child diagnosed with high 
cholesterol. 
 
definitely false: ____: ____: ____: ____: ____: ____: ____: 
   (-3)    (-2)    (-1)     (0)    (+1)    (+2)   (+3) 
definitely true  
 
 Calculating Behavioral Intentions 
 Only direct measures are assessed for behavioral intention.  As a result, direct 
measure items for each respondent are summed and averaged to create an index score. 
Regression analyses (calculations illustrated in Equation 3.1 and 3.2) were conducted to 
determine the utility of the theoretical model in explaining physicians’ intentions (i.e., 
willingness).   
 
3.3.4 Studies Using the TRA 
 The TRA has been used in numerous studies to examine a variety of social 
behaviors (Petty& Cacioppo, 1981).  The theory has been used to predict and explain 
numerous health behaviors and intentions including smoking, drinking, contraceptive use, 
mammography screening, use of health care services, exercise, seat belt use, safety 
helmet use, sun protection, breastfeeding, HIV prevention, sexually transmitted disease 
prevention and substance use behaviors (Montano& Kasprzyk, 2002).   
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 Empirical research has established the utility of the TRA in predicting various 
types of behaviors considered to be under volitional control.  A meta-analysis conducted 
by Shepperd et al. (1988) investigated the utility of the TRA and found the model to be 
an overall good predictor of intention and behavior (I-B).  Researchers used 87 studies to 
investigate the I-B relationship and 87 separate studies to examine the attitude, subjective 
norm and intention relationship (Ao+SN-I).  Studies used in the meta-analysis explored 
174 behaviors including voting, exercise, work absenteeism, vaccination, birth control, 
smoking, dating, dieting, alcohol consumption, and prescription drug use.  Based on 
results of their meta-analysis, investigators found a relatively strong correlation of 
R=0.53 (p=0.01) for the I-B relationship and a strong correlation of R=0.66 (p=0.001) for 
Ao+SN-I.  Findings indicated that the 28 percent of the variance in behavior was due to 
intentions and 44 percent of the variance in intentions was owed to Ao+SN.  Though the 
results of the meta-analysis showed support for the TRA, investigators did indicate that 
only 17 studies used the model correctly to examine the I-B relationship and only 10 
studies examined the Ao+SN-I relationship as the model was originally intended.  
Sheppard et al. found that some studies were either measuring goals instead of behaviors 
(e.g., losing 10 pounds vs. taking a diet pill), measuring more than one behavior, 
providing alternative choices to respondents or measuring respondents estimation of 
performing the target behavior (instead of intention).  Nonetheless, the TRA model was 
shown to perform generally well among these studies and investigators demonstrated 
strong support for the predictive utility of the model (Sheppard et al., 1988).   
 A 2002 meta-analysis, conducted by Haggar et al., further supports the efficiency 
of the TRA (Hagger et al., 2002).  Investigators reviewed 72 TRA studies to assess the   
I-B and Ao+SN-I relationships.  Studies reviewed in the meta-analysis involved assessing 
exercise and leisure behaviors.  Using path analysis, relationships between behavior, 
behavioral intentions, attitudes, subjective norms and several other predictor variables 
were explored.  Under the TRA, investigators found intention to be a “good” predictor of 
behavior.  Results showed that intentions significantly predicted behavior (β=0.51, 
p<0.01).  Attitudes were also seen as a significant predictor of intention (β=0.56, p<0.01) 
and subjective norms had a small but significant influence on intentions (β=0.12,p<0.01).  
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Overall, the TRA constructs explained approximately 37 percent of the variance in 
intentions (Ao+SN-I) and 26 percent of the variance in behavior (I-B) (Hagger et al., 
2002).   
 As shown above, a review of the literature found the TRA model to be an 
adequate predictor of various health behaviors under volitional control.  However, 
relatively few studies have used the TRA to examine physician behaviors (Millstein, 
1996; Lambert et al., 1997).   
 
 TRA Physician Studies   
 The Millstein (1996) study found the TRA model to be an adequate predictor of 
physician intentions and behavior.  A pretest-posttest survey of 765 California primary 
care physicians was conducted to examine the utility of the TRA (and theory of planned 
behavior) for predicting physicians’ delivery of preventative services (i.e., educating 
adolescent patients about sexually transmitted diseases).  Two separate surveys were 
administered to participants six months apart.  Pretest data (Time 1) were used to analyze 
the Ao+SN-I relationship and posttest data (Time 2) were used to analyze the I-B 
relationship.  Results for Time 1 data showed that regressing intention on the attitude and 
subjective norm constructs yielded a significant overall model (R=0.39, p<0.0001), 
accounting for 15 percent of the variance in intention.  The TRA model yielded 
significant beta weights for attitudes (β=0.22, p<0.0001) and subjective norms (β=0.28, 
p<0.0001).  Results for Time 2 showed attitude (β=0.26, p<0.0001) and subjective norm 
(β =0.15 p<0.0001) to be significantly associated with subsequent behavior.  Intention 
was also observed to have a significant relationship with behavior (β =0.56, p<0.0001).  
Overall, the TRA model accounted for 27 percent of the variance in behavior (R =0.61, 
p<0.0001).  Study findings also confirmed the importance of social normative beliefs in 
influencing physician behavior.  Millstein concluded that though the TRA was able to 
predict the indirect effects of attitudes and subjective norms on behavior, study findings 
may be applicable only to behaviors that are perceived to be under complete volitional 
control (Millstein, 1996).  As a result, the model may not be appropriate in predicting 
certain behaviors that are not under complete volitional control of the physician. 
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 A study conducted by Lambert et al. (1997) found the TRA to be a poor predictor 
of physician prescribing behavior.  In a cross-sectional study of 25 managed care 
physicians, investigators used the TRA model to examine attitudinal and social normative 
factors believed to influence the prescribing of seven antibiotics listed within a U.S. 
managed care formulary (Lambert et al., 1997).  Results of correlational and multiple 
regression analyses found intention to be significantly associated with attitude and 
subjective norm (p<0.05).  Data showed a significant correlation between direct measures 
of attitude and intention for each of the seven antibiotics (r values ranged from 0.41 to 
0.74, p<0.05).  Direct measures of subjective norm and intention were also significantly 
correlated (r values ranged from 0.53 to 0.88, p<0.01).  However, physician prescribing 
intentions were not significantly correlated with actual antibiotic prescribing behaviors.  
Lambert et al. concluded the Ao+SN-I constructs were poor predictors of actual antibiotic 
prescribing behavior.  It was interesting to note that, similar to the Millstein (1996) study, 
social norms exerted a stronger influence on prescribing intentions than did attitudinal 
considerations for this study.  Investigators posited that physician prescribing behaviors 
were more strongly influenced by what others thought (e.g., managed care, staff) than by 
their own beliefs or attitudes.  Some of the more prominent limitations addressed by 
investigators included small sample size, physicians’ response bias to provide socially 
desirable answers, and the assumption that physicians had complete volitional control in 
prescribing behavior (Lambert et al., 1997). 
 
 Limitations of TRA 
Though the TRA provides a well-defined framework to examine the attitude, 
subjective norm, and behavioral intention constructs, it does have several limitations.  
The following include, but are not limited to, some of the more common limitations of 
the TRA.  The most important limitation is that the TRA can only predict behaviors that 
are under complete volitional control (Ajzen, 1991; Montano& Kasprzyk, 2002).  As a 
result, the model is not appropriate for assessing behaviors that are not under complete 
volitional control of the individual being examined.  Another limitation is that the theory 
is applicable to individuals who are considered “rational actors.” These individuals must 
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be able to cognitively process information and are motivated to act on it (Fishbein& 
Ajzen, 1975).  A third limitation is the model’s reduced predictive ability for cross-
sectional studies.  Applying the model to cross-sectional studies may result in poorer 
prediction of previous behavior, particularly if the respondents’ intentions or beliefs 
change over time (Ajzen& Fishbein, 1980; Montano& Kasprzyk, 2002).  Finally, poorly 
conducted elicitation interviews and selection bias (e.g., focus group participants) may 
result in inadequate identification of underlying outcomes and social influence (i.e., 
referents) which could lead to poorly constructed TRA measures and subsequent 
inadequate behavioral prediction (Montano& Kasprzyk, 2002; Ajzen& Fishbein, 2004).   
Recognizing the limitations of the TRA, specifically the model’s inability to 
confidently predict behaviors that are not under complete volitional control, researchers 
developed the Theory of Planned Behavior (TPB) to assess non-volitional actions 
(Ajzen& Madden, 1986; Ajzen, 1991; Ajzen& Driver, 1992).  Originally developed by 
Ajzen (1985), the revised theory incorporates an additional construct to the model to 
assess the individual’s perceived control over the behavior of interest. The next section 
discusses the TPB and its application in predicting behaviors that are not under complete 
volitional control.   
 
 
3.4 Theory of Planned Behavior (TPB) 
 The Theory of Planned Behavior (TPB) is an extension of the theory of reasoned 
action (Ajzen, 1985).  Developed by Ajzen and colleagues, the TPB attempts to predict 
behaviors over which people do not have complete volitional control (Ajzen& Madden, 
1986; Ajzen, 1991; Ajzen& Driver, 1992).  The theory postulates three conceptually 
independent determinants of behavioral intention (Figure 3.3).  Similar to the TRA 
model, the first two determinants of behavioral intention are attitude (Ao) toward the 
behavior and subjective norm (SN).  The third predictor relates to the degree of perceived 


















The TPB model also posits that PBC may be used to directly predict behavior.  
Ajzen provides two rationales for the direct relationship (Ajzen, 1991).  First, holding 
behavioral intention constant, it is reasoned that efforts used to bring a behavior to a 
successful conclusion will increase as PBC increases.  For example, an individual who is 
more confident in performing a target behavior will be more likely to persevere in 
performing the behavior compared to an individual who doubts his ability.  Second, PBC 
may be used as a substitute measure for actual behavior when individuals who have high 
levels of PBC also successfully perform the behavior of interest (Ajzen, 1991).  The 
following sections will discuss the PBC construct and methods used to assess the direct 
and indirect measures of the TPB model (Table 3.4). 
 


























Table 3.4 Theory of Planned Behavior Constructs and Definitions 
 
Construct Definition Measure 
   
1. Behavioral Intention   
     a. Direct Measure Perceived likelihood of 
performing the behavior 
Bipolar scale; e.g., unlikely-likely; 
scored –3 to +3 
   
2. Attitude   
     a. Direct Measure Overall evaluation of the behavior Semantic differential scales;  
e.g.,good-bad; favorable-unfavorable, 
pleasant-nonpleasant  
   
     b. Indirect Measure   
         - Behavioral Belief Belief that behavioral performance 
is associated with certain 
attributes or outcomes 
 
Unipolar or bipolar scale;  
e.g., unlikely-likely  
scored 1 to 7 or –3 to +3 
         - Evaluation Value attached to a behavioral 
outcome or attribute 
Bipolar scale; e.g., bad-good, 
undesirable-desirable  
scored –3  to +3 
   
3. Subjective Norm   
     a. Direct Measure Belief about whether most people 
approve or disapprove of the 
behavior 
Semantic differential scales;  
e.g., disagree-agree, likely-unlikely, 
would-would not  
   
     b. Indirect Measure   
         - Normative Belief Belief about whether each referent 
approves or disapproves of the 
behavior 
 
Bipolar scale; e.g., likely-unlikely; 
approve-disapprove; 
scored –3 to +3  
 
         - Motivation to comply Motivation to do what each 
referent thinks 
Unipolar or bipolar scale;  
e.g., likely-unlikely; 
scored 1 to 7 or –3 to +3 
4. Perceived Behavioral 
Control 
  
     a. Direct Measure Overall measure of perceived 
control over the behavior 
Semantic differential scales: e.g., up 
to me-not up to me, difficult-easy, 
disagree-agree 
  
   
    b.  Indirect Measure   
         - Control belief Perceived likelihood of occurrence 
of each facilitating or constraining 
condition 
 
Unipolar or bipolar scale; 
e.g., unlikely-likely, difficult-easy;  
scored 1 to 7 or –3 to +3 
         - Perceived power Perceived effect of each condition 
in making behavioral performance  
difficult or easy 
Bipolar scale; e.g., difficult-easy,    
no control-complete control; 
scored -3 to +3 
   
Source: adapted from (Montano& Kasprzyk, 2002; Francis, 2004) 
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3.4.1 Perceived Behavioral Control 
 Ajzen and colleagues describe Perceived Behavioral Control (PBC) as “a person’s 
beliefs as to how easy or difficult the performance of a behavior is likely to be [when] 
beliefs about resources and opportunities may be viewed as underlying perceived 
control”  (Ajzen& Madden, 1986).  PBC was added to the original TRA model in an 
effort to account for those factors considered outside an individual’s control, that may 
influence his/her intention or behavior (Montano& Kasprzyk, 2002).  This extension was 
based on the rationale that a person’s action (behavioral performance) is determined by 
his/her motivation (intention) and ability (behavioral control).  Ajzen argues that “a 
person will expend more effort to perform a behavior when his/her perception of 
behavioral control is high” (Montano& Kasprzyk, 2002).  For example, if a person holds 
strong control beliefs regarding the existence of specific factors that will facilitate a 
specific behavior, then he is considered to have a high level of PBC over the target 
behavior.  On the other hand, if a person holds strong control beliefs about the existence 
of specific factors that will impede his behavior, then he is considered to have a low level 
of PBC over the target behavior (Ajzen, 1991).   
 Under the TPB framework, PBC together with intention may be used to directly 
predict behavior.  Ajzen (1991) argues that an individual who perceives that he/she has 
high control over a specific behavior will expend more effort to perform the action of 
interest.  The rationale for this assumption is that behavioral performance is determined 
jointly by motivation (intention) and ability (behavioral control) (Montano& Kasprzyk, 
2002).   
 The PBC construct is similar to Bandura’s construct of self-efficacy and 
Triandis’s conceptualization of facilitating conditions (Triandis, 1980; Bandura, 1991).  
Ajzen combined the notions of self-efficacy and perceived control to create the PBC 
construct which is considered to be a more suitable predictor of behavior for the TPB 
model (Edwards et al., 2001).   
Perceived behavioral control is operationalized as either a global or belief-based 
measure (Notani, 1998).  Table 3.4 (previous table) provides a summary of direct and 
indirect measures for this construct.  PBC items are constructed from data gathered 
 
100 
through elicitation interviews conducted among the target population.  Both direct and 
indirect PBC items are rated using a 5-point to 7-point bipolar or unipolar scale.  Belief-
based measures are calculated using the expectancy-value model (Ajzen, 1991; Ajzen, 
2002b).   
 
 Direct Measures of Perceived Behavioral Control  
Global measures of PBC are designed to measure an individual’s overall 
confidence in his/her capabilities to carry out the behavior of interest (Ajzen, 2002b).  A 
PBC direct measure generally consists of two to four question-items (Notani, 1998).  
Ajzen suggests using two types of direct measure items: (1) self-efficacy, and (2) 
controllability (Ajzen, 2002b).  First, self-efficacy items are used to measure an 
individual’s perceived level of difficulty in performing the specific behavior.  Bipolar 
adjective items for the scale can include difficult—easy or up to me—not up to me.  
Examples of self-efficacy items are as follows:   
 
Perceived Behavioral Control - Direct measure item  
Self-efficacy 
 
For me to administer statins on a daily basis to my hyperlipidemic child would be 
very difficult : ____: ____: ____: ____: ____: ____: ____:
    (-3)    (-2)    (-1)    (0)    (+1)    (+2)   (+3) 
very easy 
 
Perceived Behavioral Control - Direct measure item  
Self-efficacy 
 
If I wanted to, I could administer statins on a daily basis to my hyperlipidemic 
child.  
 
strongly disagree: ____: ____: ____: ____: ____: ____: ____: 
    (-3)    (-2)    (-1)    (0)    (+1)    (+2)   (+3) 
strongly agree  
 
 
 Second, controllability items are used to assess the level of control a person 
believes he/she has over the target behavior.  This type of global measure examines the 
degree to which an individual believes the performance of the target behavior is up to 
him/her.  The following examples illustrate this type of direct measure items:   
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Perceived Behavioral Control - Direct measure item  
Controllability 
 
How much control do you believe you have over administering statins on daily 
basis to your hyperlipidemic child? 
 
no control : ____: ____: ____: ____: ____: ____: ____:
    (-3)    (-2)    (-1)     (0)   (+1)    (+2)   (+3) 
complete control 
 
Perceived Behavioral Control - Direct measure item  
Controllability 
 
It is mostly up to me whether or not I administer statins on a daily basis to my 
child diagnosed with high cholesterol. 
 
strongly disagree: ____: ____: ____: ____: ____: ____: 
____: 
    (-3)    (-2)    (-1)     (0)   (+1)    (+2)   (+3)
strongly agree  
 
 Ajzen suggests using both self-efficacy and controllability item scales to assess 
direct measure items for PBC.  He further points out that direct measure scales be 
developed so that each set of items used has a high degree of internal consistency (Ajzen, 
2002b).   
 
 Indirect Measures of Perceived Behavioral Control  
The indirect measure of PBC is determined by two variables: (1) control belief (c) 
and (2) perceived power (p).  The first variable, c, is described as a salient belief an 
individual holds concerning the existence of specific factors which may facilitate or 
impede behavioral performance.  The second variable, p, involves the level of perceived 
power (i.e., impact) each factor has on facilitating or impeding the target behavior 
(Montano& Kasprzyk, 2002).  The expectancy-value model uses the equation            
PBC = Σ cp to calculate an overall belief-based measure of perceived behavioral control 
(Ajzen, 1991). 
Similar to procedures used for attitude and subjective norm, control beliefs are 
identified through elicitation interviews.  Once salient control beliefs are identified, 
Ajzen suggests using a 7-point semantic differential scale to measure indirect items 
(Ajzen, 2002b).  Control beliefs and perceived power may be measured using a either 
unipolar (1 to 7) or bipolar (-3 to +3) response scale  (Ajzen, 1991; Francis, 2004).  
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Examples of indirect PBC questions-items are as follows:   
 
Perceived behavioral control - Indirect measure item 
Control belief strength (c) 
 
I expect that my child will be able to swallow his/her statin medication. 
 highly unlikely : ____: ____: ____: ____: ____: ____: ____:
    (-3)   (-2)    (-1)     (0)     (+1)   (+2)   (+3) 
highly likely 
 
Perceived behavioral control - Indirect measure item 
Perceived power (p) 
 
I feel that I have no control/complete control over getting my child to swallow 
his/her statin medication on daily basis  
 
no  control : ____: ____: ____: ____: ____: ____: 
____: 





 Calculating Perceived Behavioral Control 
Table 3.5 illustrates how control beliefs and perceived power would be calculated 
and interpreted for PBC.  Using the statin scenario, three salient control beliefs that are 
believed to affect a parent’s perceived control in administering statins are: (1) the child’s 
inability to swallow a statin pill, (2) access to transportation to pick up medication from 
the pharmacy, and (3) the ability to soothe muscle soreness (i.e., rhabdomyolysis).  The 
respondent will rate the likelihood of encountering each of the factors (c), and the 
level/degree to which they perceived each factor (p) would make it easier or difficult to 











Table 3.5 Perceived Behavioral Control (PBC) from ci and pi 
Perceived control over the daily administration of 









(ci) x (pi) 
 
1. Child’s inability to swallow pills  (-3) x (+2) = -6 
 
2. Access to transportation to pick up medication  
    from pharmacy   




3. Inability to soothe child’s muscle soreness  
    resulting from statin use   
 
(-3) x (+2) 
 
= -6 
    -9 
N         .     
PBC = Σ cipi =  -9 
i=1        . 
Because there are 3 items, the possible range of total scores is (3x ±7) x 3 = - 63 to +63  
----------------------------------------------------------------------------------------------------------------------------------- 
PBC = Respondent’s perceived behavioral control about administering statins to treat children with  
             hyperlipidemia 
ci  =      Respondent’s control beliefs about administering statins to treat children with hyperlipidemia 




Results from Table 3.5 show that the respondent believes that the inability for a 
child to swallow a statin pill would make it extremely difficult (-3) to administer the 
medication.  In addition, the respondent feels he/she would have slight power in getting 
their child to swallow his/her medication (+2) under the this condition.  For the 
transportation item, the respondent believes access to transportation to make it extremely 
easy (+3) to administer statins, however he/she feels they have no power in getting 
transportation (+1) to pick up the child’s medication from the pharmacy.  For the third 
item, the respondent indicates that it is extremely likely (+3) that his/her child encounter 
muscle soreness while taking statins and the respondent believes that they he/she will 
have little power (-2) in relieving the muscle soreness.  The summed cross product for all 
items results in a negative score for PBC (-9).  Therefore, the score of the participant 
reflects a weak level of negative control (i.e., administering statins on a daily basis to a 




3.4.2 Studies Using TPB 
More researchers are using the Theory of Planned Behavior (TPB) to explain a 
variety of behaviors that are considered not under complete volitional control.  Empirical 
research has examined the TPBs utility for non-volitional behaviors such as alcohol and 
caffeine consumption, eating, exercising, gift-giving, health screening, oral hygiene, 
weight loss, shopping, sleeping, taking vitamins, and others (Madden et al., 1992; Notani, 
1998; Armitage& Conner, 2001; Hagger et al., 2002).  Most studies investigating the 
efficacy of the TPB generally examine the perceived behavioral control (PBC) construct.  
A 1992 study conducted by Madden et al. compared the efficiency of the TPB to the 
Theory of Reasoned Action (TRA) (Madden et al., 1992).  They examined 10 different 
types of domestic behaviors (such as, sleeping, shopping, exercising, washing the car, 
talking to friends, doing laundry, consuming caffeine, renting videocassettes, buying 
albums and taking vitamins) among a group of 94 college students.  Results indicted that 
the TPB constructs increased the prediction of behavioral intention from 48 percent for 
the TRA model to 59 percent for the TPB model.  In addition, Madden et al. found the 
TPB to be a better predictor of behavior (R2=0.38) when compared to the TRA (R2=0.28) 
(Madden et al., 1992).   
Other studies investigating the utility of the TPB have found the model to be a 
relatively good predictor of behavioral intention and behavior.  A 1998 meta-analysis 
conducted by Notani (1998) assessed the utility of the TPB, specifically examining the 
PBC construct.  The investigator found the model to be a good predictor of behavioral 
intentions.  In his analysis, Notani reviewed 63 studies using the TPB.  The types of 
studies reviewed included those assessing behaviors such as exercise programs, breast 
self-exams, voting, gift giving, weight loss, alcohol consumption, and others.  Results of 
the meta-analysis found significant correlations between intention and each of the 
constructs: the I-B relationship (R=0.38, p<0.01), the Ao-I relationship (R=0.37, p<0.01), 
the SN-I relationship (R=0.23, p<0.01), and the PBC-I relationship (R=0.16, p<0.01).  
However, results for the PBC-B relationship were somewhat weak (R=0.14,  p<0.10).  
Overall, the TPB model performed well in the prediction of behavioral intentions and 
PBC served as a significant predictor of intention (Notani, 1998).   
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Armitage and Conner’s (2001) meta-analytic review of the TPB found similar 
results.  Their review of 185 studies that used TPB to assess various behaviors found that 
intention and PBC accounted for 27 percent of the variance in behavior and the 
Ao+SN+PBC constructs accounted for 39 percent of the variance in intention.  The PBC-I 
correlation was considered to be strong (r=0.43) and accounted for 6 percent of the 
variance in behavior, when controlling for Ao+SN (Armitage& Conner, 2001).   
Haggar et al. (2002) conducted a meta-analysis comparing the TPB model to the 
TRA model.  Their analysis of 72 studies found the TPB model to be a much better 
predictor of behavioral intention when compared to the TRA.  Results showed that the 
TPB model accounted for 45 percent of the variance in intention compared to the TRA 
which accounted for 37 percent (Hagger et al., 2002).   
The TPB has been found to perform well across a wide range of health-related 
domains (Montano& Kasprzyk, 2002).  Godin and Kok (1996) reviewed the applications 
of the TPB in the domains of health behavior.  The focus of their research was to verify 
the efficiency of the theory in predicting health behaviors.  Researchers reviewed 56 
studies examining patient behaviors which included addiction, driving, eating, health 
screening, eating, exercising, HIV/AIDS and oral hygiene.  Fifty-eight behavioral and 87 
intentional applications were examined for the above mentioned behaviors.  Study 
findings indicated that attitude, subjective norms, and perceived behavioral control 
(Ao+SN+PBC) accounted for an average of 41 percent of the variance in intention.  The 
investigators noted that variance in intention ranged according to the study categories 
(32% for eating disorders to 47% for hygiene behaviors).  Each of the TPB’s constructs 
were seen to be significant components in the prediction of intention.  Attitude and 
perceived behavioral control were observed to account for most of the variance in 
intention among the studies examined.  Further, when added to Ao+SN, the PBC 
accounted for an additional 13 percent of the explained variance in intention.  Subjective 
norms appeared to explain less of the variance in intentions.  The model’s ability to 
predict behavior yielded an average R2 of 0.34.  The investigators concluded that the TPB 
performs well across various health-related behaviors.  However, the efficiency of the 
theory varies among health-related behavior categories (Godin& Kok, 1996). 
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Like the TRA, most of the health-related TPB studies reviewed were focused on 
predicting the intentions and behavior of patients/consumers.  Because of the nature of 
this project, the remainder of the review will be limited to TPB studies examining the 
behaviors of health providers administering care.  The following two categories of TPB 
studies are briefly examined: (1) research studies examining physicians’ intentions-
behaviors and (2) studies assessing health care providers’ intentions to use opioid 
analgesics to treat patients in pain.   
Few studies were found that utilized the TPB to assess physician behavior (Table 
3.6), but all concluded that the TPB was a relevant predictor of behavior among health 
care providers (Nash et al., 1993; Godin& Kok, 1996; Millstein, 1996; Lambert et al., 
1997; Edwards et al., 2001; Walker et al., 2001; Limbert& Lamb, 2002) 
 
Table 3.6 Review of Studies Using the Theory of Planned Behavior to Predict 
Intentions of Healthcare Provider Behaviors 
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β =0.10 β =-0.09 β =0.46*** R2=0.21*** 






sr2=0.22** sr2=0.29** sr2=0.32** R2=0.39** 
Ao-I = Attitudes-Intention, SN-I = Subjective Norms-Intention, PBC-I = Perceived Behavioral Control-Intention, na = not available 
 *p<0.05, **p<0.01, ***p<0.001, ****significant (p value not indicated)  
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TPB Physician Studies 
The Millstein study examined the utility of the TPB and the TRA in assessing 
physicians’ behavioral performance of preventative health service behaviors (Millstein, 
1996).  A prospective study of 765 physicians found the TPB to be a significant predictor 
of counseling behaviors among physicians.  Multiple regression analysis indicated that 
the TPB constructs (Ao+SN+PBC) were significant predictors of intention, yielding an   
R2 of 0.27 (p<0.0001).  The model also yielded significant beta weights for attitudes 
(β=0.11, p<0.0001), subjective norms (β=0.21, p<0.0001), and perceived behavioral 
control (β=0.37, p<0.0001).  The model’s constructs accounted for 27 percent of the 
variance in intention.  An additional regression analysis was conducted to determine 
whether the addition of PBC added to the predictability of behavioral intention.  PBC was 
entered in as a separate, last step.  Results showed the change in R2 to be significant 
(R2=0.12, p<0.001), indicating that PBC improved the predictability of the model.  
Analysis of actual physician behavior found significant effects for subjective norms 
(β=0.19, p<0.0001) and perceived behavioral control (β=0.36, p<0.0001), however 
attitude had a non-significant effect in predicting behavior (β=0.06, p> 0.05).  The TPB 
model accounted for 40 percent of the variance in subsequent behavior.  To assess 
whether PBC had a direct effect on behavior above and beyond its effects through 
intention, PBC was simultaneously regressed onto the three constructs (Ao+SN-I).  The 
beta weight for PBC (β=0.18, p<0.0001) showed it to have a direct effect on behavior.  
Interpretation of the study results indicated that physicians who believed they had more 
control over the situation had greater intentions to provide preventative services.  In all, 
Millstein found the TPB model to account for 27 percent of the variance in intention 
compared to the TRA which predicted 15 percent of variance.  The TPB accounted for 
slightly more variance in behavior (40 percent) compared to the TRA (37 percent).  
Overall, the TPB model was observed to be a better predictor of intentions and behavior 






TPB Prescribing Studies  
Few studies have used Ajzen and Fishbein’s models to understand physicians’ 
prescribing behavior (Walker et al, 2001; Limbert and Lamb,2002).  In a 2001 study, 
Walker and colleagues used the TPB to examine antibiotic prescribing intentions of 
primary care physicians (Walker et al., 2001).  In their cross-sectional study of 126 
general practitioners, researchers investigated the strength of intention to prescribe 
antibiotics.  Results of the study found the TPB predictor variables (Ao+SN+PBC) to 
explain 48 percent of the variance in intention to prescribe.  The most important 
independent predictor variables was direct attitude (β=0.33, p<0.01).  Indirect attitude 
and subjective norm were considered a non-significant predictor of physicians’ 
willingness.  However, control beliefs (β=0.36, p<0.01) were seen to be significant.  
Overall, the investigators concluded that the TPB model was statistically significant 
(F=22.02, p<0.0001) in predicting physicians’ future prescribing intentions.   
 Limbert and Lamb (2002) conducted two TPB studies examining factors that 
influence physicians’ use of guidelines (both studies were published in the same article).  
The first TPB study examined the intentions of 223 junior physicians to use guidelines 
for the management of acute asthma in the emergency room.  Multiple regression 
analysis revealed subjective norm to be the strongest predictor of intentions (Attitude, 
β=0.15; SN, β=0.58; PBC, β =0.17; no p values given).  Results showed that the TPB 
model explained 58 percent of the variance in physicians’ intention scores.  Subjective 
norm was found to share a considerable amount of variance with attitude (r=0.48, 
p<0.001).  It is important to note that investigators modified the attitude variable to 
include three items (individuality, evidence, and useful) to assess physician behavior.  
Since they did not use “traditional” attitude questions for the asthma study measure, the 
construct may have been assessed incorrectly (Limbert& Lamb, 2002).  Limbert and 
Lamb’s second study examined the intentions of a more senior group of physicians.  
Investigators surveyed 214 surgeons to assess their intentions to follow antibiotic 
prescribing guidelines.  Unlike the previous study, attitudinal item-measures used for this 
study adhered more closely to “traditional” TPB measures.  Findings showed the model 
predicted 52 percent of physician intentions to adopt the clinical guidelines.  Attitude was 
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found to be a better predictor of intention in this particular study (Attitude, β=0.64; SN, 
β=0.11; PBC, β=0.10, no p values given).  Investigators further analyzed this study using 
the “non-traditional” attitudinal measures (evidence, individuality, and useful).  Results 
showed subjective norm as the strongest predictor for intention. Attitude and perceived 
behavioral control also accounted for a substantial amount of variance (Attitude, β=0.25; 
SN, β =0.38; PBC, β=0.23; no p values given).  Investigators concluded that the results 
from each study model provided support for the use of the TPB to explain physician 
behavior.  Findings from both studies appear to suggest that intentions among junior 
physicians to use guidelines are influenced to a greater extent by subjective norm and 
perceived behavioral control, while intentions of more senior physicians seem to be more 
greatly influenced by attitudes.  This could be a function of physician experience 
(Limbert& Lamb, 2002).  The authors pointed out that the differences between the two 
studies suggest that different factors are relevant to decision making with regards to the 
different guidelines (Limbert& Lamb, 2002).   
 
 TPB Pain Management Studies 
 The TPB has been used in studies to assess health providers’ intentions and 
behaviors toward pain management.  A Nash et al. (1993) study found nurses’ intentions 
to conduct pain assessment was predicted by attitude, subjective norm, and perceived 
behavioral control.  Their study of 100 Australian nurses found the TPB model to account 
for 21 percent of the variance in behavioral intention.  Results showed attitude and 
subjective norm to be non-significant within the model (Attitude, β=0.10; SN, β=-0.09).  
However, perceived behavioral control made a large and significant contribution to the 
prediction of intention (PBC, β=0.46, p<0.001).  Results for this study are questionable.  
Investigators pointed out several methodological issues regarding this research study.  
First, the small sample size limited the power of the study.  More importantly, the nursing 
population who identified the relevant behavioral and normative beliefs was different 
from that of the main sample.  These and other limitations may have affected results of 
the attitude and subjective norm constructs (which contributed relatively little to the 
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model).  However, investigators indicated that the perceived behavioral control findings 
were consistent with results found in previous TPB studies (Nash et al., 1993). 
During this literature search, only one published study was found using the TPB 
to examine health care providers’ intentions to use opioids to treat patients’ pain.  
Edwards et al. (2001) used the TPB to examine nurses’ intentions to administer opioids 
for pain relief.  In their cross-sectional study of 446 hospital nurses, researchers 
investigated the behavioral intention to administer opiate analgesics as needed (p.r.n.) to 
patients in pain.  Multiple regression yielded a significant R of 0.63 (F4,441=708, p<0.01).  
Direct attitude, indirect belief-based attitude, subjective norms, and direct control 
variables were observed as significant independent contributors to intention (Direct 
attitude, sr2=0.22; Indirect attitude, sr2=0.13; SN, sr2=0.29; PBC, sr2=0.32, p<0.01).  
Overall, 39 percent of the variability in nurses’ intention was predicted by the model.  
Results showed nurses to have an overall positive attitude towards opioids and their use 
in pain management.  Social norm appeared to play an important role in their decisions to 
administer opioids (i.e., nurses were influenced by patients, medical staff, and 
colleagues).  Perceived control in opioid administration p.r.n. was strong among nurses.  
Edwards et al. concluded that their model supported the TPB’s ability to predict nurses’ 
intentions, however, they expressed a need to further explore the unexplained factors 
affecting the remaining 60 percent of variation in intention scores (Edwards et al., 2001).   
 
Limitations of TPB  
Overall the TPB provides a well-defined framework to examine behaviors that are 
not under complete volitional control.  The TPB has been shown to be a useful model in 
predicting intentions from attitude, subjective norm and perceived behavioral control. 
However, like the TRA, it does have several limitations that should be addressed (refer to 
Limitations of TRA Section 3.3.4).  Some of these limitations include the following: (1) 
the model is applicable only to individuals who are considered “rational actors,” (2) the 
model has reduced predictive ability for cross-sectional studies, (3) poorly conducted 
elicitation interviews may result in inadequate identification of salient belief items, and 
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(4) the model is designed specifically to predict behavioral intentions which is assumed 
to lead to actual behavior  (Montano& Kasprzyk, 2002; Ajzen& Fishbein, 2004).   
Studies have shown the TPB to significantly contribute to the prediction of health 
care professionals’ (e.g., physicians, nurses) intentions to deliver health-related services 
to patients/consumers.  The model has been useful in better understanding health 
providers prescribing and pain management behaviors.  As a result, the TPB model may 
be useful for predicting physicians’ intentions (willingness) to provide pain management 
services to patients/consumers. Additional studies should be conducted to further 
examine the decision-making process among physicians to better predict health-related 
intentions and behaviors. 
 
 
3.5 Theoretical Framework 
 In order to examine family physicians’ willingness to prescribe CR opioids to 
patients with moderate to severe CNMP, a theoretical model was designed to predict 
willingness.  As previously discussed, the TRA and TPB are two models that have been 
used extensively to explain and predict health-related intentions and behaviors.  Due to 
the nature of the proposed study, the TPB will be used as the social cognitive model.  The 
models’ ability to assess behaviors that may not be under the complete volitional control 
of the physician makes this an appropriate model for assessing physician intentions (and 
behaviors).  The addition of the PBC construct to the attitude and subjective norm 
constructs may allow the model to better assess intention and behavior.  Therefore, the 
TPB was used to predict family physicians’ willingness to prescribe CR opioids to 
patients with moderate to severe CNMP.  
 The term “willingness” was used in place of “intention” for the study model.  The 
concept of intention involves a level of planning and commitment to engage in a 
particular behavior.  Similar to the intention construct, willingness can be used to assess 
behavior through the use of predictor variables found under Ajzen and Fishbein’s 
theoretical model.  However, unlike intention, the willingness component is described as 
concerning a relative lack of planning or premeditation (Gibbons& Gerrard, 1995; 
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Gibbons et al., 1998).  For example, willingness questions are interested in “what are you 
willing to do?” which is not the same as “what are you planning to do?”  The primary 
distinction involves the reactive rather than deliberative nature of willingness.  The 
willingness variable has been used in studies that involve assessing risk-like behaviors.  
Some of these studies include behaviors such as smoking, drinking, reckless driving and 
contraception (Gibbons& Gerrard, 1995).  The willingness measure has been applied to 
assess behavioral intentions of health providers.  For example, it has been used in a study 
examining clinical psychology students’ willingness to interact with patients with 
HIV(Berger& O'Brien, 1998).  More recently, it has been used to assess pharmacists’ 
willingness to dispense syringes to known or suspected intravenous drug users 
(Mashburn, 2004). The controversies surrounding both the legitimate and illegitimate use 
of opioids may make willingness a more suitable measure than intention.  Therefore, 
willingness may be a more appropriate measure for this study.   
 The recent past behavior variable was added to the model.  Past experience with 
the behavior of interest is considered to provide important information in regards to 
future behavior (Ajzen,1991).  Furthermore, prior behavior has been shown to add to the 
predictability of the TPB (Millstein, 1996; Walker et al., 2001).  In Walker et al.’s study, 
inclusion of the past prescribing behavior variable (β =0.58, p<0.01) to the TPB model 
significantly improved the proportion of the variance explained in physicians’ intentions 
to prescribe antibiotics to 63 percent (R2 change =0.15, F change=45.57, p<0.0001).  
Similar effects were seen in the Millstein (1996) study where by adding physicians’ 
previous counseling behavior to the TPB increased the amount of variance predicted by 
the model to 42 percent (R2 change=0.05, p<0.001).   
 A continuing medical education (CME) variable was also added to the model.  
Researchers have found that CME training in pain management improved physicians’ 
knowledge and beliefs toward prescribing opioids for CNMP (Morley-Forster et al., 
2003).  Further, similar studies have shown that physicians receiving up-to-date 
education on opioids in pain management could hold more positive beliefs toward using 
CR opioids when treating patients with chronic pain (Gilson& Joranson, 2001; Gourlay et 
al., 2004; McCarberg, 2004; Potter et al., 2004; Otis& Fudin, 2005).  It is therefore 
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important to examine the relationship between physician continuing education in pain 
management and the TPB model.  
 Geographic location was examined in this study.  Practice location may provide 
important information in regards to physicians’ attitudes, perceived behavioral control, 
and willingness toward CR opioids.  Studies have found that physician respondents 
practicing in rural areas generally hold more negative views toward opioids compared to 
physicians in larger communities (Weinstein et al., 2000).  Further, compared to urban 
family physicians, rural family practitioners were less knowledgeable about pain 
management (Probst et al., 2002).  Therefore, it is important to examine the relationship 







































 Figure 3.4 illustrates the model for the proposed study.  According to the model, 
family physicians would be more willing to prescribe CR opioids to patients with 
moderate to severe CNMP if they held favorable attitudes toward the target behavior.  
Further, physicians should be willing to prescribe CR opioids to CNMP patients if 
favorable subjective norms are present, supporting the behavior of interest.  Third, the 
model illustrates that physicians’ willingness to prescribe will increase with higher levels 
of perceived behavioral control over prescribing CR opioids.  Fourth, recent past 
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behavior (previous prescribing behavior) is also expected to directly affect willingness to 
prescribe CR opioids.  Finally, continuing education is expected to have a positive 
relationship with attitudes and willingness.   
 
 
3.6 Objectives and Hypotheses 
 The purpose of this study was to achieve a better understanding of why physicians 
are willing or not willing to prescribe controlled-release (CR) opioids to patients 
diagnosed with moderate to severe chronic non-malignant pain (CNMP).  A social 
cognitive model, the Theory of Planned Behavior (TPB), was be used to achieve a better 
understanding of this health-related willingness formation.   
 A review of the literature has shown that individuals who hold favorable attitudes 
toward a specific behavior, who are strongly influenced by supportive social norms and 
who have high perceived behavioral control over the behavior are more likely to form 
intentions (i.e., be willing) to perform the target behavior.  The following objectives and 
hypotheses (Hi) were examined using the TPB model.  Objectives and hypotheses were 
discussed in more detail in Chapter 4, Methodology. 
 
Objective 1:  To explore the utility of the TPB constructs (attitude, subjective norm, 
perceived behavioral control) and the predictive strength of each TPB 
component in predicting family physicians’ willingness to prescribe CR 
opioids to treat patients with moderate to severe CNMP. 
 
H1:  Attitude, subjective norm, and perceived behavioral control constructs will 
explain a significant amount of variance in physicians’ willingness to 
prescribe CR opioids to patients with moderate to severe CNMP. 
  
H2: Favorable attitudes will be a positive and significant predictor of 
willingness to prescribe CR opioids to patients with moderate to severe 
CNMP, while controlling for subjective norm and perceived behavioral 
control.  
 
H3: Social norms supporting the prescribing of CR opioids to patients with 
moderate to severe CNMP will be a positive and significant predictor of 
willingness to prescribe, while controlling for attitudes and perceived 




H4: Strong perceptions of behavioral control will be a positive and significant 
predictor of willingness to prescribe CR opioids to patients with moderate 
to severe CNMP, when controlling for attitude and subjective norm. 
 
Objective 2: To determine if the perceived behavioral control construct adds to the 
prediction of family physicians’ willingness to prescribe CR opioids to 
patients with moderate to severe CNMP beyond the attitude and subjective 
norm constructs. 
 
H5:  The perceived behavioral control construct will significantly increase the 
explanatory power of the regression model compared to only using 
attitude and subjective norm to explain family physicians’ willingness to 
prescribe CR opioids to patients with moderate to severe CNMP. 
 
Objective 3:  To determine if the recent past behavior (RPB) construct adds to the 
prediction of family physicians’ willingness to prescribe CR opioids to 
patients with moderate to severe CNMP (beyond the TPB constructs). 
 
H6: The recent past behavior construct will significantly increase the 
explanatory power of the regression model compared to only using the 
TPB constructs to explain physicians’ willingness to prescribe CR opioids 
to treat moderate to severe CNMP patients. 
 
Objective 4:  To determine if family physician willingness and attitude toward 
prescribing CR opioids to patients with moderate to severe CNMP differs 
by the level of exposure to continuing education (CE) in pain 
management. 
 
H7: Physicians who have received CE in pain management will be more 
willing to prescribe CR opioids to moderate to severe CNMP patients 
versus physicians who have not received CE. 
 
H8: Physicians who have received CE in pain management will have more 
favorable attitudes toward prescribing CR opioids to patients with 
moderate to severe CNMP versus physicians who have not received CE. 
 
Objective 5:  To determine if family physicians’ attitude, subjective norm, or perceived 
behavioral control toward prescribing CR opioids to patients with 
moderate to severe CNMP differs by geography. 
 
H9: Family physicians who practice in suburban areas will have a significantly 
more favorable attitude toward prescribing CR opioids to patients with 
moderate to severe CNMP versus family physicians who practice in rural 




H10: Family physicians who practice in suburban areas will have significantly 
more favorable social norms supporting the prescribing CR opioids to 
patients with moderate to severe CNMP versus family physicians who 
practice in rural or urban areas. 
 
H11: Family physicians who practice in suburban areas will have a significantly 
stronger perception of behavioral control in prescribing CR opioids to 
patients with moderate to severe CNMP versus family physicians who 
practice in rural or urban areas. 
 
Objective 6:  To determine if family physicians’ attitude, subjective norm, or perceived 
behavioral control toward prescribing CR opioids to patients with 
moderate to severe CNMP differs by physician demographics and practice 
characteristics. 
 
H12: There is no difference in physicians’ attitudes toward prescribing CR 
opioids to moderate to severe CNMP patients between male and female 
physicians. 
  
H13: There is no difference in physicians’ subjective norm when prescribing 
CR opioids to moderate to severe CNMP patients between male and 
female physicians. 
 
H14: There is no difference in physicians’ perceived behavioral control over 
prescribing CR opioids to moderate to severe CNMP patients between 
male and female physicians, controlling for 
 
H15: There is no difference in physicians’ attitudes toward prescribing CR 
opioids to moderate to severe CNMP patients and years of experience. 
 
H16: There is no difference in physicians’ subjective norm when prescribing 
CR opioids to moderate to severe CNMP patients and years of experience. 
 
H17: There is no difference in physicians’ perceived behavioral control over 
prescribing CR opioids to moderate to severe CNMP patients and years of 
experience. 
  
H18: There is no difference in physicians’ attitudes toward prescribing CR 
opioids to moderate to severe CNMP patients and physician ethnicity. 
 
H19: There is no difference in physicians’ subjective norm when prescribing 




H20: There is no difference in physicians’ perceived behavioral control over 
prescribing CR opioids to moderate to severe CNMP patients and 
physician ethnicity. 
  
H21: There is no difference in physicians’ attitudes toward prescribing CR 
opioids to moderate to severe CNMP patients and type of practice. 
 
H22: There is no difference in physicians’ subjective norm when prescribing 
CR opioids to moderate to severe CNMP patients and type of practice. 
 
H23: There is no difference in physicians’ perceived behavioral control over 





 In summary, the TPB has been established in the literature as a useful predictor of 
behavioral intentions.  The theory is a well-developed and tested behavioral model that 
has been successfully used to predict a variety of health-related behaviors.  The attitude, 
subjective norm, and perceived behavioral control constructs are useful in predicting 
behaviors not under complete volitional control.  More recently, studies have 
demonstrated that the TPB model is not only useful in predicting behaviors among 
patients/consumers but also among health care providers.  Furthermore, the model has 
been shown to predict the treatment intentions of nurses and physicians.  The TPB model 
may be useful for predicting physicians’ willingness to provide pain management 
services, particularly in the use of controlled substances for the treatment of persistent 
non-life threatening pain.  This research project recognizes the utility of the TPB in 
predicting the health-related intentions and behaviors of health care providers.  Therefore, 
the model was used to further examine the decision-making process of physicians 
regarding their willingness to prescribe CR opioids to patients with CNMP. 
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CHAPTER 4:  METHODOLOGY 
 
 This study was designed to examine family physicians’ (FPs) willingness to 
prescribe controlled-release opioids (CR opioids) to patients experiencing moderate to 
severe chronic non-malignant pain (CNMP).  As mentioned in Chapter 3, the Theory of 
Planned Behavior (TPB) was used to examine the predictors (attitude, subjective norm, 
and perceived behavioral control) of willingness to prescribe.  Recent past behavior 
(RPB), continuing education (CE), and physician demographic/practice characteristic 
variables were also examined.  This chapter outlines the research methodology that was 
used to conduct the study.  The chapter is divided into five major sections: (1) Study 
Design, (2) Instrument Development, (3) Instrument Distribution, (4) Data Collection, 
and (5) Data Analyses. 
 
 
4.1 Study Design 
 A cross-sectional non-experimental survey design was employed for this study.  
Based on the exploratory nature of this research, the study design falls under the “ex post 
facto” or correlational research design (Polit& Hungler, 1995).  The study used a self-
report web-survey data collection instrument (i.e., electronic questionnaire) to measure 
factors that may influence physicians’ willingness to prescribe CR opioids for patients 
with CNMP.  The electronic questionnaire instrument was used to capture physician 
responses. 
 
4.1.1 Group Selection 
 The study population selected for this research study were FPs actively practicing 
in Texas.  FPs were chosen because of their level of exposure in treating diverse patient 
populations seeking medical care for CNMP (refer back to Chapter 2, Section 2.6).   
 The population utilized in this study included all members of the Texas Academy 
of Family Physicians (TAFP) actively practicing in Texas (2006 calendar year).  TAFP 
members were chosen based on the following reasons: (1) the TAFP membership 
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represents approximately 5,354 of the 7,009 registered family physicians practicing in the 
state of Texas (Texas Medical Board, 2006); (2) researchers had access to FP focus 
groups through the TAFP organization; (3) researchers had access to the study 
population’s e-mail listing to send electronic questionnaires; and (4) budget constraints 
required a cost-efficient mode of administering surveys to the target group. 
 
4.1.2 Inclusion and Exclusion Criteria 
Inclusion Criteria 
 Participants eligible for this study were “active TAFP members.”  The study 
population was comprised of male and female FPs of various backgrounds and 
experience levels.  It was assumed that FP participants were knowledgeable in the uses 
of CR opioids to treat pain, had attained prescribing privileges through the Texas 
Department of Public Safety and had a controlled substances license granted to them by 
the Drug Enforcement Agency.  The 2006 TAFP membership database served as the 
study population data source. 
  
The inclusion criteria for this study were as follows: 
1. Active member of the TAFP currently practicing in the state of Texas; 
 
2. Texas medical board (TMB) certified family physician (or licensed physician 
actively seeking board certification); 
 
3. Valid e-mail address listed in the TAFP membership database; 
 
4. Physician with access to a computer that has the required web-browser 
software to complete the electronic questionnaire; and 
 
5. Access to the Internet. 
 
 Exclusion Criteria 
 As stated previously, the purpose of this study was to measure predictors of 
family physicians’ willingness (intention) to prescribe CR opioids to patients with 
CNMP.  Since physicians who were not actively practicing were unlikely to be exposed 
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to current pain management barriers (discussed in chapters 1, 2, and 3), they were 
ineligible to participate in this study.  Additionally, TAFP members not licensed by the 
TMB or not actively seeking licensure were excluded from the study.  Exclusion of these 
individuals enhances the generalizabilty of study findings to only family physicians 
practicing in Texas.   
 
4.1.3 Target Population 
 The target population for this study was all actively practicing Texas family 
physicians.  The accessible population for this study was TAFP members with e-mail 
addresses in the TAFP database.  Researchers had access to the entire TAFP membership 
e-mail listing.  As a result, the sampling frame for this study included all TAFP members 
who conformed to the designated inclusion criteria.   
 
4.1.4 IRB Procedures 
 This research study followed survey procedures as outlined by The University of 
Texas Institutional Review Board (IRB).  The project was approved by the University of 
Texas at Austin’s IRB. 
 
 
4.2 Instrument Development 
 The survey instrument was developed to measure the following Theory of 
Planned Behavior constructs: attitude (Ao), subjective norm (SN), and perceived 
behavioral control (PBC).  Recent past behavior (RPB), continuing education (CE) and 
physician demographics/ practice characteristics were also assessed.  The instrument was 
developed from information gathered from the literature and through elicitation 
interviews (focus groups).  A pretest of the instrument was conducted among a 






4.2.1 Focus Groups 
 The purpose of conducting the focus group (i.e., elicitation) interviews was to 
identify relevant behavioral belief items, referents perceived to influence physician’s 
willingness , and control beliefs.  Following the recommendations of Fishbein and Ajzen 
(1980), three focus group interviews were conducted in 2005 among a total of 15 family 
physicians.  Participants were asked to respond to three general categories of questions, 
as they related to the TPB.  First, participants were asked to describe the perceived 
advantages and disadvantages of prescribing CR opioids to patients with CNMP.  
Second, participants were asked to identify and describe any important individuals or 
groups (referents) that may influence their prescribing behavior. For example, 
participants were asked to list referents that are either in favor or opposed to physicians 
prescribing CR opioids to patients with CNMP.  Third, physicians described their control 
beliefs over prescribing CR opioids.  Identified salient beliefs and related data gathered 
from the three focus groups were used to develop the questionnaire items for the pretest.   
 
 Physician Focus Group Procedure 
 The TAFP membership coordinator was contacted to assist in planning and 
implementing a recruitment strategy of volunteer family physician participants.  A list of 
names and e-mail addresses were obtained of TAFP members actively serving on a TAFP 
committee who may be willing to participate in the focus groups.  An e-mail invitation 
was sent to TAFP committee members to participate in focus groups conducted during 
either of the two TAFP conferences held in 2005.  Researchers attempted to recruit 10 
volunteers for each interview session via e-mail in an effort to meet the minimum 
recommended focus group size.  Focus group volunteers were contacted twice via e-mail 
to remind them of the time, date and location of their respective focus group meetings.  
The first contact was one week before the scheduled focus group meeting date and the 
second contact was two days before the meeting. 
 Prior to conducting the focus groups, an interview guide was developed to help 
focus and guide the discussions (Appendix A).  Focus group questions were created from 
criteria developed by Ajzen and Fishbien (Ajzen& Fishbein, 1980; Ajzen, 1991). 
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 Three focus groups were conducted to collect data on behavioral, normative, and 
control beliefs, held among TAFP physicians about the use of CR opioids for moderate to 
severe CNMP.  Responses were gathered in the form of open-ended elicitation 
interviews.  The first focus group took place in Austin, Texas.  This focus group was 
comprised of three family physician volunteers who were attending a TAFP conference.    
The second focus group took place on day two of the conference and was comprised of 
six family physicians.  The third focus group was also comprised of six family physician 
volunteers who were attending a different TAFP conference in San Antonio, Texas.   
 For this research study, each focus group lasted one to two hours and asked 
physicians to elicit responses on the following salient belief item questions: 
 
Behavioral beliefs 
1. Identify the perceived advantages associated with family physicians prescribing 
CR opioids to treat patients with moderate to severe CNMP. 
 
2. Identify the perceived disadvantages associated with family physicians 
prescribing CR opioids to treat patients with moderate to severe CNMP. 
 
3. Identify other perceived advantages or disadvantages associated with family 
physicians prescribing CR opioids to treat patients with moderate to severe 
CNMP. 
 
Normative beliefs (referents) 
4. Identify individuals or groups who would approve of family physicians 
prescribing CR opioids to treat patients with moderate to severe CNMP. 
 
5. Identify individuals or groups who would not approve of family physicians 
prescribing CR opioids to treat patients with moderate to severe CNMP. 
 
6. Identify other individuals or groups who would or would not approve of family 








7. Identify perceived factors that would make it easier for family physicians to 
prescribe CR opioids to treat patients with moderate to severe CNMP. 
 
8. Identify perceived factors that would make it difficult for family physicians to 
prescribe CR opioids to treat patients with moderate to severe CNMP. 
 
9. Identify other perceived factors that would make it easier or more difficult for 
family physicians to prescribe CR opioids to treat patients with moderate to 
severe CNMP. 
 
 As recommend by Ajzen and Fishbein (1980), a minimum of five to nine of the 
most frequently mentioned outcomes (salient beliefs) discussed during the elicitation 
interviews were used to construct the survey instrument.  The results section will discuss 
modal beliefs elicited during the focus group sessions and describe techniques used in 
selecting salient beliefs for each of the constructs. 
 
 
4.2.2 Study Variables 
 This section describes the independent and dependent variables that were used for 
this study.  The following TPB constructs were examined: (1) Attitudes, (2) Subjective 
Norms, (3) Perceived Behavioral Control, and (4) Behavioral Intention (i.e.,Willingness).  
Information about the Recent Past Behavior, continuing education, and other 
demographic variables were also be collected and examined.  Figure 4.1 is the conceptual 




























 Independent Variables  
 According to Fishbein and Ajzen (1980), the most important determinant of 
behavior is behavioral intention (willingness).  As seen in Figure 4.1, under the TPB 
model, the direct determinants of the physician’s willingness to prescribe CR opioids are 
 
Figure 4.1 The Conceptual Model: Using TPB to Predict Physicians’ Willingness to 
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his/her attitude toward the behavior, the subjective norm associated with the behavior, 
and the perceived behavioral control over the behavior of interest.  Recent past behavior 
was also included in the model as a direct predictor of willingness.  The details of each 
predictor variable are described below.  
    
 Attitude 
 Attitude (Ao), as defined by Fishbein and Ajzen (1975) is “a learned 
predisposition to respond in a consistently favorable or unfavorable manner with respect 
to a given object.”  As previously discussed in Chapter 3, attitude can be determined 
through the assessment of a person’s beliefs about performing the behavior of interest, 
weighted by an evaluation of the outcomes or attributes of performing the behavior of 
interest.  Attitude can either be a positive or negative evaluation toward performing a 
behavior.   
 For this study, Ao was operationalized as the beliefs and perceived likelihood of 
outcomes relative to the use of CR opioids to treat patients with moderate to severe 
CNMP.  Ao was assessed through direct and indirect measurement scales.  The direct 
measure of attitude was assessed using a single multi-item question asking respondents 
their overall evaluation of the behavior of interest.  This direct measure utilized a 
semantic differential scale (e.g., good–bad).  Indirect measures of attitude were assessed 
by measuring the two variables of the Ao construct: behavioral beliefs (b) and outcome 
evaluation (e).  For this study, b measured physicians’ salient beliefs about prescribing 
CR opioids to patients with moderate to severe CNMP and e measured the evaluation of 
outcomes associated with the behavior.  Indirect measures were assessed using two sets 
of questions, each using a bipolar scale (e.g., unlikely–likely; good–bad).  The utilization 
of each of the measurement scales was important to this study, for two reasons.  First, 
under the TPB framework, direct measures are more strongly associated with intention 
and behavior than are indirect measures (Montano& Kasprzyk, 2002).  As a result, it was 
important to demonstrate the association between direct attitudes and intention before 
conducting analyses on indirect measures.  Second, it was necessary to demonstrate that 
indirect measures are strongly associated with direct measures, in order to show 
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confidence that the appropriate physician beliefs are being measured (refer to Chapter 3, 
Section 3.3.1).   
 As previously mentioned in the Focus Group Section 4.2.1, the independent 
variables used for each of these constructs were determined from data collected from the 
three focus group interviews conducted.  Physicians’ behavioral beliefs, b, and outcome 
evaluations, e, were determined from the responses gathered during focus group 
interviews.  Once the b and e were identified, variable items were incorporated into the 
questionnaire to measure indirect physician attitudes. 
 As recommended by Ajzen (2002), both direct and indirect measurement scales 
were used in the questionnaire to assess physician attitudes.  The questionnaire contains a 
multi-item direct measure attitude question.  Direct attitude was measured using a 7-point 
bipolar semantic differential scale containing evaluative terms (adjectives) such as: 
extremely bad (-3)/ extremely good (+3) (Osgood et al., 1957).  Direct attitude questions 
were asked in the following manner: 
 
Q: “I feel that prescribing long-acting opiates to patients with moderate to 
severe  CNMP is…” [5 adjective items] (Survey Q4) 
 
 
 Indirect (belief-based) measure items were developed from information gathered 
from focus group interviews.  An “attitude toward CR opioids scale” was constructed 
using the most salient behavioral belief items reported among focus group participants.  
The scale was designed to evaluate each of the identified beliefs.  Each b was rated using 
a bipolar 7-point semantic differential scale ranging from extremely unlikely (-3) to 
extremely likely (+3).  Behavioral belief questions were asked in the following manner:  
 
Q:  “How likely do you think the following outcomes will occur if you 
prescribe long-acting opiates to patients with moderate to severe CNMP?” 





 Similar to assessing behavioral beliefs, the e scale was designed to measure each 
of the evaluative outcomes and attributes associated with the respective behavioral belief.  
Each e was rated using a bipolar 7-point semantic differential scale, ranging from 
extremely bad (-3) to extremely good (+3).  Evaluative outcome questions were asked in 
the following manner:  
 
Q: “Even though you may not agree with the outcomes listed, how good or 
bad do you feel each of the following outcomes would be if you 
prescribed long-acting opiates to treat patients with moderate to severe 
CNMP?” [10 outcome evaluation items] (Survey Q3) 
 
 
 Calculating attitude belief items 
 As discussed in Chapter 3, attitudes toward prescribing CR opioids to treat CNMP 
patients were determined by multiplying the respondents’ belief-strength toward using 
CR opioids by the evaluative outcomes (b x e) and then summed for the total set of belief 




 For example, if a physician believes that it is somewhat unlikely (-2) that his/her 
prescribing CR opioids for CNMP leads to patient addiction and believes addiction would 
be extremely undesirable (-3), then the cross-product for the belief for that respondent is 
+6. (possible range -9 to +9)  Hence, the physician’s view that it is unlikely that 
 
Equation 1. Attitude Formation 
(based on expectancy-value model) 
 
Ao = Σ biei 
 
         Ao = attitude toward object, issue, etc. 
          bi =  behavioral belief about object’s    
                  attributes or  about the act’s consequences
          ei =  evaluations of attributes or consequences
 
         Source: (Ajzen and Fishbein, 1975) 
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prescribing CR opioids leads to addiction among his/her CNMP patients would positively 
influence his/her attitude score (i.e., contribute to an unfavorable attitude toward 
prescribing CR opioids for CNMP).  Refer to Chapter 3, section 3.3.1 for a review of 
calculating the attitude construct. 
 
 Subjective Norm 
 Subjective norm (SN), as defined by Ajzen and Fishbein, is “a person’s belief that 
most of his or her important others think he/she should or should not perform the 
behavior in question” (1980).  The SN construct is based on an individual’s expectations 
that important referents (i.e., groups or individuals) endorse his/her performing a specific 
behavior and evaluates the level of an individual’s motivation to comply with each of the 
referents (Ajzen, 1991).  For this study, SN was operationalized as the influence “others” 
may have on physicians’ willingness to prescribe CR opioids to treat patients with 
moderate to severe CNMP.   
 Similar to attitudes, SN was assessed through direct and indirect measurement 
scales.  The items used for the SN construct were developed from responses collected 
during the three focus group interviews.  The survey instrument contained a single-item 
direct measure question to assess subjective norm.  The direct measure SN question was 
measured using Osgood’s bipolar 7-point semantic differential scale ranging from 
strongly disagree (-3) to strongly agree (+3) and asked the following:  
 
Q: “If I prescribe long-acting opioids to treat patients with moderate to severe 




 Indirect (belief-based) measures of SN were assessed by measuring two variables: 
normative beliefs (n) and an individual’s motivation to comply (m) with each of the 
referents of interest.  Normative belief is an individual’s belief of what other referents 
think he/she should do in a particular circumstance.  Salient referents were determined by 
data gathered from focus group interviews.   
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 Normative beliefs were measured using a bipolar 7-point semantic differential 
scale which ranged from extremely unlikely (-3) to extremely likely (+3).  Normative 
belief questions were asked in the following manner:  
 
Q: “How likely is that each of the following individuals or groups would 
think that you should prescribe long-acting opioids to treat patients with 
moderate to severe CNMP?”  [7 normative belief items] (Survey Q5) 
 
 
 Motivation to comply (m) is an individual’s belief that he/she will do what 
referent groups or individuals think he/she should do.  Similar to procedures used to 
assess normative beliefs, motivation to comply was measured by asking a series of 
question-items to determine how likely the individual would comply with the wishes of 
others.  Motivation to comply was measured using a bipolar 7-point semantic differential 
scale ranging from extremely unlikely (-3) to extremely likely (+3).  Motivation to 
comply questions were asked in the following manner:  
 
Q: “Generally speaking, how likely are you to do what the following 
individuals or groups want you to do when it comes to prescribing long-
acting opioids to treat patients with moderate to severe CNMP?”   
 [7 motivation to comply items] (Survey Q6) 
 
 
 Calculating normative belief items 
 Subjective norms were determined by multiplying the products of the 
respondents’ normative beliefs by the corresponding motivation to comply (n x m) and 






 For example, if a physician respondent indicated that his/her colleagues would be 
extremely likely (+3) to think that they should prescribe CR opioids to patients with 
moderate to severe CNMP and the respondent is extremely likely (+3) to comply with 
his/her colleagues wishes, then the cross-product for the SN for that respondent is +9 
(possible range -9 to +9).  Hence, the cross-product would indicate that the respondent’s 
colleagues positively influence the physician’s SN score (i.e., are supportive of him/her 
prescribing CR opioids for CNMP).  Refer to Chapter 3, Section 3.3.2 for a detailed 
overview on calculating the SN construct. 
 
Perceived Behavioral Control 
 The third construct that was assessed is perceived behavioral control (PBC).  As 
defined by Ajzen, PBC refers “to an individual’s perception of the ease or difficulty of 
performing the behavior of interest” (Ajzen, 1991).     
 For this study, PBC was operationalized as the perceived ease or difficulty for 
physicians to prescribe CR opioids to patients with moderate to severe CNMP.   
 Similar to attitude and subjective norm, the direct and indirect measure item-
scales were utilized.  The direct measure question-items asked physician respondents to 
rate their overall perceived control over prescribing CR opioids to treat moderate to 
severe CNMP patients.  The survey instrument contained two single-item direct measure 
questions to assess PBC.  The PBC questions were measured using a bipolar 7-point 
Equation 2. Subjective Norm Formation 
(based on expectancy-value model) 
 
 
SN = Σ nimi 
 
        SN = Subjective norm toward the object 
          ni = normative beliefs (strength) 
         mi = motivation to comply (w/ the referent) 
 




semantic differential scale ranging from strongly disagree (-3) to strongly agree (+3) and 
asked the following:  
 
Q: “It is easy for me to prescribe CR opioids to treat patients with moderate 
to severe CNMP.” [1-item] (Survey Q10) 
 
Q: “I have complete control over whether or not I will prescribe CR opioids 
to treat patients with moderate to severe CNMP.” [1-item] (Survey Q11) 
 
 
 Indirect (belief-based) measures of PBC were assessed by measuring the 
variables: control beliefs (c) and perceived power (p).  To determine c and p items, focus 
group participants were asked to identify and describe factors (i.e., situations) that would 
make it easier or more difficult for them to prescribe CR opioids to CNMP patients.  
Responses collected were used to develop control belief and perceived power statements 
in the survey instrument.   
 Control beliefs (c) were measured using an indirect measurement scale.  To 
determine c, respondents were asked to assess how much a specific factor would increase 
or decrease the difficulty of him/her performing the behavior of interest (i.e., prescribing 
CR opioids to patients with moderate to severe CNMP).  Control belief questions were 
measured using a bipolar 7-point semantic differential scale ranging from extremely 
difficult (-3) to extremely easy (+3).  Control beliefs were measured by asking the 
following question items: 
 
Q: “Will the following factors make it easier or more difficult for me to 
prescribe CR opioids to treat patients with moderate to severe CNMP?” 
[10 control-belief items] (Survey Q8) 
 
 
 Perceived power (p) was measured utilizing an indirect scale question.  To 
determine p, respondents were asked to respond to a multi-item question using a unipolar 
7-point scale ranging from no control (+1) to complete control (+7).  Perceived power 
questions determined how much control the respondents believed they had in a particular 
 
133 
circumstance as it relates to the behavior of interest.  Perceived power was measured by 
asking the following question:   
 
Q: “How much control do you feel you have over the following when it 
comes to prescribing CR opioids to patients with moderate to severe 
CNMP?” [10 perceived power items]  (Survey Q9) 
 
 
Calculating control beliefs 
 The indirect measures of PBC were determined by multiplying the cross-products 
of the respondent’s control beliefs and perceived power (c x p).  The cross-products were 




 For example, having “access to pain management tools” was identified as one 
factor believed to affect a physician’s perceived control over prescribing CR opioids to 
patients with CNMP.  If a physician respondent believes (c) that having access pain 
management tools will make it somewhat easier (+2) to prescribe CR opioids to CNMP 
patients and he/she believes that they will have some control (p) in accessing pain tools 
(+4), then the mathematical cross-product for PBC is +8 (possible range -21 to +21).  The 
score of the respondent indicates that, when considering access pain management tools, 
Equation 3. Perceived Behavioral Control 
(based on expectancy-value model) 
 
PBC = Σ cipi 
 
PBC =  Perceived behavioral control 
ci      =  Control beliefs toward the factor under 
             consideration 
pi      =  Perceived power of the control factor 
             under consideration 
 
Source: (Ajzen, 1991) 
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he/she feels they have a moderate level of positive control over prescribing CR opioids to 
CNMP patients,   
  
 Recent Past Behavior   
 One factor that was not originally included in the TPB model is recent past 
behavior (RPB).  Studies have shown past behavior to be the best predictor of future 
behavior (Ajzen, 2002; Rhodes& Courneya, 2003).  This study included the variable for 
RPB construct into the TPB framework.  Two questions were used to measure recent past 
behavior.  The first RPB question assessed physicians previous prescribing behavior 
using a 7-point scale ranging from never (+1) to always (+7).  The following question 
was used to measure RPB: 
 
Q: “How often did you prescribe long-acting opioids to patients with 
moderate to severe CNMP in the last month?” [1-item] (Survey Q12) 
 
 
The second RPB question assessed previous prescribing behavior using a 5-point Likert 
scale ranging from never (+1) to always (+5).  The following question was used to 
measure RPB by assessing the percentage of CNMP patients receiving CR opioids.  This 
measure of RPB question was assessed by the following question: 
 
Q: “How often do you prescribe long-acting opioids to patients with moderate 
to severe CNMP in the last month?”[1-item] (Survey Q20) 
 
 
Continuing Medical Education 
 Respondents were asked five questions regarding their continuing medical 
education (CME) in pain management.  The first question assessed if respondents 
received CME in pain management in the last three years dichotomous (yes/no).  The 
second question asked respondents if they believed they had access to CME courses in 
pain management (using a bipolar 7-point scale ranging from strongly disagree (-3) to 
strongly easy (+3)). The third question inquired if they plan to attend any CME programs 
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in pain management (using a bipolar 7-point scale ranging from very unlikely (-3) to very 
likely (+3)). The fourth question asked the likelihood of the respondent to attend a CME 
activity sponsored by TAFP (bipolar 7-point scale ranging from very unlikely (-3) to very 
likely (+3)).  The fifth question asked the type of venue the respondent would prefer to 
receive CME in pain management (e.g., live, monograph, internet). 
 
Demographic/Practice Characteristics 
 The following demographic and physician practice variables were collected (for 
actual questions refer to survey instrument in Appendix D): 
• Gender; 
 
• Ethnic background (African American/Black, Asian or Pacific Islander, 
Latino/Latin American/Hispanic, Native American/ Indigenous Peoples, 
White/European American, and Other); 
 
• Physician practice experience (number of years respondent has been a 
practicing physician); 
   
• Board certification (yes/no); 
 
• Practice type (solo practice, partnership practice, physician group, managed 
care, hospital or clinical institution, or other); 
 
• Practice location (urban, suburban or rural); and 
 
• Average number of patients seen with CNMP per month. 
 
 
 Dependent Variable 
 
 Willingness 
 The dependent variable for this study was willingness (behavioral intention) to 
prescribe CR opioids to patients with moderate to severe CNMP.  As discussed in 
Chapter 3, under the TPB structure, behavioral intention (BI) is based on the weighted 
sums of the predictors (Ao+SN+PBC) toward the behavior itself (Equation 4).  Each 
predictor is weighted for its importance in relation to the specific behavior and population 




 BI is seen to include a premeditated or a pre-planned response to the behavior of 
interest.  However, the question of whether or not a physician’s decision to use CR 
opioids when confronted with patients with CNMP is considered premeditated can be 
raised.  Are physician prescribing behaviors premeditated or is it more spontaneous, 
based on the specific circumstance of the individual patient?   
 A search of the literature found several studies that examined this issue.  Gibbons 
et al.(1998) proposed the prototype/willingness (P/W) model which adds elements of 
spontaneous reaction (reactiveness) to the behavioral theory.  Still operating under the 
TPB framework, their model replaces the traditional concept of behavioral intention with 
the concept of willingness as a pre-determinant of actual behavior.  The use of the P/W 
model has been supported by several studies (Berger& O'Brien, 1998; Gibbons et al., 
1998; Brown& Topcu, 2003; Mashburn, 2004; Pinsky et al., 2004). 
 For this study, the willingness concept was used in place of the traditional 
behavioral intention construct.  It was assumed that the actual behavior of prescribing CR 
opioids is preceded by a physician’s willingness to use this type of opiate analgesic to 
treat moderate to severe CNMP patients (refer to Chapter 3, Section 3.3.3).  Willingness 
for this study was operationalized as follows:  
 
   W = (w1)(Ao) + (w2)(SN) + (w3)(PBC) 
 
Equation 4. Behavioral Intention 
 
 
BI = (W1)(Ao) + (W2)(SN) +(W3)(PBC) 
 
BI = Behavioral Intention (Willingness) 
W1-3 = beta weight 
Ao = Attitude 
SN = Subjective Norm 
PBC = Perceived Behavioral Control 
 
Source: (Fishbein& Ajzen, 1975) 
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 Willingness was measured using a bipolar 7-point differential scale ranging from 
extremely unlikely (-3) to extremely likely (+3).  The following one-item question was 
used to measure willingness.  
 
Q. “I am willing to prescribe CR opioids to treat patients with moderate to 
severe CNMP.” [1-item] (Survey Q1) 
 
 
 The weighted sums of attitude, subjective norm, perceived behavioral control and 
recent past behavior was the framework for the willingness value.  Beta weights for the 
predicted willingness formula were calculated using multiple regression analysis. 
 
 
4.3 Pretesting Survey Instrument 
 The survey instrument was pretested to identify issues that may have affected 
survey length, face validity, content, clarity, format, and organization.  The purpose of 
pretesting a survey was to identify any parts of the survey instrument that may be 
difficult for the target population of participants to read or understand and also to identify 
any parts of the data collection method that participants may find objectionable or 
offensive.  The pretest also enabled researchers to determine whether the sequence of 
communications (e.g., e-mail cover letter, consent form, questions) are smooth and 
effective to determine the needs for training of researchers or data collection personnel, 
and to determine if measures yield data with sufficient variability.   
 A sample of 10 family physicians was invited to participate in a pilot study.  
Respondents participating in the pilot study were asked to provide feedback on the 
electronic questionnaire.  Pretest study participants were then instructed to record the 
time it took them to complete the survey instrument, point out concerns regarding clarity 
and relevance of items, and indicate any issues on the format of the questionnaire.  
Respondents were asked to e-mail their written comments to the researchers.  Instrument 
reliability was tested using Cronbach’s alpha.  The final survey instrument was submitted 
to the IRB for review and approval after it had been fully developed.  TAFP members 
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4.4 Data Collection 
This section describes the procedure that was employed to distribute the web-
survey and collect survey responses. 
Recognizing that surveys conducted among physicians can be different from 
surveying the general population, a review of the literature was conducted to determine 
appropriate methods for conducting web-surveys among physicians (Couper, 2000; 
Dillman, 2000; Dillman& Bowker, 2001; Kellerman& Herold, 2001; Couper et al., 
2004; Leece et al., 2004; Olmsted et al., 2005).   
Historically, survey response rates have varied widely among health care 
practitioners (means ranging from 11% to 77%) (Raziano et al., 2001; Braithwaite et 
al., 2003; McMahon et al., 2003; Leece et al., 2004).  A review of the literature found 
that a multiple contact technique involving pre-notification, and follow-up notification 
correspondence increased response rates among physicians and related health care 
professionals, compared to making a single contact (Raziano et al., 2001; Braithwaite et 
al., 2003; McMahon et al., 2003).   Further, the ability to minimize survey length and 
the use of progress indicators were associated with improved survey participation rates 
(Couper, 2000; Kellerman& Herold, 2001; Couper et al., 2004; Leece et al., 2004; 
Olmsted et al., 2005).   
This survey study employed Dillman’s (2000) multiple notification technique to 
increase the likelihood of physician responses.  The survey technique included the use 
of a pre-notification e-mail, an e-mail cover letter, and a follow-up e-mail reminder to 
increase awareness among the target population.  In addition, attempts were made to 
shorten survey length to improve the response rate.  Each of the methods has been 
shown to have a positive impact on the level of survey participation among respondents 




Pre-notification E-mail  
For this study, a pre-notification e-mail was sent to eligible participants two 
weeks prior to the distribution of the “survey cover letter.” The content of the pre-
notification e-mail identified the study investigators, outlined the objectives of the 
study, included a link to the background of the study, and requested participation in the 
study.  The e-mail also provided information on how participants may elect to be 
excluded from the survey and be excluded from receiving future e-mails from the 
investigators.  A printed copy of the pre-notification e-mail is located in Appendix B. 
 
Survey cover letter  
Physicians were sent a survey cover letter e-mail two weeks after the pre-
notification e-mail.  This e-mail contained a hyperlink to the electronic questionnaire.  
The e-mail cover letter was sent to those study participants who did not “opt-out” of the 
study (this option was provided in the pre-notification e-mail).  Similar to the pre-
notification e-mail, the survey cover letter e-mail identified the research investigators, 
stated the study objectives, and contained a link directing study participants to the 
online consent form for the electronic questionnaire.  A printed copy of the survey 
cover letter e-mail can be found in Appendix B. 
 
Online consent form  
Survey participants were directed to an online electronic “minimal risk” consent 
form.  The online consent form resided on the TAFP computer web-server (at the 
tafp.org website).  The consent form identified the title of the study, cited the IRB 
protocol number, identified the investigators of the study, described the purpose of the 
study, explained the activities participants were expected to complete as part of the 
survey process, identified the risks and benefits of the study, and included the 
confidentiality agreement.  Study participants who consented to participate in the survey 
clicked on a form button labeled “I Agree” to proceed on to the electronic 





Electronic Questionnaire  
Participants were automatically redirected to the electronic questionnaire once 
they had read the online consent form and consented to participate in the study by 
clicking the “I Agree” button.  As this was an anonymous electronic questionnaire, no 
personally identifiable information was requested or collected from respondents.  The 
electronic questionnaire resided on the TAFP’s computer web-server.  Questionnaire 
responses submitted by study participants were sent to an online Microsoft Access 
database residing on the TAFP’s computer web-server.  In order to protect the 
anonymity of the participant, response fields constructed to collect electronic responses 
were devoid of any unique identifiers.  A printed copy of the electronic questionnaire 
can be found in Appendix D. 
 
Follow-up E-mail.  
Eligible participants were sent a follow-up e-mail two weeks after the survey 
cover letter e-mail.  Due to the anonymity of the study, the e-mail was sent to all 
eligible study participants who did not opt-out of the study (from the pre-notification e-
mail).  The follow-up e-mail asked eligible participants to complete the electronic 
questionnaire, if they have not already done so.  Similar to the survey cover letter e-
mail, the follow-up e-mail identified the research investigators, restated the study 
objectives, and contained a link directing study participants to the online consent form 
for the electronic questionnaire.  A printed copy of the follow-up cover letter e-mail can 
be found in Appendix B. 
 
 
4.5 Data Analyses 
 Data used in the analyses came from a physician-based online survey of 
willingness to prescribe CR opioids for CNMP.  Data collected by the electronic 
questionnaire were stored on a Microsoft Access database that resided on TAFP’s 
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computer server.  Survey data were coded and transferred from the Access database to an 
SPSS 13.0 (SPSS, 2005) statistical package software program. 
 Cronbach’s alpha was utilized to test the reliability of scales used in the survey 
instrument.  Based upon a review of the literature, a Cronbach’s alpha at α =0.6 was 
considered acceptable for this study (Edwards et al., 2001).   
 
 Descriptive Analyses 
 Descriptive statistical analyses were conducted using frequency distributions, 
means, and standard deviations to describe the respondent population and to identify 
trends or data abnormalities among study variables (i.e., amount of continuing education, 
board certification, gender, patients with CNMP, practice location, practice type, 
race/ethnicity, and years of practice experience).  Means and standard deviations were 
obtained for direct and indirect measures of the TPB constructs of attitude (Ao), 
subjective norm (SN), and perceived behavioral control (PBC), along with willingness, 
recent past behavior (RPB), and continuing medical education (CME) variables.   
 
 T-Test Analyses 
 T-Tests were used to assess differences between means among physicians willing 
to prescribe CR opioids and those who are not willing with regards to significant 
predictors of Ao, SN, and PBC.  Anchors utilized in the semantic scale used to assess 
willingness ranged from -3 (extremely unwilling) to +3 (extremely willing).  To conduct 
the t-test analysis, willingness was dichotomized as willing and unwilling.  Physician 
respondents who were willing to prescribe CR opioids to treat moderate to severe CNMP 
patients had a score ranging between +1 (somewhat willing) to +3 (very willing) on the 
7-point bipolar semantic differential scale.  Non-willing respondents had a score ranging 
between -1 (somewhat unwilling) to -3 (extremely unwilling).  Responders who indicated 
0 (i.e., neutral) were not included in the t-test analyses.  T-Tests were conducted to 
evaluate differences among physicians who had received CME education in the past three 
years (dichotomous variable) with regards to willingness (continuous variable).  T-Tests 
were also conducted to assess the differences between CME and attitudes (continuous 
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variable).  Additionally, T-tests were used to evaluate differences between means among 
men and women with regards to the indirect/direct TPB constructs (Ao, SN, PBC, and 
willingness). 
 
 Analysis of Variance (ANOVA)  
 ANOVA was conducted to assess differences between the means of the TPB 
constructs (Ao, SN, PBC, and willingness) and for each non-dichotomous categorical 
variable (i.e., geographic location, physician ethnicity, and type of practice).  ANOVA 
was conducted for both direct and indirect measure variables. 
 
 Correlational Analyses 
 A correlation analysis was conducted to determine if a significant association 
existsed between years of physician experience and the direct/indirect TPB constructs 
(Ao, SN, PBC, and willingness) and RPB.   
 
 Multiple Regression Analyses 
 A multivariate analysis was conducted to determine if the TPB constructs were 
significant predictors of willingness.  The willingness variable was regressed onto the 
direct/indirect measures of Ao, SN, PBC, and the RPB variable to determine if they were 
significant predictors of physician willingness to prescribe CR opioids to patients with 




4.6 Regression Model 
 The primary goal of this study was to identify the predictor variables using 
constructs of the TPB and recent past behavior to predict Texas family physicians’ 
willingness to prescribe CR opioids to patients with moderate to severe CNMP.  This was 
done by developing a multiple regression model based on the dimensions of the direct 
and indirect TPB constructs (Ao, SN, PBC, willingness), and RPB.  The purpose of this 
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model was to predict variable Y, with maximum accuracy, from a linear combination of 
independent variables (Tabachnick& Fidell, 2001).  This study used the following 
regression model for both indirect and direct TPB measures: 
 
   Y = b1X1 + b2X2 + b3X3 + b4X4 +E 
 
 The regression coefficient variable is represented as bx.  The independent variable 
for attitude (Ao) is represented as X1, the subjective norm (SN) independent variable is 
X2, the perceived behavioral control (PBC) independent variable is X3, the recent past 
behavior (RPB) independent variable is X4, and E represents the residual (or error 
estimate).  Y represents the dependent variable of “physicians’ willingness to prescribe 
CR opioids to patients with moderate to severe CNMP.”  
 
 
4.7 Objectives and Hypotheses Tests 
 The purpose of this study was to explore the predictive utility of the Theory of 
Planned Behavior (TPB) in understanding physicians’ willingness to prescribe CR 
opioids to treat patients with moderate to severe CNMP.  Table 4.1 illustrates the 
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Table 4.1 Study Objectives and Hypotheses Tests 
Objectives Hypotheses 
Variables 
Dependent Variable (DV)/  
Independent Variable (IV) Statistical Test 
Objective 1 To explore the utility of the TPB constructs (attitude, subjective norm, 
perceived behavioral control) and the predictive strength of each TPB 
component in predicting family physicians’ willingness to prescribe CR 





Attitude (Ao), subjective norm (SN), and perceived behavioral control 
(PBC) constructs will explain a significant amount of variance in 
physicians’ willingness to prescribe CR opioids to patients with moderate 





DV= Willingness  
 
IV=   Direct measure of Ao 
IV=   Direct measure of SN  
IV=   Direct measure of PBC 
IV=   Indirect measure of Ao (b,e, b x e ) 
IV=   Indirect measure of SN (n,m, n x m) 
IV=   Indirect measure of PBC (c, p, c x p)  
Direct measures :  




Indirect measures:  
Multiple Regression; R2  
F-Test 
 H2 Favorable attitudes will be a positive and significant predictor of 
willingness to prescribe CR opioids to patients with moderate to severe 
CNMP, while controlling for subjective norm and perceived behavioral 
control. 
 
DV=  Willingness 
 
IV =   Direct measure of Ao 




Social norms supporting the prescribing of CR opioids to patients with 
moderate to severe CNMP will be a positive and significant predictor of 
willingness to prescribe, while controlling for attitude and perceived 
behavioral control. 
 
DV=  Willingness  
 
IV =   Direct measure of SN 
 
IV =  Indirect measures of SN (n,m, n x m) 
 
 H4 Strong perceptions of behavioral control will be a positive and significant 
predictor of willingness to prescribe CR opioids to patients with 
moderate to severe CNMP, while controlling for attitude and subjective 
norm. 
 
DV= Willingness  
 
IV =  Direct measure of PBC 
 
IV =  Indirect measure of PBC(c, p, c x p) 
 
Ao= Attitudes, SN= Subjective Norms, PBC= Perceived Behavioral Control;  Belief-based measures:  b= behavioral beliefs, e= outcome evaluation, b x e = indirect Ao,  
n= normative belief, m= motivation to comply, n x m= indirect SN, c= control belief,  p= perceived power, c x p = indirect PBC 
 









Dependent Variable (DV)/  
Independent Variable (IV) Statistical Test                      
Objective 2 To determine if the perceived behavioral control construct adds to the 
prediction of family physicians’ willingness to prescribe CR opioids to patients 





The perceived behavioral control construct will significantly increase the 
explanatory power of the regression model compared to only using 
attitude and subjective norm to explain family physicians’ willingness to 
prescribe CR opioids to patients with moderate to severe CNMP. 
 
DV= Willingness  
 
IVs=  Direct measures of Ao, SN, and PBC  
 
 
IVs=  Indirect measures of Ao ,SN,and PBC  
Direct measures  
Hierarchical Regression; R2 
F-Test 
Indirect measures 
Hierarchical Regression; R2 
F-Test 
Objective 3 To determine if the recent past behavior (RPB) construct adds to the prediction 
of family physicians’ willingness to prescribe CR opioids to patients with 




The recent past behavior construct will significantly increase the 
explanatory power of the regression model compared to only using the 
TPB constructs to explain physicians’ willingness to prescribe CR 




IVs=  Direct measures of Ao, SN, PBC, and RPB
 
IVs=  Indirect measures of Ao ,SN, PBC, and 
RPB  
Direct measures:  
Hierarchical Regression; R2 
F-Test 
Indirect measures:  
Hierarchical Regression; R2 
F-Test 
Objective 4 To determine if the willingness and attitude toward prescribing CR opioids to 
patients with moderate to severe CNMP differs by exposure to continuing 





Physicians who have received CE in pain management will be more 
willing to prescribe CR opioids to moderate to severe CNMP patients 
versus physicians who have not received CE. 
DV= Willingness 
IV =  CE 
  
Direct measures: T-test 
 
Indirect measures: T-test  
 H8 
 
Physicians who have received CE in pain management will have more 
favorable attitudes toward prescribing CR opioids to patients with 
moderate to severe CNMP versus physicians who have not received CE. 
DV= Direct/Indirect measures of Ao 
IV =  CE 
 
Direct measures:   T-test 
 
Indirect measures: T-test 
Ao= Attitudes, SN= Subjective Norms, PBC= Perceived Behavioral Control; RPB= Recent Past Behavior, CE= Continuing education;  Belief-based measures:   
b= behavioral beliefs, e= outcome evaluation, b x e = indirect Ao, n= normative belief, m= motivation to comply, n x m= indirect SN, c= control belief,   
p= perceived power,  c x p = indirect PBC 
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Objectives 




Dependent Variable (DV)/  
Independent Variable (IV)  Statistical Test                      
Objective 5 To determine if family physicians’ attitude, subjective norm, or perceived 
behavioral control toward prescribing CR opioids to patients with moderate to 




Family physicians that practice in suburban areas will have a 
significantly more favorable attitude toward prescribing CR opioids to 
patients with moderate to severe CNMP versus family physicians who 
practice in rural, suburban, or urban areas. 
DVs= Direct/Indirect measures of Ao 
 
IV =  Geography 
 
Direct measures: ANOVA 
 
Indirect measures: ANOVA 
 H10 
 
Family physicians that practice in suburban areas will have significantly 
more favorable subjective norms supporting the prescribing CR opioids 
to patients with moderate to severe CNMP versus family physicians who 
practice in rural, suburban, or urban areas. 
DVs= Direct/Indirect measures of SN 
 
IV =  Geography 
 
Direct measures:   ANOVA 
 
Indirect measures: ANOVA 
 H11 
 
Family physicians that practice in suburban areas will have a 
significantly stronger perception of behavioral control in prescribing CR 
opioids to patients with moderate to severe CNMP versus family 
physicians who practice in rural, suburban, or urban areas. 
DV= Direct/Indirect measures of PBC 
 
IV =  Geography 
 
Direct measures:   ANOVA 
 
Indirect measures: ANOVA 
Objective 6 To determine if family physicians’ attitude, subjective norm, or perceived 
behavioral control toward prescribing CR opioids to patients with moderate to 




There is no difference in physicians’ attitudes toward prescribing CR 
opioids to moderate to severe CNMP patients between male and female 
physicians. 
DVs= Direct/Indirect measures of Ao 
 
IV =  Gender 
Direct measures:   T-test 
 
Indirect measures: T-test 
 H13 
 
There is no difference in physicians’ subjective norm when prescribing 
CR opioids to moderate to severe CNMP patients between male and 
female physicians. 
DVs= Direct/Indirect measures of SN 
 
IV =  Gender 
Direct measures:   T-test 
 
Indirect measures: T-test 
 H14 
 
There is no difference in physicians’ perceived behavioral control over 
prescribing CR opioids to moderate to severe CNMP patients between 
male and female physicians. 
DV= Direct/Indirect measures of PBC 
 
IV =  Gender 
Direct measures:   T-test 
 
Indirect measures: T-test 
Ao= Attitudes, SN= Subjective Norms, PBC= Perceived Behavioral Control;  Belief-based measures:  b= behavioral beliefs, e= outcome evaluation, b x e = indirect Ao,  
n= normative belief, m= motivation to comply, n x m= indirect SN, c= control belief,  p= perceived power,  c x p = indirect PBC 
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Objectives 




Dependent Variable (DV)/  
Independent Variable (IV)  Statistical Test                       
Objective 6 H15 
 
There is no difference in physicians’ attitudes toward prescribing CR 
opioids to moderate to severe CNMP patients and physicians years of 
experience 
DVs= Direct/Indirect measures of Ao 
 
IV=  Years of experience  






There is no difference in physicians’ subjective norm when prescribing 
CR opioids to moderate to severe CNMP patients and physicians years of 
experience 
DVs= Direct/Indirect measures of SN 
 
IV=  Years of experience  






There is no difference in physicians’ perceived behavioral control over 
prescribing CR opioids to moderate to severe CNMP patients and 
physicians years of experience 
DV= Direct/Indirect measures of PBC 
 
IV=  Years of experience  






There is no difference in physicians’ attitudes toward prescribing CR 
opioids to moderate to severe CNMP patients and physician ethnicity. 
DVs= Direct/Indirect measures of Ao 
 
IV =  Physician ethnicity 
Direct measures: ANOVA 
 
Indirect measures: ANOVA 
 H19 
 
There is no difference in physicians’ subjective norm when prescribing 
CR opioids to moderate to severe CNMP patients and physician ethnicity.
DVs= Direct/Indirect measures of SN 
 
IV =  Physician ethnicity 
Direct measures: ANOVA 
 
Indirect measures: ANOVA 
 H20 
 
There is no difference in physicians’ perceived behavioral control over 
prescribing CR opioids to moderate to severe CNMP patients and 
physician ethnicity. 
DVs= Direct/Indirect measures of Ao 
 
IV =  Physician ethnicity 
Direct measures: ANOVA 
 
Indirect measures: ANOVA 
 H21 There is no difference in physicians’ attitudes toward prescribing CR 
opioids to moderate to severe CNMP patients and type of physician 
practice. 
DV= Direct/Indirect measures of PBC 
 
IV =  Type of practice 
Direct measures: ANOVA 
 
Indirect measures: ANOVA 
 H22 There is no difference in physicians’ subjective norm when prescribing 
CR opioids to moderate to severe CNMP patients and type of physician 
practice. 
DVs= Direct/Indirect measures of SN 
 
IV =  Type of practice 
Direct measures: ANOVA 
 
Indirect measures: ANOVA 
 H23 There is no difference in physicians’ perceived behavioral control over 
prescribing CR opioids to moderate to severe CNMP patients and type of 
physician practice. 
DV= Direct/Indirect measures of PBC 
 
IV =  Type of practice 
Direct measures: ANOVA 
 
Indirect measures: ANOVA 
Ao= Attitudes, SN= Subjective Norms, PBC= Perceived Behavioral Control;  Belief-based measures:  b= behavioral beliefs, e= outcome evaluation, b x e = indirect Ao,  




 There are several limitations associated with using multiple regression analysis.  
As mentioned above, regression analyses were conducted to examine relationships 
among variables and will not imply that the relationships are causal.  Further, it was not 
known in advance if the study model would satisfy all of the assumptions necessary for 
regression analysis.  Pre-analysis screening procedures were conducted to test the 
assumption of normality, linearity, and homoscedasticity between predicted scores and 
errors of prediction.  Examination of residuals scatterplots, histograms, and normal 
probability plots were conducted to detect violations for the assumptions (Tabachnick& 
Fidell, 2001).  It should be recognized that the TPB study model may not have been 
extremely sensitive to the specific combination of independent variables included in it.  
The use of regression coefficients (beta weights) may change among different family 
physician populations when independent variables are added or subtracted from the 
model.  As a result, this instability can make it more difficult to determine the true 
contributions of the independent and dependent variables (Tabachnick& Fidell, 2001).  
Further, the addition or removal of independent variables can change the value of R2, the 
coefficient of multiple determination, and partial correlations yielded by the model 
(Tabachnick& Fidell, 2001).  Ultimately, each of these factors affect the F-test of 
significance.  In addition, a high multicollinearity found in the multiple regression 




 Elements of the research design and methods proposed for this study were 
reviewed.  A description of procedures that were used to develop the instrument items, 
which include techniques used in elicitation interviews, examination of study variables, 
and proposed procedures for pretesting the questionnaire were discussed.  Methods that 
were used in instrument distribution, data collection, and data analyses were reviewed.  
Finally, the objectives, hypotheses, and statistical tests were outlined.   
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CHAPTER 5:  RESULTS 
 
 The purpose of this study was to achieve a better understanding of family 
physicians’ willingness to prescribe controlled release opioids (CR opioids) to patients 
with moderate to severe chronic non-malignant pain (CNMP).  The Theory of Planned 
Behavior (TPB) model was used to examine factors believed to influence physicians’ 
willingness to prescribe.  A survey questionnaire was developed and employed to 
measure the underlying TPB constructs influencing willingness.  This chapter presents 
the following: (1) findings from the three focus groups used to develop the questionnaire 
instrument; (2) results from the pretest conducted among a small sample of the target 
population; (3) demographic and practice characteristics of the study sample; (4) results 
of the direct and indirect TPB measures; and (5) results of the hypotheses tests.   
 
 
5.1 Focus Group Results 
 Three focus group interviews were conducted using members of the Texas 
Academy of Family Physician (TAFP).  As previously described in Section 4.2.1, the 
purpose of conducting focus group interviews was to identify the relevant behavioral, 
normative and control beliefs that make up physicians’ willingness.  Data collected from 
focus group participants were used to develop the belief-based items of the TPB 
questionnaire instrument.  
 A total of 15 TAFP members volunteered to participate in focus group interviews.  
The first focus group took place in Austin, Texas.  This focus group was comprised of 
three family physicians who were attending a TAFP conference.  The second focus group 
took place on day two of the conference and was comprised of six family physicians.  
The third focus group was comprised of six family physicians who were attending a 
different TAFP conference held in San Antonio, Texas.  The first focus group lasted 
approximately 30 minutes, the second group lasted 75 minutes and the third focus group 
lasted 60 minutes.  No compensation was given to TAFP members participating in the 
focus groups.  Three sets of questions were used in each focus group; behavioral beliefs, 
 
150 
normative beliefs, and control belief questions.  Appendix A contains the interview guide 
used to conduct the focus group.  Participants were asked to respond to the following nine 
focus group questions: 
 
Behavioral Belief Questions 
1. What do you think are some of the advantages associated with family physicians 
(FPs) prescribing CR Opioids to treat patients with moderate to severe CNMP? 
 
2. What do you think are some of the disadvantages associated with FPs prescribing 
CR Opioids to treat patients with moderate to severe CNMP? 
 
3. Are there any other advantages or disadvantages associated with FPs prescribing 
CR Opioids to treat patients with moderate to severe CNMP? 
 
 
Normative Belief Questions 
4. Are there any individuals or groups who would approve of FPs prescribing CR- 
Opioids to treat patients with moderate to severe CNMP? 
 
5. Are there any individuals or groups who would not approve of FPs prescribing 
CR Opioids to treat patients with moderate to severe CNMP? 
 
6. Are there any other individuals or groups who would or would not approve of FPs 
prescribing CR Opioids to treat patients with moderate to severe CNMP? 
 
 
Control Belief Questions 
7. What do you think would make it easier for FPs prescribing CR Opioids to treat 
patients with moderate to severe CNMP? 
 
8. What do you think would make it more difficult for FPs prescribing CR Opioids 
to treat patients with moderate to severe CNMP? 
 
9. Are there any other factors that you think would make it easier or more difficult 
for FPs prescribing CR Opioids to treat patients with moderate to severe CNMP? 
 
A content analysis was conducted on focus group responses (Ajzen& Fishbein, 1980).  
Focus group transcripts were analyzed for emerging themes elicited by the participants.  
Individual responses to question items were examined, and key words and phrases were 
grouped into belief categories.  Tables 5.1, 5.2, and 5.3 provide a summary of the 
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responses to the nine focus group questions.  Frequencies for each of the three belief 
categories were tabulated and then ranked from highest to lowest modal belief categories.   
 
 Behavioral Beliefs  
 Table 5.1 presents a summary list of behavioral beliefs identified from the focus 
group interviews of TAFP participants.  Based on the three behavioral belief questions 
(Questions 1-3), a total of 22 belief categories were identified and grouped according to 
frequency.  Focus group results showed that 13 of the 15 physicians interviewed believed 
that prescribing CR opioids for moderate to severe CNMP might lead to abusive drug 
behaviors.  A total of 13 physicians indicated that additional patient history would be 
required if CR opioids were prescribed.  Other salient behavioral beliefs included lengthy 
office visits, effectiveness in controlling pain, improvement of patient quality of life, 
costs compared to short-acting alternatives, ease/difficulty in managing patients on 
multiple medications and/or co-morbidities, higher possibility of addiction, and 


















Table 5.1 Behavioral Belief Items: Content Analysis of Focus Group Responses (N=15) 
 
Questions 1-3:  What are the advantages/disadvantages associated with family physicians  
    prescribing CR Opioids to patients with moderate to severe CNMP? 
Belief Responses Frequency
1 
Will lead to abusive drug behaviors (e.g., drug seeking, illicit use, 
diversion) 13 
2 Will require additional patient history 13 
3 Will lengthen office visits 9 
4 Will be effective in controlling the patients pain 6 
5 Will improve the patient’s quality of life 6 
6 Is less expensive compared to other short-release drugs 4 
7 Will make it easier to manage those patients on multiple medications 4 
8 Will lead to patient addiction 3 
9 Will make it easier to manage patients with co morbidities 3 
10 Will lead to increased regulatory scrutiny 3 
11 Results in no clear end-point in treating patient’s pain 2 
12 Will increase my use of patient contracts 2 
13 Will cause patients to experience side effects  (e.g., constipation, sedation) 2 
14 Will increase my legal liability 1 
15 Will increase my level of professional satisfaction 1 
16 Will cause me to become properly trained in CNMP 1 
17 Will cause my patient to become pseudo addicted 1 
18 Will increase robbery to my practice 1 
19 Will cause my patient to be stigmatized as an aberrant drug user 1 
20 Will cause me to seek support from other health specialists 1 
21 Will increase the level of support needed from my staff 1 
22 Will cause patient tolerance to the medication 1 
 Total 79 
 
 
 According to the TPB framework, a minimum of five to nine belief items are 
needed to construct the indirect attitude measure (Ajzen& Fishbein, 1980).  For this 
study, behavioral beliefs reported by at least three or more focus group participants were 
used (Table 5.1).  As a result, 10 of the most frequently mentioned beliefs were selected 






Table 5.2 Normative Beliefs Items: Content Analysis of Focus Group Responses (N=15) 
 
Questions 4-6:  Which individuals or groups would/would not approve of FPs prescribing  
                          CR Opioids to treat patients with moderate to severe CNMP? 
Belief Responses Frequency
1 Regulatory Agencies 6 
2 Other primary care physician colleagues 3 
3 Consumer groups 3 
4 Pain specialty physicians 3 
5 Patients 3 
6 Texas Medical Board 2 
7 Other Healthcare Providers and staff 2 
8 Community 1 
9 Hospice 1 
10 Hospital Administrators 1 
11 Legislators 1 
12 Managed Care Organizations (e.g., insurance, Medicaid, Medicare) 1 
13 Media 1 
14 Medical Associations (e.g., AAFP, AMA,) 1 
15 Patients' relatives 1 
 Total 30 
 
 Normative Beliefs 
 Focus group participants were asked to list important individuals/groups (i.e., 
referents) that would approve or disapprove of family physicians using CR opioids to 
treat patients with moderate to severe CNMP.  Table 5.2 provides a summary list of the 
salient normative beliefs identified from focus group interviews.  Based on the three 
belief questions (Questions 4-6), a total of 15 normative belief categories were identified 
and grouped according to frequency.  The most common normative belief was that 
regulatory agencies would either approve or disapprove of their prescribing CR opioids 
for moderate to severe CNMP.  Other more frequently identified beliefs included 
physicians’ colleagues, consumer groups, specialists, patients, and other health providers 
who may approve/disapprove of prescribing CR opioids.  
 Similar to behavioral beliefs, a minimum of five to nine belief items are required 
to construct the normative belief-based measure (Ajzen& Fishbein, 1980).  For this study, 
normative beliefs mentioned by two or more focus group participants were included as 
items in the questionnaire.  As a result, seven of the most frequently mentioned referents 
were used to construct the normative belief scale used in the survey. 
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Table 5.3 Control Beliefs Items: Content Analysis of Focus Group Responses  (N=15) 
 
Questions 7-9:  What factors do you think would make it easier/difficult for family physicians  
                          to prescribe CR opioids to treat patients with moderate to severe CNMP? 
Belief  Responses Frequency
1 Having more knowledge in pain management 12 
2 Access to pain management tools 11 
3 Not having to write triplicates prescriptions  6 
4 Patients who are on multiple medications 5 
5 Complete compensation for services associated w/ prescribing CR opioids 5 
6 Access to multidisciplinary teams 3 
7 Ready access to patient medical records 3 
8 More evidence-based studies 3 
9 Patients who have multiple co morbidities   3 
10 Less regulatory scrutiny 3 
11 More access to other treatment modalities 2 
12 Less expensive drugs  2 
13 Less legal liability  2 
14 Less abuse by patients 1 
15 Less addictive drug  1 
16 Less drug seeking patients 1 
17 Less physical dependence 1 
18 More patient education  1 
19 More time available for patients  1 
20 No clear end-points  1 
21 No side effects  1 
22 Robbery  1 
23 Stigmatization  1 
 Total 71 
 
 Control Beliefs 
 Focus group participants were asked to list factors that they believed would make 
it easier or more difficult to prescribe CR opioids to patients with moderate to severe 
CNMP.  Table 5.3 outlines the responses for the modal control beliefs elicited.  Based on 
the three control belief questions asked (Questions 7-9), a total of 23 control belief 
categories were identified and grouped according to frequency.  Results showed 12 of the 
15 physicians interviewed believed that having more knowledge in pain management 
would make it easier for them to prescribe CR opioids to patients with moderate to severe 
CNMP.  A total of 11 physicians indicated that access to pain management tools (e.g., 
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algorithms, protocols, guides, contracts, diagnostic kits) would make it easier to prescribe 
CR opioids.  Six focus group participants indicated that writing triplicates made it more 
difficult for them to prescribe CR opioids for CNMP.  Other control beliefs mentioned 
included having patients on multiple medications, receiving complete compensation for 
services associated with prescribing CR opioids, having access to multi-disciplinary 
teams and patient medical records, availability of more evidence-based studies, patients 
with co-morbidities, and regulatory scrutiny. 
 Similar to methods used to select behavioral and normative beliefs, a minimum of 
five to nine belief items are needed to construct the indirect perceived behavioral control 
measure.  For this study, control beliefs reported by at least three or more focus group 
participants were used, resulting in 10 belief-based items used in the final questionnaire 





















Table 5.4 Theory of Planned Behavior Questionnaire Items  
(Summary of Direct and Indirect Items) 
 





Willingness  1 1 
    
Attitude (indirect) Behavioral beliefs 10 2a thru 2j 
 Outcome evaluation 10 3a thru 3j 
    
Attitude (direct)  4 4a thru 4d 
    
Subjective Norm 
(indirect) Normative beliefs 7 5a thru 5g 
 Motivation to comply 7 6a thru 6g 
    
Subjective Norm (direct)  1 7 
    
Perceived Behavioral 
Control (indirect)  Control beliefs 10 8a thru 8j 
 Perceived power 10 9a thru 9j 
    
Perceived Behavioral 




 Table 5.4 gives a breakdown of the number and type of TPB scales used in the 
questionnaire instrument.  One question item was used to assess physicians’ willingness 
to prescribe CR opioids for CNMP.  A total of 20 items were used to assess indirect 
attitude. Four items were used to assess direct attitude.  For indirect subjective norm, 14 
items were used. One item was used to assess direct subjective norm.  A total of 20 items 
were used for indirect perceived behavioral control and direct perceived behavioral 
control was assessed using two items. 
 
 
5.2 Pretesting Survey 
 The TPB survey was pretested to identify issues that may affect instrument 
length, face validity, content, clarity, format, and organization.  Ten family physicians 
were invited to participate in pretesting the electronic questionnaire.  Physicians were 
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sent a cover letter e-mail that contained a hyperlink to the electronic questionnaire and 
were instructed to review the online questionnaire for its ease of readability, clarity and 
relevance of items, and format.  Participants also were asked to record the time it took 
them to complete the survey instrument.   
 Seven family physicians participated in the pretest.  The internal consistency of 
the instrument was examined.  Cronbach’s alpha was used to test instrument reliability of 
the three TPB indirect (belief-based) scales.  Alpha coefficients for the indirect attitude 
(0.73) and perceived behavioral control (0.83) scales were considered adequate 
(Cronbach, 1951), however the alpha coefficient obtained for indirect subjective norm 
(0.63) was slightly below adequate.  One possible explanation for the low reliability of 
the subjective norm scale may be attributed to the low number of participants (N=7) used 
in the pretest.  Examination of internal consistency for the direct TPB scales showed 
acceptable alpha coefficient for direct attitude (0.99) and perceived behavioral control 
scale (0.73).  Cronbach’s alpha was not computed for the direct subjective norm scale due 
to it being only one item. 
 
 
5.3 Distribution of Survey Response Rates 
 Of the 2,750 web surveys initially e-mailed on June 27th, 2006 to eligible TAFP 
members, approximately 150 e-mail addresses bounced back to the TAFP computer 
server (i.e., non-working or invalid e-mail address).  A follow-up e-mail was resent to the 
TAFP group two weeks later, July 11, 2006.  In an effort to further increase the survey 
response rate, a final e-mail was sent out by the 2006 TAFP Research Chair, on August 
10, 2006.  A total of five physicians opted out of participating in the survey.  The survey 
enrollment period ended August 23, 2006 (total data collection period was nine weeks).  
Of the 2,600 presumably valid survey e-mails sent, a total of 267 usable surveys were 







5.4 Assessment of Data Normality 
 Routine pre-analysis screening procedures were conducted to assess the normality 
of the data.  The skewness and kurtosis of each variable was examined to determine how 
much the distribution among the variables varied from the normal distribution.  Curran et 
al. (1996) recommend further examination of distribution when univariate skewness is 
greater than |2.0| and kurtosis is greater than |7.0|.  
 Examination of the skewness and kurtosis statistics for each of the variables 
indicated all TPB variables were within the threshold values for normality except one.  
The demographic variable “average number of CNMP patients seen per week” 
(skewness=6.379) exceeded the threshold for non-normality.  Further examination of the 
data revealed outliers among three respondents on this particular item.  When the average 
number of CNMP patients /week variable was collapsed into 6 categories skewness for 
the ordinal measure was 1.462.   
 
 
5.5 Assessment of Missing Data 
 A total of 390 instances of missing data were observed across 77 survey items 
(N=267 respondents).  Further examination of the survey data found that 28.8 percent 
(N=77) of respondents had at least one missing data value. The rate of missing data did 













Table 5.5 Internal Consistency Analysis of  Indirect and Direct Item Scales 






Indirect Scale (belief-based items)   
Belief-Based Attitude 20 0.79 
Belief-Based Subjective Norm 14 0.71 
Belief-Based Perceived Behavioral Control 20 0.82 
   
Direct Scale   
Direct Attitude 4 0.95 
Direct Subjective Norm 1 N/A* 
Direct Perceived Behavioral Control 2 0.56 
*Only 1-item used to assess the construct    
 
 
5.6 Internal Consistency 
 Cronbach’s alpha was used to assess the internal consistency of the indirect and 
direct TPB measurement scales (variables).  All three indirect measurement scales 
demonstrated a composite alpha coefficient score exceeding the 0.60 threshold (Edwards 
et al., 2001).  Table 5.5 illustrates the reliability coefficients for each scale.  Internal 
consistency for the direct attitude scale indicated a high alpha coefficient (0.95), however 
the alpha coefficient obtained for the direct perceived behavioral control scale (0.56) was 
slightly below adequate.  One possible explanation for the low reliability of the perceived 
behavioral control scale may be attributed to the low number of items used to assess the 
construct.  Cronbach’s alpha was not computed for the direct subjective norm scale due 






Table 5.6 Demographic Characteristics: Gender, Years Experience, and Ethnicity 
      







      
Gendera      
  Male 165 (61.8)     
  Female 98 (36.7)     
  Missing 4 (1.5)     
      
Years experienceb 262 (98.1) 16.5 10.7 1 57 
  Missing 5 (1.9)     
      
Ethnicityc      
  White/European American 194 (72.7)    
  Latino/Latin American Hispanic 31 (11.6)    
  Asian or Pacific Islander 15 (5.6)    
  African-American/Black 5 (1.9)    
  Native American/Indigenous 
Peoples 0 (0.0)    
  Other 16 (6.0)     
  Missing 6 (2.2)     
   
a4 physicians failed to indicate gender (N=263) 
b5 physicians failed to indicate years experience (N=262) 




5.7 Demographics and Practice Characteristics 
 Table 5.6 illustrates respondent demographics.  Approximately 62 percent of the 
physician’s responding to the survey were male. The average number of years of practice 
experience among family physician respondents was 16.5 years (median=16, SD=10.7).  








Table 5.7 Practice Characteristics: Type of practice, Practice location, Number of 
CNMP patients seen per week 
      







      
Type of Primary Practicea      
  Physician Group 93 (34.8)     
  Solo Practice 54 (20.2)     
  Hospital or Clinical Institution 41 (15.4)     
  Partnership Practice 40 (15.0)     
  Managed Care 5  (1.9)     
  Other 27 (10.1)     
  Missing 7 (2.6)     
      
Location of Primary Practiceb      
  Urban 93 (34.8)     
  Suburban 92 (34.5)     
  Rural 75 (28.1)     
  Missing 7  (2.6)     
      
Number of CNMP Patients seen 
per weekb 254 (95.1) 7.9 15.5 0 150 
  Missing 13 (4.9)     
  
a7 physicians failed to indicate type of primary practice (N=260) 
b7 physicians failed to indicate location of primary (N=260) 




 Table 5.7 depicts the practice characteristics of family physician respondents. 
Over one-third (34.8%) of respondents reported “physician group” as their primary type 
of practice while 20 percent indicated having a “solo practice.”  Responses to primary 
practice location showed that 34.8 percent of physicians reported their primary practice 
being located in an “urban” setting, while 34.5 percent practiced in a “suburban” setting, 





Table 5.8 Number of Chronic Non-Malignant Pain (CNMP) patients seen per week 
     
  Number of CNMP Patients 





  Zero 20 8.1% 8.1%  
  1 to 5 143 57.9% 66.0%  
  6 to 10 42 17.0% 83.0%  
  11 to 15 21 8.5% 91.5%  
  16 to 20 9 3.6% 95.1%  
  > 21  12 4.9% 100.0%  
 Total 247 100%   
Missing  20 7.5%  
a20 physicians failed to complete this variable  
 
 Respondents reported seeing an average of eight CNMP patients per week 
(median=5, SD=15.5).  The average number of CNMP patients seen by family physicians 
ranged from zero to 150 per week.  As previously mentioned, a skewed distribution was 
observed for this variable (skewness=6.379).  Results of this non-normal distribution may 
be due to the influence of three outlier and several extreme values observed among a 
small group of physician respondents treating a substantial number of CNMP patients.  
For example, one physician reported seeing an average of 150 CNMP patients per week, 
while two other respondents saw an average of 120 patients per week.  When the variable 
was collapsed into six ordinal categories the skewness for this variable was 1.46.  Table 
5.8 illustrates the number of CNMP patients seen by family physicians grouped by 
categories.  Examination of the categorical data shows that approximately 66 percent of 
physician respondents reported seeing an average of five or less CNMP patients per week 
while 4.9 percent of physician respondents reported seeing at least an average of 21 or 
more CNMP patients per week. 
 Family physicians were asked how often they prescribed CR opioids to patients 
with moderate to severe CNMP within the last month (Table 5.9).  Using an ordinal 
measurement scale (1=Never to 6=Always), 23 percent of respondents indicated that they 
“never” prescribed CR opioids to patients while two percent indicated that they always 
prescribed CR opioids.  To test the reliability of the item measure, a second variable was 
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used to assess how often respondents prescribed CR opioids to CNMP patients.  Results 
to the second item measure showed that 17 percent of physicians indicated that they 
“never” prescribed CR opioids and none of the respondents indicated they always 
prescribed CR opioids for moderate to severe CNMP.  Cronbach’s alpha showed an 
acceptable reliability estimate (0.75) between the two variables.  The second variable was 
used as the direct measure for the recent past behavior scale (a component of the TPB 
model).  Further analysis of this variable will be discussed in Section 5.10.1. 
 
Table 5.9 Family physicians’ past prescribing behavior of CR opioids for moderate to 
severe CNMP 
 
Respondents were asked to rate the following recent past behavior questions: 
 
  Question 12: “How often have you prescribed long-acting opioids to patients with moderate to 
                           severe CNMP in the last month?” 
 
  Question 20: “How often do you prescribe long-acting opioids to patients with moderate to  
                           severe CNMP?” 
    
Frequency Distribution of Responses (%) 
 N Mean SD 
Never 
(1)  (2)  (3) (4)  (5)  (6) 
Always
(7) 
Q12. Prescribe CR 
opioids in the last month? 264
a 3.50 1.91 22.7% 17.0% 7.6%
14.8
% 18.2% 17.4% 2.3% 
          












Q20. Prescribe CR 
opioids (in general) 262
b 2.32 0.94 17.2% 49.2% 17.6% 16.0% 0.0% 
a3 physicians failed to answer (N=264) 
b5 physicians failed to answer (N=262) 
 
 In terms of generalizability of demographic data, a comparison of demographic 
and practice characteristics of the study sample and population data, obtained from the 
2006 TAFP membership database, showed the characteristics of physician respondents to 
be fairly similar to that of the TAFP population (Appendix E).  Some dissimilarities were 
noted. A higher proportion of physicians practicing in rural areas responded to the 
survey.  Physician respondents with solo practices were underrepresented in the survey 





5.8 Continuing Medical Education   
 The survey asked family physicians three questions regarding their views toward 
exposure to continuing medical education (CME) in chronic pain management (Table 
5.10). Of the 262 family physicians responding to the following CME question:  
“Have you received any CME in chronic pain management in the last three years?” 
approximately 71 percent (N=190) of respondents reported receiving this type of 
continuing education in the last three years.  This variable was used in assessing 
physicians’ willingness and attitudes (will be discussed in Section 5.10).  Table 5.10 
shows the mean frequency distribution of respondents’ views toward access to CME 
programs in chronic pain management.   
 
Table 5.10 Family physicians’ views toward continuing medical education (CME) in 
chronic pain management 
 
Respondents were asked to rate the following CME questions: 
 
  Question 22: “I feel that I have access to CME courses in chronic pain management (CPM).” 
 
  Question 23: “How likely would you be to attend CPM CME activities in the next year?” 
 
  Question 24: “How likely would you be to attend CPM CME activities offered by TAFP?” 
 
    
Frequency Distribution of Responses (%) 





















Q22. Access to CME 263a 1.24 1.35 0.8% 3.4% 10.3% 6.5% 31.2% 31.6% 16.3%
           





















Q23. CME next year 262b 0.65 1.51 4.6% 8.0% 9.2% 9.9% 38.9% 22.9% 6.5% 
Q24. CME by TAFP 263c 0.89 1.48 3.4% 6.8% 8.7% 6.1% 36.1% 30.4% 8.4% 
a4 physicians failed to answer (N=263) 
b5 physicians failed to answer (N=262) 





 Overall, 79 percent of physician respondents agreed (+1=“slightly agree” to 
+3=“strongly agree”) with the statement that they felt they had access to CME courses in 
chronic pain management (Mean=1.24, SD=1.35, range -3 to +3).  However, 14.5 percent 
of family physicians disagreed with the statement.  The next set of CME questions asked 
if family physicians would attend CME in chronic pain management in the next year or 
would attend if it was offered by the Texas Academy of Family Physicians (TAFP). Of 
the 262 respondents, 68.3 percent indicated they were likely to attend a CME activity in 
the next year.  Three-fourths of physician respondents indicated that they would likely 












Figure 5.1 TPB Study Model: Direct Measure Constructs 
 
5.9 Constructs of the Theory of Planned Behavior 
 The questionnaire measured the TPB constructs willingness, attitude, subjective 
norm, and perceived behavioral control.  For the purpose of this study, the willingness 
construct was assessed using a direct measure.  The attitude, subjective norm, and 
perceived behavioral control constructs were measured using both direct and indirect 
(belief-based) measures.  The TPB model also included the additional predictor variable 
recent past behavior— RPB (variables was a direct measure).  
 
5.9.1 Direct Measures 
 Direct measures of willingness, attitude, subjective norm, and perceived 
behavioral control toward prescribing CR opioids to CNMP patients were developed 
from a review of the literature and Fishbein and Ajzen’s TPB model (Figure 5.1).   
 The TPB direct measure variables were measured using a 7-point Likert scale 
(each question-item anchored by -3 to +3).  Willingness was measured using one 
question- item, direct attitude was measured using four items, direct subjective norm was  
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The recent past behavior variable was measured with one question item using a 5-point 
Likert scale (anchored by 0=never to 5=always).   
 
 
Table 5.11 Willingness to prescribe CR opioids to chronic non-malignant pain patients  
 
  Respondents were asked to rate the following willingness question based on 1 item: 
 
  Question: “I am willing to prescribe long-acting opioids to treat patients with moderate  
                     to severe chronic non-malignant pain (CNMP).” 
 
 
    Frequency Distribution of Responses (%) 



















n SD (-3) (-2) (-1) (0) (+1) (+2) (+3) 
Q1. Willingness 267 a 0.47 1.71 5.6% 12.0% 15.4% 4.5% 28.8% 26.6% 7.1% 
           
aAll physician respondents answered this question item (N=267) 
 
 
 Direct Measure of Willingness  
 Direct willingness was measured with a 1-item question.  Table 5.11 shows the 
mean frequency and distribution of willingness.  The mean willingness score was 0.47 
(SD=1.71, range -3 to +3), indicating that overall, physician respondents were slightly 
willing to prescribe CR opioids to patients with moderate to severe CNMP.  Out of the 
267 family physicians who responded to the question, one-third of responses (N=88) 
were between -1 and -3, indicating that 33 percent of respondents were unwilling to 
prescribe CR opioids to CNMP patients.  Only 5.6 percent of respondents indicated that 
they were extremely unwilling (-3) to prescribe CR opioids to their CNMP patients.  










  Respondents were asked to rate the following attitude question based on 5 items: 
 
  Question:  "I feel that prescribing long-acting opiates to patients with moderate to severe  
                      chronic non-malignant pain is..." 
 
    Frequency Distribution of Responses (%) 
    
Very  
Bad   Neutral   
Very 
Good 
Question Items Na Mean SD (-3) (-2) (-1) (0) (+1) (+2) (+3) 
Q1. Bad/Good 265 0.72 1.38 1.5% 6.4% 7.9% 26.0% 27.9% 20.8% 9.4% 
    
Very 
Harmful   Neutral   
Very 
Beneficial
    (-3) (-2) (-1) (0) (+1) (+2) (+3) 
Q2. Harm/Benefit 265 0.86 1.41 1.9% 5.3% 9.4% 17.7% 30.9% 23.8% 10.9% 
    
Very 
Useless   Neutral   
Very 
Useful 
    (-3) (-2) (-1) (0) (+1) (+2) (+3) 
Q3. Useless/ Useful 265 1.00 1.35 1.5% 4.9% 6.8% 15.1% 33.6% 26.8% 11.3% 
    
Very 
Foolish   Neutral   
Very 
Wise 
    (-3) (-2) (-1) (0) (+1) (+2) (+3) 
Q4. Foolish/Wise 264 0.52 1.44 3.8% 6.4% 7.6% 31.4% 25.0% 18.2% 7.6% 
    
Very 
Useless   Neutral   
Very 
Useful 
    (-3) (-2) (-1) (0) (+1) (+2) (+3) 
Q5. Worthless/  
       Valuable  264 0.88 1.39 3.0% 3.0% 7.2% 21.2% 31.4% 23.1% 11.0% 
           Scale Total 263 3.96 b 6.33        
a Respondents answering each question-item ranged from 264 to 265 (Total survey respondents N=267) 
b Scale total indicates the Composite Score for Direct Attitude 
 
 
 Direct Measure of Attitudes 
 Table 5.12 shows the mean frequency and distribution of direct attitudes.  
Physicians’ direct attitudes were measured with five question-items.  Each item used a 7-
point bipolar semantic differential scale with the following anchors: bad/good, harmful/ 
beneficial, useless/useful, foolish/wise, and worthless/valuable.  The mean scale total 
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(i.e., composite score) for direct attitude was 3.96 (SD=6.33, range -15 to +15), 
indicating that physicians held an overall favorable attitude toward prescribing CR 
opioids to their CNMP patients. Respondents mean item scores (range -3 to +3) for direct 
attitude were between 0.72 for the good/bad item, 0.86 for harmful/ beneficial, 1.00 for 
useless/useful, 0.52 for foolish/wise, and 0.88 for worthless/valuable.   
 
 
Table 5.13 Direct subjective norm toward prescribing CR opioids to chronic non-
malignant pain patients    
 
Respondents were asked to rate the following subjective norm question based on 1 item: 
 
  Question:  “If I prescribe long-acting opioids for patients with moderate to severe CNMP,  
                       most people who are important to me would approve?” 
 
 
    Frequency Distribution of Responses (%) 














Question Item N Mean SD (-3) (-2) (-1) (0) (+1) (+2) (+3) 
Q1.  264a 1.03 1.52 1.9% 6.4% 10.2% 11.4% 22.3% 33.7% 14.0% 
a Physician respondents answered this question item (N=264) 
 
 
 Direct Measure of Subjective Norm 
 Direct subjective norm was measured with a 1-item question (using a 7-point 
bipolar scale).  Table 5.13 shows the mean frequency and distribution of direct subjective 
norm.  The mean composite score for direct subjective norm was 1.03 (SD=1.52, range -3 
to +3). Out of the 264 respondents, 70 percent (N=185) of physician respondents 
“slightly agreed” to “strongly agreed” with the statement, “If I prescribe long-acting 
opioids for patients with moderate to severe CNMP, most people who are important to 
me would approve.” Interpretation of the direct subjective norm score implies that a weak 
positive social pressure may influence physicians’ decisions to prescribe CR opioids to 






Table 5.14 Direct perceived behavioral control over prescribing CR opioids to 
chronic non-malignant pain patients 
 
Respondents were asked to rate the following two perceived behavioral control question items: 
 
  Question 1:  “It is easy for me to prescribe long-acting opioids to treat patients with  
                         moderate to severe CNMP.” 
 
  Question 2:  “I have complete control over whether or not I will prescribe long-acting  
                         opioids for patients with moderate to severe CNMP.” 
 
 
    Frequency Distribution of Responses (%) 















Question Item N a Mean SD (-3) (-2) (-1) (0) (+1) (+2) (+3) 
Q1. Easy for me to 
Rx CR opioids 260 0.17 1.99 14.6% 11.5% 13.5% 8.1% 16.9% 25.8% 9.6%
Q2. Complete control 
over Rx CR opioids 263 1.30 1.78 4.9% 6.8% 7.2% 5.7% 14.4% 31.2% 29.7%
Scale Total 259    1.45 b 3.12 ---- ---- ---- ---- ---- ---- ---- 
a Respondents answering each question-item ranged from 260 to 263 (Total survey respondents N=267) 
b Scale total indicates the Composite Score for Direct Perceived Behavioral Control  
 
 
 Direct Measure of Perceived Behavioral Control 
 Two question-items were used to measure physicians’ direct perceived behavioral 
control (PBC). Each question-item used a 7-point bipolar scale, ranging from -3= 
“strongly disagree” to +3=“strongly agree.”  Table 5.14 shows the mean frequencies and 
distributions of each item and the overall direct PBC mean score.  The mean composite 
score for direct PBC was 1.45 (SD=3.12, range -9 to +9), indicating that physicians felt 
they had a slight level of control over prescribing CR opioids to patients with moderate to 
severe CNMP.  The mean responses to the first question-item “It is easy for me to 
prescribe long-acting opioids to treat patients with moderate to severe CNMP,” was 0.17 
(SD=1.99, range -3 to +3).  Of the 260 physicians responding to this item, 52.3 percent 
(N=136) of respondents slightly agreed to strongly agreed with the statement. 
Conversely, about 40 percent of respondents disagreed with the statement.  Responses to  
 
171 
the second direct PBC question-item, “I have complete control over whether or not I will 
prescribe long-acting opioids for patients with moderate to severe CNMP,” showed a 
mean of 1.3 (SD=1,78, range -3 to +3).  Over three-fourths of the respondents (N=197) 
felt they had complete control over prescribing CR opioids to their CNMP patients while 
18.9 percent of physicians disagreed with the statement. 
 
Table 5.15 Direct recent past behavior in prescribing CR opioids to chronic non-
malignant pain patients    
 
Respondents were asked to rate the following recent past behavior question based on 1 item: 
 




    Frequency Distribution of Responses (%) 
    Never Sometimes 
About Half 
the Time 
Most of the 
Time Always 
Question Item N Mean SD (+1) (+2) (+3) (+4) (+5) 
Q1. 262 2.32 0.94 17.2% 49.2% 17.6% 16.0% 0.0% 
 
a Physician respondents answered this question item (N=262) 
 
 
 Direct Measure of Recent Past Behavior Construct 
Direct recent past behavior (RPB) was measured with a 1-item question using a 5-point 
unipolar Likert scale (ranging from 1= “never” to +5= “always”).  Table 5.15 shows the 
mean frequencies and distributions of each item and the overall direct RPB mean score.  
The mean RPB score was 2.32 (SD=0.94), indicating that overall, physician respondents 
prescribed CR opioids to CNMP patients sometimes to about half the time. Out of the 
262 valid responses, one-third of physicians (N=88) indicated that they prescribed CR 
opioids to their CNMP patients at least half the time.  However, approximately 17.2 
percent of respondents indicated that they never prescribed CR opioids to their moderate 






Continuing Medical Education 
 One question-item was used to measure physicians’ direct continuing medical 
education (CME) in chronic pain management.  This question item was measured as a 
dichotomous variable.  Results for the CME measure showed that approximately 71 
percent (N=190) of the 262 physicians respondents reported receiving CME in chronic 
















5.9.2 Indirect (Belief-Based) Measures 
 The indirect measures of attitude, subjective norm, and perceived behavioral 
control were developed from salient belief data gathered during focus group interviews 
(Figure 5.2).  All belief-based variables utilized in the questionnaire instrument were 
measured using a 7-point Likert scale (question-items used were either anchored by -3 to 
+3 or 1 to +7).  Belief-based attitude was measured using a total of 20 question-items, 
belief-based subjective norm was measured utilizing 14 items, and belief-based perceived 
behavioral was measured using 20 items.  Composite scores were calculated for each of 
the belief-based measure constructs.  
 
 Belief-based Attitudes 
 The belief-based attitude measure is comprised of two components, behavioral 
beliefs and outcome evaluations.  Table 5.16 illustrates the mean frequency and 
distribution of the behavioral beliefs (bi).  For this belief component, respondents were 
asked to rate the likelihood of 10 separate belief items (b1-10) occurring if they prescribed 
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 Next, outcome evaluation (ei) was calculated for each of the behavioral-belief 
items.  Family physicians were asked to rate how “good” or “bad” the consequences of 
each belief-item would be if they prescribed CR opioids to patients with moderate to 
severe CNMP.  Table 5.17 illustrates the mean frequency and distribution of outcome 
evaluation (e1-10) items which make up indirect attitude.   
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Table 5.16   Behavioral beliefs of physicians toward prescribing CR opioids to patients with chronic non-malignant pain 
 
Respondents were asked to rate the following indirect attitude question based on 10 behavioral-belief items: 
 
  Question: "How likely do you think the following outcomes will occur if you prescribe long-acting  
                    opioids to patients with moderate to severe CNMP?” 
 
    Frequency Distribution of Responses (%)a 
    
Extremely 
Unlikely   Neutral   
Extremely
Likely 
Behavioral-Belief Items (bi) Nb Mean SD (-3) (-2) (-1) (0) (+1) (+2) (+3) 
1.  Leads to abusive behaviors 265 -0.09 1.51 3.4 21.1 16.2 15.5 31.3 9.1 3.4 
2.  Require additional patient history 263 1.75 1.20 0.8 2.3 2.3 6.5 20.2 39.9 28.1 
3.  Lengthen patient office visits 266 0.97 1.52 1.1 6.8 10.9 16.5 19.9 29.3 15.4 
4.  Effective in controlling pain 266 1.33 1.20 0.8 2.3 6.4 9.8 25.2 45.5 10.2 
5.  Improve patient quality-of-life 265 1.28 1.28 0.8 4.2 5.3 10.2 27.9 39.2 12.5 
6.  Less expensive than short-acting opioids 266 0.12 1.46 4.9 9.4 15.4 33.5 16.5 16.5 3.8 
7.  More difficult to manage patients on multiple Rxs  266 -0.05 1.48 2.6 16.5 24.1 16.2 24.4 12.8 3.4 
8.  More difficult to manage patients with co-
morbidities 265 -0.09 1.45 3.0 15.5 26.0 15.8 24.9 12.5 2.3 
9.  Leads to increased regulatory scrutiny 266 1.33 1.39 0.4 5.3 5.6 10.5 28.9 26.7 22.6 
10. Leads to patient addiction 265 0.22 1.62 4.5 16.2 11.7 16.6 28.7 16.2 6.0 
          
a Bipolar Scale: Extremely Unlikely= -3; Quite unlikely= -2; Somewhat Unlikely= -1; Neither= 0; Somewhat Likely= +1; Quite Likely= +2; 
Extremely Likely= +3 
b Number of respondents for each item ranged from 263 to 266; Number of valid respondents used to compute the composite score N= 259 
 
     
176
Table 5.17   Outcome evaluations of physicians toward prescribing CR opioids to patients with chronic non-malignant pain 
 
Respondents were asked to rate the following indirect attitude question based on 10 outcome evaluation items: 
 
  Question:  “How good or bad do you feel each of the following outcomes (if they occurred) would  
                       be if you prescribed long-acting opioids to patients with moderate to severe CNMP?” 
 
    Frequency Distribution of Responses (%)a 
    
Extremely 
Bad   Neutral   
Extremely
Good 
Outcome Evaluation Items (ei) Nb Mean SD (-3) (-2) (-1) (0) (+1) (+2) (+3) 
1.  Leads to abusive behaviors 260 -2.02 1.06 37.3 40.0 14.2 6.2 1.2 0.4 0.8 
2.  Require additional patient history 260 0.16 1.12 0.4 4.6 18.8 48.1 13.8 11.2 3.1 
3.  Lengthen patient office visits 260 -0.54 0.98 0.8 12.7 40.8 35.4 7.7 1.2 1.5 
4.  Effective in controlling pain 260 1.75 1.14 0.8 1.2 2.7 6.9 20.8 41.9 25.8 
5.  Improve patient quality-of-life 261 2.03 1.13 0.8 1.1 2.3 4.2 13.0 39.1 39.5 
6.  Less expensive than short-acting opioids 260 1.31 1.16 0.4 0.8 4.6 20.0 24.2 36.2 13.8 
7.  More difficult to manage patients on multiple Rxs 260 -0.79 0.99 2.7 17.7 46.2 26.2 3.8 3.5 0.0 
8.  More difficult to manage patients with co-
morbidities 259 -0.86 0.98 3.9 17.8 47.9 23.9 3.9 2.7 0.0 
9.  Leads to increased regulatory scrutiny 261 -1.66 1.30 32.2 26.8 26.1 8.8 3.1 1.9 1.1 
10. Leads to patient addiction 258 -1.90 1.13 34.9 34.9 20.2 7.8 0.8 0.4 1.2 
          
a Bipolar Scale: Extremely Unlikely= -3; Quite unlikely= -2; Somewhat Unlikely= -1; Neither= 0; Somewhat Likely= +1; Quite Likely= +2; 
Extremely Likely= +3 
b Number of respondents for each item ranged from 259 to 261; Number of valid respondents used to compute the composite score N=250 
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 The composite score for indirect attitude was calculated from the cross-products 
of the mean behavioral belief (b1-10) and outcome evaluation (e1-10) items.  Table 5.18 
shows the mean cross-product scores (b1-10 x e 1-10) for each of the 10 questions and the 
“sum total” score for the overall belief-based attitude (Σb1-10Σe1-10).  An examination of 
the 10 items shows both positive and negative belief scores.  Overall, the family 
physician group showed a slightly favorable attitude (Mean=2.96, SD=17.75, possible 
range -90 to +90) toward prescribing CR opioids to patients with moderate to severe 
CNMP. 
 Positive mean scores were observed for five of the 10 belief-based items (items 1, 
2, 4, 5, and 6), indicating that physician respondents held favorable attitudes toward CR 
opioids for CNMP when considering each of the belief items independently.  Results 
show that physicians had a favorable attitude toward prescribing CR opioids for CNMP 
when considering its “effectiveness in controlling pain” (Mean=3.07, SD=2.85, possible 
range -9 to +9).  In addition, favorable attitudes were observed among the respondents 
when they considered how CR opioids might “improve the patients’ quality of life” 
(Mean=3.37, SD=3.32).   
 Negative mean scores were observed for the remaining five belief-based attitude 
items (items 3, 7, 8, 9, and 10).  Physicians were seen to have unfavorable attitudes 
toward prescribing CR opioids for CNMP when the issue of it leading to regulatory 
scrutiny was considered (Mean =-2.02, SD=1.06).  Unfavorable attitudes were also 
observed among the respondents when they considered how prescribing CR opioids to 
CNMP patients may lengthen patient office visits (Mean=-0.64, SD=2.34) or lead to 
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Table 5.18   Indirect Attitudes Composite Score (behavioral beliefs x outcome evaluations) 
 
Cross-products were calculated for behavioral belief (bi) and outcome evaluation (ei) question-items.  
 
  Behavioral-belief question:        “How likely do you think the following outcomes will occur if you prescribe long-acting opioids  
                                                          to patients with moderate to severe CNMP?” 
 
  Outcome evaluation question:   “How good or bad do you feel each of the following outcomes would be if you prescribed  
                                                          long-acting opioids to patients with moderate to severe CNMP?” 
 
  Score Rangea   
Question Items (Σ biei ) N b Min Max Meanc SD 
1.  Leads to abusive behaviors  (Σ b1e1) 261 -9 9 0.12 3.69 
2.  Requires additional patient history  (Σ b2e2) 260 -6 9 0.48 2.60 
3.  Lengthens patient office visits (Σ b3e3) 260 -9 9 -0.64 2.34 
4.  Effective in controlling pain (Σ b4e 4) 260 -4 9 3.07 2.85 
5.  Improve patient quality-of-life (Σ b5e5) 260 -6 9 3.37 3.22 
6.  Less expensive than short-acting opioids (Σ b6e6) 260 -9 9 0.56 3.01 
7.  More difficult to manage patients on multiple Rxs (Σ b7e7)  261 -9 6 -0.29 2.09 
8.  More difficult to manage patients with co-morbidities (Σ b8e8) 261 -9 6 -0.37 2.13 
9.  Leads to increased regulatory scrutiny (Σ b9e9) 261 -9 9 -2.71 3.80 
10. Leads to patient addiction (Σ b10e10) 258 -9 9 -0.51 3.81 
Indirect Attitude Composite Score 250 -54 53 2.96 d 17.75  
a Possible score range for each item -9 to +9; Possible range for sum total -90 to + 90 
b Number of respondents for each item ranged from 258 to 261; Number of valid respondents used to compute the composite score N=250 
c The average of cross-products for the behavioral-belief items and outcome evaluation items  
d Sum total represents the “Composite Score” for the 10 belief-based attitudes (Sum of b1e1 through b10e10 ) /10) 
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 Belief-based Subjective Norm 
 The belief-based subjective norm is comprised of two components, normative 
beliefs and motivation to comply.  For normative beliefs (ni), physicians were asked to 
rate the likelihood that seven individuals/groups (i.e. referents) would or would not want 
them to prescribe CR opioids to patients with moderate to severe CNMP.  Table 5.19 
illustrates the mean frequency and distribution of the normative beliefs (n1-7) which make 
up indirect subjective norm. 
 Next, motivation to comply (mi) was calculated for each of the normative beliefs.  
Family physicians were asked to respond to the likelihood that they would comply with 
the wishes of each of the referents.  Table 5.20 illustrates the mean frequency and 
distribution of the motivation to comply components (m1-7) which make up indirect 
subjective norm.   
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Table 5.19   Normative beliefs of physicians’ toward prescribing CR opioids to patients with chronic non-malignant pain  
 
Respondents were asked to rate the following indirect subjective norm question based on seven normative-belief items: 
 
  Question: “How likely is it that each of the following individuals or groups would think that you should prescribe  
                     long-acting opioids to patients with moderate to severe CNMP?” 
 
    Frequency Distribution of Responses (%)a 
    
Extremely 
Unlikely   Neutral   
Extremely
Likely 
Normative-Belief Item (ni) Nb Mean SD (-3) (-2) (-1) (0) (+1) (+2) (+3) 
1. Regulatory agencies 265 -0.65 1.54 13.6 18.1 25.3 15.8 17.7 9.1 0.4 
2. Other primary care physicians 265 -0.12 1.37 3.4 11.7 30.9 14.3 27.2 11.7 0.8 
3. Consumer groups 265 0.35 1.45 3.4 7.9 16.2 22.3 29.1 15.5 5.7 
4. Pain specialty groups 264 1.16 1.63 3.0 6.4 10.2 5.7 21.6 32.6 20.5 
5. Patients 265 1.62 1.04 0.8 0.4 2.6 6.4 29.8 41.9 18.1 
6. Texas Medical Board 265 -0.45 1.58 14.7 9.8 24.5 20.0 19.2 10.6 1.1 
7. Other healthcare providers and office staff 265 -0.09 1.36 4.9 9.8 23.0 27.2 23.4 10.2 1.5 
          
 
a Bipolar Scale: Extremely Unlikely= -3; Quite unlikely= -2; Somewhat Unlikely= -1; Neither= 0; Somewhat Unlikely= +1;  Quite Likely= +2; 
Extremely Likely= +3 
b Number of respondents for each item ranged from 264 to 265; Number of valid respondents used to compute the composite score N=264 
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Table 5.20   Motivation to comply of physicians’ toward prescribing CR opioids to patients with chronic non-malignant pain  
 
Respondents were asked to rate the following indirect subjective norm question based on seven motivation to comply belief items: 
 
  Question:  “How likely are you to do what the following individuals or groups want you to do when prescribing  
                      long-acting opiates to patients with moderate to severe CNMP?” 
 
    Frequency Distribution of Responses (%)a 
    
Extremely 
Unlikely   Neutral   
Extremely
Likely 
Motivation to Comply Item (mi) Nb Mean SD (-3) (-2) (-1) (0) (+1) (+2) (+3) 
1. Regulatory agencies 257 1.39 1.42 2.3 3.9 3.5 10.5 23.7 34.6 21.4 
2. Other primary care physicians 258 0.44 1.19 2.7 3.9 10.9 29.5 37.2 14.0 1.9 
3. Consumer groups 258 -0.26 1.22 6.6 9.7 16.7 41.9 20.5 4.3 0.4 
4. Pain specialty groups 258 0.90 1.29 1.6 4.7 5.8 20.2 34.5 25.2 8.1 
5. Patients 258 0.55 1.13 1.6 4.3 7.4 31.0 39.1 14.0 2.7 
6. Texas Medical Board 257 1.57 1.40 1.9 1.6 3.9 14.8 16.3 30.7 30.7 
7. Other healthcare providers and office staff 257 0.07 1.22 3.9 7.8 12.5 39.7 26.5 8.6 1.2 
          
a Bipolar Scale: Extremely Unlikely= -3; Quite unlikely= -2; Somewhat Unlikely= -1; Neither= 0; Somewhat Likely= +1; Quite Likely= +2; 
Extremely Likely= +3 
b Number of respondents for each item ranged from 257 to 258; Number of valid respondents used to compute the composite score N=255 
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 Table 5.21 shows the mean cross-product scores (ni x mi) for each of the seven 
questions and the composite score for indirect subjective norm (Σn1-7m1-7).  Overall, 
family physicians showed a positive subjective norm score (Mean=2.19, SD=11.75, 
possible range -63 to +63).  Interpretation of the results indicates a fairly weak positive 
social pressure for physicians to prescribe CR opioids to patients with moderate to severe 
CNMP. 
 Both positive and negative belief scores were observed among the subjective 
norm items.  Positive mean scores were observed for five of the seven subjective norm 
items (items 2, 3, 4, 5, and 7).  Respondents indicated that “pain specialty groups” were 
likely to want them to prescribe CR opioids to treat CNMP patients (Mean=1.76, 
SD=3.04) and physicians indicated that were likely to do what the pain specialists wanted 
them to do.  In addition, physicians indicated that they believed “patients” would exert a 
positive social pressure for them to prescribe CR opioids (Mean=1.03, SD=2.35). 
 Negative mean scores were observed for belief items one and six  For item-1, 
physician respondents indicated that “regulatory agencies” were not likely to want them 
to prescribe CR opioids to treat CNMP patients (mean=-0.83, SD=3.51) and respondents 
indicated that were likely to do what the “regulatory agencies” wanted them to do. 
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Table 5.21   Indirect Subjective Norm Composite Score (normative beliefs x motivation to comply) 
 
  Cross-products were calculated for the normative belief (ni) and motivation to comply (mi) question-items.  
 
  Normative belief question:          “How likely is it that each of the following individuals or groups would think that  
                                                           you should prescribe long-acting opioids to patients with moderate to severe CNMP?” 
 
  Motivation to comply question:  “How likely are you to do what the following individuals or groups want you   
                                                            to do when prescribing long-acting opiates to patients with moderate to severe CNMP?” 
 
 
  Score Rangea   
Question Items (Σ nimi) N b Min Max Meanc SD 
1.  Regulatory agencies  (Σ n1m1) 258 -9 9 -0.83 3.51 
2.  Other primary care physicians  (Σ n2m2) 258 -9 9 0.24 2.02 
3.  Consumer groups  (Σ n3m3) 259 -9 9 0.07 2.07 
4.  Pain specialty groups  (Σ n4m4) 257 -6 9 1.76 3.04 
5.  Patients  (Σ n5m5) 259 -9 9 1.03 2.35 
6.  Texas Medical Board  (Σ n6m6) 258 -9 9 -0.45 3.82 
7.  Other healthcare providers and office staff  (Σ n7m7) 260 -6 9 0.37 1.82 
Indirect Subjective Norm Composite Score 255 -30 45 + 2.19 d 11.75  
 
a Possible score range for each item -9 to +9; Possible range for sum total -63 to + 63 
b Number of respondents for each item ranged from 257 to 260; Number of valid respondents used to compute the composite score N=255) 
c The average of cross-products for the behavioral-belief items and outcome evaluation items  
d Sum total represents the “Composite Score” for the 7 belief-based subjective norms (Sum of n1m1 through n7m7 ) /7) 
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 Belief-based Perceived Behavioral Control (PBC) 
 Indirect perceived behavioral control is comprised of two components, control 
beliefs and perceived power.  For control beliefs (ci), family physicians were asked to 
evaluate 10 factors that would make it easier or more difficult for them to prescribe CR 
opioids to patients with moderate to severe CNMP.  Table 5.22 illustrates the mean 
frequency and distribution of the control beliefs (c1-10) which make-up indirect PBC. 
 Next, perceived power (pi) was calculated.  Family physicians were asked to rate 
“how much power” they feel they have over the respective control belief item when 
prescribing CR opioids to patients with moderate to severe CNMP.  Table 5.23 illustrates 
the mean frequency and distribution for the 10 perceived power items (p1-10).  
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Table 5.22   Control beliefs of physicians’ toward prescribing CR opioids to patients with chronic non-malignant pain 
 
Respondents were asked to rate the following indirect PBC question based on 10 control-belief items: 
 
  Question: “Will the following factors make it easy or difficult for you to prescribe long-acting opioids  
                      to patients with moderate to severe CNMP?” 
 
    Frequency Distribution of Responses (%)a 
    
Extremely 
Difficult   Neutral   
Extremely
Easy 
Control Belief Items (ci) Nb Mean SD (-3) (-2) (-1) (0) (+1) (+2) (+3) 
1.  More knowledge in pain management 264 1.34 1.00 0.4 1.5 1.5 12.1 38.3 37.5 8.7 
2.  Access to pain management tools 264 1.27 1.05 0.4 2.3 1.5 14.8 36.4 36.4 8.3 
3.  Writing triplicate prescriptions 264 -0.51 1.33 3.8 15.9 40.5 20.1 9.5 7.6 2.7 
4.  Managing patients who are on multiple medications 264 -0.59 1.12 3.8 11.0 46.2 24.6 9.5 3.8 1.1 
5.  Receiving full compensation for services associated 
     with prescribing CR opioids 264 0.54 1.46 3.0 6.8 12.5 23.1 26.9 20.5 7.2 
6.  Access to multidisciplinary teams 264 0.91 1.44 3.0 3.8 11.4 12.5 29.5 30.3 9.5 
7.  Ready access to patient medical records 264 1.14 1.36 1.5 3.4 8.7 12.1 27.7 33.7 12.9 
8.  More evidence-based studies 263 1.17 1.26 0.8 2.3 5.7 19.0 28.5 29.7 14.1 
9.  Managing patients who have co-morbidities 263 -0.29 1.20 2.3 9.1 37.3 28.5 14.4 6.5 1.9 
10. Less regulatory scrutiny 263 0.97 1.33 2.7 1.9 6.1 21.3 33.1 23.2 11.8 
          
a Bipolar Scale: Extremely Unlikely= -3; Quite unlikely= -2; Somewhat Unlikely= -1; Neither= 0; Somewhat Likely= +1; Quite Likely= +2; 
Extremely Likely= +3 
b Number of respondents for each item ranged from 263 to 264; Number of valid respondents used to compute the composite score N=261) 
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Table 5.23   Perceived power of physicians’ over prescribing CR opioids to patients with chronic non-malignant pain 
 
Respondents were asked to rate the following indirect PBC question based on 10 perceived power items: 
 
  Question: “How much control do you feel you have over the following when it comes to prescribing  
                      long-acting opioids to patients with moderate to severe CNMP?” 
 
    Frequency Distribution of Responses (%)a 
    
No  
Control      
Complete 
Control
Perceived Power Items (pi) Nb Mean SD (+1) (+2) (+3) (+4) (+5) (+6) (+7) 
1.  More knowledge in pain management 261 4.11 1.12 1.1 0.4 4.2 24.1 28.0 35.2 6.9 
2.  Access to pain management tools 261 3.41 1.19 2.3 1.5 15.3 36.8 24.1 17.6 2.3 
3.  Writing triplicate prescriptions 259 3.32 2.07 19.7 2.3 10.8 12.0 18.5 21.6 15.1 
4.  Managing patients who are on multiple medications 257 3.62 1.21 1.6 3.1 9.3 32.3 29.2 20.2 4.3 
5.  Receiving full compensation for services associated 
     with prescribing CR opioids 258 1.46 1.48 39.1 14.3 22.1 14.3 6.2 3.5 0.4 
6.  Access to multidisciplinary teams 259 2.10 1.39 16.6 15.8 28.6 23.6 11.6 3.1 0.8 
7.  Ready access to patient medical records 259 2.95 1.53 6.9 10.0 20.5 29.0 15.8 13.1 4.6 
8.  More evidence-based studies 257 2.54 1.57 13.6 12.8 19.5 27.6 15.2 8.9 2.3 
9.  Managing patients who have co-morbidities 259 3.27 1.32 3.9 5.8 14.3 32.0 26.3 15.4 2.3 
10. Less regulatory scrutiny 256 1.09 1.49 56.3 12.5 10.9 10.5 6.3 3.5 0.0 
          
 
a Unipolar Scale: No Control = +1; +2; +3; +4;  +5; +6 Complete Control = +7 
b Number of respondents for each item ranged from 257 to 261; Number of valid respondents used to compute the composite score N=261) 
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 The composite score for indirect perceived behavioral control was calculated from 
the cross-products of the mean control belief (c1-10) and outcome evaluation (p1-10) items.  
Table 5.24 illustrates the mean cross-product scores (ci x pi) for each of the 10 perceived 
behavioral control (PBC) items and the “sum total” (Σ c1-10p1-10), yielding the indirect 
PBC composite score.  Overall, respondents showed a slightly favorable belief-based 
PBC composite score (Mean=18.02, SD=32.27, possible range -210 to +210).  
Interpretation of the indirect PBC score indicates that, overall, respondents felt slightly in 
control of prescribing CR opioids to patients with moderate to severe CNMP.  
 Positive mean scores were observed for seven of the 10 PBC items (items 1, 2, 5, 
6, 7, 8, and 10).  Each of these factor-items were perceived to make it easier for 
physicians to prescribe CR opioids for CNMP (i.e. physicians felt more in control of 
prescribing CR opioids when the factor was present).  Results showed that possessing 
“more knowledge in pain management” allowed respondents to feel more in control of 
prescribing CR opioids for CNMP (Mean=5.62, SD=4.57, possible range -21 to +21).  In 
addition, respondents believed that “access to pain management tools” allowed them to 
feel more in control over prescribing CR opioids (Mean=4.38, SD=4.23, range -21 to 
+21). Other items such as access to patient medical records, more evidence-based studies, 
and access to multidisciplinary teams allowed respondents to feel more in control of 
prescribing CR opioids for CNMP.  
 Negative mean scores were observed for three items (items 3, 4, and 9).  Each 
factor-item was perceived to make it slightly more difficult for physicians to prescribe 
CR opioids for CNMP, meaning physicians felt they had less control over prescribing CR 
opioids when this factor was present.  Results showed that “managing patients on 
multiple medications” caused respondents to slightly feel in less control of prescribing 
CR opioids for CNMP (Mean =-1.62 , SD=4.34, possible range -21 to +21).  The next 
sections will examine the results for the hypotheses tests conducted. 
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Table 5.24   Indirect Perceived Behavioral Control Composite Score (control beliefs x perceived power) 
 
Cross-products were calculated for the control belief (ci) and perceived power (pi) question-items.  
 
  Control-belief question:       “Will the following factors make it easy or difficult for you to prescribe long-acting   
                                                   opioids to patients with moderate to severe CNMP”  
 
  Perceived power question:   “How much control do you feel you have over the following when it comes to  
                                                   prescribing long-acting opioids to patients with moderate to severe CNMP?” 
 
  Score Rangea   
Question Items (Σ cipi ) N b Min Max Meanc SD 
1.  More knowledge in pain management (Σ c1p1) 262 -12 18 5.63 4.57 
2.  Access to pain management tools (Σ c2p2) 262 -12 18 4.38 4.23 
3.  Writing triplicate prescriptions (Σ c3p3) 259 -18 18 -0.55 5.71 
4.  Managing patients who are on multiple medications (Σ c4p4) 258 -15 18 -1.62 4.34 
5.  Full compensation for services associated w/ Rx CR opioids (Σ c5p5) 260 -8 15 0.73 2.66 
6.  Access to multidisciplinary teams (Σ c6p6) 260 -15 15 2.05 3.66 
7.  Ready access to patient medical records (Σ c7p7) 260 -8 18 3.72 4.41 
8.  More evidence-based studies (Σ c8p8) 257 -15 18 3.10 4.20 
9.  Managing patients who have co-morbidities (Σ c9p9) 260 -10 18 -0.34 4.32 
10. Less regulatory scrutiny (Σ c10p10) 259 -15 15 0.92 2.92 
Indirect Perceived Behavioral Control Composite Score 248 -75 +144 +18.02d 32.27  
a Possible score range for each item -21 to +21; Possible range for sum total -210 to + 210 
b Number of respondents for each item ranged from 257 to 262; Number of valid respondents used to compute the composite score N=248) 
c The average of cross-products for the behavioral-belief items and outcome evaluation items  
d Sum total represents the “Composite Score” for the 10 belief-based perceived behavioral control (Sum of c1p1 through c10p10 ) /10) 
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Table 5.25 illustrates a summary of the composite mean scores yielded for each of the 
direct and indirect TPB constructs.  
 
Table 5.25 Summary of the Composite Scores for the Direct and Indirect Constructs  
Theory of Planned Behavior Constructs  
  Score Range   Possible 
Variables N Min Max Mean SD Score Range
Direct TPB Constructs        
Willingness 267  -3 +3 0.47 a 1.71 -3 +3 
Direct Attitude 263 -15 +15 3.96 b 6.33 -15 +15
Direct Subjective Norm 264 -3 +3 1.03 c 1.52 -3 +3 
Direct Perceived Behavioral Control 259 -6 +6 1.45 d 3.12 -6 +6 
        
Indirect (belief-based)TPB Constructs         
Belief-Based Attitude 250 -54 +53 2.96 e 17.75 -90 +90
Belief-Based Subjective Norm 255 -30 +45 2.19 f 11.75 -63 +63
Belief-Based Perceived Behavioral Control 248 -75 +144 18.02 g 32.27 -210 +210
a Score for 1 willingness measure item 
b Sum Score for 5 direct attitude items  
c Score for 1 direct subjective norm item 
d Sum Score for 2 direct perceived behavioral control items 
e Composite Score for the 10 belief-based attitudes (Sum of b1e1 through b10e10 ) /10) 
f Composite Score for the 7 belief-based subjective norms (Sum of n1m1 through n7m7 ) /7) 








Hypotheses Tests  
 Several statistical tests were conducted to assess the utility of the Theory of 
Planned Behavior (TPB) model in explaining family physicians’ willingness to prescribe 
CR opioids to patients with moderate to severe CNMP.  This section presents the results 
of the hypotheses tests conducted.   
 
H1:  Attitude, subjective norm, and perceived behavioral control constructs will 
explain a significant amount of variance in physicians’ willingness to 
prescribe CR opioids to patients with moderate to severe CNMP. 
 
 For H1, multiple regression analysis was used to regress the willingness variable 
on to the direct and indirect TPB constructs (attitude, subjective norm, and perceived 
behavioral control).  As shown in Table 5.26, the direct TPB model accounted for 49 
percent of the variance in explaining family physicians willingness to prescribe CR 
opioids to patients with CNMP.  Results show all three direct measure constructs as 
significant predictor variables, yielding a statistically significant overall model 
(F3,252=81.5, p<0.001). Therefore, H1 was supported using the direct TPB constructs. 
 
 
Table 5.26 Multiple regression analysis for direct measure constructs of the Theory 
of Planned Behavior Constructs 
 










Error Beta P Values
 0.70 0.49 0.49     
Attitude    0.12 0.014 0.45 p<0.001
Subjective Norm    0.23 0.060 0.21 p<0.001
Perceived 
Behavioral Control 
   0.12 0.027 0.22 p<0.001
         
Total sample size N=256 
Dependent variable = Willingness 




Table 5.27 Multiple regression analysis for indirect measure (belief-based) constructs 
of the Theory of Planned Behavior 
 










Error Beta P Values
 0.63 0.39 0.38     
Attitude    0.04 0.005 0.41 p<0.001
Subjective Norm    0.03 0.008 0.20 p<0.001
Perceived 
Behavioral Control 
   0.01 0.003 0.20 p=0.001
         
Total sample size N=226 
Dependent variable = Willingness 
Independent variables = Attitude, Subjective Norm, and Perceived Behavioral Control 
 
 Table 5.27 shows the indirect (belief-based) TPB constructs accounted for 39 
percent of the variance in explaining willingness to prescribe CR opioids to patients with 
moderate to severe CNMP.  Results showed all three belief-based constructs as 
significant predictor variables in the model.  The overall model was statistically 
significant (F3,222=47.4, p<0.001).  Therefore, H1 was supported using the belief-based 
constructs (indirect TPB model).  The following hypotheses examined the predictive 
strength of each direct and indirect TPB variables. 
  
H2: Favorable attitudes will be a positive and significant predictor of 
willingness to prescribe CR opioids to patients with moderate to severe 
CNMP, controlling for subjective norm and perceived behavioral control.  
 
H3: Social norms supporting the prescribing of CR opioids to patients with 
moderate to severe CNMP will be a positive and significant predictor of 
willingness to prescribe, controlling for attitude and perceived behavioral 
control. 
 
H4: Higher perceptions of behavioral control will be a positive and significant 
predictor of willingness to prescribe CR opioids to patients with moderate 
to severe CNMP, controlling for attitude and perceived behavioral control. 
 
 For H2, H3, and H4, the beta weights for direct and indirect measures of attitude,  
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subjective norm and perceived behavioral control were examined to determine the 
positive/negative relationships each variable has with willingness (refer to results in 
Tables 5.26 and 5.27).  For H2, regressing willingness on attitude yielded a significant 
overall model with statistically significant and positive beta weights observed for both 
direct attitude (β=0.45, p<0.001) and indirect attitude (β=0.41, p<0.001) constructs.  For 
H3, statistically significant and positive beta weights were observed for both direct 
subjective norm (β=0.21, p<0.001) and indirect subjective norm (β=0.20, p<0.001) 
constructs.  Results for H4 showed statistically significant and positive beta weights for 
direct perceived behavioral control (β=0.22, p<0.001) and indirect perceived behavioral 
control (β=0.20, p<0.001) constructs.  Therefore, H2, H3, and H4 were supported using 
both direct and indirect belief-based TPB models. 
 
 Belief-Based Attitudes vs. Willingness 
 Each of the TPB constructs were significant predictors of willingness to prescribe.  
As a result, further analyses of the belief-based constructs were conducted to assess how 
each construct differed among physicians willing to prescribe CR opioids for CNMP and 
those unwilling.  Since attitudes were seen to be a significant positive predictor of 
willingness, t-tests were conducted to assess which behavioral beliefs (bi), outcome 
evaluations (ei), and products (bixei) differed significantly among willing and unwilling 
respondents.  For this analysis, willingness was converted to a dichotomous variable.  
Based on the 7-point bipolar willingness scale, willing respondents scored +1 to +3 and 
unwilling respondents scored -1 to -3.  Neutral responders (scoring 0) were not included 
in the analysis.  Tables 5.28, 5.29, and 5.30 illustrate the differences observed among 
willing/unwilling physicians for bi, ei, and bixei components.    
 For behavioral beliefs, statistically significant differences existed in the mean bi 
scores among physicians willing to prescribe versus those unwilling except for the 
following item, “will be less expensive than short-acting opioids” (Table 5.28).  For ei, 
significant differences existed for all mean ei scores except for “abusive behaviors,” 
“increased regulatory scrutiny,” and “patient addiction” (Table 5.29). All product mean 
scores bixei were significant between willing and unwilling physicians (Table 5.30).  
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Table 5.28 Behavioral beliefs among family physicians willing versus unwilling to 
prescribe CR opioids to patients with moderate to severe CNMP 
 
Mean Scores for 
Behavioral Belief items (bi)a  
Question: How likely do you think the following 















-0.54 0.69 -6.64 
(1.43) (1.38) (p<0.001)
a.  Will lead to abusive behaviors  (N=253) (n=166) (n=87)  
1.95 1.45 2.87 
(1.05) (1.42) (p<0.005)
b.  Will require additional patient history  (N=251) (n=165) (n=86)  
0.83 1.25 -2.10 
(1.50) (1.56) (p<0.035)
c.  Will lengthen patient office visits  (N=254) (n=167) (n=87)  
1.69 0.70 6.11 
(0.96) (1.35) (p<0.001)
d.  Will be effective in controlling pain  (N=254) (n=167) (n=87)  
1.80 0.45 8.65 
(0.96) (1.27) (p<0.001)
e.  Will improve patient quality-of-life  (N=253) (n=166) (n=87)  
0.29 -0.07 1.96 
(1.53) (1.29) (p=0.052)f.  Will be less expensive than short-acting opioids 
     (N=254) (n=167) (n=87)  
-0.38 0.51 -4.61 
(1.47) (1.40) (p<0.001)g.  Will be more difficult to manage patients on  
     multiple prescriptions (N=254) (n=167) (n=87)  
-0.45 0.52 -5.24 
(1.42) (1.36) (p<0.001)h.  Will be more difficult to manage patients with  
      co-morbidities (N=253) (n=166) (n=87)  
1.12 1.70 -3.19 
(1.40) (1.34) (p=0.002)i.  Will lead to increased regulatory scrutiny  
    (N=254) (n=167) (n=87)  
-0.31 1.11 -7.87 
(1.60) (1.23) (p<0.001)
j.  Will lead to patient addiction (N=253) (n=166) (n=87)  
 
a Bipolar Scale: Extremely Unlikely= -3; Quite Unlikely= -2; Somewhat Unlikely= -1; Neither= 0; Somewhat Likely= +1; Quite 




Table 5.29  Outcome evaluations among family physicians willing and unwilling 
to prescribe CR opioids to patients with moderate to severe CNMP 
 
Mean Scores for  
Outcome Evaluation items 
(ei) a  
Question: How good or bad do you feel each of the 
following outcomes would be if you prescribed CR 
opioids for CNMP? 
 
 











-1.97 -2.14 1.127 
(0.95) (1.23) (p=2.62) 
a.  Will lead to abusive behaviors  (N=249) (n=164) (n=85)  
0.34 -0.17 3.47 
(1.14) (1.04) (p<0.001)
b.  Will require additional patient history  (N=249) (n=163) (n=86)  
-0.41 -0.76 2.65 
(0.97) (0.99) (p<0.01) 
c.  Will lengthen patient office visits  (N=249) (n=163) (n=86)  
2.02 1.31 4.49 
(0.98) (1.27) (p<0.001)
d.  Will be effective in controlling pain  (N=249) (n=163) (n=86)  
2.36 1.48 5.50 
(0.86) (1.35) (p<0.001)
e.  Will improve patient quality-of-life  (N=249) (n=164) (n=86)  
1.43 1.09 2.193 
(1.15) (1.14) (p<0.03) f.  Will be less expensive than short-acting opioids 
     (N=249) (n=163) (n=86)  
-0.63 -1.11 3.70 
(0.95) (0.99) (p<0.001)g.  Will be more difficult to manage patients on  
     multiple prescriptions (N=249) (n=164) (n=85)  
-0.72 -1.13 3.19 
(0.94) (1.01) (p<0.001)h.  Will be more difficult to manage patients with  
     co-morbidities (N=248) (n=163) (n=85)  
-1.63 -1.70 3.62 
(1.20) (1.52) (p=0.064)i.  Will lead to increased regulatory scrutiny  
    (N=249) (n=164) (n=86)  
-1.82 -2.06 1.57 
(1.02) (1.30) (p<0.118)
j.  Will lead to patient addiction (N=248) (n=163) (n=85)  
 
a Bipolar Scale: Extremely Bad= -3; Quite Bad = -2; Somewhat Bad = -1; Neither= 0; Somewhat Good= +1; Quite Good = +2; 




Table 5.30 Indirect attitude products (behavioral beliefs x outcome evaluations) of 
family physicians willing/unwilling to prescribe CR opioids to patients 
with moderate to severe CNMP 
 
Means scores for  
attitude cross-products  
(bi x ei) a  
Cross-products were calculated for behavioral belief (bi) 
and outcome evaluation (ei) question-items. 
 











0.98 -1.41 5.07 
(3.40) (3.79 (p<0.001)
a.  Will lead to abusive behaviors  (N=250) (n=164) (n=86)  
0.96 -0.40 4.24 
(2.77) (2.17) (p<0.001)
b.  Will require additional patient history  (N=249) (n=163) (n=86)  
-0.27 -1.34 3.47 
(2.21) (2.48) (p=0.001)
c.  Will lengthen patient office visits  (N=249) (n=163) (n=86)  
3.90 1.72 6.12 
(2.60) (2.80) (p<0.001)
d.  Will be effective in controlling pain  (N=249) (n=163) (n=86)  
4.64 1.38 8.88 
(2.73) (2.81) (p<0.001)
e.  Will improve patient quality-of-life  (N=249) (n=163) (n=86)  
0.93 0.02 2.47 
(3.27) (2.42) (p<0.001)f.  Will be less expensive than short-acting opioids 
     (N=249) (n=163) (n=86)  
0.09 -0.98 3.50 
(1.82) (2.49) (p<0.001)g.  Will be more difficult to manage patients on  
     multiple prescriptions (N=249) (n=164) (n=85)  
-0.01 -1.01 3.27 
(1.88) (2.50) (p=0.001)h.  Will be more difficult to manage patients with  
     co-morbidities (N=249) (n=163) (n=86)  
-2.24 -3.56 2.48 
(3.53) (4.23) (p=0.014)i.  Will lead to increased regulatory scrutiny  
     (N=259) (n=164) (n=86)  
0.59 -2.40 6.27 
(3.55) (3.59) (p<0.001)
j.  Will lead to patient addiction (N=247) (n=162) (n=85)  





 Belief-Based Subjective Norm vs. Willingness  
 Subjective norm was seen as a significant positive predictor of willingness for 
both TPB models.  As a result, t-tests were conducted for the belief-based subjective 
norm components.  Respondents’ normative beliefs (ni), motivation to comply (mi), and 
cross-products (nixmi) were examined to determine if significant differences existed 
among physicians willing to prescribe CR opioids versus those unwilling to prescribe.  
Tables 5.31, 5.32, 5.33 show the results of each of the constructs components.   
     For normative belief items, statistically significant differences existed in all ni 
mean scores between willing and unwilling respondents except for “consumer groups” 
and “patients” (Tables 5.31).  Mean motivation to comply scores were statistically 
significant among willing and unwilling respondents for only two mi items, “pain 
specialty groups” and “patients” (Table 5.32).  Subjective norm cross product scores were 
significant among the two groups for all nixmi items except for “consumer groups” and 



















Table 5.31 Normative beliefs of family physicians willing/unwilling to 
prescribe CR opioids to patients with moderate to severe CNMP 
 
Mean scores for  
Normative Beliefs (n i)a  
Question: How likely do you think each of the following 
referents would want you to prescribe CR opioids to 
patients with CNMP? 
 
 











-0.42 -1.12 3.48 
(1.52) (1.50) (p<0.001)
a.  Regulatory agencies (N=253) (n=167) (n=86)  
0.22 -0.80 5.88 
(1.33) (1.28) (p<0.001)
b.  Other primary care physicians  (N=253) (n=167) (n=86)  
0.41 0.21 1.05 
(1.42) (1.53) (p=0.293)
c.  Consumer groups N=253) (n=167) (n=86)  
1.53 0.44 4.91 
(1.41) (1.79) (p<0.001)
d.  Pain specialty groups (N=252) (n=166) (n=86)  
1.69 1.52 1.28 
(1.03) (0.97) (p=0.203)
e.  Patients (N=253) (n=167) (n=86)  
-0.17 -0.91 3.61 
(1.59) (1.44) (p<0.001)
f.  Texas Medical Board (N=253) (n=167) (n=86)  
0.17 -0.57 4.17 
(1.34) (1.32) (p<0.001)g.  Other healthcare providers and office staff  
     (N=253) (n=167) (n=86)  
 
a Bipolar Scale: Extremely Unlikely= -3; Quite Unlikely= -2; Somewhat Unlikely= -1; Neither= 0; Somewhat Likely= +1;  Quite 












Table 5.32 Motivation to comply among family physicians willing/unwilling to 
prescribe CR opioids to patients with moderate to severe CNMP 
 
Mean Scores for  
Motivation to Comply (m i)a  
Question: How likely are you to do what the following 















1.42 1.38 0.217 
(1.37) (1.50) (p=0.829)
a.  Regulatory agencies (N=245) (n=161) (n=84)  
0.43 0.48 -0.292 
(1.25) (1.15) (p=0.771)
b.  Other primary care physicians  (N=246) (n=161) (n=85)  
-0.22 -0.35 0.820 
(1.30) (1.10) (p=0.413)
c.  Consumer groups N=246) (n=161) (n=85)  
1.18 0.34 4.98 
(1.31) (1.15) (p<0.001)
d.  Pain specialty groups (N=246) (n=161) (n=85  
0.86 -0.01 6.04 
(1.00) (1.20) (p<0.001)
e.  Patients (N=246) (n=161) (n=85  
1.58 1.64 -.287 
(1.36) (1.48) (p=0.774)
f.  Texas Medical Board (N=245) (n=160) (n=85  
0.18 -0.07 1.54 
(1.22) (1.21) (p=0.126)g.  Other healthcare providers and office staff  
     (N=245) (n=161) (n=84)  
 
a Bipolar Scale: Extremely Unlikely= -3; Quite Unlikely= -2; Somewhat Unlikely= -1; Neither= 0; Somewhat Likely= +1; Quite 











Table 5.33 Indirect subjective norm products (normative beliefs x motivation to 
comply) of family physicians willing/unwilling to prescribe CR opioids 
to patients with moderate to severe CNMP 
 
Means Scores for 
 SN cross-products (n i x m i)a  Cross-products were calculated for normative beliefs (ni) 
and motivation to comply (mi) question-items. 
 
 











-0.36 -1.66 2.77 
(3.25) (3.91) (p<0.01) 
a.  Regulatory agencies (N=246) (n=161) (n=85)  
0.50 -0.25 2.72 
(1.92) (2.25) (p<0.01) 
b.  Other primary care physicians (N=246) (n=161) (n=85)  
0.27 -0.24 1.83 
(2.16) (1.95) (p=0.068)
c.  Consumer groups (N=247) (n=161) (n=86)  
2.49 0.52 5.02 
(3.18) (2.37) (p<0.001)
d.  Pain specialty groups (N=245) (n=160) (n=85)  
1.60 0.03 5.20 
(2.15) (2.45) (p<0.001)
e.  Patients (N=247) (n=161) (n=86)  
0.19 -1.56 3.47 
(3.56) (4.15) (p=0.001)
f.  Texas Medical Board (N=246) (n=161) (n=85)  
0.49 0.09 1.62 
(1.62) (2.17) (p=0.106)g.  Other healthcare providers and office staff  
     (N=248) (n=163) (n=85)  
 












 Perceived Behavioral Control vs. Willingness 
 Perceived behavioral control (PBC) was seen as a significant positive predictor of 
willingness for both TPB models.  As a result, t-tests were conducted for the belief-based 
PBC components.  Respondents’ control beliefs (ci), perceived power (pi), and cross-
products (cixpi) were examined to determine if significant differences existed among 
physicians willing to prescribe CR opioids for moderate to severe CNMP versus those 
unwilling to prescribe.  Tables 5.34, 5.35, 5.36 show the results of each of the constructs 
components.   
 For control beliefs, statistically significant differences existed for all mean ci item 
scores among willing and unwilling respondents. Further, larger differences in mean 
scores were observed among the following items, “More knowledge in pain 
management” and “Access to pain management tools.” For perceived power, statistically 
significant differences existed in the mean pi scores between the two groups for the 
following five items, “Managing patients who are on multiple medications,” “Access to 
multidisciplinary specialty groups,” “Ready access to patient medical records,” 
“Managing patients who have co-morbidities,” and “Less regulatory scrutiny.”  All 
















Table 5.34 Control beliefs of family physicians willing/ unwilling to prescribe CR 
opioids to patients with moderate to severe CNMP 
 
Mean Scores for  
Control Beliefs (c i)a  
Question: Will the following factors make it easy or 















1.69 0.73 8.14 
(0.77) (1.08) (p<0.001)
a.  More knowledge in pain management (N=252) (n=167) (n=85)  
1.65 0.62 7.61 
(0.82) (1.10) (p<0.001)
b.  Access to pain management tools (N=252) (n=167) (n=85)  
-0.32 -0.92 3.43 
(1.34) (1.26) (p<0.001)
c.  Writing triplicate prescriptions (N=252) (n=167) (n=85)  
-0.39 -1.01 4.39 
(1.11) (1.04) (p<0.001)d.  Managing patients who are on multiple  
     medications (N=252) (n=167) (n=85)  
0.79 0.07 3.76 
(1.46) (1.36) (p<0.001)e.  Receiving full compensation for services  
     associated with prescribing CR opioids (N=252) (n=167) (n=85)  
1.17 0.44 3.92 
(1.40) (1.42) (p<0.001)f.  Access to multidisciplinary specialty  
     teams(N=252) (n=167) (n=85)  
1.44 0.64 4.67 
(1.30) (1.29) (p<0.001)
g.  Ready access to patient medical records (N=252) (n=167) (n=85)  
1.42 0.78 3.98 
(1.12) (1.38) (p<0.001)
h.  More evidence-based studies (N=251) (n=166) (n=85)  
-0.05 -0.77 4.64 
(1.20) (1.07) (p<0.001)i.  Managing patients who have co-morbidities  
     (N=251) (n=167) (n=84)  
1.11 0.78 1.89 
(1.34) (1.28) (p<0.001)
j. Less regulatory scrutiny (N=251) (n=166) (n=85)  
 
a Bipolar Scale: Extremely Unlikely= -3; Quite unlikely= -2; Somewhat Unlikely= -1; Neither= 0; Somewhat Likely= +1; Quite 





Table 5.35 Perceived power of family physicians willing/ unwilling to prescribe CR 
opioids to patients with moderate to severe CNMP 
 
Mean Scores for  
Perceived Power (p i)a  
Question: How much control do you feel you have over 















5.20 5.02 1.19 
(0.99) (1.28) (p=0.235)
a.  More knowledge in pain management (N=249) (n=166) (n=83)  
4.51 4.25 1.61 
(1.17) (1.25) (p=0.108)
b.  Access to pain management tools (N=249) (n=166) (n=83)  
4.31 4.37 -0.22 
(2.13) (2.02) (p=0.825)
c.  Writing triplicate prescriptions (N=247) (n=164) (n=83)  
4.80 4.32 2.92 
(1.14) (1.32) (p<0.01) d.  Managing patients who are on multiple  
     medications (N=245) (n=164) (n=81)  
2.45 2.43 0.14 
(1.47) (1.55) (p<0.891)e.  Receiving full compensation for services  
     associated with prescribing CR opioids (N=246) (n=165) (n=82)  
3.23 2.84 2.07 
(1.31) (1.53) (p<0.039)
f.  Access to multidisciplinary teams (N=246) (n=165) (n=82)  
4.10 3.66 2.15 
(1.48) (1.63) (p<0.033)
g.  Ready access to patient medical records (N=246) (n=165) (n=82)  
3.58 3.51 0.31 
(1.57) (1.62) (p<0.755)
h.  More evidence-based studies (N=246) (n=164) (n=82)  
4.52 3.79 4.16 
(1.28) (1.34) (p<0.001)i.  Managing patients who have co-morbidities  
     (N=246) (n=165) (n=82)  
2.21 1.79 2.23 
(1.56) (1.32) (p=0.027)
j. Less regulatory scrutiny (N=246) (n=163) (n=81)  
 





Table 5.36 Indirect PBC products (control beliefs x perceived power) of family 
physicians willing/ unwilling to prescribe CR opioids to patients with 
moderate to severe CNMP 
 
 
Mean Scores for  
PBC cross-products (c i x p i)a  
Indirect Perceived Behavioral Control Products 











8.84 3.76 7.59 
(4.51) (5.85) (p<0.001)
a.  More knowledge in pain management (N=250) (n=166) (n=84)  
7.43 2.62 7.68 
(4.36) (5.25) (p<0.001)
b.  Access to pain management tools (N=250) (n=166) (n=84)  
0.19 -3.46 3.98 
(6.89) (6.62) (p<0.001)
c.  Writing triplicate prescriptions (N=249) (n=164) (n=83)  
-1.37 -3.98 3.61 
(5.48) (4.99) (p<0.001)d.  Managing patients who are on multiple  
     medications (N=246) (n=165) (n=81)  
1.85 0.14 3.67 
(3.94) (3.19) (p<0.001)e.  Receiving full compensation for services  
     associated with prescribing CR opioids (N=246) (n=166) (n=83)  
3.64 1.81 2.84 
(5.16) (3.97) (p<0.01) 
f.  Access to multidisciplinary teams(N=248) (n=165) (n=83)  
6.15 2.72 5.31 
(5.78) (4.20) (p<0.001)
g.  Ready access to patient medical records (N=248) (n=165) (n=83)  
5.04 3.12 2.76 
(4.82) (5.74) (p<0.01) 
h.  More evidence-based studies (N=247) (n=163) (n=83)  
0.19 -2.26 3.73 
(5.84) (4.27) (p<0.001)i.  Managing patients who have co-morbidities  
     (N=248) (n=166) (n=82)  
2.23 1.31 2.1 
(4.11) (2.70) (p<0.05) 
j. Less regulatory scrutiny (N=247) (n=164) (n=83)  
 





Table 5.37 Results of Hierarchical Regression Analysis for direct measure constructs 
of the Theory of Planned Behavior 














Error Beta P Values
Model 1a          
 Attitude     0.13 0.014 0.49 p<0.001
 Subjective Norm 0.45 0.45 0.45 105.26 c 0.32 0.059 0.28 p<0.001
          
Model 2b          
 Attitude     0.12 0.014 0.45 p<0.001




Control 0.49 0.49 0.04 19.15 d 0.12 0.027 0.22 p<0.001
          
Total sample size N=256 
Dependent variable = Willingness 
a Model: Willingness = Direct Measure Attitude (A) + Direct Measure Subjective Norm (SN) 
b Model: Willingness = Direct A + Direct SN + Direct Measure Perceived Behavioral Control 
c d.f.=2,253, p<0.001;   
d d.f.=1,252, p<0.001 
 
H5:  The perceived behavioral control construct will significantly increase the 
explanatory power of the regression model compared to only using 
attitude and subjective norm to explain family physicians’ willingness to 
prescribe CR opioids to patients with moderate to severe CNMP. 
 
 Hierarchical Regression of the TPB Constructs  
 For H5, hierarchical multiple regression analysis was conducted to determine if 
the direct measure perceived behavioral control construct accounted for a significant 
increase in the variance explained beyond direct attitude and subjective norm measures.  
As shown in Table 5.37, the direct attitude and subjective norm measures (Model 1) 
accounted for 45.4 percent of the variance in explaining physicians’ willingness to 
prescribe CR opioids to patients with CNMP.  The perceived behavioral control variable 
was entered in a separate, last step (Model 2).  Adding perceived behavioral control 
significantly improved the overall model, accounting for 49.3 percent of the variance in 
physicians' willingness (R2 change=0.04, F Change 1,252=19.15, p<0.001).  Under Model 
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2, significant beta weights were observed for direct attitude (β=0.45, p<0.001), subjective 
norm (β=0.21, p<0.001), and perceived behavioral control constructs (β=0.22, p<0.001).  
Therefore, H5 was supported using the direct TPB constructs.  
 A second hierarchical regression analysis was conducted for the indirect (belief-
based) measure constructs.  As shown in Table 5.38, the belief-based attitude and 
subjective norm variables (Model 1) accounted for 35.7 percent of the variance in 
willingness to prescribe.  Adding the belief-based perceived behavioral control variable 
(Model 2) significantly improved the model, accounting for 39.1 percent of the variance 
in physicians’ willingness (R2 change=0.03, F Change 1,222=12.37, p<0.001).  Significant 
beta weights were observed for belief-based attitude (β=0.41, p<0.001), subjective norm 
(β=0.20, p<0.001), and perceived behavioral control (β=0.20, p<0.001).  Therefore, H5 
was supported using the indirect TPB constructs. 
 
Table 5.38 Results of Hierarchical Regression Analysis for indirect measure 
(belief-based) constructs of the Theory of Planned Behavior 














Error Beta P Values
Model 1a          
 Attitude     0.04 0.005 0.47 p<0.001
 Subjective Norm 0.36 0.35 0.36 61.88c 0.04 0.008 0.24 p<0.001
          
Model 2b          
 Attitude     0.04 0.005 0.41 p<0.001




Control 0.39 0.38 0.03 12.37 d 0.01 0.003 0.20 p<0.001
          
Total sample size N=226 
Dependent variable = Willingness 
a Model: Willingness = Indirect Measure Attitude (A) + Indirect Measure Subjective Norm (SN) 
b Model: Willingness = Indirect A + Indirect SN + Indirect Measure Perceived Behavioral Control 
c d.f.=2,223, p<0.001 
d d.f.=1,222, p<0.001 
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Table 5.39 Results of Hierarchical Regression Analysis for Recent Past Behavior 
with Direct Measure Theory of Planned Behavior Constructs 
















Error Beta P Values
Model 1a          
 Attitude     0.08 0.013 0.32 p<0.001




Control 0.49 0.49 0.49 80.77 c 0.07 0.025 0.13 p=0.007
          




Behavior 0.59 0.58 0.09 58.22 d 0.68 0.089 0.38 p<0.001
          
Total sample size N=255 
Dependent variable = Willingness 
a Model: Willingness = Direct Measure Attitude (A) + Direct Measure Subjective Norm (SN) + Direct Measure 
Perceived Behavioral Control (PBC) 
b Model: Willingness = Direct A + Direct SN + Direct PBC + Direct Recent Past Behavior 
c d.f.=2,251, p<0.001 
d d.f.=1,250, p<0.001 
 
 
H6: The recent past behavior construct will significantly increase the 
explanatory power of the regression model compared to only using the 
TPB constructs to explain physicians’ willingness to prescribe CR opioids 
to treat moderate to severe CNMP patients. 
 
 Hierarchical Regression of the TPB Constructs and Recent Past Behavior 
 For H6, hierarchical multiple regression analysis was conducted to determine if 
the recent past behavior variable adds to the prediction of family physicians’ willingness 
to prescribe CR opioids to patients with moderate to severe CNMP (beyond the TPB 
constructs).   Table 5.39 illustrates the results of the regression analysis for direct 
measure TPB constructs.  Results show recent past behavior (Model 2) to significantly 
improve the overall direct measure TPB model, accounting for 59 percent of the variance 
in physician willingness (R2 change=0.09, F Change 1,250=58.22, p<0.001).  Under the 
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model, significant beta weights were observed for direct attitude (β=0.32, p<0.001),    
subjective norm (β=0.16, p=0.002), perceived behavioral control (β=0.13, p=0.007), and 
recent past behavior (β=0.38, p<0.001).  Therefore, H6 was supported using direct 
measure TPB constructs. 
 A second hierarchical regression analysis was conducted using the indirect TPB 
measures.  Shown in Table 5.40, adding recent past behavior (Model 2) significantly 
improved the belief-based TPB model, accounting for 57 percent of the variance in 
willingness (R2 change=0.18, F Change 1,221=88.85, p<0.001).  Significant beta weights 
existed for belief-based attitude (β=0.25, p<0.001), subjective norm (β=0.10, p<0.001), 
perceived behavioral control (β=0.17, p<0.001), and recent past behavior (β=0.48,        
p<0.001). Therefore, H6 was supported using indirect measure TPB constructs. 
 
Table 5.40 Results of Hierarchical Regression Analysis for Recent Past Behavior with 
Indirect (belief-based) Measure Theory of Planned Behavior 
 














Error Beta P Values
         
Block 1a          
 Attitude     0.02 0.005 0.25 P<0.001




Control 0.39 0.38 0.39 c 47.48 0.01 0.003 0.17 P=0.001




Behavior 0.57 0.56 0.18 d 88.85 0.87 0.092 0.48 P<0.001
          
Total sample size N=255 
Dependent variable = Willingness 
a Model: Willingness = Indirect Measure Attitude (A) + Indirect Measure Subjective Norm (SN) + Indirect Measure 
Perceived Behavioral Control (PBC) 
b Model: Willingness = Indirect A + Indirect SN + Indirect PBC + Indirect Recent Past Behavior 
c d.f.=2,251, p<0.001 




H7: Physicians who have received continuing education (CE) in pain 
management will be more willing to prescribe CR opioids to moderate to 
severe CNMP patients versus physicians who have not received CE. 
 
H8: Physicians who have received CE in pain management will have more 
favorable attitudes toward prescribing CR opioids to patients with 
moderate to severe CNMP versus physicians who have not received CE. 
 
 Continuing Education vs. Willingness 
 For H7 and H8, two-tailed t-tests were conducted to examine the mean score 
differences for willingness and attitude among physicians who received continuing 
education (CE) in pain management versus physicians those who did not.  For H7, 
differences in willingness mean scores were observed between the two groups 
(willingness score range: -3 = unwilling to +3 = willing).  Results showed physicians who 
received CE in pain management in the last three years were slightly more willing to 
prescribe CR opioids to patients with moderate to severe CNMP (N=190, Mean=0.60, 
SD=1.6) versus physicians who had not received CE (N=72; Mean=0.14, SD=1.72).      
T-test analysis showed the differences between willing and unwilling physicians to be 
statistically significant (t=1.97, d.f.=260, p<0.05), therefore H7 was supported. 
 
 Continuing Medical Education vs. Attitudes 
 For H8, t-tests were conducted for both direct and indirect attitude measures.  
Results showed statistically significant differences for the direct measure of attitude 
(possible score range -16 to +16) among physicians who had received CME versus those 
who had not.  Physicians who received CME in pain management in the last three years 
held more favorable attitudes toward prescribing CR opioids to patients with moderate to 
severe CNMP (N=189, Mean=4.49, SD=6.40) compared to the attitudes of physicians 
who had not received CE (N=71; Mean=2.45, SD=5.92).  The mean score difference 
between the two groups was statistically significant (t=2.33, d.f.=258, p=0.02).  
Therefore, H8 was supported using the direct attitude construct.  T-tests were also 
performed using the indirect attitude measure (score range -90 to +90).  Results showed 
physicians receiving CME in the last three years held more favorable attitudes toward 
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prescribing CR opioids for CNMP (N=181, Mean=4.21, SD=17.41) compared to those 
who had no exposure CME (N=66; Mean=-0.046, SD=18.49).  No statistically significant 
differences were found between the groups (t=1.67, d.f.=245, p=0.096). Therefore, H8 
was not supported using the indirect attitude construct. 
 
H9: Family physicians who practice in suburban areas will have a significantly 
more favorable attitude toward prescribing CR opioids to patients with 
moderate to severe CNMP versus family physicians who practice in rural 
or urban areas. 
 
H10: Family physicians who practice in suburban areas will have significantly 
more favorable social norms supporting the prescribing CR opioids to 
patients with moderate to severe CNMP versus family physicians who 
practice in rural or urban areas. 
 
H11: Family physicians who practice in suburban areas will have a significantly 
stronger perception of behavioral control in prescribing CR opioids to 
patients with moderate to severe CNMP versus family physicians who 
practice in rural or urban areas. 
 
 
 Primary Practice Location vs. TPB Constructs 
 One-way ANOVAs were conducted to determine if physicians’ attitudes, 
subjective norms, or perceived behavioral control toward prescribing CR opioids to 
patients with CNMP differed by primary practice location (urban, suburban, and rural).  
For H9, H10, and H11, one-way ANOVAs results showed no statistically significant 
difference in the mean scores among urban, suburban, and rural physicians for direct 
measures of attitude (F2,255=0.26, p=0.77), direct subjective norm (F2,256=1.07, p=0.34), 
or direct perceived behavioral control (F2,253=0.23, p=0.79).  In addition, no significant 
differences were observed for physician practice location and the belief-based measures 
of attitude (F2,242=1.24, p=0.30), subjective norm (F2,247=0.21, p=0.81), or perceived 
behavioral control (F2,256=0.32, p=0.73).  As a result, H9, H10, and H11 were not 





H12: There is no difference in attitude toward prescribing CR opioids to 
moderate to severe CNMP patients between male and female physicians. 
 
H13: There is no difference in subjective norms to prescribe CR opioids to 
moderate to severe CNMP patients between male and female physicians. 
 
H14: There is no difference in perceived behavioral control over prescribing CR 




 Gender vs. TPB Constructs  
 Analyses of H12, H13, and H14 utilized two-tailed t-tests to examine the mean 
score differences for attitudes, subjective norms and perceived behavioral control among 
male and female respondents.  No statistically significant differences existed between 
male and female physicians and mean scores for direct attitude (t=1.88, d.f.=259, 
p=0.06), direct subjective norm (t=0.72, d.f.=260, p=0.47), or direct perceived behavioral 
control (t=1.38, d.f.=256, p=0.17).  Therefore H12, H13, and H14 were supported using 
direct TPB measure constructs. 
 No significant differences were found for the belief-based measures of attitude 
(t=0.49, d.f.=246, p=0.62) or perceived behavioral control (t=0.31, d.f.=245, p=0.76) and 
gender.  Therefore, H12 and H14 were supported using the indirect measures of attitude 
and perceived behavioral control.  Statistically significant differences existed in the mean 
scores for indirect subjective norms and gender (t=2.98, d.f.=251, p=0.003).  Male 
physicians had higher subjective norms toward prescribing CR opioids to CNMP patients 
(N=156, Mean=3.66, SD=11.37, score range -63 to +63) compared to female physicians 
(N=97; Mean=-0.70, SD=11.20, score range -63 to +63).  As a result, H13 was not 
supported when using the indirect subjective norm measure.  Additional analyses were 
conducted on the components that make up the belief-based subjective norm construct 





Table 5.41 Normative beliefs of male and female family physicians toward 
prescribing CR opioids to patients with moderate to severe CNMP 
 
Means Scores for 
 Normative beliefs (n i)a  
Question: How likely do you think each of the following 
referents would want you to prescribe CR opioids to 
patients with CNMP? 
 
 
Normative Belief Items 










-0.55 -0.80 1.284 
(1.56) (1.47) (p=0.200)
a.  Regulatory agencies (N=263) (n=165) (n=98)  
-0.02 -0.23 1.249 
(1.40) (1.28) (p=0.213)
b.  Other primary care physicians (N=263) (n=165) (n=98)  
0.45 0.18 1.549 
(1.54) (1.26) (p=0.123)
c.  Consumer groups (N=263) (n=165) (n=98)  
1.40 0.76 3.121 
(1.57) (1.67) (p=0.002)
d.  Pain specialty groups (N=263) (n=164) (n=98)  
1.69 1.49 1.518 
(1.01) (1.09) (p=0.130)
e.  Patients (N=263) (n=165) (n=98)  
-0.35 -0.59 1.198 
(1.59) (1.55) (p=0.232)
f.  Texas Medical Board (N=263) (n=165) (n=98)  
-0.07 -0.08 0.052 
(1.38) (1.31) (p=0.959)g.  Other healthcare providers and office staff 
(N=263) (n=165) (n=98)  
 
a Bipolar Scale: Extremely Unlikely= -3; Quite unlikely= -2; Somewhat Unlikely= -1; Neither= 0; Somewhat Likely= +1; Quite 
Likely= +2;   Extremely Likely= +3 
 
 
 T-tests were conducted on the normative belief (ni), motivation to comply (mi), 
and cross-products (nixmi) components to determine what significant differences existed 
between male and female physicians (Table 5.41, 5.42, 5.43).  Table 5.41 shows mean 
normative belief scores to be statistically significant for “pain specialty groups” (score 
range -3 to +3).  Interpretation of the ni table results indicate male respondents were more 
likely (Mean=1.40, SD=1.57) to believe that pain specialty groups would want them to 
prescribe CR opioids for CNMP compared to female physicians (Mean=0.76, SD=1.67).   
 
212 
Table 5.42 Motivation to comply between male and female family physicians 
toward prescribing CR opioids to patients with moderate to severe 
CNMP 
 
Means Scores for 
 SN cross-products (n i x m i) a  
Question: How likely are you to do what the following 




Motivation to comply 










1.33 1.52 -1.05 
(1.51) (1.21) (p=0.295)
a.  Regulatory agencies (N=263) (n=157) (n=98)  
0.46 0.48 -0.159 
(1.18) (1.16) (p=0.874)
b.  Other primary care physicians (N=263) (n=158) (n=98)  
-0.26 -0.24 -0.93 
(1.28) (1.12) (p=0.926)
c.  Consumer groups (N=263) (n=158) (n=98)  
0.90 0.88 0.127 
(1.35) (1.21) (p=0.899)
d.  Pain specialty groups (N=263) (n=158) (n=98)  
0.68 0.32 2.424 
(1.02) (1.26) (p=0.016)
e.  Patients (N=263) (n=158) (n=98)  
1.46 1.79 -2.00 
(1.50) (1.13) (p=0.046)
f.  Texas Medical Board (N=263) (n=158) (n=97)  
-0.04 0.32 -2.344 
(1.29) (1.03) (p=0.020)g.  Other healthcare providers and office staff 
(N=263) (n=157) (n=98)  
 
a Bipolar Scale: Extremely Unlikely= -3; Quite unlikely= -2; Somewhat Unlikely= -1; Neither= 0; Somewhat Likely= +1; Quite 
Likely= +2;   Extremely Likely= +3 
 
 
 Table 5.42 shows significant mean score differences for motivation to comply 
among male and female respondents (score range -3 to +3).  Results for this belief-based 
component (mi) indicate that male respondents are slightly more likely to comply with 
wishes of the “patient” versus female physicians.  However, female respondents were 
slightly more likely to comply with the wishes of the “Texas Medical Board” or “other 
healthcare providers” compared to males. 
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Table 5.43 Subjective Norm (normative beliefs x motivation to comply) between 
male and female family physicians toward prescribing CR opioids to 
patients with moderate to severe CNMP 
 
Means Scores for 
 SN cross-products (n i x m i) a  
Indirect Subjective Norm Products  (ni x mi) 










-0.54 -1.37 1.87 
(3.50) (3.36) (p=0.062)
a.  Regulatory agencies (N=263) (n=158) (n=98)  
0.20 0.17 0.09 
(2.08) (1.69) (p=0.927)
b.  Other primary care physicians (N=263) (n=158) (n=98)  
0.24 -0.27 2.12 
(2.33) (1.50) (p=0.035)
c.  Consumer groups (N=263) (n=159) (n=98)  
2.21 1.03 3.06 
(3.13) (2.77) (p=0.002)
d.  Pain specialty groups (N=263) (n=157) (n=98)  
1.23 0.66 1.90 
(2.27) (2.41) (p=0.058)
e.  Patients (N=263) (n=159) (n=98)  
-0.13 -1.08 1.96 
(3.82) (3.68) (p=0.051)
f.  Texas Medical Board (N=263) (n=159) (n=97)  
0.43 0.18 1.08 
(1.82) (1.61) (p=0.281)g.  Other healthcare providers and office staff 
(N=263) (n=160) (n=98)  
 
a Possible score range for each item -9 to +9; Possible range for sum total -63 to + 63 
 
 
 Table 5.43 illustrates the results of cross-products mean scores among male and 
female respondents (scores range -3 to +3).  Statistically significant differences existed in 
the nixmi mean scores between male and female respondents. Results indicate that male 
physicians were more likely to be positively influenced to prescribe CR opioids for 
CNMP by “consumer groups” and “pain specialty groups” compared to female 




H15: There is no difference in attitude to prescribe CR opioids to moderate to 
severe CNMP patients and years of experience. 
 
H16: There is no difference in subjective norm to prescribe CR opioids to 
moderate to severe CNMP patients and years of experience. 
 
H17: There is no difference in perceived behavioral control to prescribe CR 
opioids to moderate to severe CNMP patients and years of experience. 
 
 
Physicians Years of Experience vs. TPB Constructs  
 For H15, H16, and H17, Pearson correlation analyses were conducted to 
determine if attitude, subjective norm, or perceived behavioral control over prescribing 
CR opioids for patients with CNMP differed by physicians’ years of experience.  No 
statistically significant differences were found for the direct subjective norm (R=-0.05, 
p=0.212) and perceived behavioral control constructs (R=0.04, p=0.252) and years of 
experience.  However, a negative correlation was observed for direct attitude (R=-0.11, 
p=0.033) and years of experience. As a result, H15 was not supported and H16 and H17 
were supported using the direct measures of TPB.  No statistically significant differences 
were observed for indirect attitude (R=-0.019, p=0.386), subjective norm (R=0.08, 
p=0.108), or perceived behavioral control (R=-0.07, p=0.130). Therefore, H15, H16, and 
H17 were supported using the indirect TPB constructs.   
 
H18: There is no difference in attitude toward prescribing CR opioids to 
moderate to severe CNMP patients and physician ethnicity. 
 
H19: There is no difference in subjective norm to prescribe CR opioids to 
moderate to severe CNMP patients and physician ethnicity. 
 
H20: There is no difference in perceived behavioral control over prescribing  
CR opioids to moderate to severe CNMP patients and physician ethnicity. 
 
 
Physicians Ethnicity vs. TPB Constructs 
 For H18, H19, and H20, one-way ANOVAs were conducted to determine if 
physicians’ attitudes, subjective norms, or perceived behavioral control toward 
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prescribing CR opioids to patients with CNMP differed by ethnicity.  As shown in the 
demographic section 5.7, the ethnic make-up of the sample was Asian or Pacific Islander 
(N=15), Black/ African American (N=5), Latino/Latin American/ Hispanic (N=31), 
White/European American (N=194), and other (N=16).  For this analysis, due to the low 
number of African-American respondents, this ethnic group was collapsed into the 
“other” category.  Results of one-way ANOVAs found no statistically significant 
differences in mean scores for the direct measures of attitude (F3,255=1.60, p=0.189), 
subjective norm (F3,256=1.13, p=0.336), and perceived behavioral control (F3,252=1.30, 
p=0.275).  Therefore H18, H19, and H20 were supported using the direct measures of the 
TPB construct. 
 One-way ANOVAs were performed on indirect TPB measures and statistically 
significant differences existed among the mean scores for belief-based attitude 
(F3,242=2.83, p=0.039) and subjective norm (F3,247=2.89, p=0.036) based on ethnicity.  
However, belief-based perceived behavioral control was not significant (F3,241=0.59, 
p=0.620).  As a result, H18 and H19 were not supported and H20 was supported using 
the indirect measures of TPB.   
 Post hoc analyses were conducted for the belief-based attitude and subjective 
norm variables.  Tukey HSD showed the mean scores for the belief-based attitude 
construct (score range -90 to +90) to be significantly higher for White/European 
Americans (Mean=3.22, SD=17.12) when compared to respondents in the “Other” 
category (Mean= -8.50, SD=15.89).  For belief-based subjective norm (possible scores 
range from -63 to +63), Tukey HSD showed subjective norm mean scores for 
Latino/Latin American/ Hispanic respondents (Mean=7.34, SD=13.95) to be significantly 
higher than Asian/Pacific Islanders (Mean=-2.79, SD=12.04).   
 Given the small number of respondents in the non-white categories, a non-white 
group was created.  Further analysis was performed to determine if differences existed for 
the TPB constructs among “white” and “non-white" respondents.  White/ European 
American respondents (N=194) were compared to all of the other ethnic groups that were 
placed into the “non-white” category (N=73).  T-tests yielded no statistically significant 
differences for direct attitude (t=0.66, d.f.=257, p=0.508) direct subjective norm (t=-0.07, 
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d.f.=258, p=0.946), or direct perceived behavioral control (t=-0.48, d.f.=254, p=0.625).  
In addition, no significant differences were seen in the mean scores of indirect attitude 
(t=1.82, d.f.=244, p=0.070), indirect subjective norm (t=-0.83, d.f.=249, p=0.408) and 
indirect perceived behavioral control (t=-1.06, d.f.=243, p=0.289) among the two groups.   
 
 
H21: There is no difference in attitude toward prescribing CR opioids to 
moderate to severe CNMP patients and type of practice. 
 
 
H22: There is no difference in subjective norm to prescribe CR opioids to 
moderate to severe CNMP patients and type of practice. 
 
 
H23: There is no difference in perceived behavioral control over prescribing  
CR opioids to moderate to severe CNMP patients and type of practice. 
 
 
 Physician Practice Type vs. TPB Constructs 
 For H21, H22, and H23, one-way ANOVAs were conducted to determine if 
physicians’ attitudes, subjective norms, or perceived behavioral control toward 
prescribing CR opioids to patients with CNMP differed by the type of physician practice 
(i.e., solo practice, partnership, group, managed care, hospital, or other).  Results from 
one-way ANOVAs found no significant mean score differences among the different 
practice types and the direct measures of attitude (F2,253=0.80, p=0.550), subjective norm 
(F2,253=1.10, p=0.362), and perceived behavioral control (F2,249=0.07, p=0.997).  
Additionally, no significant mean differences were found for the belief-based measures of 
attitude (F2,239=0.70, p=0.625), subjective norm (F2,245=0.74, p=0597), and perceived 
behavioral control (F2,238=0.39, p=0.857).  Therefore, H21, H22, and H23 were 







5.10 Assumptions of Linear Regression 
 As discussed in section 4.3, routine pre-analysis screening procedures were 
conducted to assess the normality of multivariate data.  For this study, it was assumed 
that the following criteria for linear regression analyses: normality, linearity, 
homoscedasticity and multicollinearity were satisfied.  In order to determine if the 
assumptions for linear regression were violated, an examination of the residuals 
(predicted minus expected values) was conducted for the four assumptions.   
 It is assumed in linear regression that residuals are normally distributed for 
sample data.  Normally distributed residuals indicate that sample data used for analysis 
are drawn from an independent and random sampled population in which the relationship 
between the dependent (DV) and independent variable (IV) is linear (Tabachnick& 
Fidell, 2001).  Histograms, as well as, normal probability plots were used to inspect the 
distribution of the residual values.  Appendix F includes histograms illustrating residual 
distributions that appear to be fairly normal.  Appendix G shows cumulative probability 
plots (P-P) conducted.  Observations of the P-P plot shows standardized residuals falling 
along the reference line, indicating a normal distribution of the sample data.  Therefore, 
the assumption of normality was not violated.   
 The assumption of linearity assumes that the relationship between the DV and IVs 
is linear (Tabachnick& Fidell, 2001).  Appendix H illustrates the scatterplots for the 
variables of interest.  Visual examination of the partial regression plots did not show a 
curvature in the relationships between the DV and IVs.  Further, residuals of both 
scatterplots reveal a concentration of residuals in the center (“0” value) of the plots at 
each value of the predicted score.  This concentration of residual scores around the center 
indicates that the assumption for linearity was not violated. 
 The assumption of homoscedasticity (equal distribution of variances around the 
regression line) was assessed by examining the scatterplots of standardized residuals 
against the standardized predicted values.  Appendices H and I show the scatterplots used 
to assess normality and homoscedasticity.  Appendix H illustrates residuals for the 
scatterplot to collect around the center of each plot.  Appendix I shows the partial 
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regression scatterplots of residuals of the dependent variable and an independent variable 
when both variables are regressed separately on the rest of the independent variables.  
Visual examination of each of the scatterplots shows the residuals to be evenly 
distributed around the horizontal, indicating the that assumption of homoscedasticity was 
not violated.  
 Multicollinearity (and collinearity) involves a linear inter-correlation among 
variables.  It is described as an undesirable occurrence whereby the correlations among 
the independent variables are highly correlated to one another and become redundant 
measures of the outcome of interest (Tabachnick& Fidell, 2001).  Multicollinearity can 
cause an over-fitting of the regression model which can make it difficult to determine the 
particular effects (contributions) of each variable.  The ideal regression models consist of 
predictor variables that correlate highly with the DV but correlate minimally with one 
another.  For this study, multicollinearity was assessed by examining the absolute values 
of correlation coefficients of the regression variables, variance inflation factors, and 


















Table 5.44 Correlation Matrix for Direct and Indirect Measure Theory of Planned Behavior 
Constructs, Past Behavior, Continuing Education, and Willingness 
    
  Direct Measures Indirect Measures  (belief-based)  









































































































 Willingness 1.00 0.63 0.52 0.47 0.66 -0.12 0.54 0.36 0.41 0.66 -0.12
Attitude 0.63 1.00 0.48 0.36 0.50 -0.14 0.61 0.49 0.49 0.50 -0.14
Subjective Norm 0.52 0.48 1.00 0.44 0.41 -0.08 0.47 0.44 0.31 0.41 -0.08
Perceived Behavioral Control 0.47 0.36 0.44 1.00 0.43 -0.11 0.42 0.40 0.31 0.43 -0.11








Continuing Education -0.12 -0.14 -0.08 -0.11 -0.13 1.00 -0.11 -0.10 -0.02 -0.13 1.00
Attitude  0.54 0.61 0.47 0.42 0.43 -0.11 1.00 0.34 0.36 0.43 -0.11
Subjective Norm 0.36 0.49 0.44 0.40 0.29 -0.10 0.34 1.00 0.31 0.29 -0.10
Perceived Behavioral Control 0.41 0.49 0.31 0.31 0.24 -0.02 0.36 0.31 1.00 0.24 -0.02






















 Table 5.44 illustrates the correlation matrices for the direct TPB measures and the 
indirect TPB measures.  Correlation coefficients > 0.75 are considered to have high-
multicollinearity and may be problematic (Graphpad, 1990).  For the direct TPB 
constructs (Ao+SN+PBC), the highest correlation among the IVs was between direct 
attitude and direct subjective norm (R=0.48).  For the indirect TPB constructs, belief-
based attitude and perceived behavioral control had the highest correlations (R=0.36).   
Therefore, multicollinearity was not a serious problem for this model.    
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Table 5.45 Tolerance and Variance Inflation Factors (VIF) of Independent Variables 
Independent Variables Tolerance  VIF 
Direct Measure Attitude 0.649 1.540 
Direct Measure Subjective Norm 0.676 1.480 
Direct Measure Perceived Behavioral Control 0.734 1.363 
Direct Recent Past Behavior 0.665 1.503 
Direct Continuing Education 0.977 1.024 
Indirect Measure Attitude Belief-Based Attitude 0.720 1.388 
Indirect Measure Subjective Norm 0.810 1.234 
Indirect Measure Perceived Behavioral Control 0.831 1.203 
Indirect Recent Past Behavior 0.759 1.318 




 Variance Inflation Factors (VIF) were explored for the direct and indirect TPB 
models to determine how much of a variable’s variance can be explained by the other 
variables in the model.  Table 5.45 illustrates VIF values.  VIF values range from 0 to 
infinity with large VIF values indicating multicollinearity (Noursis, 2005).  Unstable 
regression coefficients have high VIF factor values.  Though there is no formal criteria on 
what constitutes an acceptable VIF value, values > 5 are considered to signify high 
multicollinearity within a regression model (Tabachnick& Fidell, 2001).  The tolerance 
statistic was examined to determine how much the independent variables are linearly 
related to one another.  The statistic describes the proportion of a variable's variance not 
accounted for by other IVs in the regression model (Noursis, 2005).  The tolerance value 
has a range of 0 to 1.  Variables with low tolerance contribute little information to the 
model.   
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Table 5.46 Eigenvalues and Condition Indices 
Independent Variables Eigenvalue  Condition Index 
Direct Measure Attitude 0.937 2.081 
Direct Measure Subjective Norm 0.507 2.831 
Direct Measure Perceived Behavioral Control 0.358 3.367 
Direct Recent Past Behavior 0.100 6.361 
Direct Continuing Education 0.037 10.503 
Indirect Measure Attitude Belief-Based Attitude 1.287 1.644 
Indirect Measure Subjective Norm 0.646 2.320 
Indirect Measure Perceived Behavioral Control 0.440 2.813 
Indirect Recent Past Behavior 0.112 5.567 





 Eigenvalues and condition indices were two collinearity diagnostic procedures 
used to assess correlations among IVs.  Eigenvalues provide an indication of the number 
of distinct dimensions that exist among IVs.  Eigenvalues close to zero are considered to 
be highly intercorrelated and small changes in the data values may lead to large changes 
in the estimate coefficients (Noursis, 2005).  Condition indices were also examined for 
the two models.  Condition index values are calculated from the square root of the ratios 
of the largest eigenvalue to each successive eigenvalue (Noursis, 2005).  A condition 
index > 15 indicates potential collinearity problem.  Table 5.46 shows the eigenvalues 
and condition indices. Collinearity among the data was not a serious problem for the 
direct and indirect TPB regression models. 
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CHAPTER 6:  DISCUSSION 
 
 This chapter discusses the findings of this research study.  The chapter is divided 
into four sections: The first section includes a brief discussion of the focus group research 
used to develop the instrument.  Next, the second section discusses significant and 
important findings, generated from the data analyses.  The third section discusses the 
limitations of the study. Finally, the fourth section includes direction for future research 
and the conclusion. 
 The purpose of this research study was to better understand factors that explain 
family physicians’ (FPs) willingness to prescribe controlled-release opioids (CR opioids) 
to patients with moderate to severe chronic non-malignant pain (CNMP).  The goals of 
the study were to: (1) determine if the Theory of Planned Behavior (TPB) was a useful 
model in explaining physicians’ willingness to prescribe CR opioids, (2) determine if the 
TPB constructs (i.e., attitude, subjective norm, and perceived behavioral control) as well 
as recent past behavior (RPB), and (3) determine if differences in attitude, subjective 
norm, perceived behavioral control, and RPB existed among willing and unwilling 
physicians based on demographic and practice characteristics.   
 
 
6.1 Focus Group Findings 
 The focus group sessions generated the qualitative data that were used to develop 
the study’s questionnaire instrument.  Open-ended elicitation interviews with 15 family 
physicians identified salient beliefs concerning positive and negative consequences of 
prescribing CR opioids to patients with moderate to severe CNMP.  Results of the focus 
group interviews confirmed much of what has been published in the literature regarding 
physicians’ views towards opioids and CNMP (Turk et al., 1994; Potter et al., 2001; 
Morley-Forster et al., 2003).   
 Willingness.  As a general inquiry, physicians were asked to describe what comes 
to mind when prescribing CR opioids.  Initial responses included abuse, diversion, 
addiction, withdrawal, and drug seeking.  Interestingly, the concept of effective pain 
 
223 
control was not initially discussed.  Maybe physicians did not immediately address this 
point because it was understood that this class of analgesic provides the highest level of 
pain relief.  Next, focus group participants were asked how willing they were to prescribe 
CR opioids for CNMP.  Generally speaking, most of the physicians interviewed indicated 
that they were willing to prescribe CR opioids to treat their CNMP patients.  However, 
several physicians indicated strong reservations about using CR opioids as the only 
method of pain control.  For example, one physician indicated that he was more unlikely 
to prescribe CR opioids due to concerns that his patients would exhibit malingerer type 
behaviors or become complacent with their standard of care once placed on chronic 
opiate therapy.  Other physicians who agreed further emphasized the need for a holistic 
or comprehensive pain management approach to treating CNMP patients (e.g., physical 
therapy, counseling, and other non-opioid treatment methods).  As a follow-up, focus 
groups members were asked how likely they were to prescribe CR opioids.  All of the 
focus group participants indicated that they were generally willing to prescribe CR 
opioids to those patients who needed it.     
 Attitudes.  Physicians were asked to describe the advantages and disadvantages of 
prescribing CR opioids to patients with moderate to severe CNMP.  A majority of 
physicians interviewed believed that prescribing CR opioids could lead to abusive drug 
behaviors.  Most physicians also indicated that a thorough patient history would be 
required if CR opioids were prescribed.  Positive normative beliefs identified included 
the effectiveness of CR opioids in controlling pain, the effects they have on patient 
quality-of-life, and cost savings compared to short-acting alternatives.  Interestingly, 
physicians discussed the association of placing patients on CR opioid therapy and the 
amount of time it consumes during their office visits.  Several physicians indicated that it 
was not uncommon to have office visits lasting one to two hours when chronic pain 
patients who were placed on opioids.  Further, focus group discussions found that treating 
CNMP patients becomes mentally exhausting for physicians due to the level of probing 
required by physicians to learn the full extent of their patients’ pain.  The respondents felt 
that additional counseling time was required to create and monitor CNMP treatments 
using more potent opiate analgesics such as CR opioids.  Other salient beliefs identified 
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included the effects of CR opioids when managing patients on multiple medications 
and/or co-morbidities, the potential of patient addiction, and concerns of regulatory 
scrutiny.  A total of 10 normative belief items were used in the web questionnaire. 
 Social norms.  Physicians were asked to list individuals or groups who would or 
would not approve of family physicians prescribing CR opioids to patients with moderate 
to severe CNMP.  A total of 15 referents were identified from the physician elicitation 
interviews.  The most frequent normative belief elicited by participants included the 
effects of regulatory agencies on physician opioid prescribing behaviors.  Participants 
generally believed that regulatory agencies would only approve of limited prescribing of 
CR opioids for CNMP.  Focus group findings were consistent with the literature whereby 
other salient referents identified by the focus group included colleagues, pain specialists, 
other health providers, patients, and consumer groups (Turk et al., 1994; Potter et al., 
2001; Morley-Forster et al., 2003).  Several physicians indicated the need to establish a 
closer working relationship with pain specialists when deciding how to treat their 
moderate to severe chronic pain patients.  However, it appeared that an equal number of 
physicians voiced concerns regarding pain specialty providers.  Specifically, several 
family physicians felt that many of their patients who were referred to a pain specialist 
received the “usual standard of care” which often resulted in expensive and short-term 
pain relief therapy.  Participants indicated that it was normal for patients with severe 
chronic back pain who are referred to a pain specialist to return back to the family 
physician for follow-up care once the specialist determined that long-term therapies are 
required to manage the patients’ pain.  Of the referents identified, a total of seven salient 
normative belief items were used in the web questionnaire. 
 Perceived behavioral control.  Physicians were asked to list factors that they 
believed would make it easier or more difficult to prescribe CR opioids to patients with 
moderate to severe CNMP.  Of the more frequent beliefs mentioned, a majority of 
participants felt that having more knowledge in pain management would make it easier 
for them to prescribe CR opioids.  Physicians also indicated that access to more evidence-
based studies and pain management tools (e.g., algorithms, protocols, guides, contracts, 
diagnostic kits) would make it easier to prescribe.  Having to write triplicates made it 
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more difficult for participants to prescribe CR opioids for CNMP.  Other salient beliefs 
that participants perceived would make it easier/difficult to prescribe CR opioids 
included receiving complete compensation for services associated with prescribing CR 
opioids, having access to multi-disciplinary teams, prescribing to patients with co-
morbidities or on multiple medications, and risk of regulatory scrutiny. A total of 10 
control belief items were used in the web questionnaire. 
 Overall, focus group participants appeared to hold strong beliefs regarding the use 
of long-acting opiates in CNMP.  Beliefs that took up a majority of the discussion were 
those concerning patient abuse and diversion.  In general, focus group participants 
indicated that they did not have much concern regarding investigation by regulatory 
agencies.  However, when the discussion turned to managing a high volume of chronic 
pain patients specifically in their own practice, several physicians expressed the need for 
caution in prescribing too many opiates due to the potential of raising flags that could 
result in the subsequent investigation by the of Drug Enforcement Agency (DEA) or 
Texas Medical Board.  Physicians also raised concerns about the difficulty of establishing 
and maintaining a trusting relationship with new patients who presented with signs of 
chronic pain.  They also pointed to concerns of turning their patients into potential 
abusers, which complicated their decisions to prescribe CR opiates for CNMP.  The focus 
group discussed the stigma attached to “over prescribing” opiate analgesics to their 
patients.  The avoidance of appearing as a “dope pusher” in the community and among 
their colleagues sometimes affected their prescribing decisions.  Further, they did not 
want to be targeted by drug seeking patients.   
 Physicians criticized the length and repetitive nature of the elicitation interviews.  
Specifically, physicians were challenging the way that questions were being asked.  They 
were also resistant to the term controlled-release opioids being used to describe long-
acting opiates and often requested clarification of the type and duration of chronic non-
malignant pain that was being discussed.  Overall, the discussions held among focus 
groups participants provided invaluable insight into some of the underlying issues to 




6.2 Summary of Study Findings  
 As hypothesized, the key determinants of family physicians’ willingness to 
prescribe CR opioids to patients with moderate to severe CNMP included the attitude, 
subjective norm, and perceived behavioral control.  Study findings showed each of the 
constructs played a significant role in explaining physicians’ overall willingness to 
prescribe.  In addition, family physicians’ past prescribing behavior served as a relatively 
strong predictor of their future intentions (i.e., willingness) to prescribe.  
 
 Willingness 
 In this study, the majority of family physicians (63%) surveyed were willing to 
prescribe CR opioids to patients with moderate to severe CNMP.  However, one-third of 
physicians indicated that they were unwilling to prescribe long-acting opioids for this 
condition.  This figure seems high in light of the growing acceptance of CR opioids to 
treat CNMP (Arkinstall et al., 1995; Davis et al., 2003; Goli& Finley, 2005).  Findings 
from this study are comparable to data from a 1997 California survey and a 2001 
Canadian study which both reported that 35 percent of primary care physicians (PCPs) 
were not willing to prescribe long-acting opioids to patients with CNMP, even after 
exhaustive attempts using other treatments. (Potter et al., 2001; Morley-Forster et al., 
2003).  The rationale for physicians’ willingness can be attributed to the perceptions of 
risks and benefits they associate with the use of CR opioids among patients with CNMP.  
The literature points to a variety of factors that are involved in influencing physicians’ 
willingness to prescribe, especially when long-acting opioids are considered (Turk et al., 
1994; Potter et al., 2001; Morley-Forster et al., 2003).  Using the TPB model, this study 
examined some of the predictors of willingness (i.e., attitudes, subjective norm, perceived 
behavioral control, and recent past behavior) to determine how these factors may 
potentially influence physicians’ prescribing behavior.  
 
 Attitude 
 For this study, Texas family physicians held a slightly favorable (if not fairly 
neutral) attitude toward prescribing CR opioids to patients with moderate to severe 
 
227 
CNMP.  As seen in previous studies, attitude was observed to be highly correlated with 
willingness (i.e., intentions) among physicians (Millstein, 1996; Lambert et al., 1997; 
Walker et al., 2001).  In this study, the majority of family physicians believed that 
prescribing CR opioids would be beneficial to patients with moderate to severe CNMP.  
In addition, over three-fourths of the physicians surveyed felt that long-acting opioids 
were not only effective in controlling chronic pain among CNMP patients but were also 
likely to improve patients’ overall quality of life.  However, physicians were almost 
evenly divided in their beliefs that prescribing CR opioids for CNMP would lead to 
abusive behaviors among their patients (41% felt it would likely lead to abuse versus 
44% who did not).  One-third of family physicians believed that prescribing CR opioids 
for CNMP would lead to patient addiction, despite evidence from previous studies 
indicating that the risk of patient addiction to prescribed opioids is relatively low 
(Porter& Jick, 1980; Portenoy, 1994).  One explanation for these results could be the 
clarity of the term addiction.  Research has shown that the terms addiction, physical 
dependence and tolerance are often used interchangeably among physicians.  For 
example, Potter et al. (2001) found that physician concerns about these three conditions 
were highly intercorrelated when considering their willingness to prescribe opioids for 
CNMP.  This raises the issue that physicians may be unclear about what distinguishes 
one of these outcomes from another which may have skewed the results (since attitudes 
regarding physical dependence and tolerance were not assessed).  
 Significant differences in attitudes were found among respondents “willing to 
prescribe” CR opioids for CNMP versus those “unwilling to prescribe.”  As expected, 
Texas family physicians (34%) who were unwilling to prescribe were found to have less 
favorable attitudes toward prescribing CR opioids compared to willing physicians.  
Unwilling physicians tended to believe that prescribing CR opioids would lead to patient 
abuse and addiction, resulting in more negative attitudes toward prescribing it for CNMP.  
These findings are not surprising and concerns of patient misuse of CR opioids are not 
without merit (as pointed out in section 2.7.1).  Educational efforts should be directed at 
clarifying the misconceptions of addiction and abuse so that physicians base their 
prescribing decisions on a more accurate understanding of the disease and less on 
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erroneous preconceptions which could ultimately interfere with effective pain 
management.   
 Family physicians’ attitudes were seen to differ on several other belief items. Not 
all physicians believed that long-acting opiates were effective in controlling pain, despite 
recent studies (Hale et al., 1999; Salzman et al., 1999; Davis et al., 2003) showing CR 
opioids to be as effective as short-acting opiates in managing CNMP.  In addition, 
physicians unwilling to prescribe CR opioids were less likely to believe that long-acting 
opiate therapies improved patient quality of life among CNMP sufferers.  The groups’ 
beliefs are not without reason.  Even though research suggests that CR opioids can 
significantly improve quality of life, experts agree that more evidence-based data is 
needed to substantiate the recently discovered attributes of CR opioids, particularly as it 
relates to improving quality of life (e.g., less sleep disturbances, overall improvement in 
physical functioning) (Fisher, 2004a).  Consequentially, a greater systematic effort is 
needed to collect and disseminate information from published studies that have 
demonstrated the actual benefits of CR opioids as they relate to quality of life indicators.  
 This study found physicians who were unwilling to prescribe were more likely to 
believe that CR opioids would make it more difficult for them to manage CNMP patients 
on polypharmacy or with co-morbidities.  Clinical findings have shown that most patients 
who are prescribed CR opioids for CNMP often require more than one drug to achieve 
adequate pain control, through combinations of non-opioid, opioid, and adjuvant 
therapies (McCarberg, 2004).  The issue of using multiple medications to treat CNMP is 
further complicated by the limited data on which combinations of non-opioid and opioid 
therapies work best.  Side effects, drug interactions, ease of use and cost must also be 
considered.  It is understandable that when considering these factors, prescribing of CR 
opioids could further complicate the patient’s existing drug regimen, hence discouraging 
physicians from using this type of opiate therapy.  Physicians face similar issues when 
deciding if a CR opioid is appropriate for CNMP patients with co-morbid conditions 
(given that they are likely to be on other therapies to manage these conditions).  Family 
physicians should turn to pain specialty groups when requiring guidance in using CR 
opioid therapies among polypharmacy and co-morbid patients.  Further, continuing 
 
229 
education curricula should focus on pain management guidelines to assist physicians in 
deciding what CNMP therapy is appropriate.   
 Other areas where physician attitudes differed significantly included beliefs that 
prescribing CR opioids for CNMP would lengthen patient office visits and require a more 
in-depth collection of patient history.  Another important study finding showed that over 
78 percent of respondents believed that prescribing CR opioids would likely lead to 
regulatory investigation.  Less favorable attitudes were observed among physicians 
unwilling (34%) to prescribe CR opioids for CNMP (Mean=-3.56, SD=4.23, range -9 to 
+9) when the issue of regulatory scrutiny was considered, compared to physicians who 
were willing to prescribe (62%) (Mean=-2.24, SD=3.53, p=0.014).  Fear of regulatory 
scrutiny has often been cited as negatively affecting physician willingness in other studies 
(Turk, 1996; Turk& Okifuji, 1997; Potter et al., 2001; Morley-Forster et al., 2003; 
Ponte& Johnson-Tribino, 2005).  For example, approximately 40 percent of physicians in 
the Potter et al. (2001) California survey indicated that fear of regulatory investigation 
restricted their use of opioids for CNMP.  The official stance of regulatory bodies in 
Texas is that they support the appropriate use of stronger-acting opioids for CNMP 
(Texas Medical Board, 2005).  Despite recently published guidelines, physicians are 
reluctant to prescribe what they may consider excessive amounts of opioids.  Further, it is 
not clear what affect, if any, these guidelines have on increasing or decreasing physician 
concerns of regulatory scrutiny.  Future studies should examine whether differences in 
family physician attitudes and willingness to prescribe CR opioids are related to the 
awareness of the guidelines in Texas. 
 
 Subjective Norm 
 As hypothesized, subjective norm was a key determinant of physicians’ 
willingness to prescribe.  Like the attitude construct, family physicians held a slightly 
positive (if not fairly neutral) subjective norm.  Most physicians surveyed believed that 
referents would be supportive in their prescribing of CR opioids for moderate to severe 
CNMP.  Family physicians were more likely to be influenced (i.e., comply with requests) 
by regulatory agencies (82%), pain specialty groups (68%), other primary physicians 
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(53%), and (importantly) their patients (56%).  A closer look at the study results showed 
a majority of physicians believed that regulatory agencies (e.g., Texas Medical Board) 
would not condone their prescribing of long-acting opioids for CNMP.  Further, over 80 
percent of physicians indicated that they were likely to comply with requests of 
regulatory agencies when it came to prescribing CR opioids.  These findings are not 
surprising given that established federal/state-based opioid policies have been focused on 
reducing diversion and prescription drug abuse, particularly for this class of opiate 
analgesic.  For this reason, many physicians are keenly aware of the various regulatory 
efforts to discourage prescribing of this class of opiates and the tactics used to investigate 
clinicians identified as having excessive or suspicious opiate prescribing behaviors 
(Joranson et al., 2002).   
 Recently, agencies such as the DEA have publicly acknowledged the crucial role 
CR opioids play in enhancing the quality of care among patients suffering from moderate 
to severe CNMP (Gallagher, 2004).  The agency clarified its new commitment to avoid 
regulatory restrictions that obstruct the appropriate use of opiate analgesics and improve 
its policies on supporting the prescribing of long-acting opioids for CNMP.  Other 
agencies such as the Federation of State Medical Boards (FSMB) and the Texas Medical 
Board have articulated similar doctrines, conveying a need to improve their current 
policies to promote the legitimate prescribing of long-acting opioids for moderate to 
severe CNMP (FSMB, 2003; Texas Medical Board, 2005).  Despite the recent positive 
changes in regulatory policies toward CR opioids, it appears many physicians (in this 
survey) continue to be reluctant to prescribe CR opioids for CNMP because of regulatory 
scrutiny.  As pointed in the attitude section, further study should be conducted to assess 
family physicians’ awareness of Texas regulatory guidelines as they relate to prescribing 
CR opioids for CNMP.  In addition, increased efforts should focus on educating Texas 
family physicians about current regulatory policies to improve their knowledge and 
change negative normative beliefs toward CR opioids in pain management.  Learning 
modules outlining current state medical board pain guidelines (e.g., Texas intractable 
pain treatment act of 1989) would be an appropriate method to educate physicians on 
prescribing standards for CR opioid and other controlled substances.   
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 Pain specialists were another group that influenced physicians’ willingness to 
prescribe.  This study found that 68 percent of respondents were likely to comply with the 
recommendations of pain specialty groups when considering prescribing CR opioids for 
CNMP.  However, statistically significant differences in the normative belief scores for 
pain specialists were observed between willing and unwilling physicians. Physicians 
unwilling to prescribe (Mean=0.44, SD=1.79, , range -3 to +3) were less likely to believe 
that pain specialists would support their prescribing of CR opioids for CNMP compared 
to those willing to prescribe (Mean=1.53, SD=1.41, p<0.001). Furthermore, respondents 
unwilling to prescribe CR opioids indicated they were less likely to comply with requests 
from pain specialists when it came to treating CNMP patients with long-acting opiates.  
Various hypotheses can be presented as to why unwilling physicians are less inclined to 
comply with pain specialists requests.  One explanation may involve the level of access 
(i.e., exposure) physicians have to pain specialty groups.  Several studies have suggested 
that physicians who do not have adequate access to pain specialists are less supportive in 
using long-acting opioids to manage chronic pain (Jamison et al., 2002).  A California 
study by Potter et al. (2001) examining physicians’ attitudes toward CNMP found 45 
percent of primary care physicians (PCPs) felt they had inadequate consultation and 
referral services to assist them in adequately managing their CNMP patients.  When 
asked about their use of pain specialists, 52 percent of physicians reported that they 
required (always or usually) their patients to undergo evaluation by a pain specialist 
before prescribing opioids for CNMP.  These findings are comparable to a Canadian 
study that reported 40 percent of physicians felt that pain specialists are not common 
where they practiced.  Based on these findings, pain specialists may not be fully available 
to assist family physicians.  Findings from this and other studies should be used to 
highlight the importance of community-based pain specialty groups and the need for 
more information about pain management resources available to family physicians.  
 Over half of the physicians surveyed (56%) indicated that they were likely to 
comply with patients who requested long-acting opioids for CNMP.  These results are 
consistent with previous findings on the effects of patient demands on physician 
prescribing (Stevenson et al., 1999).  Examination of responses among willing and 
 
232 
unwilling respondents found small but significant differences in the mean scores between 
the two groups.  Willing physicians (Mean=0.86, SD=1.00, p<0.001, range -3 to +3) were 
slightly more likely to comply with requests from patients with CNMP compared to 
unwilling physicians (Mean=-0.01, SD=1.20).  Though CNMP patients can influence 
physicians’ decisions to prescribe CR opioids, physicians are seen to be particularly 
cautious when deciding to use stronger-acting opioids for chronic conditions (Potter et 
al., 2001).  Results from the Turk et al. (1997) study found patients who were observed to 
have significant functional limitations were more likely to be prescribed opioids.  
However, verbal reports of pain, distress, and disability were reported to play a mild role 
among patients who were prescribed opioids from those who did not.  It is not clear what 
effect patient requests have on increasing or decreasing physician’s willingness to 
prescribe, but additional studies should further examine this issue.  Another area where 
subjective norms significantly differed among willing and unwilling respondents was for 
other primary care physicians.  Family physicians who were unwilling to prescribe 
tended to believe that other primary care physicians would not want them to prescribe CR 
opioids for CNMP.  Though no known studies have specifically examined the influence 
of colleagues on physician prescribing of CR opioids for CNMP, these findings are 
comparable to the Weinstein et al. (2000b) survey which reported that half of physicians 
disagreed with the statement that their colleagues were more willing to give narcotics for 
cancer pain.   
 
Perceived Behavioral Control 
 Overall, family physicians felt that they were somewhat in control of prescribing 
CR opioids to CNMP patients (though the overall PBC score was marginally above 
neutral).  The majority of family physicians surveyed (85%) indicated that possessing 
more knowledge in pain management would improve their level of control over 
prescribing CR opioids for CNMP.  Many of these physicians also indicated that access 
to pain management tools (81%) and more evidenced-based studies (61%) would make it 
easier for them to prescribe CR opioids.  These findings corroborate previous research 
that suggest that physicians’ knowledge in the use of opioids in chronic pain management 
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is deficient (Marks& Sachar, 1973; Von Roenn et al., 1993; Turk et al., 1994; Von 
Gunten& Von Roenn, 1994; Turk, 1996; Weinstein et al., 2000a, 2000b; Gilson& 
Joranson, 2001; Potter et al., 2001).  For example, a survey of West Virginian family 
physicians revealed that respondents had difficulty in understanding how to properly 
manage opioid-induced adverse events and side effects (Ponte& Johnson-Tribino, 2005).  
Further, in the Morley-Forster et al. (2003) study, 68 percent of physicians felt that 
CNMP was not well managed within their practices.  A primary reason given for this 
finding involves physicians’ beliefs that their formal medical training did not adequately 
prepare them to effectively manage pain.  Regardless, CNMP patients may be suffering 
due to physician knowledge gaps in pain management.  It seems logical to conclude that 
additional educational programs focused on educating family physicians about current 
pain management practices (involving up-to-date pain management guidelines, treatment 
protocols, and standards of practice supported by evidence-based research) would 
improve their overall clinical knowledge in treating CNMP.   
 Interestingly, a majority of physicians (71%) indicated that receiving full 
compensation for services associated with prescribing CR opioids for CNMP positively 
affected their control beliefs over prescribing CR opioids.  This finding may be due, in 
part, to physician beliefs that pain management is a time consuming practice.  Like 
previous research (Morley-Forster et al., 2003; Ponte& Johnson-Tribino, 2005), 
physicians in this study, may have felt that additional compensation was needed for the 
amount of time spent on counseling CNMP patients, particularly when those patients are 
placed on chronic opioid therapy (refer to focus group section 6.1).  Other areas where 
perceived behavioral control differed significantly included regulatory scrutiny.  Almost 
70 percent of physicians surveyed believed that less regulatory scrutiny would make it 
easier for them to prescribe CR opioids.  In general, regulatory scrutiny/agencies were 
seen as a barrier for all three constructs used to assess willingness. 
 When examining the differences in perceived behavioral control among 
willing/unwilling physicians, it was found that physicians who were willing to prescribe 
CR opioids for CNMP felt more in control when managing patients on multiple 
medications and/or co-morbidities compared to those unwilling.  Unwilling physicians 
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felt writing triplicate prescriptions made it more difficult for them to prescribe CR 
opioids compared to willing physicians.  Additional findings showed similar differences 
in the final mean composite scores for each of the perceived behavioral control items.  It 
is important to note that these findings should be reviewed with some caution due in part 
to methodologies used to assess the perceived behavioral control construct.  For example, 
there is a lack of consensus in the literature on the most appropriate scaling technique that 
should be used to assess the indirect PBC measures.  Further exploration on the 
implication of the PBC construct is needed.  
 
 Recent Past Behavior 
 As hypothesized, past prescribing behavior was found to significantly increase the 
explanatory power of the study model.  When recent past behavior was added to the 
regression model, belief-based TPB accounted for 57 percent of the variance in 
willingness (R2 change=0.18, F Change 1,221=88.85, p<0.001).  Existing theoretical 
literature have shown previous behavior to substantially add to the predictability of the 
TPB model (Millstein, 1996; Walker et al., 2001).   
 Study findings showed that 17 percent of respondents indicated that they “never” 
prescribed CR opioids to patients with moderate to severe CNMP.  However, these 
responses substantially differed from data reported in the Potter et al. (2001) study, which 
found that one-third of primary care physicians never used long-acting opioids to treat 
CNMP patients.  Compared to the Potter et al. (2001) study, results from this study imply 
that Texas family physicians may prescribe CR opioids more often to treat CNMP.  It is 
unclear if Texas family physicians actually prescribe long-acting opioids for CNMP more 
often compared to California PCPs.  Regardless, study findings confirmed Ajzen’s (1991) 
premise that past experience with the behavior of interest (i.e., prescribing CR opioids) is 
considered to provide important information with regard to an individual’s future 






 Continuing Medical Education 
 This study examined the relationship between physicians receiving continuing 
medical education (CME) in pain management and their willingness to prescribe CR 
opioids for CNMP.  As hypothesized, physicians who received CME in pain management 
over the last three years were somewhat more willing to prescribe CR opioids to their 
CNMP patients compared to those who did not receive this type of CME.  Differences in 
mean scores between the willing (Mean=0.60, SD=1.6, range -3 to +3) and unwilling 
physicians (Mean=0.14, SD=1.72) were statistically significant (t=1.97, d.f.=260, 
p<0.05), suggesting a relationship between CME and willingness to prescribe.  However, 
as this was a cross-sectional study, a causal relationship between willingness and CME 
cannot be established without further study.  Future research should include a 
longitudinal/pretest-posttest study design to examine the effects of continuing education 
interventions on willingness. 
 The relationship between family physician attitudes and CME was also examined.  
Study findings showed that physicians who received CME in pain management in the last 
three years held more favorable direct attitudes toward prescribing CR opioids for CNMP 
compared to physicians who did not receive pain management CME.  Mean score 
differences between the willing (Mean=4.49, SD=6.40, range -3 to +3) and unwilling 
physicians (Mean=2.45, SD=5.92) were statistically significant (t=2.33, d.f.=258, 
p=0.02), however, indirect attitudes were not significantly different.  Similar to findings 
in other studies examining continuing education in pain management and attitudes toward 
CR opioids (Gilson& Joranson, 2001; Gourlay et al., 2004; McCarberg, 2004; Potter et 
al., 2004; Otis& Fudin, 2005), it is possible that CME activities can be used to positively 
reinforce family physician attitudes toward CR opioids in pain management.   
 
 Other Variables 
Other barriers have been found to affect physicians’ pain management practice.  
As previously discussed, negative beliefs regarding addiction, abuse, regulatory scrutiny, 
and knowledge deficiencies have been found to act as barriers to prescribing CR opioids 
for CNMP.  However, these are not the only barriers.  Other factors such as physician 
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gender, ethnicity, experience, practice type and location may influence physician 
prescribing of long-acting opiate analgesics for CNMP as well (Weinstein et al., 2000b; 
Weisse et al., 2001; Probst et al., 2002; Tamayo-Sarver et al., 2003; Weisse et al., 2003; 
Goli& Finley, 2005). 
 
 Gender. For this study, no statistically significant differences existed in attitudes 
between male and female family physicians.  Also, no differences in perceived behavioral 
control were observed between the two groups.  However, significant differences were 
observed in the social norms between male and female respondents (t=2.98, d.f.=251, 
p=0.003).  Male physicians tended to believe that pain specialty groups would be more 
supportive in their prescribing of CR opioids for CNMP compared to female physicians.  
In addition, patients appeared to have more influence among male physicians.  Male 
respondents were more likely to comply with requests from patients seeking CR opioids 
compared to female physicians.  On the other hand, female respondents were more likely 
to be influenced by other healthcare providers and office staff when considering the 
prescribing of long-acting opioids for CNMP.  There is limited literature available to 
explain the differences observed between male and female respondents  (Weisse et al., 
2001; Weisse et al., 2003; Goli& Finley, 2005).  Perhaps female physicians are more 
concerned about the safety issue of placing CNMP patients on long-acting opiates.  The 
Weisse et al. (2001) study suggested that potential complications arising from the use of 
opioids could influence opioid prescribing decisions among female physicians.  Further, 
female physicians may be more comfortable referring patients to a pain specialist rather 
than prescribing long-acting opiates themselves.  Future TPB research should further 
examine how social influences may affect willingness to prescribe CR opioids for CNMP 
when physician gender is considered to better understand treatment patterns among male 
and female physicians. 
 
 Ethnicity. This study examined the relationship between physician ethnicity and 
the TPB constructs affecting willingness to prescribe.  Statistically significant differences 
existed in physician ethnicity among the mean scores for indirect (belief-based) attitude 
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(F3,242=2.83, p=0.039) and subjective norm (F3,247=2.89, p=0.036).  It should be noted 
that because of the low number of African-American respondents, this ethnic group was 
collapsed into the “other” category.  With that in mind, the study found white family 
physicians to hold more positive attitudes toward prescribing CR opioids for CNMP 
when compared to respondents in the “Other” category. Latino respondents were 
observed to have significantly higher subjective norm scores compared to Asians, 
indicating that Latino physicians felt they had more positive social influences supporting 
their prescribing behaviors compared to Asian physicians.  Given the relatively low 
sample size of ethnic minority respondents, these results should be interpreted with 
caution.  Future TPB research examining physician willingness should employ sampling 
techniques that allow for an adequate sample size of ethnic minority groups.   
 
 Years Experience. Based on the literature, it was assumed that less experienced 
(i.e., junior level) family physicians would be influenced to a greater extent by outside 
social factors such as colleagues and experts when it came to their willingness to 
prescribe (Limbert& Lamb, 2002).  Though the results of the study showed a negative 
correlation between direct attitudes and years of practice experience, the study found, no 
statistically significant differences between years of experience and willingness.  Nor did 
significant differences exist in the mean scores of the other direct or indirect measures of 
the TPB constructs.  
 
 Geographic Location. It was hypothesized that family physicians practicing in 
suburban areas would have significantly more favorable attitudes toward prescribing CR 
opioids for moderate to severe CNMP (compared to physicians in urban or rural areas).  
Previous studies have found that physician respondents practicing in rural areas generally 
hold more negative views toward opioids compared to physicians in larger communities 
(Weinstein et al., 2000; Probst et al., 2002).  However, in this study no significant 
differences in attitudes among physicians practicing in suburban, urban, or rural areas 
were found.  Furthermore, no differences existed in the mean scores of the subjective 




 Practice Type. No differences were found in type of practice and the TPB 
constructs.  It was expected that significant differences in subjective norm would be 
observed between family physicians in solo and partner/group practices.  However, no 
substantial differences were observed in the mean scores for this construct. 
 
 
6.3 Study Model 
 The TPB model was considered to be a relatively good predictor of family 
physicians’ willingness to prescribe.  Similar to Nash et al.’s (1993) previous research 
findings examining health providers’ intentions (R2=21, p<0.001) to use opioids, the TPB 
model for this study explained a significant amount of variance (R=0.62, p<0.001).  As 
hypothesized, the TPB (attitude + subjective norm + perceived behavioral control) 
accounted for more variation (39 percent) in physicians’ willingness compared to the 
TRA model (attitude + subjective norm) which explained 36 percent.  These findings 
show that the addition of the perceived behavioral control construct significantly 
improved the explanatory power of the TPB model (R2 change=0.03, F Change 
1,222=12.37, p<0.001) when compared to only using the attitude and subjective norm 
constructs (refer to section 5.11).  These findings further support the argument that the 
TPB is a more appropriate model to assess behaviors that are considered not to be under 
full volitional control (i.e., prescribing CR opioids). 
 As discussed in previous sections, both direct and indirect TPB constructs 
explained significant amounts of variance in physicians’ willingness to prescribe CR 
opioids for CNMP.  This study was particularly geared towards understanding the 
indirect (belief-based) constructs.  Attitude, subjective norm, and perceived behavioral 
control were all found to be significant predictors of willingness to prescribe.  Results of 
the analyses showed beta weights for indirect attitude (β=0.41, p<0.001), social norms 
(β=0.20, p<0.001), and perceived behavioral control (β=0.20, p<0.001) to significantly 
explain physician’ willingness to prescribe CR opioids for CNMP.  The addition of the 
recent past behavior variable significantly improved the explanatory power of the TPB 
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model, accounting for 57 percent of the variance in willingness (R2 change=0.18, F 
Change 1,221=88.85, p<0.001).  Findings are similar to results from other TPB physician 
studies that showed inclusion of past behavior to the model significantly increased the 
proportion of variance explained by the TPB (Millstein, 1996; Walker et al., 2001).  Beta 
weights for the final TPB model showed belief-based attitude (β=0.25, p<0.001), 
subjective norm (β=0.10, p<0.001), perceived behavioral control (β=0.17, p<0.001), and 
recent past behavior (β=0.48, p<0.001) to be relatively strong predictors.  In all, findings 
for this study reinforce Ajzen’s (1991) premise that past behavior can provide important 




 This study was subject to a number of limitations. As with many surveys, because 
of the low response rate (10% response) and limited sample, data from the questionnaire 
should be interpreted with some caution.  Since this was a cross-sectional study, all data 
were collected at one point in time, and, as a result, causality among variables cannot be 
determined.  Therefore, interpretation of the findings should not assume a causal 
relationship between the TPB variables being examined and willingness to prescribe CR 
opioids to patients with moderate to severe CNMP.  The survey was sent to TAFP 
members.  Therefore, caution should be taken when attempting to extrapolate these 
results to family physicians or other primary care physicians outside the TAFP 
organization.  Moreover, since this was a voluntary survey, results may be skewed and 
not be representative of all TAFP members.  Due to the sensitive nature of the topic, 
social desirability bias may have occurred, which may have led respondents to modify 
their actual responses to demonstrate that they are not over-prescribing controlled 
substance or under treating their patients who suffer from CNMP.  Further, clarification 
on the specific types of moderate to severe CNMP may have been useful in helping 
physicians to assess questionnaire items.  Since this was an electronic web-based survey, 
selection bias may have occurred among physicians who were more technologically 
inclined or have ready access to a computer and the internet.  As a result, this web-based 
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survey technique may have excluded potential participants who normally respond to 
traditional paper-based surveys (i.e., postal and fax surveys).  Not all physicians may 
have received the electronic survey.  E-mail addresses used to contact physicians may 
have been incorrect or out-dated.  Physicians may have had e-mail filters that blocked 
unwanted solicitations or what is considered “spam.”  In addition, physician 
“gatekeepers,” such as receptionists, office managers, nurses, and other staff members 
may have screened physician e-mail communications to protect doctors from unwanted 
intrusions of their time (Olmsted et al., 2005).  There was also the potential for 
gatekeepers to fill out the survey themselves.  The length of the questionnaire instrument 
(over 60 question items) may have affected overall response rate and survey completion.   
 Not all salient belief items may have been identified.  Focus group interviews may 
not have captured the most readily available salient beliefs held among the target 
population.  In addition, scales used to measure the direct TPB construct, subjective 
norm, only consisted of one item.  Though there is no set method to construct this scale, it 
may have been more appropriate to include several direct measure-items that better 
assessed the injunctive and descriptive qualities to enhance the variability associated with 
each item (Ajzen, 2002b).  Historical and maturation bias may have occurred.  Since 
focus groups were held several months prior to the administration of the survey, the 
general viewpoints of the target population may have changed during that time period 
(due to new pain guidelines, opioid regulatory changes, or personal experience).   
 
 
6.5 Future Research 
 This study attempted to identify factors that influence family physicians’ 
willingness to use long-acting opioids for moderate to severe CNMP.  As this was an 
exploratory study, it should be understood that not all factors influencing physician 
willingness were identified.  Nevertheless, information gathered from this study should 
be disseminated among family physicians and the medical community in effort to educate 
health practitioners on the potential barriers associated with prescribing long-acting 
opioids to their CNMP patients.   
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 As with all empirical research, a need exists to validate the findings of this study 
among other family physician groups.  Therefore, additional studies should be conducted 
to determine the generalizability of results among family physicians practicing in Texas 
and other states.  As the scope of this study was restricted to Texas family physicians, 
future research could be performed to ascertain how willingness to prescribe CR opioids 
for CNMP may differ among other primary care physicians, such as internists and general 
practitioners.  However, additional studies should not be limited to physicians only.  
Physician assistants and nurse practitioners also play a critical role in the delivery of care 
to patients with chronic pain.  Depending on their state of residence, a number of these 
professionals have been granted controlled-substance prescribing privileges under a 
supervising physician. It would be interesting to see how identified factors may influence 
their willingness to use or administer CR opioids among CNMP patients.   
 There is much debate about the validity of the TPB model, particularly whether 
willingness (behavioral intention) leads to the actual behavior.  As a follow-up to this 
study, future research should examine the links between willingness to prescribe CR 
opioids and future prescribing behavior.  Further, longitudinal studies should be designed 
to assess the impact of educational interventions on willingness and monitor the effects of 
these interventions on actual prescribing behavior. These future studies could be used to 
develop a more comprehensive TPB model that would be more useful in assessing 




 This research is among the first to use a theoretical model to examine physicians’ 
willingness to prescribe long-acting opioids for moderate to severe CNMP.  Through the 
use of the Theory of Planned Behavior, factors influencing family physicians’ willingness 
to prescribe CR opioids for CNMP were identified and tested.  The results of the present 
study showed a majority of Texas family physicians were willing to prescribe CR opioids 
for CNMP.  However, a significant number of family physicians indicated that they were 
unwilling to prescribe this type of opiate analgesic.  The TPB model and RPB accounted 
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for 57 percent of the variance in explaining physicians’ willingness to prescribe CR 
opioids for CNMP and all three TPB constructs (attitude + subjective norm + perceived 
behavioral control) and RPB were found to be significant predictors of willingness.  
Given the current level of interest in improving pain management among patients with 
CNMP, information presented in this study could be used to build interventions that focus 
on improving physicians’ standard of care when it comes to treating CNMP patients with 
CR opioids.  Additional research using the TPB could be informative in identifying the 
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Focus Group Cover letter 
 
Introduction 
My name is Esmond Nwokeji and I will be your moderator for this focus group session. 
The purpose of this focus group session is to get your perceptions, and experiences 
regarding the use of schedule II controlled released opioids (CR-Opioids) to treat patients 
suffering from moderate to severe chronic non-malignant pain (CNMP). The information 
obtained from this focus group session will be used to develop an anonymous survey that 
will be administered to the Texas Academy of Family Physicians (TAFP) members. 
 
This session will be audio (cassettes) recorded. However, no names will be used for any 
portion of the larger study. Information obtained from this focus group session will not be 
associated with any specific focus group participant. The purpose of the audio recordings 
during the focus group session is to ensure that no important information is missed when 
constructing the final survey instrument. The cassettes will be coded so that no personally 
identifying information is visible on them. Cassettes will be stored in a locked file cabinet 
in the investigators office and will be heard only for research purposes by the investigator 
and his or her research associates. The audio recordings will be destroyed at the 
completion of the study.  
 
This session is expected to last one to two hours and you have the right to stop 
participating at any time. 
 
Group Rules 
As the moderator, I will ask the questions and keep everyone on track. I will keep track 
of time, and therefore, I may need to interrupt the discussion and move forward if I see 
we are getting short on time. It is important that everyone feels comfortable during the 
discussion. There are no right and wrong answers. Everyone’s input is vital. I encourage 
you to speak freely and openly about the issues discussed during this session. 
 
General Questions 
1. Briefly tell me what you think about when you think of prescribing CR-Opioids to treat 
patients with moderate to severe (CNMP). 
 
2a. What comes to mind when you hear “How willing are you to prescribe CR-Opioids to 
patients with CNMP?” 
 
2b. How does this question differ from “How likely are you to prescribe CR-Opioids to 




Texas Academy of Family Physicians Focus Group 
 
 
Focus Group Questions 
 
 
1. What do you think are some of the advantages associated with FPs 
prescribing controlled released opioids (CR-Opioids) to treat patients with 
moderate to severe chronic non-malignant pain (CNMP)? 
 
 
2. What do you think are some of the disadvantages associated with FPs 
prescribing CR-Opioids to treat patients with moderate to severe CNMP? 
 
 
3. Are there any other advantages and disadvantages associated with FPs 





4. Are there any individuals or groups who would approve of FPs 
prescribing CR-Opioids to treat patients with moderate to severe CNMP? 
 
 
5. Are there any individuals or groups who would not approve of FPs 
prescribing CR-Opioids to treat patients with moderate to severe CNMP? 
 
 
6. Are there any other individuals or groups who would or would not 












Focus Group Questions (cont’d) 
 
 
7. What do you think would make it easier for FPs prescribing CR-Opioids 
to treat patients with moderate to severe CNMP? 
 
 
8. What do you think would make it more difficult for FPs prescribing CR-
Opioids to treat patients with moderate to severe CNMP? 
 
 
9. Are there any other factors you think would make it easier or more 

















Dear Dr. X, 
 
Within the next few days, you will receive a request to participate in an anonymous 




The purpose of the study is to survey family physicians' attitudes and views regarding the 
use of controlled-release opiate analgesics to treat patients with chronic non-malignant 
pain (CNMP) in an effort to learn more about factors (e.g., concerns of patient addiction, 
illicit usage, and regulatory scrutiny) that may affect a physicians willingness to use 
controlled release opioids for patients with CNMP. 
 
 
We sincerely hope that you choose to participate in this important study. If you have 
questions about the survey, please contact either Paige Newman at e-mail 
pnewman@tafp.org (phone: 512-329-8666 ext 35) or Esmond Nwokeji at 





Esmond D. Nwokeji, PhD student, University of Texas at Austin, College of Pharmacy  
 





E-mail Cover Letter 
 
Dear Dr. X, 
 
The University of Texas in cooperation with the TAFP-SPARRC is conducting an 
anonymous online survey to examine our TAFP members’ attitudes and views toward 
long-acting opiate analgesics to treat patients with chronic non-malignant pain (CNMP). 
 
 
As an active TAFP member, your name was selected from the TAFP membership 
database to participate in this important study. The purpose of this study is to better 
understand how factors such as, concerns of patient addiction, illicit use and regulatory 
scrutiny can influence FPs decisions to prescribe long-acting opiates for CNMP patients.  
Information gathered from the study may be used by FPs and health organizations to 
better meet the needs of their CNMP patients within the community. 
 
 
This survey is coordinated by a PhD student at The University of Texas at Austin, 
College of Pharmacy, in cooperation with the TAFP-SPARRC.  You may be assured that 
your responses to the electronic questionnaire are anonymous and no personally 
identifiable information will be collected. This voluntary online questionnaire takes 
approximately xx minutes to complete. Please complete the survey by day, month XX. 
 
 




We sincerely hope that you choose to participate in this important study. If you have 
questions about the survey, please contact either Paige Newman at e-mail 
pnewman@tafp.org (phone: 512-329-8666 ext 35) or Esmond Nwokeji at 
esmondn@mail.utexas.edu.   
 






Esmond D. Nwokeji, PhD Candidate, University of Texas at Austin, College of 
Pharmacy 
 







Dear TAFP Member, 
 
About two weeks ago, you should have received an e-mail asking for your participation 
in an anonymous online web-survey.  The purpose of this study is to better understand 
how factors such as, concerns of patient addiction, illicit use and regulatory scrutiny can 
influence FPs decisions to use long-acting opioids among patients with chronic non-
malignant pain. The results of the study can be used by FPs and public health officials to 
better meet the needs of their patients who suffer from chronic pain.  
 
If you have already completed the anonymous questionnaire, please accept our sincere 
thanks. If you have not yet completed the electronic questionnaire, we kindly ask for your 
assistance by completing it as soon as possible. As an active TAFP member and a 
practicing family physician, your responses are important to us. A link to the survey 
questionnaire can be found below. 
 
 




We sincerely hope that you choose to participate in this important study. If you have 
questions about the survey, please contact either Paige Newman at e-mail 
pnewman@tafp.org (phone: 512-329-8666 ext 35) or Esmond Nwokeji at 
esmondn@mail.utexas.edu.  Thank you in advance for your help. 
 






Esmond D. Nwokeji, PhD Candidate, University of Texas at Austin, College of 
Pharmacy 
 

















(Text from above web page’s online consent form scrolling text box) 
 
ONLINE CONSENT FORM 
 
TITLE: 
Examining the attitudes and beliefs of family physicians toward the use of controlled-
release opioids for treating patients suffering from chronic non-malignant pain.   
  
IRB PROTOCOL # 2005-04-0101  
 
CONDUCTED BY:  
Esmond D. Nwokeji, PhD student, The University of Texas at Austin, College of 
Pharmacy (UTCOP); 
Andrew Eisenberg, M.D. MHA, TAFP Member, SPARCC, Dissertation Committee 
Member; 
Carolyn M. Brown, Ph.D., Associate Professor and Dissertation Co-supervisor, UTCOP; 
and 
Dr. Karen L. Rascati, PhD., Professor and Dissertation Co-supervisor, UTCOP. 
 
University of Texas at Austin: Pharmacy Administration Dept; Telephone (512) 471-
6892. 
 
You are being asked to participate in a research study.  This form provides you with 
information about the study.  The person in charge of this research can also describe this 
study to you and answer all of your questions. Please read the information below and call 
or e-mail your questions about anything you don’t understand before deciding whether or 
not to take part. Your participation is entirely voluntary and you can refuse to participate 
without penalty or loss of benefits to which you are otherwise entitled.  You can stop 
your participation at any time. 
 
THE PURPOSE OF THIS STUDY is to better understand how factors such as, "concerns 
of patient addiction, illicit use and regulatory scrutiny" can influence FPs decisions to use 
long-acting opioids among patients with chronic non-malignant pain (CNMP). THE 
RESULTS of the study can be used by FPs and public health officials to better meet the 
needs of their patients who suffer from chronic pain.  
 
Go to http://www.tafp.org/SPARRC/Opioid_Pain_study.htm for more information on 
background of study 
 
IF YOU AGREE TO BE IN THIS STUDY, WE WILL ASK YOU TO DO THE 
FOLLOWING THINGS: 
1. complete a 1 page electronic questionnaire on your views toward long-acting opioids 
used to treat patients with chronic non malignant pain 





TOTAL ESTIMATED TIME to participate in study is 10 to 15 minutes 
 
RISK AND BENEFITS of being in the study: 
1.  no personally identifiable information will be collected from you  
2.  there are no benefits but summary information will be available on the TAFP website 
when the study is complete 
 
COMPENSATION: 
1. No compensation is provided for this study 
 
The RECORDS of this study will be stored securely and kept private. Authorized persons 
from The University of Texas at Austin, members of the Institutional Review Board, and 
TAFP have the legal right to review research records and will protect the 
CONFIDENTIALITY of those records to the extent permitted by law.  All publications 
will exclude any information that will make it possible to identify you as a subject. The 
information gathered from this survey will be used for academic purposes only and will 
be shared and published with TAFP in aggregate form only. 
 
This STUDY has received NO OUTSIDE FUNDING and is supported by the TAFP. 
 
CONTACTS AND QUESTIONS: 
If you have any questions about the study please ask now.  If you have questions later or 
want additional information, call the researchers conducting the study.  Their names, 
phone numbers, and e-mail addresses are at the bottom of this page. 
 
If you have questions about your rights as a research participant, please contact Clarke A. 
Burnham, Ph.D., Chair, The University of Texas at Austin Institutional Review Board for 
the Protection of Human Subjects, (512) 232-4383. 
 
Please print a copy of this information to keep for your records. 
 
STATEMENT OF CONSENT: 
I have read the above information and have sufficient information to make a decision 
about participating in this study.  I consent to participate in the study. 
 
Answering questions on the electronic questionnaire will serve as your consent to 
participate in the study. 
 
















































































Comparison of Demographic/Practice Characteristics 









Comparison of demographic and practice characteristics between study sample and 
2006 Texas Academy of Family Physician membership population 
Demographic/Practice Characteristics 
2006 TAFP  
Active Membership
% (N)  
2006 TAFP  
Study Sample 
% (N) 
      
Gender    
  Male 69.7% (2669)  61.8%  (165) 
  Female 30.2% (1158)  36.7% (98) 
  Missing/Unknown 0.1% (4)  1.5% (4) 
    
Ethnicity    
  White/European American 64.8% (2485)  72.7% (194) 
  Latino/Latin American Hispanic 13.0% (498)  11.6% (31) 
  Asian or Pacific Islander 12.2% (467)  5.6% (15) 
  African-American/Black 3.4% (129)  1.9% (5) 
  Native American/Indigenous Peoples 0.2% (8)  0.0% (0) 
  Other N/Aa  6.0% (16) 
  Missing/Unknown 6.4% (244)  2.2% (6) 
    
Primary Practice Setting    
  Urban/Suburban 84.9% (3224)  69.3% (185) 
  Rural 15.1% (572)  28.1% (75) 
  Missing/Unknown N/Aa  2.6% (7) 
    
Years Practicing    
0-4 years 14.6% (39)  15.5% (596) 
5-9 years 18.4% (49)  20.1% (769) 
10-14 years 10.5% (28)  13.8% (528) 
15-20 years 16.9% (45)  18.8% (720) 
21-24 years 12.0% (32)  10.8% (415) 
25-29 years 15.7% (42)  9.7% (372) 
30-34 years 5.6% (15)  6.1% (235) 
35-39 years 2.2% (6)  2.6% (98) 
40+ years 2.2% (6)  2.2% (84) 
Missing/Unknown 1.9% (5)  0.4% (14) 
    
Primary Practice Type    
  Partnership/ Group 51.5% (1861)  49.8% (133) 
  Solo Practice 30.2% (1091)  20.2% (54) 
  Hospital/Military/ Clinical Institution 13.3% (481)  15.4% (41) 
  Managed Care 1.7% (61)  1.9% (5) 
  Other 3.3% (120)  10.1% (27) 
  Missing/Unknown N/Aa  2.6% (7) 







































































































































































































































































































































Partial Regression Plots of Direct TPB 
 





















Willingness vs. Direct Subjective Norm 
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Willingness vs. Recent Past Behavior 
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Partial Regression Plots of Indirect TPB 
 




















Willingness vs. Indirect  (belief-based) Subjective Norm 
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